journal0907 - justice.gov.il€¦ · web viewg01s 181711 05/03/2007 מערכת רדאר...

9/2007ג'/התשס"ח

רשומותISRAEL STATE RECORDS

December 3, 2007 התשס"ח בכסלו כ"ג

והמדגמים הפטנטים יומןPATENTS AND DESIGNS JOURNAL

PATENTSעמודפטנטיםPage

3358Applications filedשהוגשו בקשות3496Applications acceptedשקובלו בקשות3657Patents grantedשניתנו פטנטים3658Patents renewedשחודשו פטנטים3659Patents not in forceפקעו שתוקפם פטנטים3661Patents expiredתוקפם שפג פטנטים3662Patent extensionsפטנטים הארכות3663Noticesהודעותרשומים בפרטים שינויים

3664בפנקס Changes in particulars entered

in register3665Country codesלמדינות קודים

iIndices of applications acceptedשקובלו לבקשות מפתחות

DESIGNSמדגמים3667Designs registeredשנרשמו מדגמים3679Designs renewedשחודשו מדגמים3680Designs voidשבוטלו מדגמים

כלליות ידיעות

אל: לשלוח יש ומדגמים פטנטים מכתבים, מסמכים, וכו' בענייני, ירושלים4 והמדגמים, רח' הסדנא הפטנטים רשם

חול בימי לציבור פתוחה והיא , תלפיות, ירושלים4 ברח' הסדנא נמצאת הפטנטים לשכת.12:30 ו- 8:30 השעות בין מועד או שבת ערבי שאינם כל בעד שקלים2.50 של במחיר ושרטוטים פירוטים של תצלומים מספקת הפטנטים לשכתממנו. חלק או עמוד

מס' הדואר בבנק הלשכה לחשבון תשלום ידי על ורק אך מתקבלות הפטנטים ללשכת אגרות האגרה שעבורה לפעולה הבקשה עם יחד ללשכה הדואר בנק קבלת להציג . יש0-24145-2

שולמה.

GENERAL INFORMATION

Letters, documents, etc. concerning Patents and Designs should be addressed to:The Commissioner of Patents and Designs, 4 Hasadnah St., Jerusalem

The Patent Office is located at 4 Hasadnah St., Talpiot, Jerusalem and is open to the public on weekdays, except on Fridays or on the eves of holydays, from 08:30 to 12:30 hrs.

The Patent Office supplies photocopies of specifications and drawings at the rate of NIS 2.50 per page or part thereof.

Fees to the Patent Office can be accepted only by payment to the Postal Bank Account of the Office, No. 0-24145-2. The receipt of the Postal Bank must be presented to the office together with the application for the action for which the fee has been paid.

שמורה אלה בתקצירים היוצרים זכותמת להעתיק ישראל, אין למדינתקצירים

הפטנטים. לשכת ברשות אלא אלה

Copyright by the State of Israel. No Extracts may be published except with the permission of the Patent Office.

.Price per single issue (incl. VAT) : NIS 96.₪ 96מ.ע.מ.( )כולל בודדת חוברת מחיר: לכל

:Annual subscription (incl. VAT).₪ 1,152מ.ע.מ.( )כולל לשנה חתימה דמיNIS 1,152.

אצל: להשיג אפשר ב' הממשלה, רחוב פרסומי של ההפצה שרות, הקריה, תל-אביב.29מס'

Available at the Distribution Service of Government Publications, 29 B-Street, Hakirya, Tel-Aviv.

NOTICE UNDER SECTION 16 OF THE הפטנטים לחוק16 סעיף לפי הודעה

December 3, 2007 –התשס"ח בכסלו כ"ג 3356

1967PATENTS LAW, 5727-1967- תשכ"ז

חדשות בקשות רשימת להלןשנקבעו הדרישות אחר הממלאות

הפטנטים, )א( לתקנות32 בתקנה:1968תשכ"ח–

In the following there are listed newApplications complying with theProvisions of rule 32(a) of the PatentRegulations, 5728-1968

לפי מובאים הבקשות פרטיזה: סדר

Particulars of the applications aregiven in the following order:

הגשתה ותאריך – הבקשה מספרשל הראשונים הסמנים וארבעה

הבינלאומי הסיווג

Number and date of application And the first four symbols of theInternational Classification

ע"י שהוצע )כפי האמצאה שםהמבקש(

Title of invention(as proposed by applicant)

Applicantהמבקש– האיגוד קדימה: מדינת דין

ומספר תאריך החוץ בקשת

Priority right: Convention country – Number and date of Foreign application

International Application Numberבינלאומית בקשה מספר

International Publication Numberבינלאומי מס' פרסום

G01S17070830/03/2004

ריבוי-מסלולים למיתון ושיטה מערכתבצבר מיקום באותות שימוש באמצעות

A SYSTEM AND METHOD FOR MULTIPATH MITIGATION USING CLUSTERED POSITIONING SIGNALS

December 3, 20073357 –התשס"ח בכסלו כ"ג

LOCATA CORPORATION31/03/2003

2003901463AU

PCT/AU/2004/000419WO/2004/088349

A61K17221201/06/2004

ABUSE RESISTANT AMPHETAMINEאלימות להקטנת אמפטמין תרכובותCOMPOUNDSNEW RIVER PHARMACEUTICALS, INC.

29/05/2003

60/473929US

05/05/2004

60/567801US

PCT/US/2004/017204WO/2005/000334

H04B18002012/12/2006

-ENCRYPTION -AND DECRYPTIONופענוח הצפנה יכולת בעלי ממשקיםENABLED INTERFACES

.HUMAN INTERFACE SECURITY LTDבע"מ סקיוריטי אינטרפייס היומן

F41A18002913/12/2006

NON -LETHAL PERSONAL WEAPONקטלני לא אישי נשקVISIONARY LTDבע"מ ויז'יונרי חברת


A61M18006614/12/2006

REINFORCING TOOL FOR Aרפואית מחט עבור מחזק כליMEDICAL NEEDLESHERWOOD SERVICES AG

26/12/2005

2005-371422JP

B62D18010014/12/2006

קונפיגורציה בעלת זחלית הנעה מערכתמשתנה

CRAWLER MOVING SYSTEM HAVING VARIABLE CONFIGURATIONOTO MELARA S.P.A.

19/12/2005

MI2005A 002414IT

B60F18013517/12/2006

מסוכנים טיסה תנאי לחיווי ושיטה מערכתMETHOD AND DEVICE FOR INDICATING DANGEOUROUS FLIGHT CONDITIONS

H.M. DA CONSULTING ANDבע"מ ופיתוח יעוץ ה.מ.דעDEVELOPMENT LTD.

G07F18018419/12/2006

CONTROL AND MANAGEMENTוניהול לשליטה מערכתSYTEM

ROVATEC LTDבע"מ רובעטק


H01B18033426/12/2006

חשמלי כבל על לניטור ומערכת שיטהתת–קרקעי

METHOD AND SYSTEM FOR MONITORING AN UNDERGROUND ELECTRIC CABLE

.ELTA SYSTEMS LTDבע"מ מערכות אלתא

G08B18041428/12/2006

METHOD AND APPARATUS FORעקבות לאיסוף ומכשיר שיטהTRACE COLLECTION

.TRACEGUARD TECHNOLOGIES LTDבע"מ טכנולוגיות פרלברג, טרייסגארד גיל

G01S18045731/12/2006

ניווט מערכות לשיפור ושיטה מכשיררגל הולכי כגון נעים לגופים אינרציאליות

APPARATUS AND METHODS FOR AUGMENTING INERTIAL NAVIGATION SYSTEMS FOR MOVING BODIES SUCH AS PEDESTRIANS

ISRAEL AEROSPACE INDUSTRIESבע"מ לישראל האוירית התעשיהLTD.

B29C18053003/01/2007

PROTECTIVE LAYER AND METHODלהתקנתה ושיטה מגן שכבתFOR INSTALLING SAME

AMOS KLEINקליין עמוס


H04B18053704/01/2007

MIMOMIMO COMMUNICATION SYSTEM תקשורת ושיטת מערכתAND METHOD

.RUNCOM TECHNOLOGIES LTDבע"מ טכנולוגיות רנכום

F41A18059008/01/2007

DEFENCE WALL AGAINST SHORTקצרה בהתראה ירי בפני הגנה חומתNOTICE SHOOTIMG

BARAM AMIעמי ברעם

B65G18059108/01/2007

APROVED OFF-GROUNDאל–קרקעי–משופר שינוע התקןTRANSPORT DEVICE

NEHEMIA COHENכהן נחמיה

H04B18067311/01/2007

LOW POWER RADIO FREQUENCYנמוך הספק בעל רדיו תדר מקלטRECEIVER

AUDIODENT ISRAEL LTDבע"מ ישראל אודיודנט


H04B18069314/01/2007

בסביבת תשדורת לניהול ושיטה מערכתרגיש מידע

SYSTEM AND METHOD FOR MANAGING TRANSMISSION IN A SENSITIVE INFORMATION ENVIRONMENT

ISRAEL AEROSPACE INDUSTRIESבע"מ לישראל האוירית התעשיהLTD.

G09B18074816/01/2007

SECURE ARCHIVEמאובטח ארכיון.GITA TECHNOLOGIES LTDבע"מ טכנולוגיות גיטה

G01C18083321/01/2007

PEDESTRIAN NAVIGATION SYSTEMרגלי לניווט ושיטה מערכתAND METHOD

ISRAEL AEROSPACE INDUSTRIESבע"מ לישראל האוירית התעשייהLTD.

C25B18085622/01/2007

ETERNAL ELECTROCHEMISTRYאינסופי אלקטרוכימי תאCELL

YANIV SHLOSBERGשלוסברג יניב


A61M18092224/01/2007

לשימושים נשאב נוזל של אסוף מתקןרפואיים

SUCTION FLUID COLLECTOR FOR MEDICAL APPLICATIONSSHERWOOD SERVICES AG

08/03/2006

2006-62340JP

H01G18096825/01/2007

HIGH GAIN ANTENNA FORמיקרוגל לתדרי גבוה הגבר בעלת אנטנהMICROWAVE FREQUENCIES

.ELTA SYSTEMS LTDבע"מ מערכות אלתא25/01/2006

11/338883US

G09B18097525/01/2007

MULTI-STORY PROTECTED SPACEקומתי רב מוגן מרחב.ROLAN LTDבע"מ רולן

G01S18103029/01/2007

TIME-SPACE MULTIPLEXED LADARמרחב זמן מרובב אופטי מכ"מ

RAFAEL - ARMAMENTבע"מ לחימה אמצעי פתוח רשות רפאלDEVELOPMENT AUTHORITY LTD

26/01/2006173420IL

20/02/2006173818IL


05/03/2006174111IL

F16C18113904/02/2007

ONE-TIME-USE THRUST BEARINGחד–פעמי לשימוש דחף מיסב התקןDEVICE

YEFIM KERETHרייבר ירון

G01C18136715/02/2007

מהירות למדידת רוטט ג'רוסקופי התקןזויתית

VIBRATORY GYROSCOPIC DEVICE FOR DETERMINING ANGULAR VELOCITY

אלאופ אלקטרו-אופטיקה מערכות אלביטבע"מ.

ELBIT SYSTEMS ELECTRO-OPTICS ELOP LTD.

H04L18139818/02/2007

MIMOMIMO DECODING SYSTEM AND לפענוח וישטה מערכתMETHOD

.RUNCOM TECHNOLOGIES LTDבע"מ טכנולוגיות רנכום

G01C18169004/03/2007


TARGET ACQUISITION SYSTEMSמטרות לרכישת ושיטות מערכותAND METHODS

NA-OR LTDבע"מ נ-אור

G01S18171105/03/2007

PROXIMITY SENSOR RADARמיקום לזהוי רדאר מערכתSYSTEM

BEAM NETWORKS LTDבע"מ נטוורקס בים

G08B18185312/03/2007

METHOD AND SYSTEM FORממונע גוף לגילוי ושיטה מערכתDETECTING MOTORIZED OBJECTS


G08B18185412/03/2007

METHOD AND SYSTEM FORממונע גוף לגילוי ושיטה מערכתDETECTING MOTORIZED OBJECTS


G01S18188913/03/2007


ידועה ייחוס נקודת לקבוע ומערכת שיטהאווירית הדמייה פלטפורמת עבור

METHOD AND SYSTEM FOR PROVIDING A KNOWN REFERENCE POINT FOR AN AIRBORNE IMAGING PLATFORM

ISRAEL AEROSPACE INDUSTRIESבע"מ לישראל האוירית התעשייהLTD.

H04L18211122/03/2007

תקשורת רשת לבדיקת חומרה ישוםתקשורת רשת התקן ביצוע אחרי ומעקב

HARDWARE IMPLEMENTATION OF NETWORK TESTING AND PERFORMANCE MONITORING IN A NETWORK DEVICE

MARVELL SEMICONDUCTORבע"מ ישראל סמיקונדקטור מארוולISRAEL LTD

22/03/2006

11/387549US

B23B18215222/03/2007

CUTTER APPARATUS AND METHODושיטה לחיתוך מתקןG.R.G. PATENTS LTDבע"מ ג'י. אר. ג'י. פטנטים

G08B18216825/03/2007

AUTOMATIC SURVEILLANCEאוטומטית מעקב מערכתSYSTEM

GADI SHAVITשביט גדי


G06K18220126/03/2007

SYSTEM FOR EMBEDDING DATAמידע להטמעת מערכתNDS LIMITED

B64D18300606/05/2007

להתמצאות בילטראלית רובוטית מערכת לנשיאה חכם מארז בלעת כיוונית כלל

להשלכה הניתן

A BILATERAL ROBOTIC OMNI-DIRECTIONAL SITUATIONAL AWARNESS SYSTEM HAVING A SMART THROW ABLE TRANSPORTAION CASE

.WAVE GROUP LTDבע"מ גל קבוצת

A61B18308509/05/2007

עבור יחידתית השגה מערכת המודינמי אבחוני ופיקוח אלקטרופיזילוגיה

קליני פולשני הליך בעת פיזיולוגי

SINGLE ACQUISITION SYSTEM FOR ELECTROPHYSIOLOGY AND HEMODYNAMIC PHYSIOLOGICAL DIAGNOSTIC MONITORING DURING A CLINICAL INVASIVE PROCEDUREGENERAL ELECTRIC COMPANY

15/05/2006

11/434049US

B64C18327517/05/2007

VEHICLE BARRIERרכב מחסום


RAFAEL ARMAMENTבע"מ לחימה אמצעי לפיתוח רשות רפא"לDEVELOPMENT AUTHORITY LTD.

A61M18329517/05/2007

DRUG DELIVERY DEVICEתרופה למתן מתקןALCON, INC.

17/05/2006

11/435906US

G06T18332020/05/2007

TRACKING AND IMAGING DATAומהדמיה ממעקב מידע מיזוגFUSION

RAFAEL-ARMAMENTבע"מ לחימה אמצעי לפיתוח רפא"ל-רשותDEVELOPMENT AUTHORITY LTD.

E05D18332621/05/2007

H.M.S.A.S-HAZARDOUSמ.ה.ס.מ–מערכתYVSTIGNEEV SERGEYיבסטיגנייב סרגיי

G01S18335921/05/2007

באמצעות למחצה מוליך פרוסת בקרת בפס קצרים דפקים של מתמשכת הקרנה

רחב

WAFER INSPECTION USING SHORT-PULSED CONTINUOUS BROADBAND ILLUMINATIONNEGEVTECH, LTD

26/05/2006

60/808816US


09/03/2007

11/684191US

G02C18336921/05/2007

עיניות תוך בעדשות כרומטיות סטיות תיקוןCORRECTION OF CHROMATIC ABERRATIONS IN INTRAOCULAR LENSESALCON, INC.

31/05/2006

11/444113US

G01S18364204/06/2007

QUADRATIC FREQUENCYסונר במערכות ריבועי תדר אפנוןMODULATION IN SONAR SYSTEMS

RAFAEL-ARMAMENTבע"מ לחימה אמצעי לפיתוח רפאל-רשותDEVELOPMENT AUTHORITY LTD.

A41D18368305/06/2007

MODULAR GARMENTמודולרי בגדSAGEM DEFENSE SECURITE

06/06/20060605018FR

A61B18385511/06/2007

CASSETTE CLAMPING MECHANISMנוזלים צינורית לצביטת מנגנוןALCON, INC.


12/06/2006

11/451050US

A47J18398017/06/2007

MECHANICALLY AGITATED WOKמכנית מעורבב ווקYOSSI LEVY BACHARבכר לוי יוסי

A47F18399217/06/2007

MOBILE HANGING CONTRIVANCEנייד תלייה התקןMEIR AMIRAMעמירם מאיר

D03D18460317/01/2006

הדומים וערב שתי לאריגת ומכשיר שיטהמהם המיוצר וחומר לסרט

METHOD AND APPARATUS FOR WEAVING TAPE-LIKE WARP AND WEFT AND MATERIAL THEREOFTAPE WEAVING SWEDEN AB

17/01/2005

0500115-1SE

PCT/SE/2006/000061WO/2006/075961

D03D18460417/01/2006


הדומים וערב שתי הכולל ארוג חומרשלו לאריגה ושיטה לסרט, ומכשיר

A WOVEN MATERIAL COMPRISING TAPE-LIKE WARP AND WEFT, AND AN APPARATUS AND METHOD FOR WEAVING THEREOFTAPE WEAVING SWEDEN AB

17/01/2005

0500114-4SE

PCT/SE/2006/000062WO/2006/075962

H04L18460628/01/2005

במערכת משתמש של ואישור הרשאהתיקשורות

USER AUTHENTICATION AND AUTHORIZATION IN A COMMUNICATIONS SYSTEMTELEFONAKTIEBOLAGET LM ERICSSON (PUBL)

PCT/EP/2005/050372WO/2006/079419

A61M18460726/01/2006

עבור תרכיב להתזת משופר התקןעתה זה שנולדו אפרוחים

IMPROVED VACCINE SPRAYING APPARATUS FOR NEWBORN CHICKSAVITECH, LLC

26/01/2005

60/646618US

PCT/US/2006/002691WO/2006/081316

A61F18460812/01/2006

של דם כלי דרך השתלה עבור צנתרתותבים לב שסתומי

CATHETER FOR THE TRANSVASCULAR IMPLANTATION OF PROSTHETIC HEART VALVESJENAVALVE TECHNOLOGY GMBH

20/01/2005

102005003632.5DE

PCT/DE/2006/000056WO/2006/076890


A61K18460913/01/2006

מסיעה ופפטיד אנטיגן המכילים תכשיריםCOMPOSITIONS CONTAINING AN ANTIGEN AND AN ADJUVENT PEPTIDEUNIVERSITY OF MARYLAND

14/01/2005

60/643606US

PCT/US/2006/001254WO/2006/076587

C23C18461009/02/2006

ושיטות אטומה פלסטית אמפולהלאטימתה

A SEALED PLASTIC AMPOULE AND METHODS FOR SEALING THE SAMEBREATH LIMITED

09/02/2005

0502666.1GB

05/05/2005

0509210.1GB

PCT/GB/2006/000433WO/2006/085063

F25J18461324/02/2006

טבעי גז זרם לקירור ומערכת שיטהשונים למקטעים המקורר הזרם והפרדת

METHOD AND SYSTEM FOR COOLING A NATURAL GAS STREAM AND SEPARATING THE COOLED STREAM INTO VARIOUS FRACTIONTWISTER B.V.

24/02/2005

05101420.7EP

PCT/EP/2006/060260WO/2006/089948

G06F18461428/03/2006


מורחבת הפרעה לבקר ושיטות מערכותמלאכותיים הפרעה ומקורות

SYSTEMS AND METHODS FOR AN AUGMENTED INTERRUPT CONTROLLER AND SYNTHETIC INTERRUPT SOURCESMICROSOFT CORPORATION

28/03/2005

11/092012US

PCT/US/2006/011487WO/2006/105208

G01N18461509/11/2005

בתווך חומניות תכונות למדידת התקןבתווך לחות תכולת לקביעת ושיטה

DEVICE FOR MEASURING THERMAL PROPERTIES IN A MEDIUM AND METHOD FOR DETERMINING THE MOISTURE CONTENT IN THE MEDIUMPLANTCARE AG.

02/02/2005149/05CH

07/06/2005960/05CH

PCT/CH/2005/000663WO/2006/081693

F04B18461615/07/2007

PUMP SET WITH SAFETYבטיחותי חיבור עם משאבה מערכתINTERLOCKCOVIDIEN AG

05/01/2007

11/620353US


C07K18461731/01/2006

DR5 ANTIBODIES AND USESבהם ושימוש5DR נוגדניםTHEREOFGENENTECH, INC.

02/02/2005

60/649550US

30/01/2006

11/344564US

PCT/US/2006/003577WO/2006/083971

C03C18462218/01/2006

מזכוכית העשוי מרכיב לייצור תהליך למחצה מוליכים בייצור לשימוש קוורץ

תהליך אותו ידי על המיוצר ומרכיב

PROCESS FOR PRODUCING A QUARTZ GALSS COMPONENT FOR USE IN SEMICONDUCTOR MANUFACTURE AND COMPONENT PRODUCED BY THIS PROCESSHERAEUS QUARZGLAS GMBH & CO. KG

03/02/2005

102005005196.0DE

PCT/EP/2006/000381WO/2006/081940

A01N18462513/01/2006

PERFUSION AND/OR PRESERVATIONאיברים עבור פרפוסיה ו/או שימור תמיסתSOLUTION FOR ORGANSPHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE

14/01/2005

11/035197US

PCT/US/2006/001266WO/2006/076590

A45C18462612/01/2006

BAG THAT CAN BE USED AS Aכמגבת לשמש שיכול תיקTOWELGROSSER, ROY


15/01/200500055/05CH

PCT/IB/2006/000168WO/2006/075249

C07D18462802/02/2006

פעילות בעלות אמיד אינדאן נגזרות פוספורילאז, תהליכים גליקוגן מעכבת

אותן המכילים רוקחות לייצורן, תכשירי פעילות לעיכוב תרופות לייצור בהן ושימוש דם בעלי בבעלי–חיים פוספורילאז גליקוגן

חם

INDAN AMIDE DERIVATIVES POSSESSING GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY, PROCESSES FOR THEIR MANUFACTURE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE THEREOF IN THE MANUFACTURE OF MEDICAMENTS TO INHIBIT GLYCOGEN PHOSPHORYLASE ACTIVITY IN WARM-BLOODED ANIMALSASTRAZENECA AB

05/02/2005

0502466.6GB

05/02/2005

0502465.8GB

PCT/GB/2006/000349WO/2006/082401

C04B18465113/04/2006

(VI) כרום יוני לחיזור שמסייע חומר (III) לכרום

ADJUVANT FOR REDUCING CHROMIUM (VI) IONS CHROMIUM (III)CHRYSO

18/04/20050503855FR

PCT/FR/2006/000816WO/2006/111639


C12N18465301/02/2006

NUCLEIC ACID CONSTRUCTSגרעין חומצת של מבניםPOWDERJECT VACCINES, INC.

01/02/2005

60/648382US

19/04/2005

60/672497US

20/04/2005

0507997.5GB

PCT/GB/2006/000344WO/2006/082398

C12N18465527/01/2006

לעשות ושיטה מוגדל יבול בעלי צמחיםזאת

PLANTS HAVING INCREASED YIELD AND A METHOD FOR MAKING THE SAMECROPDESIGN N.V.

27/01/2005

05100537.9EP

01/02/2005

60/649041US

26/10/2005

60/730403US

PCT/EP/2006/050489WO/2006/079655

A61K18465614/02/2006

של מבוקר לשחרור ושיטה מתן צורתמותמרת פיראזין תרכובת

DOSAGE FORM AND METHOD FOR SUSTAINED RELEASE OF A SUBSTITUTED PYRAZINE COMPOUNDJAZZ PHARMACEUTICALS, INC.

15/02/2005

60/653444US

PCT/US/2006/005076WO/2006/088814


G01N18465702/02/2006

ADAMADAM-9 MODULATORS– 9 מאפנניRAVEN BIOTECHNOLOGIES, INC.

02/02/2005

60/649787US

PCT/US/2006/003748WO/2006/084075

A61K18465820/01/2006

מתן בצורת מתכת/טטראציקלין תצמידימוצקה

A TETRACYCLINE METAL COMPLEX IN A SOLID DOSAGE FORMWARNER CHILCOTT COMPANY, INC

21/01/2005

60/646357US

PCT/US/2006/002070WO/2006/078925

C07K18465906/02/2006

ANTIBODY VARIANTS AND USESבהם ושימוש נוגדנים של וריאנטיםTHEREOFGENENTECH, INC.

07/02/2005

60/651111US

10/06/2005

60/689404US

25/07/2005

60/702571US

PCT/US/2006/004232WO/2006/084264

H05G18466018/01/2006

הקרנת זמן משך על לבקרה והתקן שיטהדנטלי רדיולוגי בהתקןX קרני

METHOD AND DEVICE FOR CONTROLLING THE DURATION OF THE EMISSION X-RAYS IN A DENTAL RADIOLOGY DEVICESOPRO

09/02/20050501290FR

PCT/FR/2006/000106


WO/2006/084967

C02F18466118/01/2006

מזוהמים ממים אורגניים מזהמים סילוקREMOVAL OF ORGANIC POLLUTANTS FROM CONTAMINATED WATER

של המחקר לפיתוח חברה יישוםבירושלים העברית האוניברסיטה

YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM

18/01/2005

60/644022US

PCT/IL/2006/000072WO/2006/077583

G07F18466218/01/2006

FLEXIBLE ONLINE INSTANTברשת וגמיש מיידי לוטו משחקLOTTERY GAMEGTECH RHODE ISLAND CORPORAION

18/01/2005

60/645488US

PCT/US/2006/002088WO/2006/078938

B26D18466619/01/2006

REMOVAL OF MATERIAL FROM Aמראש מוכנה מטבליה חומר הסרתPREFORMED TABLET


ACCU-BREAK PHARMACEUTICALS, INC.

19/01/2005

60/644939US

PCT/US/2006/001777WO/2006/078745

A61M18466720/01/2006

RECIPROCATING PROCEDUREחוזרים תהליך מזרקיSYRINGESAVANCA MEDICAL DEVICES, INC.

21/01/2005

60/646190US

PCT/US/2006/002219WO/2006/079004

B65D18466820/01/2005

CLOSURE WITH TAMPER-EVIDENTזיהוי–פתיחה אמצעי עם סגירהMEANSOBSHCHESTVO S ORGANICHENNOI OTVETSTVENNOSTYU "GLETCHER INVEST"

PCT/RU/2004/000504WO/2006/036085

G01N18466920/01/2006

טיפול גורמי של שאריות לניטור שיטות בתהליכי טיפול גורמי של מינון על ושליטה

במים טיפול

METHOD OF MONITORING TREATING AGENT RESIDUALS AND CONTROLLING TREATING AGENT DOSAGE IN WATER TREATMENT PROCESSESNALCO COMPANY

20/01/2005

11/038718US

13/01/2006

11/331864US

PCT/US/2006/001948WO/2006/078847


C07D18467324/01/2006

,Raf–B מעכבת פעילות בעלות תרכובות רוקחות להכנתן, תכשירי תהליכים לייצור בהן והשימוש אותם המכילים סרטן נוגד אפקט ליצירת תרופות

חם דם בעלי בבעלי–חיים

COMPOUNDS POSSESSING B-Raf INHIBITORY ACTIVITY, PROCESSES FOR THEIR MANUFACTURE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE THEREOF IN THE MANUFACTURE OF MEDICAMENTS FOR PRODUCING AN ANTI-CANCER EFFECT IN WARM-BLOODED ANIMALSASTRAZENECA AB

25/01/2005

60/646820US

PCT/GB/2006/000223WO/2006/079791

C07D18467401/02/2006

המשמשות פיראזולילאמינופירידין נגזרותקינאז כמעכבי

PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORSASTRAZENECA AB

04/02/2005

60/650053US

16/02/2005

60/653329US

29/09/2005

60/721633US

PCT/GB/2006/000334WO/2006/082392

G06F18467511/01/2006

ניהול לתוכנות לוח–זמנים קביעתפלאש זכרון במערכות

SCHEDULING OF HOUSEKEEPING OPERATIONS IN FLASH MEMORY SYSTEMSSANDISK CORPORATION


20/01/2005

11/040325US

19/12/2005

11/312985US

PCT/US/2006/001070WO/2006/078531

A61F18467617/01/2006

ראיה לתיקון מוקדי דו עיני תוך טלסקופחלשה

BIFOCAL INTRAOCULAR TELESCOPE FOR LOW VISION CORRECTIONTELEDIOPTIC LENS SYSTEM, LLC

17/01/2005

11/038320US

PCT/US/2006/001510WO/2006/078608

C07D18467713/02/2006

–])בנזיל(–3– טריפלואורו–1,1,1 תרכובות–2)פירימידין–

מותמרות –איל2איל(אמינו[פרופנ–

SUBSTITUTED 1,1,1-TRIFLUORO-3-[(BENZYL)-

(PYRIMIDIN-2-YL-)AMINO]-PROP AN-2-OL COMPOUNDSPFIZER PRODUCTS INC.

23/02/2005

60/655740US

PCT/IB/2006/000374WO/2006/090250


C07F18467810/02/2006

PROTEASOME INHIBITORS ANDבהם לשימוש ושיטות פרוטיאזומים מעכביMETHODS OF USING THE SAMECEPHALON, INC.

11/02/2005

60/652370US

09/02/2006

11/351193US

PCT/US/2006/004664WO/2006/086600

E04H18467907/02/2006

AUTOMATED PARKING GARAGEאוטומטית חניה מוסךROBOTIC TECHNOLOGY ADMINISTRATION, LLC

07/02/2005

11/052631US

PCT/US/2006/004196WO/2006/086348

A61K18468024/01/2006

המכילות מולקולות להצמדת שיטהלאמצעים אמינותיאול

METHOD OF CONJUGATING AMINOTHIOL CONTAINING MOLECULES TO VEHICLESAMGEN, INC.

24/01/2005

60/646685US

23/01/2006

11/338371US

PCT/US/2006/002608WO/2006/079099

A61K18468124/03/2005

THICKENED SPREADABLEלמריחה הניתן מסמיך מחמם סיכה חומרWARMING LUBRICANTANSELL HEALTHCARE PRODUCTS LLC


23/02/2005

11/064284US

PCT/US/2005/009877WO/2006/091206

H04B18468229/03/2006

יכולת מקסימום של לאיתות והתקן שיטה בסיס לתחנת משתמש ציוד של מידע שידור שידור חבילת העלאת של תזמון לשם

ניידת תקשורת במערכת

METHOD AND APPARATUS FOR SIGNALING MAXIMUM UE TRANSMITTER POWER INFORMATION TO BASE STATION FOR SCHEDULING OF UPLINK PACKET TRANSMISSION IN A MOBILE COMMUNICATION SYSTEMSAMSUNG ELECTRONICS CO, LTD.

29/03/2005

10-2005-0025893KR

PCT/KR/2006/001149WO/2006/104348

G06F18468320/01/2006

זיכרון של דינאמי לניהול והתקנים שיטותנערם

METHODS AND APPARATUS FOR DYNAMICALLY MANAGING BANKED MEMORYQUALCOMM INCORPORATED

21/01/2005

11/040600US

PCT/US/2006/001934WO/2006/078837

C07D18468608/06/2001


–2, 1 תולדות להכנת תהליכיםדיהידרופירידין

PROCESSES FOR PRODUCING 1,2-DIHYDROPYRIDINE DERIVATIVESEISAI R&D MANAGEMENT CO., LTD.

12/06/2000

2000-175966JP

13/09/2000

0022483.2GB

PCT/JP/2001/004857WO/2001/096308

C07D18468708/06/2001

–2,1 של תולדה המכילים רוקחות תכשירי– און2דיהידרופירידינ–

PHARMACEUTICAL COMPOSITIONS CONTAINING 1,2-DIHYDROPYRIDIN-2-ONE DERIVATIVESEISAI R&D MANAGEMENT CO., LTD.

12/06/2000

2000-175966JP

13/09/2000

0022483.2GB

PCT/JP/2001/004857WO/2001/096308

H04Q18468821/10/2005

לעמית עמית תיקשורות להספקת סידורציבורית יבשתית ניידת ברשת

ARRANGEMENT FOR PROVIDING PEER-TO-PEER COMMUNICATIONS IN A PUBLIC LAND MOBILE NETWORKTELEFONAKTIEBOLAGET LM ERICSSON (PUBL)

18/02/2005

0500384-3SE

PCT/SE/2005/001575WO/2006/088402


A61K18469031/01/2006

PROCESS FOR PRODUCINGפולימריים צמדים להכנת תהליךPOLYMER CONJUGATESENZON PHARMACEUTICALS, INC.

04/02/2005

11/051009US

PCT/US/2006/003766WO/2006/084089

A61K18469126/02/1998

תהליכים ליישום רוקחות תכשירי הכנתחיסוני וויסות של סלקטיבי

PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR PROCESSES FOR IMPLEMENTING SELECTIVE IMMUNE DOWN REGULATIONENZO THERAPEUTICS, INC.

28/02/1997

08/808629US

PCT/US/1998/003606WO/1998/037917

C07D18469427/02/2006

ריפאקסימין, של חדשות פולימרפיות צורותהתרופתי ושימושן לייצורן תהליכים

NEW POLYMORPHOUS FORMS OF RIFAZIMIN, PROCESSES FOR THEIR PRODUCTION AND USE THEREOF IN THE MEDICINALALFA WASSERMANN S.P.A.

03/03/2005

05004695.2EP

PCT/EP/2006/001755WO/2006/094662

A61K18469506/03/2006

בקיבה העמידות רוקחיות פורמולציותריפאקסימין המכילות

GASTRORESISTANT PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMIN


ALFA WASSERMANN S.P.A.07/03/2005BO2005A000123IT

PCT/EP/2006/002022WO/2006/094737

C12N18469627/01/2006

אפוקסידK ויטמין של רקומביננטי ביטוי חלבוני ביטוי לשיפור1 יחידה תת רדוקטאז

K בויטמין התלוי

RECOMBINANT CO-EXPERSSION OF VITAMIN K EPOXIDE REDUCTASE SUBUNIT 1 TO IMPROVE VITAMIN K DEPENDENT PROTEIN EXPRESSIONBAXTER INTERNATIONAL INC.

28/02/2005

60/657041US

PCT/EP/2006/000734WO/2006/089613

A61K18469730/01/2006

ומלחיו דיקלופניק של להזרק הרכביםהרוקחיים

INJECTABLE PREPARATIONS OF DICLOFENIC AND ITS PHARMACEUTICALLY ACCEPTABLE SALTSTROIKAA PHARMACEUTICALS LTD

01/02/2005

96/MUM/2005IN

PCT/IN/2006/000033WO/2006/095363

A01N18469820/02/2006

COMPOSITION AND METHOD FORהצמח בריאות לשיפור ושיטה תכשירIMPROVING PLANT HEALTHBASF AKTIENGESELLSCHAFT

22/02/2005

60/655208US

PCT/EP/2006/060103WO/2006/089876


C12N18469925/06/1996

TNFל– דומה ליגנד המכיל איחוי חלבוןאפופטיזה המשרה

(TRAILוהכנתו )

A FUSION PROTEIN COMPRISING A TNF RELATED APOPTOSIS INDUCING LIGAND

(TRAIL )PEPTIDE AND ITS PREPARATIONIMMUNEX CORPORATION

29/06/1995

08/496632US

01/11/1995

08/548368US

PCT/US/1996/010895WO/1997/001633

C12M18470026/01/2006

זמין תאי חומר של מיידית לאספקה שיטהשלו ותכשיר מדם הנגזר

METHOD OF PROVIDING READILY AVAILABLE CELLULAR MATERIAL DERIVED FROM CORD BLOOD, AND COMPOSITION THEREOFREGENETECH, INC.

27/01/2005

60/647588US

PCT/US/2006/002961WO/2006/081435

G06K18470220/01/2006

PRODUCT AUTHENTICITYואמינות תוקף בר למוצר מערכתVALIDATION SYSTEMVANJANI, Govind, W.

21/01/2005

11/038046US


PCT/US/2006/002152WO/2006/078965

A61J18470317/01/2006

A DEVICE FOR BABY DISPENSERSלפעוטות יניקה לבקבוק התקןTAMIR SMADARתמיר סמדר

18/01/2005

11/036061US

18/01/2005166368IL

18/04/2005

60/672067US

PCT/IL/2006/000067WO/2006/077580

C07D18470525/01/2006

ושימושן מותמרות ארילמין תרכובות6HT –5 כמוסתי

SUBSTITUTED ARYLAMINE COMPOUNDS AND THEIR USE AS 5-HT6 MODULATORSEPIX DELAWARE, INC.

25/01/2005

60/646957US

22/07/2005

60/701853US

PCT/US/2006/002718WO/2006/081332

G10L18470616/01/2006

באיתות דיגיטלי סימן–מים לשיבוץ שיטהשימושי

METHOD OF EMBEDDING A DIGITAL WATERMARK IN A USEFUL SIGNAL


UNLIMITED MEDIA GMBH21/01/2005

05001222.8EP

PCT/EP/2006/000330WO/2006/077061

G10L18470716/01/2006

איתות בשביל –עקב סימן ליצירת שיטהאודיו

METHOD OF GENERATING A FOOTPRINT FOR AN AUDIO SIGNALUNLIMITED MEDIA GMBH

21/01/2005

05001258.2EP

PCT/EP/2006/000331WO/2006/077062

G07B18470830/09/2005

ציבורי אתר לאבטחת והתקן שיטהחזותי זיהוי ע"י פרטי או

METHOD AND DEVICE FOR PROTECTING A PUBLIC OR PRIVATE SITE BY VISUAL IDENTIFICATIONBERNARD THOORENS

08/02/2005PCT/BE2005/000018BE

PCT/IB/2005/053228WO/2006/051432

C07D18471001/02/2006

1 –H–קרבוקסאמידים2–פירול– ושימושם –קרבוקסאמידים5ואימיידזול–

ו–KDR , FAK הקינאזות של כמודולטוריםTIEבסרטן בטיפול

1-H-PYRROLE-2-CARBOXAMIDES AND IMIDAZOLE-5-CARBOXAMIDES AND USE THEREOF AS FAK, KDR AND TIE2 KINASE MODULATORS FOR THE TREATMENT OF CANCERAVENTIS PHARMA S.A.

03/02/20050501092FR

PCT/FR/2006/000220WO/2006/082309


C07D18471203/02/2006

פירזולו–פירימידין של תולדותmGluR2 של כאנטגוניסטים

PYRAZOLO-PYRIMIDINE DERIVATIVES AS mGluR2 ANTAGONISTSF. HOFFMANN-LA ROCHE AG

11/02/2005

05101027.0EP

PCT/EP/2006/000940WO/2006/084634

A61K18471302/02/2006

של סינרגיסטי שילוב חומר עםE 25קסולייר/אומאליזומאב/

חיסון מדכא

SYNERGISTIC COMBINATION OF XOLAIR/OMALIZUMAB/E25 WITH IMMUNOSUPPRESSIVE AGENTNOVARTIS AG

04/02/2005

0502358.5GB

PCT/EP/2006/000911WO/2006/082052

A61K18471402/02/2006

להכנת מהירה רטובה מעיכה שיטתסידן המכילות תרכובות

FAST WET-MASSING METHOD FOR THE PREPARATION OF CALCIUM-CONTAINING COMPOSITIONSNYCOMED PHARMA AS

03/02/2005PA200500168DK


PCT/IB/2006/000195WO/2006/082501

C07C18471507/02/2006

PROCESS FOR THE PREPARATIONביניים חומרי להכנת תהליךOF INTERMEDIATESSYNGENTA PARTICIPATIONS AG

09/02/2005

60/651175US

PCT/EP/2006/001068WO/2006/084663

C07D18471723/02/2006

( פירידיןA– 2, 1) אימידזו תרכובות2R– VEGF כמעכבי

IMIDAZO (1,2-A)PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORSELI LILLY AND COMPANY

24/02/2005

60/655981US

PCT/US/2006/006283WO/2006/091671

C23C18471823/01/2006

גז לפזת כימית להסתננות שיטה פחמן עם נקבובי מצע של לדנסיפיקציה

פירוליטי

METHOD FOR CHEMICAL INFILTRATION IN THE GAS PHASE FOR THE DENSIFICATION OF POROUS SUBSTRATES WITH PYROLYTIC CARBONSNECMA PROPULSION SOLIDE

24/01/20050500696FR

PCT/FR/2006/050037WO/2006/077353

B65G18471919/01/2006


LOW FRICTION, DIRECT DRIVEנמוך חיכוך עם ישירה בהנעה מסוע חגורתCONVEYOR BELTTHERMODRIVE LLC

19/01/2005

60/593493US

PCT/US/2006/002013WO/2006/078890

C07F18472024/01/2006

BIBANDRONATE POLYMORPH B פולימורפ איבנדרונטF. HOFFMANN-LA ROCHE AG

01/02/2005

05100687.2EP

PCT/EP/2006/000579WO/2006/081962

G01N18472123/01/2006

זרחתית, חומצה לניתוח שיטהזמנית בו שניהם או פוסטיל–אלומיניום

METHOD OF ANALYZING PHOSPHOROUS ACID, FOSETYL-AL OR BOTH SIMULTANEOUSLYBAYER CROPSCIENCE S.A.

25/01/2005

05356015.7EP

11/02/2005

05356031.4EP

16/12/2005

05356216.1EP

PCT/EP/2006/001433WO/2006/079566

C07D18472223/02/2006

הלואלקילסולפונאניליד, של חדשה נגזרתלשימושן ושיטה עשבים קוטל

NOVEL HALOALKYLSULFONANILIDE DERIVATIVE, HERBICIDE, AND METHOD OF USE THEREOFNIHON NOHYAKU CO., LTD.

24/02/2005

2005-049564JP

PCT/JP/2006/303307WO/2006/090792


C12Q18472425/01/2006

גנומי למיון אוליגונוקלאוטידים גלאים אדומים, שיטות דם תאי מערכות של

אליהם הקשורות אבחון וערכות

OLIGONUCLEOTIDE PROBES FOR THE GENOMIC TYPIFYING OF ERYTHROCYTE SYSTEMS, METHODS AND RELATIVE DIAGNOSTIC KITSFONDAZIONE IRCCS OSPEDALE MAGGIORE POLICILINICO MANGIAGALLI E REGINA ELENA

25/01/2005MI2005A000098IT

PCT/IB/2006/000224WO/2006/079925

C07D18472525/01/2006

–הידרוקסי–3 אריל–3חומצה– של אמידים חומצות של –אמינו–פרופיונית, אמידים2–2– הידרוקסי–3–הטרואריל–3

קשורות אמינו–פרופיונית, ותרכובות ו/או אנלגטית פעילות בעלות

אימונוסטימולנטית

3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROAYRYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS HAVING ANALGESIC AND/OR IMMUNOSTIMULANT ACTIVITYALLERGAN, INC.

26/01/2006

60/647271US

PCT/US/2006/002557WO/2006/081273

C02F18472615/12/2005

OZONE INJECTION METHOD ANDאוזון להזרקת ושיטה מערכתSYSTEMNUTECH 03, INC

24/01/2005

11/039819US

15/09/2005

11/226358US


15/09/2005

11/226359US

21/09/2005

11/230571US

11/10/2005

11/246235US

PCT/US/2005/045738WO/2006/086073

A61M18472719/01/2006

A METHOD AND DEVICE FORייחום לזיהוי ושיטה התקןDETECTING ESTRUS

.SCR ENGINEERS LTDבע"מ הנדסה אס.סי.אר19/01/2005166394IL

PCT/IL/2006/000082WO/2006/077589

B24D18472827/01/2006

ABRASIVE ARTICLES ANDלייצורם ושיטות משייפים פריטיםMETHODS FOR MAKING SAMESAINT GOBAIN ABRASIVES, INC.

28/01/2005

60/648168US

PCT/US/2006/002836WO/2006/083688


A61K18473120/01/2006

מוסין של היפרסקרטציה מעכבי MANS פפטיד מבנה על המבוססיםשלהם ושימושים

MUCIN HYPERSECRETION INHIBITORS BASED ON THE STRUCTURE OF MANS AND METHODS OF USEBIOMARCK PHARMACEUTICALS, LTD.

20/01/2005

60/645293US

PCT/US/2006/002032WO/2006/078899

G01T18473227/01/2006

להכנתו ושיטה קרינה גלאי גבישRADIATION DETECTOR CRYSTAL AND METHOD OF FORMATION THEREOFII-VI INCORPORATED

27/01/2005

60/647589US

PCT/US/2006/003152WO/2006/081532

C07K18473317/02/2006

כאנטיגן אנושי ממקור שבטיים חד נוגדנים(PSMA) פרוסטטה לממברנת בררני

HUMAN MONOCLONAL ANTIBODIES TO PROSTATE SPECIFIC MEMBRANE

ANTIGEN (PSMA)MEDAREX, INC.

18/02/2005

60/654125US

26/09/2005

60/720499US

08/12/2005

60/748417US

PCT/US/2006/005852WO/2006/089230


C07K18473414/02/2006

ידי על המתווכות במחלות לטיפול שיטהחיוביים מתאים עורי לימפוציטי אנטיגן

METHODS OF TREATING DISEASES WHICH ARE MEDIATED BY CUTANEOUS LYMPHOCYTE ANTIGEN POSITIVE CELLSZYMOGENETICS INC.

14/02/2005

60/653114US

13/09/2005

60/716762US

13/12/2005

60/749952US

PCT/US/2006/005327WO/2006/088955

A61K18473520/01/2006

PHARMACEUTICAL FORMULATIONSבהם והשימוש רוקחות הרכביAND METHODS OF USEQUAY PHARMACEUTICALS LTD.

21/01/2005

60/645857US

PCT/US/2006/001887WO/2006/078811

A61K18473719/01/2006

ANTHELMINTIC COMPOSITIONתולעים נגד תכשירNORBROOK LABORATORIES LIMITED

21/01/2005

0501220.8GB

PCT/GB/2006/000211WO/2006/077429


H04Q18473809/02/2006

זרימת של בבקרה לתמיכה ומערכת שיטהאלחוטית ברשת נתונים

METHOD AND APPARATUS FOR SUPPORTING DATA FLOW CONTROL IN A WIRELESS MESH NETWORKINTERDIGITAL TECHNOLOGY CORPORATION

24/02/2005

60/656038US

23/09/2005

11/234755US

PCT/US/2006/004400WO/2006/091377

G06F18473924/09/2002

מידע חבילות לעיבוד סיבי רב מנועMULTI-THREADED PACKET PROCESSING ENGINE FOR STATEFUL PACKET PROCESSINGTIDAL NETWORKS, INC.

28/09/2001

60/325638US

17/12/2001

60/341689US

13/06/2002

60/388278US

PCT/US/2002/030421WO/2003/030012


A61K18474019/01/2006

בשתלי שימוש העושות להשתלה שיטותחזירי או הומאני ממקור כבד או כליה

THERAPEUTIC TRANSPLANTATION USING DEVELOPING, HUMAN OR PORCINE, RENAL OR HEPATIC, GRAFTS

YEDA RESEARCH ANDבע"מ ופיתוח למחקר חברה ידעDEVELOPMENT CO. LTD

19/01/2005

11/037025US

PCT/IL/2006/000085WO/2006/077592

G01N18474109/02/2006

של וגיבוש להפקה ושיטות תרכובותמולקולות

COMPOSITIONS AND METHODS FOR PURIFYING AND CRYSTALLIZING MOLECULES OF INTEREST

.AFFISINK BIOTECHNOLOGY LTDבע"מ ביוטכנולוגיה אפיסינק10/02/2005166800IL

12/01/2006

11/330112US

PCT/IL/2006/000173WO/2006/085321

A61N18474322/01/2006

DEVICE AND METHOD FOR SIGNALאות לעיבוד ושיטה התקןPROCESSINGNOVATRAND GROUP SA

21/01/2005

60/645025US

PCT/IL/2006/000090WO/2006/077595


A61K18474404/04/2006

HIVPREVENTION OF HIV-INFECTION זיהום מניעתTIBOTEC PHARMACEUTICALS LTD.

04/04/2005

05102616.9EP

PCT/EP/2006/061303WO/2006/106103

C07D18474527/02/2006

ו –סולפיניל2 מותמרות אימידאזול תולדותציטוקין כמעכבות ושימושן –סולפוניל2

2-SULFINYL-AND 2-SULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORSMERCKLE GMBH

28/02/2005

05004369.4EP

28/02/2005

60/656389US

PCT/EP/2006/001801WO/2006/089798

C07H18474606/02/2006

המשתמשים לקטוז להכנת תהליכים ופורמולציות פרה–סיווגיות בטכניקות

הללו בתהליכים המיוצרות רוקחיות

PROCESSES FOR MAKING LACTOSE UTILIZING PRE-CLASSIFICATION TECHNIQUES AND PHARMACEUTICAL FORMULATIONS FORMED THEREFROMGLAXO GROUP LIMITED

10/02/2005

60/651755US

PCT/US/2006/004032WO/2006/086270

C07K18474927/01/2006

ותכשירי גמא אינטרפרון נגד נוגדניםאותם המכילים רוקחות

ANTI-INTERFERON GAMMA ANTIBODIES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME


NOVIMMUNE S.A.27/01/2005

60/648219US

PCT/IB/2006/001514WO/2006/109191

H04L18475030/12/2005

עצמים של הטמנה לביצוע ושיטות מערכותברשת דינמית המיוצרים

SYSTEMS AND METHODS FOR PERFORMING CACHING OF DYNAMICALLY GENERATED OBJECTS IN A NETWORKCITRIX SYSTEMS, INC.

24/01/2005

11/039946US

29/06/2005

11/169002US

PCT/US/2005/047435WO/2006/081032

C08K18475531/01/2006

FLUOROCARBON-GRAFTEDמורכבי–פולואורוקרבונים פוליסילוקסאניםPOLYSILOXANESE.I. DU PONT DE NEMOURS AND COMPANY

04/02/2005

05290254.1EP

19/05/2005

11/132836US

PCT/US/2006/003330WO/2006/083818


C08G18475702/02/2006

המפגינים הרכבים לעשיית ושיטות הרכביםלדלק עמידות

COMPOSITIONS AND METHODS OF MAKING COMPOSITIONS EXHIBITING FUEL RESISTANCEPRC-DESOTO INTERNATIONAL, INC.

08/02/2005

11/053102US

PCT/US/2006/003725WO/2006/086211

A61K18475810/02/2006

במתן לשימוש חדשים פרמצבטיים הרכביםתרופות של טרנסמוקוזי

NEW PHARMACEUTICAL COMPOSITIONS USEFUL IN THE TRANSMUCOSAL ADMINISTRATION OF DRUGSOREXO AB

10/02/2005

60/651210US

PCT/GB/2006/000481WO/2006/085101

A61K18475923/01/2006

מעכב המכיל הפה דרך למתן רפואי תכשירלהכנתו ושיטה2ציקלואוקסיגנז–

MEDICAMENT THAT IS INTENDED FOR ORAL ADMINISTRATION COMPRISING A CYCLOOXYGENASE-2 INHIBITOR, AND PREPARATION METHOD THEREOFVETOQUINOL

24/01/20050500708FR

PCT/FR/2006/000144


WO/2006/077334

B65D18476020/12/2005

LEAK RESISTANT DRINKING CUPנזילות בפני עמידה שתייה כוסHANDI-CRAFT COMPANY

28/01/2005

11/046288US

PCT/US/2005/046385WO/2006/083420

B01J18476116/12/2005

CHROMATOGRAPHIC MEDIAכרומטוגרפית מדיהMALLINCKRODT BAKER, INC.

25/01/2005

60/646780US

PCT/US/2005/045710WO/2006/081002

G05F18476216/01/2006

DEVICE FOR SMOOTHING A CURRENTלצרכן המסופק זרם להחלקת התקןSUPPLIED TO A CONSUMERROHDE & SCHWARZ GMBH & CO. KG

26/01/2005

102005003686.4DE

PCT/EP/2006/000334WO/2006/079463

C07K18476325/01/2006

אקטיביים פרוטאינים של קונג'וגטים VIVO– IN חיים מחצית עם ביולוגיתמשופרת

CONJUGATES OF BIOLOGICALLY ACTIVE PROTEINS HAVING A MODIFIED IN VIVO HALF-LIFECELL THERAPEUTICS, INC.


25/01/2005

60/647119US

30/08/2005

60/712585US

PCT/US/2006/002501WO/2006/081249

A01N18476426/01/2006

קטופים פירות להגנת ושיטות תכשיריםמריקבון

COMPOSITIONS AND METHODS FOR PROTECTION OF HARVESTED FRUITS FROM DECAY

GAVISH-GALILEE BIOבע"מ יישומים ביו גביש-גלילAPPLICATIONS LTD

26/01/2004

60/646604US

PCT/IL/2006/000111WO/2006/080013

A61M18476524/01/2006

מחט המכיל מראש ממולא מכשירגבוה בלחץ להזרקה

PREFILLED NEEDLE ASSISTED JET INJECTORANTARES PHARMA INC.

24/01/2005

60/645590US

18/08/2005

60/709116US

PCT/US/2006/002429WO/2006/079064


C07K18476625/01/2006

בילתי קשרים לשבירת ודרכים שיטותמולקולות בין קובלנטיים

MEANS AND METHODS FOR BREAKING NONCOVALENT BINDING INTERACTIONS BETWEEN MOLECULESSTICHTING SANQUIN BLOEDVOORZIENING

25/01/2005

05075196.5EP

PCT/NL/2006/000038WO/2006/080837

H04B18476702/02/2006

METHOD FOR TRANSMITTING ANDנתונים של ולקליטה לשידור שיטהRECEIVING DATALG ELECTRONICS INC.

02/02/2005

10-2005-0009670KR

13/06/2005

10-2005-0050368KR

PCT/KR/2006/000374WO/2006/083121

C07D18476826/01/2006

המכילים מבוקר שחרור בעלי תכשיריםפסיכוטי אנטי חומר

CONTROLLED RELEASE COMPOSITIONS COMPRISING AN ANTIPSYCHOTIC AGENTELAN PHARMA INTERNATIONAL LTD.

26/01/2005

60/647311US

PCT/US/2006/002751WO/2006/081347


G01N18476910/02/2006

לקביעת תיאופפטולידים של שימושADAMTS פרוטאזות של הפעילות

USE OF THIOPEPTOLIDES FOR DETERMINING THE ACTIVITY OF ADAMTS PROTEASESSANOFI AVENTIS

11/02/2005

102005005972.4DE

PCT/EP/2006/001184WO/2006/092203

A61B18477024/01/2006

תהודה אנגיוגרפית עבור עורקים חוסםבו לשימוש מגנטית, ושיטה

TOURNIQUET FOR MAGNETIC RESONANCE ANGIOGRAPY, AND METHOD OF USING SAMEMARTIN R. PRINCE

24/01/2005

60/646434US

06/05/2005

60/678410US

13/01/2006

11/331519US

PCT/US/2006/002323WO/2006/081195

C07C18477125/01/2006

בשנים או בהלוגן מותמרות אמינו חומצותתת–הלוגניות חומצות בצירוף החנקן על

N-HALOGENATED AMINO ACIDS AND N, N-DIHALOGENATED AMINO ACIDS IN COMBINATION WITH HYPOHALOUS ACIDSNOVABAY PHARMACEUTICALS, INC.

25/01/2005

60/647366US

PCT/US/2006/002875WO/2006/081392


C07K18477413/02/2006

ספציפי חד–שבטי אנושי נוגדן סירוטיפ שלLPS לליפופוליסכארידיים

IATS 011אירוגינוזה פסיאודומונאד של

HUMAN MONOCLONAL ANTIBODY SPECIFIC FOR LIPOPOLYSACCHARIDES (LPS) OF THE PSEUDOMONAS AERUGINOSA IATS 011 SEROTYPEKENTA BIOTECH AG

14/02/2005

05003095.6EP

PCT/EP/2006/001289WO/2006/084758

A01K18477501/02/2006

TRANSGENIC CHICKENSטרנסגנים עופותORIGEN THERAPEUTICS, INC.

01/02/2005

11/049229US

15/08/2005

11/204879US

PCT/US/2006/003690WO/2006/084035

G01N18477614/02/2006

עור בדלקת טיפולית תגובה לחיזוי שיטותIL– 31 לאנטגוניסטים אטופית

METHODS OF PREDICTING THERPEUTIC RESPONSE IN ATOPIC DERMATITIS TO IL-31 ANTAGONISTSZYMOGENETICS INC.

14/02/2005

60/653114US


13/09/2005

60/716762US

13/12/2005

60/749952US

PCT/US/2006/005328WO/2006/088956

G06K18477801/02/2006

ואימות לרכישה, בדיקה ושיטות מערכתיד בכתב כתובה חתימה של

SYSTEM AND METHODS OF ACQUISITION, ANALYSIS AND AUTHENTICATION OF THE HANDWRITTEN SIGNATURES.C. SOFTWIN SRL

09/02/2005

a2005-00089RO

PCT/RO/2006/000002WO/2006/085783

C07H18477930/01/2006

או חדשה נוקליאוסיד פירימידין תרכובתמזה מלחים

NOVEL PYRIMIDINE NUCLEOSIDE COMPOUND OR SALT THEREOFTAKUMA SASAKI

31/01/2005

2005-023278JP

PCT/JP/2006/301483WO/2006/080509

C11D18478026/01/2006

למוליך מצעי של עיבוד עבור תרכובתלמחצה

COMPOSITIONS FOR PROCESSING OF SEMICONDUCTOR SUBSTRATES


ADVANCED TECHNOLOGY MATERIALS, INC.

27/01/2005

11/046262US

10/11/2005

60/736036US

PCT/US/2006/002902WO/2006/081406

C07D18478101/02/2006

H 1[4, 5–אימידאזו–b–פירידין ]אמין,5– –ציקלוהקסילמת'ילאמינו(–מת'יל(–5–]7

H 1–מת'יל, סולפאט2–איל[–2 –אינדול– ( בהם ושימוש גבישי (, טריהידראט1:1

רוקחות בתכשירי

CRYSTALLINE 1H-IMIDAZO[4,5-b]PYRIDIN-5-AMINE, 7-[5-[(CYCLOHEXYLMETHYLAMINO)-METHYL]-1H-INDOL-2-YL]-2-METHYL, SULFATE (1:1), TRIHYDRATE AND ITS PHARMACEUTICAL USESEISAI CO, LTD.

02/02/2005

60/648701US

PCT/US/2006/003463WO/2006/083908

H04B18478218/01/2006

ליצירת לוויינים בין בחיבור לשימוש לווייניםעקיף קשר נתיבי מזין

SATELLITES USING INTER-SATELLITE LINKS TO CREATE INDIRECT FEEDER LINK PATHSATC TECHNOLOGIES, LLC

22/02/2005

60/655148US

21/12/2005

11/313572US

PCT/US/2006/001701


WO/2006/091294

C07D18478324/02/2006

רוקחות ותכשירי אמינופירידין תולדותאותן המכילים

AMINOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAMEJAPAN TOBACCO INC.

28/02/2005

2005-052469JP

04/03/2005

60/658885US

19/01/2006

2006-011751JP

27/01/2006

60/763045US

PCT/JP/2006/304034WO/2006/093247

A61B18478412/12/2005

להב של אוירודינמי מעטה למדידת מכשיררוטור

ROTOR BLADE CUFF MEASURING TOOLSIKORSKY AIRCRAFT CORPORATION

21/01/2005

11/040461US

PCT/US/2005/044914WO/2007/084101

C07D18478607/02/2006

PPARAMIDE DERIVATIVES AS PPAR של כמפעילות אמיד של נגזרותACTIVATORSF. HOFFMANN-LA ROCHE AG

15/02/2005

05101129.4EP

PCT/EP/2006/001057WO/2007/028424


A61K18478703/02/2006

ORAL DOSAGE FORM COMPRISINGרוסיגליטזון המכילה אוראלי מינון של צורהROSIGLITAZONESB PHARMCO PUERTO RICO INC.

07/02/2005

0502479.9GB

PCT/EP/2006/000999WO/2006/082089

C07D18478825/01/2006

QUINOXALINE DERIVATIVES ASגידול כנוגדי קינוקסלין נגזרותANTITUMOR AGENTSWHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH

25/01/2005

60/647303US

24/01/2006

60/762221US

PCT/US/2006/002717WO/2006/081331

A61K18479003/02/2006

ORAL DOSAGE FORM COMPRISINGרוסיגליטזון המכילה אוראלי מינון של צורהROSIGLITAZONESB PHARMCO PUERTO RICO INC.

07/02/2005

0502475.7GB

PCT/EP/2006/000997WO/2006/087116

C12N18479527/07/1999


מוצמד קולטן המקדדות גרעיניות חומצותחושית בטרנסדוקציה המעורבGלחלבון–

NUCLEIC ACIDS ENCODING A G-PROTEIN COUPLED RECEPTOR INVOLVED IN SENSORY TRANSDUCTIONTHE REGENTS OF THE UNIVERSITY OF CALIFORNIA

28/07/1998

60/095464US

17/12/1998

60/112747US

PCT/US/1999/017104WO/2000/006593

H03K18479621/03/2006

INTEGRATED SMART POWERמשולב חכם כוח מתגSWITCHRAYTHEON COMPANY

01/04/2005

11/098033US

PCT/US/2006/010114WO/2006/107579

A47J18479726/01/2006

BREWING ELEMENT WITH Aמרכזי כניסה פתח עם חילוט גוףCENTRAL INLET

.CONCEPT & DESIGN LTDבע"מ ותכן רעיון26/01/2005

60/647378US

PCT/IL/2006/000114WO/2006/080016

C07D18479824/02/2006

QUINAZOLINE DERIVATIVES ASקינאז טירוזין כמעכבי קווינאזולין נגזרותTYROSINE KINASE INHIBITORSASTRAZENECA AB

26/02/2005

0504018.3GB

31/03/2005

0506657.6GB


25/11/2005

0524001.5GB

PCT/GB/2006/000656WO/2006/090163

C07C18479908/02/2006

טרנסטירטין של סיבים היווצרות מעכביעמילן המכילים

INHIBITORS OF TRANSTHYRETIN AMYLOID FIBRIL FORMATIONTHE SCRIPPS RESEARCH INSTITUTE

08/02/2005

60/651306US

PCT/US/2006/004512WO/2006/086517

C07D18480002/02/2006

METHOD FOR THE PRODUCTION OFלוסארטאן ליצור שיטהLOSARTANRATIOPHARM GMBH

03/02/2005

102005005047.6DE

PCT/DE/2006/000164WO/2006/081807

H01Q18480126/01/2006

FRACTAL DIPOLE ANTENNAפרקטאליים מדיפולים אנטנה.ELTA SYSTEMS LTDבע"מ מערכות אלתא

01/02/2005

11/046891US

PCT/IL/2006/000107WO/2006/082577

A61K18480215/02/2006


פומי למתן מוסגל חי רוטאווירוס של חיסוןLIVE ATTENUATED ROTAVIRUS VACCINE FOR ORAL ADMINISTRATIONGLAXOSMITHKLINE BIOLOGICALS S.A.

17/02/2005

0503337.8GB

PCT/EP/2006/001442WO/2006/087205

C07K18480306/02/2006

ושיטותEPHA 2ל– הנקשרים נוגדניםבהם לשימוש

ANTIBODIES THAT BIND TO EPHA2 AND METHODS OF USE THEREOFRAVEN BIOTECHNOLOGIES, INC.

04/02/2005

60/650047US

PCT/US/2006/004057WO/2006/084226

C07K18480417/02/2005

בעלי דפרס קבועי פפטידים מחקיHAIRPINפרוטאז מעכבת פעולה – ? עם

TEMPLATE-FIXED BETA-HAIRPIN PEPTIDOMIMETICS WITH PROTEASE INHIBITORY ACTIVITYUNIVERSITAT ZURICH

PCT/EP/2005/001622WO/2006/087001


C07D18480514/02/2006

–7–אלקיל–6–אלקוקסיאלקיל–5 ליצורם, אמינו–אזולופירידינים, שיטה

פטריות על לבקרה בהם שימושאלו חומרים המכילים וגורמים פתוגניות

5-ALKOXYALKYL-6-ALKYL-7-AMINO-AZOLOPYRIMIDINES, METHOD FOR THEIR PRODUCTION, THEIR USE FOR CONTROLLING PATHOGENIC FUNGI AND AGENTS CONTAINING SAID SUBSTANCESBASF AKTIENGESELLSCHAFT

16/02/2005

102005007157.0DE

PCT/EP/2006/050922WO/2006/087325

C07D18480615/02/2006

חומצה פיראזול של אנילידים וגורמים ליצורם קרבוקסילית, שיטה

פטריות של לבקרה אותם המכיליםפתוגניות

PYRAZOLE CARBOXYLIC ACID ANILIDES, METHOD FOR THE PRODUCTION THEREOF AND AGENTS CONTAINING THEM FOR CONTROLLING PATHOGENIC FUNGIBASF AKTIENGESELLSCHAFT

16/02/2005

102005007160.0DE

PCT/EP/2006/050962WO/2006/087343

F41A18480704/02/2005

CARTRIDGE COUNTERלמחסנית מונהRAUL DELGADO ACARRETA

PCT/ES/2005/070012WO/2006/084928


C07K18480809/02/2006

אינטרפרון נוגדי חד–שבטיים אלפא נוגדניםבהם לשימוש ושיטות

ANTI-INTERFERON ALPHA MONOCLONAL ANTBODIES AND METHODS FOR USEBAYLOR RESEARCH INSTITUTE

10/02/2005

60/652233US

PCT/US/2006/004643WO/2006/086586

A61K18480904/07/2005

של מיקרוקפסולות המכילות פורמולציותחיוניים שמנים

FORMULATIONS CONTAINING MICROENCAPSULATED ESSENTIAL OILS

.BOTANOCAP LTDבע"מ בוטנו-קאפ24/01/2005

11/040102US

PCT/IL/2005/000705WO/2006/077568

A61B18481308/02/2006

SPINAL FIXING DEVICEהשדרה עמוד לקיבוע מכשירKLOSS, HENNING

08/02/2005

102005005647.4DE

16/03/200560/661927US

PCT/DE/2006/000211WO/2006/084443

A61B18481408/02/2006


DEVICE FOR FORCING APART SPINOUSפרוסס ספינוס להפרדת מכשירPROCESSESKLOSS, HENNING

08/02/2005

102005005694.6DE

16/03/200560/661926US

PCT/DE/2006/000212WO/2006/084444

C07D18481625/01/2006

לרצפטורי כאנטגוניסטים אינדולים פניל22D פרוסטאגלנדין

2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTSAVENTIS PHARMACEUTICALS INC.

26/01/2005

60/647307US

PCT/US/2006/002736WO/2006/081343

B01J18481826/07/2005

DEVICE FOR STUDYINGכבודדים תאים לחקר מכשירINDIVIDUAL CELLSSENG ENTERPRISES LTD.

25/01/2005

60/646512US

PCT/IL/2005/000801WO/2006/080000

A61B18481927/01/2006

עצם של בתיקון לשימוש אורטופדי משטחקטנה

ORTHOPEDIC PLATE FOR USE IN SMALL BONE REPAIRORTHOHELIX SURGICAL DESIGNS, INC.

28/01/2005

60/648364US

26/01/2006

11/340028US


PCT/US/2006/002933WO/2006/081422

H04L18482024/01/2006

נתונים זרמי עבור וניקוב ניתוח תוכניתתקשורת במערכות מרובים

PARSER AND PUNCTURING FOR MULTIPLE DATA STREAMS IN A COMMUNICATION SYSTEMQUALCOMM INCORPORATED

24/01/2005

11/042921US

PCT/US/2006/002498WO/2006/079081

C07D18482124/01/2006

2 אמינו–4ב– המשתמשים והרכבים שיטות –איל(3–דיאוקסופיפרידין–6, 2–מתיל–3)

–דיון3–1איזואינדול–

METHODS AND COMPOSITIONS USING 4-AMINO-2-(3-METHYL-2,6-DIOXOPIPERIDIN-3-YL)-ISOINDOLE-1-3-DIONECELGENE CORPORATION

25/01/2005

60/646505US

PCT/US/2006/002503WO/2006/081251

A61K18482212/08/2005

EXTENDED RELEASE FORMULATIONלוטירסטם של ממושך שחרור פורמולציתOF LEVETIRACETAMALEMBIC LIMITED

27/01/2005

81/MUM/2005IN

PCT/IN/2005/000275WO/2006/080029

G06F18482431/01/2006

INFUSION DELIVERY SYSTEMאינפוזיה להעברת מערכתBAXTER INTERNATIONAL INC.


01/02/2005

60/649396US

PCT/US/2006/003499WO/2006/083933

C07D18482503/02/2006

– )1 המכילות מיימיות ג'ליות פורמולציות –H 1–מתילפרופיל(–2

[C[ ]1, 5–3, 4אימידאזו]אימידאזו]–אמין4נאפטירידין–

AQUEOUS GEL FORMULATIONS CONTAINING 1-(2-METHYLPROPYL)-1H-IMIDAZO [4,5-C][1,5] NAPTHYRIDIN-4-AMINETAKEDA PHARMACEUTICAL COMPANY LIMITED

04/02/2005

60/649932US

12/07/2005

60/698416US

PCT/US/2006/003745WO/2006/084073

C08K18482607/02/2006

ACCELERATED UV CURINGמואץ אולטרה–סגולי שימורAIR PRODUCTS AND CHEMICALS, INC.

09/02/2005

102005005976.7DE

PCT/EP/2006/050730WO/2006/084848

G01C18482813/02/2006

התמדית תנועה לקבלת מערכת חופש דרגות שש עם צירים יחידת/רבת

אוריינטציה לקביעת יכולת בעלתהתחלתית

SINGLE/MULTIPLE AXES SIX DEGREES OF FREEDOM (6 DOF) INERTIAL MOTION CAPTURE SYSTEM WITH INITIAL ORIENTATION DETERMINATION CAPABILITYMAGNETO INERTIAL SENSING TECHNOLOGY, INC.

15/02/2005

11/059163US

PCT/US/2006/005165WO/2006/088863


H04Q18483016/02/2006

בין נייד רב–מצבי מסוף בהעברת תמיכההטרוגניות רשתות

SUPPORTING HANDOVER OF MULTI-MODE MOBILE TERMINAL BETWEEN HETEROGENEOUS NETWORKSLG ELECTRONICS INC.

18/02/2005

10-2005-0013491KR

13/04/2005

10-2005-0030725KR

PCT/KR/2006/000536WO/2006/088318

H04Q18483117/02/2006

במערכת נייד מסוף של רשת כתובת כינוןניידת תיקשורת

ESTABLISHING NETWORK ADDRESS OF MOBILE TERMINAL IN MOBILE COMMUNICATION SYSTEMLG ELECTRONICS INC.

18/02/2005

10-2005-0013707KR

29/04/2005

10-2005-0036428KR

PCT/KR/2006/000547WO/2006/088327

H04Q18483217/02/2006

העברה לאחר קישור לשיחרור שיטהעבורה ומסוף נייד רב–מצבי המסוף

METHOD OF RELEASING LINK CONNECTION AFTER HANDOVER IN MULTI-MODE TERMINAL AND TERMINAL THEREOFLG ELECTRONICS INC.


18/02/2005

10-2005-0013493KR

PCT/KR/2006/000555WO/2006/088331

A61B18483330/09/1998

גוף, לתוך סיב להכנסת ושיטה התקןצינורית ביחידה שימוש ידי על במיוחד

DEVICE AND METHOD FOR DELIVERING FIBER INTO A BODY, PARTICULARLY BY USING A TUBULAR MEMBERBOSTON SCIENTIFIC LIMITED

02/10/1997

60/060842US

PCT/US/1998/020371WO/1999/017663

B32B18483425/01/2006

COMPOSITIONS AND METHODS FORלהכנתם ושיטות מורכביםTHE MANUFACTURE THEREOFSOUTHERN RESEARCH INSTITUTE

26/01/2005

60/647079US

PCT/US/2006/002336WO/2006/081203

B65D18483526/01/2006

נפץ חומרי של ההשפעה להפחתת מיכליםמקיפים והתקנים

EXPLOSIVE EFFECT MITIGATED CONTAINERS AND ENCLOSING DEVICESBLASTGARD INTERNATIONAL

26/01/2005

11/042318US


PCT/US/2006/002695WO/2006/081319

C07C18483623/02/2006

PROCESSES FOR PREPARINGסרטרלין להכנת תהליכיםSERTRALINEREGENT DRUGS LIMITED

23/02/200560/656134US

01/08/200560/704730US

25/01/2006

220/DEL/2006IN

25/01/2006

221/DEL/2006IN

30/01/200660/763530US

30/01/200660/763531US

14/02/200660/773567US

14/02/200660/773394US

PCT/US/2006/006416WO/2006/091732

C07H18483827/01/2006

כתרופה בו ושימוש ספירוקטל של נגזרלסוכרת

SPIROKETAL DERIVATIVE AND USE THEREOF AS DIABETIC MEDICINECHUGAI SEIYAKU KABUSHIKI KAISHA

28/01/2005

2005-020901JP


16/06/2005

2005-176690JP

PCT/JP/2006/301284WO/2006/080421

G05F18483917/01/2006

FILTER CIRCUITסינון מעגלROHDE & SCHWARZ GMBH & CO. KG

31/01/2005

102005004391.7DE

PCT/EP/2006/000373WO/2006/081939

C07D18484122/02/2006

מותמר אמינואלקיל של נזגזרותואמידואלקיל–בנזופירן

SUBSTITUTED AMINOALKYL-AND AMIDOALKYL-BENZOPYRAN DERIVATIVESNEWRON PHARMACEUTICALS S.P.A.

29/03/2005

05006752.9EP

PCT/EP/2006/001572WO/2006/102958

C07D18484214/03/2006

של כמעכבות –פירידין2 של נגזרותאלסטז ניוטרופיל

2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASEASTRAZENECA AB

16/03/2005

0500604-4SE

PCT/SE/2006/000328WO/2006/098684

C12Q18484327/02/2006


אנושי לאוטיזם לרגישות הקשורים גנים טרנספורטר נוירוטרנסמיטר מקודדים

ושימושיהם

HUMAN AUTISM SUSCEPTIBILITY GENES ENCODING A NEUROTRANSMITTER TRANSPORTER AND USES THEREOFINTEGRAGEN

28/02/2005

60/656374US

PCT/IB/2006/001100WO/2006/090288

C07K18484527/02/2006

של רקומביננטים כימרים אנטיגניםגונדיי טוקסופלסמה

CHIMERIC RECOMBINANT ANTIGENS OF TOXOPLASMA GONDIIKENTON SRL

08/03/2005

05005065.7EP

PCT/EP/2006/001760WO/2006/094665

B01L18484608/02/2006

מכשיר עיבוד בשביל ניתוח כלימיקרופלואידי

ANALYSIS INSTRUMENT FOR PROCESSING A MICROFLUIDIC DEVICELAB901 LIMITED

08/02/2005

0502556.4GB

PCT/GB/2006/000444WO/2006/085071

A61K18484727/02/2006

של נגזרת המכיל רוקחות תכשיראינדולילמלאימיד

PHARMACEUTICAL COMPOSITION COMPRISING AN INDOLYLMALEIMIDE DERIVATIVENOVARTIS AG

01/03/2005

0504203.1GB

PCT/EP/2006/001767


WO/2006/092255

C07J18484828/07/2003

של ידוע אסטר של פולימורפיזם ( פננתרנילA) דודקהידרוציקלופנטה

תיאופנקרבוקסילית וחומצה

POLYMORPHIS OF A KNOWN THIOPHENECARBOXYLIC ACID DODECAHYDROCYCLOPENTA (A) PHENANTHRENYL ESTERNOVARTIS AG

29/07/2002

0217504.0GB

PCT/EP/2003/008314WO/2004/013156

C07D18484927/01/2006

לטיפול השימושיות אורגניות תרכובות ושיטה שימושן האלצהיימר במחלתלהכנתן

ORGANIC COMPOUNDS USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE, THEIR USE AND METHOD OF PREPARATIONALMA MATER STUDIORUM-UNIVERSITA' DI BOLOGNA

27/01/2005

60/647498US

PCT/IT/2006/000049WO/2006/080043

H01S18485003/03/2005

עיצוב ידי על זיכרון כרטיסי לייצור שיטהבהזרקה

METHOD OF MAKING A MEMORY CARD BY INJECTION MOLDINGCARDXX, INC.

27/01/2005

11/044329US

PCT/US/2005/006948WO/2006/080929


C07C18485124/02/2006

PROCESS OF PRODUCING OLEFINSאולפינים לייצור תהליךMITSUI CHEMICALS, INC.

03/03/2005

2005-058731JP

14/04/2005

2005-117289JP

PCT/JP/2006/303493WO/2006/093058

C08G18485210/02/2006

נתולי פוליאורתאן של מימיים תרחיפיםמהם העשויים ממס, וחפצים

SOLVENT FREE AQUEOUS POLYURETHANE DISPERSIONS AND SHAPED ARTICLES THEREFROMINVISTA TECHNOLOGIES S.A.R.L.

11/02/2005

11/056067US

19/10/2005

11/253927US

13/12/2005

11/300229US

PCT/US/2006/004894WO/2006/086715

H04L18485327/01/2006

בהעברת מלאה לשליטה והתקן שיטה דיבור של סלולריות במערכות משאבים

לחיצה באמצעות

METHOD AND APPARATUS FOR IMPLICIT FLOOR CONTROL IN PUSH-TO-TALK OVER CELLULAR SYSTEMSQUALCOMM INCORPORATED

28/01/2005

60/648341US


26/01/2006

11/341962US

PCT/US/2006/003205WO/2006/081552

C22C18485404/10/2001

יישון ושיטת אלומיניום סגסוגת מוצרימלאכותית

ALUMINUM ALLOY PRODUCTS AND ARTIFICIAL AGING METHODALCOA INC.

21/12/2000

60/257226US

31/01/2001

09/773270US

PCT/US/2001/030895WO/2002/052053

H01L18485520/01/2006

שימוש ע"י קריטיות מידות להקטנת שיטהמרובים מיסוך בצעדי

METHOD FOR REDUCING CRITICAL DIMENSIONS USING MULTIPLE MASKING STEPSLAM RESEARCH CORPORATION

03/02/2005

11/050985US

PCT/US/2006/002164WO/2006/083592

B27L18485611/11/2005

PROCESS FOR THE MANUFACTURE OFליבוד לייצור תהליךA VENEERHD WOOD TECHNOLOGIES LIMITED


27/01/2005

102005005339.4DE

PCT/EP/2005/012118WO/2006/079374

F42B18485707/07/2003

A METHOD FOR ATTACKING Aמטרה לתקיפת שיטהTARGETRAYTHEON COMPANY

29/08/2002

60/406828US

21/11/2002

10/301302US

PCT/US/2003/021319WO/2004/097330

A61K18485827/01/2006

ALCOHOL RESISTANT DOSAGE FORMSאלכוהול בפני עמידות מינון צורותEURO-CELTIQUE S.A

28/01/20050501638.1GB

11/02/2005PCT/GB2005/050014GB

12/04/200560/670506US

26/10/200560/730339US

PCT/EP/2006/000727WO/2005/079550

C07D18486226/01/2006

-ANTHELMINTIC IMIDAZOLתולעים נוגדות אימידאזול–תיאזול תולדותTHIAZOLE DERIVATESJANSSEN PHARMACEUTICA N.V.

28/01/2005

05100580.9EP

PCT/EP/2006/050460WO/2006/079642


A61K18486323/01/2006

אלקילגלוטאמינים קופיליהידרוקסי קבוצות עם לפעולה המוכנסים

למשל ושימושיהם הידרופוביותברפואה

COPOLYHYDROXYALKYLGLUTAMINES WHICH ARE FUNCTIONALISED WITH HYDROPHOBIC GROUPS AND APPLICATIONS THEREOF, SUCH AS IN THERAPEUTICSFLAMEL TECHNOLOGIES

27/01/20050550231FRPCT/EP/2006/050369WO/2006/079614

G10L18486431/01/2006

במערכת מוסתרות מסגרות ליצור שיטהתקשורת

METHOD FOR GENERATING CONCEALMENT FRAMES IN COMMUNICATION SYSTEMSONORIT APS

31/01/2005PA200500146DK

PCT/DK/2006/000053WO/2006/079348

A61K18486527/01/2006

METHODS FOR TREATING RENALבכליות ממאירים בגידולים לטיפול שיטותCELL CARCINOMANOVARTIS VACCINES & DIAGNOSTICS, INC.


27/01/2005

60/647496US

PCT/US/2006/003116WO/2008/081510

C11D18486627/01/2006

TREATMENT OF METASTASIZEDגרורתיים בגידולים טיפולTUMORSNOVARTIS VACCINES & DIAGNOSTICS, INC.

27/01/2005

60/647568US

06/04/2005

60/669245US

29/09/2005

60/722053US

PCT/US/2006/002979WO/2006/081445

E01F18486719/05/2005

איזור סוף ו/או להתחלה מנחה אלמנט המסופק הגנה הגנה, התקן התקן של חלקים של וקיט המנחה האלמנט עם

ההגנה התקן עבור

GUIDING ELEMENT FOR THE BEGINNING AND/OR END AREA OF A PROTECTIVE DEVICE, A PROTECTIVE DEVICE PROVIDED WITH SAID GUID ELEMENT AND KIT OF PARTS FOR THE PROTECTIVE DEVICEOUTIMEX BAUTECHNIK GMBH

01/02/2005

202005001801.5DE

PCT/DE/2005/000961WO/2006/081783


A61B18486926/01/2006

DEVICE FOR TREATING SKINבעור לטיפול התקןSYNERON MEDICAL LTDבע"מ מדיקל סינרון

28/01/2005

11/044610US

PCT/IL/2006/000106WO/2006/080012

A61C18487001/02/2006

לישום והתקן דנטליים שתלים ליצור שיטההשיטה

METHOD FOR PRODUCING A DENTAL PROSTHESIS AND A DEVICE FOR CARRYING OUT SAID METHODDE MOYER, PHILIPPE, ALBERT, PAUL, GHISLAIN

03/02/2005

2005/0061BE

PCT/EP/2006/050584WO/2006/082198

C07D18487215/02/2006

המכילים רוקחות פיראזול, תכשירי נגזרות לטיפול תרופות ליצור בהם ושימוש אותם

סרטן של ולמניעה

PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE THEREOF IN THE MANUFACTURE OF MEDICAMENTS FOR TREATMENT AND PREVENTION OF CANCERS


ASTRAZENECA AB16/02/2005

60/653330US

03/11/2005

60/732965US

PCT/GB/2006/000522WO/2006/087538

C12Q18487316/02/2006

CHK1 למעכבי תגובתיות לקביעת שיטהMETHOD FOR DETERMINING RESPONSIVENESS TO CHK1 INHIBITORSASTRAZENECA AB

18/02/2005

60/654131US

PCT/GB/2006/000548WO/2006/087557

C07C18487422/02/2006

PROCESS FOR PREPARINGמוגנים אמידינים להכנת תהליךPROTECTED AMIDINESASTRAZENECA AB

23/02/2005

0503672.8GB

PCT/GB/2006/000635WO/2006/090153

A61M18487523/01/2006

MEDICATION DELIVERY DEVICEתרופה למתן התקןARES TRADING S.A.

14/02/2005

05003110.3EP

PCT/IB/2006/000262WO/2006/085204

H01J18487620/02/2006


הכוללת גבוה בלחץ פריקה מנורתגטר התקן

HIGH PRESSURE DISCHARGE LAMP CONTAINING A GETTER DEVICESAES GETTERS S.P.A.

23/02/2005MI2005A000281IT

PCT/IT/2006/000088WO/2006/090423

H05H18487706/02/2006

ATMOSPHERIC-PRESSURE PLASMAאטמוספרי בלחץ פלזמה סילוןJETVLAAMSE INSTELLING VOOR TECHNOLOGISCH ONDERZOEK N.V. (VITO)

04/02/2005

05447017.4EP

PCT/BE/2006/000008WO/2006/081637

A61M18487827/01/2006

MEDICATION DELIVERY DEVICEתרופה למתן התקןARES TRADING S.A.

14/02/2005

05003110.3EP

13/01/2006

06000693.9EP

PCT/IB/2006/000135WO/2006/085175

A61B18487906/01/2006

ELECTROLYSIS HAIR-REMOVALשיער להסרת חשמלית הפרדה מכשירDEVICEFACO S.A.

31/01/2005

05447012.5EP

PCT/BE/2006/000001WO/2006/079187


G06F18488106/04/2006

קבצים של ביטחון לאימות ושיטות מערכותברי–ביצוע

SYSTEMS AND METHODS FOR VERIFYING TRUST OF EXECUTABLE FILESMICROSOFT CORPORATION

07/04/2005

11/100770US

PCT/US/2006/013006WO/2006/110521

G01N18488227/01/2006

המייעד גורם של היעילות לאיפיון שיטהפיברוסיס סיסטיק של ראשוני פגם

A METHOD FOR CHARACTERIZING THE EFFICACY OF AN AGENT TARGETING A PRIMARY CYSTIC FIBROSIS DEFECTCHIRON CORPORATION

27/01/2005

60/647477US

PCT/US/2006/002949WO/2006/081429

A61K18488421/02/2006

או המחלה להתקדמות זמן הארכתסרטן חולי של הישרדות

EXTENDING TIME OR DISEASE PROGRESSION OR SURVIVAL IN CANCER PATIENTSGENENTECH, INC.

23/02/2005

60/655277US

PCT/US/2006/006334WO/2006/091693


C07D18488526/01/2006

–4–דיכלורו–6 , 2–)2–]4–}7–9,3מתילפנוקסי(אתוקסי[פניל{–

–און–6[נון–31.3.3דיאזאביציקלו]Sקרבוקסילית –חומצה

בנזיד –דימתיל3,2ציקלופרופיל–) ביתר לטיפול רנין של כמעכבים אמידדם לחץ

7{-4[-2(-2,6-DIHYDRO-4-METHYLPHENOXY)ETHOXYL]PHENYL-}

3,9-DIAZABICYCLO[3.3.31]NON-6-ENE-S-CARBOXYLIC ACID CYCLOPROPYL-(2,3-DIMETHYLBENZYD AMIDE AS INHIBITORS OF RENIN FOR THE TREATMENT OF HYPERTENSIONACTELION PHARMACEUTICALS LTD.

28/01/2005PCT/EP2005/00842EP

PCT/IB/2006/050285WO/2006/079988

A47K18488609/02/2006

COMBINATION WIPE ANDומגבון מיכל של צירוףCONTAINERTHE PROCTER & GAMBLE COMPANY

18/02/2005

11/061269US

PCT/US/2006/004570WO/2006/091386

H04Q18488725/01/2006

ברשתות רדיו חיבורי לייעול שיטהניידות טלקומוניקציה

METHOD OPTIMISING RADIO CONNECTIONS IN MOBILE TELECOMMUNICATIONS NETWORKSHUTCHISON WHAMPOA THREE G IP (BAHAMAS) LIMITED

27/01/2005

0501754.6GB

PCT/GB/2006/000248


WO/2006/079802

C12N18489027/01/2006

מרקמה המופק מבוגר סטרומה תא ותכשירים להפקתו אדיפוסית, שיטות

אותו המכילים

ADIPOSE-DERIVED ADULT STROMAL CELL, METHODS FOR GENERATING THE SAME AND COMPOSITIONS CONTAINING THE SAMECOGNATE THERAPEUTICS, INC.

31/01/2005

60/648630US

PCT/US/2006/004710WO/2006/084284

C07D18489430/01/2006

של מטבוליטים המכילים רוקחות תכשירי קבוצת של התמרה עם נביוולול

הידרוקסיל

PHARMACEUTICAL COMPOSITIONS CONTAINING HYDROXYL SUBSTITUTED NEBIVOLOL METABOLITESMYLAN LABORATORIES, INC.

31/01/2005

60/648551US

03/01/2006

60/755856US

PCT/US/2006/003252WO/2006/083779

C07H18489530/01/2006

של מטבוליטים המכילים רוקחות תכשיריגלוקורוניד של התמרה עם נביוולול

PHARMACEUTICAL COMPOSITIONS CONTAINING GLUCURONIDATED NEBIVOLOL METABOLITESMYLAN LABORATORIES, INC.


31/01/2005

60/648552US

30/01/2006

60/755755US

PCT/US/2006/003253WO/2006/083780

A61K18489631/01/2006

והפקת דגרניולציה ,תגובת לבקרת גורםציטוקין

AGENT FOR CONTROL OF DEGRANULATION REACTION AND CYTOKINE PRODUCTIONRIKEN

31/01/2005

2005-023196JP

PCT/JP/2006/301932WO/2006/080581

C07D18489802/02/2006

רוקחות ותכשירי פירולופירימידין תולדותאותן המכילים

PYRROLOPYRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAMEVERTEX PHARMACEUTICALS INCORPORATED

03/02/2005

60/649781US

PCT/US/2006/004019WO/2006/096270

A61B18489930/01/2006


הפרעות לביטול ומערכת שיטה רפואית, בזמן בתמונה אלקטרומגנטיות

אמת

METHOD AND SYSTEM FOR ELIMINATING ELECTROMAGNETIC INTERFERENCE IN A MEDICAL IMAGE, IN REAL-TIME

.MEDIGUIDE LTDבע"מ מדיגייד31/01/2005

60/648975US

PCT/IL/2006/000119WO/2006/080020

C07D18490024/02/2006

ותרכובות הידרזינומתיל, הידרזונומתיל הפועלים –איברים5 בעלות הטרוציקליות

כגורמים בהם והשימושMTOR כמעכביאנטי–סרטניים

HYDRAZINOMETHYL, HYDRAZONOMETHYL AND 5-MEMBERED HETEROCYLIC COMPOUNDS WHICH ACT AS MTOR INHIBITORS AND THEIR USE AS ANTI CANCER AGENTSKUDOS PHARMACEUTICALS LIMITED

25/02/2005

0503962.3GB

25/02/2005

60/656193US

PCT/GB/2006/000668WO/2006/090167

C07D18490124/02/2006

–דיאמינו–פירידופירימידין4,2 נגזרותMTOR כמעכבי בהן והשימוש

2,4-DLAMINO-PYRIDOPYRIMIDINE DERIVATIVES AND THEIR USE AS MTOR INHIBITORSKUDOS PHARMACEUTICALS LIMITED


25/02/2005

0503961.5GB

25/02/2005

60/656178US

05/12/2005

60/742403US

PCT/GB/2006/000671WO/2006/090169

G06T18490415/02/2006

METHOD AND APPARATUS FORרקמות להדמיית והתקן שיטהIMAGING TISSUES

3DV SYSTEMS LTDבע"מ די.וי. מערכות317/02/2005

60/653503US

PCT/IL/2006/000196WO/2006/087710

G01N18490531/01/2006

METHOD FOR DIAGNOSINGנפוצה טרשת לאבחון שיטהMULTIPLE SCLEROSIS

.GLYCOMINDS LTDבע"מ גליקומיינדס31/01/2005

11/047124US

PCT/IB/2006/001656WO/2006/117689

A61B18490626/01/2006

NAIL PLATE SYSTEMפלטה מקבעת מערכתDEPUY PRODUCTS INC

28/01/2005

60/648989US

PCT/US/2006/003065


WO/2006/081483

A61K18490730/01/2006

IMMUNOLOGICALLY ACTIVEחיסונית פעילים תכשיריםCOMPOSITIONSSUSAN SZATHMARY

28/01/2005

60/648165US

PCT/US/2006/003349WO/2006/081576

A01N18491002/02/2006

BIOSTATIC POLYMERIC FORMEDביוסטטיים מפולימרים המיוצרים פריטיםARTICLESNOVAPHARM RESEARCH (AUSTRALIA) PTY LTD.

02/02/2005

2005900444AU

PCT/AU/2006/000131WO/2006/081618

A01N18491102/02/2006

BIOSTATIC POLYMERביוסטטי פולימרNOVAPHARM RESEARCH (AUSTRALIA) PTY LTD.

02/02/2005

2005900444AU

PCT/AU/2006/000130WO/2006/081617

A62C18491401/02/2006


FIRE EXTINGUISHING AND OIL ANDונפט גז בארות ולשיקום אש לכיבוי מערכתGAS WELL RECOVEREY SYSTEMCENTRO DE DISENO INDUSTRIAL JOVEN, S.L.

02/02/2005P200500185ES

PCT/ES/2006/000041WO/2006/082269

G10L18491524/01/2006

METHOD AND APPARATUS FORקולית הודעה לעריכת ומערכת שיטהVOICE MESSAGE EDITINGIBM CORPORATION

16/02/2005

0503162.0GB

PCT/EP/2006/050403WO/2006/087256

A61L18491627/01/2006

A PROSTHESIS AND METHOD OFליצורו ושיטה תותבMANUFACTURING A PROSTHESISSMART IMPLANT PLC

29/01/2005

2004/8765ZA

29/01/2005

2004/10188ZA


20/04/2005

2005/3184ZA

27/05/2005

2005/04333ZA

22/08/2005

2005/06704ZA

14/09/2005

2005/07390ZA

21/10/2005

2005/08552ZA

17/11/2005

2005/09314ZA

PCT/IB/2006/000139WO/2006/079905

A61L18491727/01/2006

A PROSTHESIS AND METHOD OFליצורו ושיטה תותבMANUFACTURING A PROSTHESISSMART IMPLANT PLC

29/01/2005

2004/8765ZA

29/01/2005

2004/10188ZA

20/04/2005

2005/3184ZA

27/05/2005

2005/04333ZA

22/08/2005

2005/06704ZA

14/09/2005

2005/07390ZA

21/10/2005

2005/08552ZA

17/11/2005

2005/09314ZA

PCT/IB/2006/000142WO/2006/079908


C12Q18492009/12/2005

לדלקת מולקולריים מאבחנים סימנים זיהויבדם בלימפוציטים הרחם רירית

IDENTIFICATION OF MOLECULAR DIAGNOSTIC MARKERS FOR ENDOMETRIOSIS IN BLOOD LYMPHOCYTESTHE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES

18/02/2005

60/654331US

PCT/US/2005/044723WO/2006/091254

A61F18492131/01/2006

בין יעיל פעולה לשיתוף תקשורת קביעתחד–פעמיים לניירות סופג גורם

PROVIDING AND COMMUNICATING SYNERGIES BETWEEN ABSORBENT ARTICLES AND DISPOSABLE WIPESTHE PROCTER & GAMBLE COMPANY

25/02/2005

11/066643US

PCT/US/2006/003486WO/2006/093610

C07C18492209/02/2006

ממימן דספלוראן של הפרדה/טיהורפלוריד

SEPARATION/PURIFICATION OF DESFLURANE FROM HYDROGEN FLUORIDE


HALOCARBON PRODUCTS CORPORATION

15/02/2005

60/653146US

PCT/US/2006/004829WO/2006/121479

G02B18492410/01/2006

OPTICAL FIBRE CLEAVING DEVICEאופטי סיב לפיצול מכשירTYCO ELECTRONICS RAYCHEM N.V.

02/02/2005

0502091.2GB

PCT/GB/2006/000090WO/2006/082355

C07D18492618/01/2006

גרעין: מבוססי מבנים עם דיקטו חומצות HIVל– המכוונותHIV שכפול מעכבות

אינטגרסHIVל– המכוונות

DIKETO ACIDS WITH NUCLEOBASE SCAFFOLDS: ANTI-HIV REPLICATION INHIBITORS TARGETED AT HIV INTEGRASETHE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC.

31/01/2005

11/047229US

PCT/US/2006/001692WO/2006/083553

G10L18492731/01/2006

-METHOD FOR WEIGHTED OVERLAPתואמת תוספת לשקלול שיטהADDSONORIT APS

31/01/2005PA200500146DK


PCT/DK/2006/000054WO/2006/079349

A23L18493006/02/2006

ששונה טעם עם ואכילה רוקחות תכשירי ושיטות ארומתיות אמיד תולדות ידי על

בהן המשתמשות תכשירים של טעמן לשינוי

COMESTIBLE AND PHARMACEUTICAL COMPOSITIONS HAVING TASTE MODIFIED BY AROMATIC AMIDE DERIVATIVES AND METHODS FOR MODIFYING THE TASTE OF COMPOSITIONS USING THE SAMESENOMYX, INC.

04/02/2005

11/051567US

PCT/US/2006/004132WO/2006/084246

A61K18493123/02/2006

?, לבלבי תא של התחדשות של מקדם? לבלבי בתא אינסולין ייצור של ומקדם

PROMOTER OF REGENERATION OF PANCREATIC ? CELL, AND PROMOTER OF INSULIN PRODUCTION IN PANCREATIC ? CELLKYOTO UNIVERSITY

23/02/2005

2005-046562JP

11/01/2006

2006-003219JP


PCT/JP/2006/303243WO/2006/090767

C07D18493209/02/2006

גלוקגון, הכנתם לקולטן אנטגוניסטיםרפואיים ושימושים

GLUCAGON RECEPTOR ANTAGONISTS, PREPERATION AND THERAPEUTIC USESELI LILLY AND COMPANY

11/02/2005

60/652492US

PCT/US/2006/004461WO/2006/086488

C07K18493314/02/2006

ואנטגוניסטיםF 17 אינטרלאוקין נוגדני ושימושיהם17F– IL של אחרים מאותתים

INTERLEUKIN-17FANTIBODIES AND OTHER IL-17F SIGNALING ANTAGONISTS AND USES THEREFORWYETH

14/02/2005

60/653260US

01/04/2005

60/667492US

PCT/US/2006/005111WO/2006/088833

C07D18493423/02/2006

–3–אוקסוקווינזולינ–4 של נגזרותציטוקין של במחלות לטיפול יל–בנזמיד

4-OXOQUINAZOLINE-3-YL-BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CYTOKINE DISEASESASTRAZENECA AB

26/02/2005

0504019.1GB


PCT/GB/2006/000618WO/2006/090143

F16C18493515/02/2006

בצורה מרחף אובייקט לייצוב שיטהמגנטית

METHOD FOR STABILISING A MAGNETICALLY LEVITATED OBJECTLEVISYS

15/02/20050501514FR

PCT/FR/2006/000340WO/2006/087463

B23B18493619/05/2006

DRILL HEAD FOR DEEP HOLEעמוקים חורים עיצוב עבור מקדחה ראשMACHININGUNITAC, INCORPORATED

06/06/2005

2005-165166JP

PCT/JP/2006/310019WO/2006/132068

C04B18493923/01/2006

קרמיים, שיטה חלולים סיבים הרכבבו ושימוש לייצורו

COMPOSITE CERAMICS HOLLOW FIBRES METHOD FOR PRODUTION AND USE THEREOFUHDE GMBH


04/02/2005

102005005464.1DE

PCT/EP/2006/000546WO/2006/081959

C07D18494001/02/2006

–דימתילפנקלומדין, שימוש4 של נגזרותוהכנתן שלהן

DERIVATIVES OF 4-DEMETHYLPENCLOMEDINE, USE THEREOF AND PREPARATION THEREOFSOUTHERN RESEARCH INSTITUTE

01/02/2005

11/046692US

PCT/US/2006/003496WO/2006/083930

C07C18494305/04/2006

יציב, תהליך הידרוכלוריד אטומוקסטיןביציבותו אנליטית להכנתו, ושליטה

STABLE ATOMOXETINE HYDROCHLORIDE, A PROCESS FOR THE PREPARATION THEREOF, AND AN ANALYTICAL CONTROL OF ITS STABILITYTEVA PHARMACEUTICAL FINE CHEMICALS S.R.L.

05/04/2005

60/668741US

31/05/2005

60/686386US

07/07/2005

60/688406US

PCT/US/2006/012959


WO/2006/108120

C07D18494406/04/2006

PROCESS FOR THE PREPARATIONאנטי–סרטניות תרופות להכנת תהליךOF ANTICANCER DRUGSSICOR INC

06/04/2005

60/669132US

27/06/2005

60/694528US

PCT/US/2006/013140WO/2006/108155

C07C18494506/04/2006

CRYSTALLINE FORMS OFפרגאבלין של קריסטליניות צורותPREGABALIN

TEVA PHARMACEUTICALבע"מ פרמצבטיות תעשיות טבעINDUSTRIES LTD.

06/04/2005

60/669131US

PCT/US/2006/013127WO/2006/108151

C08L18494622/02/2006

עם אנרגיה להעברת או לתקשורת כבללאש עמידה פולימרית שכבה

POWER OR COMMUNICATIONS CABLE WITH FLAME RETARDANT POLYMER LAYERBOREALIS TECHNOLOGY OY

23/02/2005

05003931.2EP

PCT/EP/2006/001618


WO/2006/089735

G06F18494731/01/2006

במערכת תכולה להזרמת ושיטה מערכת של רחב פס יכולת ניצול תוך תקשורת

ללוויין בתקשורת לקוח

SYSTEM AND METHOD FOR STREAMING CONTENT UTILIZING CLIENT UPSTREAM COMMUNICATION BANDWIDTH CAPACITY OVER A NETWORKMEDICAL CONTRACTING SERVICES, INC.

01/02/2005

11/047878US

PCT/US/2006/003397WO/2006/083864

G10L18494831/01/2006

במערכת מסגרות לשרשור שיטהתקשורת

METHOD FOR CONCATENATING FRAMES IN COMMUNICATION SYSTEMSONORIT APS

31/01/2005PA200500146DK

PCT/DK/2006/000055WO/2006/079350

C07K18494917/02/2006


ממברנלי אנטיגן נגד חד–שבטיים נוגדנים שיירי נעדרים מהם אשר לפרוסטטה בררני

פוקוסיל

MONOCLONAL ANTIBODIES AGAINST PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LACKING IN FUCOSYL RESIDUESMEDAREX, INC.

18/02/2005

60/654266US

09/03/2005

60/660431US

PCT/US/2006/005853WO/2006/089231

C07K18495017/02/2006

מהם אשרCD 30 נגד חד–שבטיים נוגדניםפוקוסיל שיירי נעדרים

MONOCLONAL ANTIBODIES AGAINST CD30 LACKING IN FUCOSYL RESIDUESMEDAREX, INC.

18/02/2005

60/654197US

PCT/US/2006/005854WO/2006/089232

C07D18495109/02/2006

ושיטות רוקחות מיליאימיד, תכשירי תולדותבסרטן לטיפול

MELEIMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCERARQULE, INC.

09/02/2005

60/650951US

PCT/US/2006/004456WO/2006/086484


F27D18495221/02/2006

מתכת כיסוי עם מסולסל קרמי מסועלהרכבתו ושיטה בצדדיו

CERAMIC CONVEYOR ROLL WITH METAL END CAPS AND ITS ASSEMBLYVESUVIUS CRUCIBLE COMPANY

22/02/2005

05447040.6EP

PCT/EP/2006/001563WO/2006/089716

C07H18495428/02/2006

טריציקליים–נוקליאוזידים תרופות מטרימיויראליים בזיהומים לטיפול

TRICYCLIC-NUCLEOSIDE PRODRUGS FOR TREATING VIRAL INFECTIONSGENELABS TECHNOLOGIES, INC.

28/02/2005

60/657463US

PCT/US/2006/007131WO/2006/093986

C07H18495528/02/2006

לטיפול נוקליאוזידיות טריציקליות תרכובותויראליים בזיהומים

TRICYCLIC-NUCLEOSIDE COMPOUNDS FOR TREATING VIRAL INFECTIONSGILEAD SCIENCES, INC.

28/02/2005

60/657463US

PCT/US/2006/007132WO/2006/093987

A61M18495603/02/2005

A SAFETY NEEDLEבטיחות מזרקSALVUS TECHNOLOGY LTD


PCT/GB/2005/000357WO/2006/082350

C07H18495723/09/2005

של לייצור ותהליך ביניים תוצר של אנומרים ביטא מעושרי נוקליאוזידים

–ריבופוראנוסילD–דיפלואורו–21,21

INTERMEDIATE AND PROCESS FOR PREPARING OF BETA-ANOMER ENRICHED 21DEOXY,21,21-DIFLUORO-D-RIBOFURANOSYL NUCLEOSIDESDABUR PHARMA LIMITED

04/03/2005

472/DEL/2005IN

PCT/IN/2005/000322WO/2006/092808

A61N18495831/01/2006

אותות החלת עבור אלקטרודות סידורחיה של עור על אלקטרוניים

ELECTRODE ARRANGEMENT FOR APPLYING ELECTRICAL SIGNALS TO THE SKIN OF AN ANIMALWOUND SOLUTIONS LIMITED

01/02/2005

0502070.6GB

27/05/2005

11/138358US

PCT/GB/2006/000315WO/2006/082384

A01N18495914/02/2006

METHOD FOR CONTROLLINGצמחים על מזיקים חרקים לריסון שיטהINSECT PESTS ON PLANTSE.I. DU PONT DE NEMOURS AND COMPANY

14/02/2005

60/652610US

25/05/2005

60/684355US


10/06/2005

60/689697US

PCT/US/2006/005526WO/2006/089058

A61J18496013/02/2006

נוזליות תרופות לערבוב רפואי התקןרפואיים במיכלים במקום

MEDICAL DEVICE FOR IN SITU LIQUID DRUG RECONSTITUTION IN MEDICINAL VESSELS

.MEDIMOP MEDICAL PROJECTS LTDבע"מ רפואיים פרויקטים מדימופ14/02/2005

60/651999US

PCT/IL/2006/000181WO/2006/085327

C12N18496430/01/2006

עובריים גזע תאי של מכוונת דיפרנציאציהבהם והשימושים

DIRECTED DIFFERENTIATION OF EMBRYONIC STEM CELLS AND USES THEREOFES CELL INTERNATIONAL PTE LTD.

31/01/2005

60/648640US

17/06/2005

60/691954US

22/12/2005

60/753431US

PCT/US/2006/003257WO/2006/083782

A61K18496531/01/2006


גרעינית מגנטית להדמיה ניגוד חומריגידולים של ופרוגנוזה לדיאגנוזה

MRI CONTRAST AGENTS FOR DIAGNOSIS AND PROGNOSIS OF TUMORS


31/01/2005

60/647821US

PCT/IL/2006/000124WO/2006/080022

A61K18496602/02/2006

לטיפול סינטטיים פפטידיים קופולימריםקרדיו–וסקולריים ליקוים של ומניעה

SYNTHETIC PEPTIDE COPOLYMERS FOR TREATMENT AND PREVENTION OF CARDIOVASCULAR DISORDERS


02/02/2005

60/648708US

PCT/IL/2006/000134WO/2006/082581

G02B18496705/02/2006

בעוצמה להדמיה ושיטה התקן, מערכתמופחתת

DEVICE, SYSTEM, AND METHOD OF REDUCED-POWER IMAGING

.MTEYE SECURITY LTDבע"מ אם.טי.איי. סקיוריטי24/02/2005

60/655433US

PCT/IL/2006/000138WO/2006/090359


H04N18496831/01/2006

של זריזה לקליטה ושיטה התקן, מערכתתמונה

DEVICE, SYSTEM, AND METHOD OF RAPID IMAGE ACQUISITION

.MTEYE SECURITY LTDבע"מ אם.טי.איי. סקיוריטי02/02/2005

60/648698US

PCT/IL/2006/000126WO/2006/082579

A61L18496927/01/2006

STERILISERחיטוי מתקןJACKEL INTERNATIONAL LIMITED

31/01/2005

0501946.8GB

PCT/GB/2006/000273WO/2006/079820

C07C18497302/03/2006

METHOD FOR PRODUCINGמותמרים ביפנילים ליצור שיטהSUBSTITUTED BIPHENYLSBASF AKTIENGESELLSCHAFT

02/03/2005

102005010107.0DE

PCT/EP/2006/060400WO/2006/092429

C07C18497411/04/2006

-PROCESS FOR MAKING (S)(–פרגאבליןS) להכנת תהליךPREGABALIN


11/04/2005

60/670425US


PCT/US/2006/013565WO/2006/110783

A23L18497506/02/2006

אריל הטרו קבוצות המכילות תרכובות שינוי שעבר טעם בעלי אכילים ותכשיריםאותן המכילים

COMPOUNDS CONTAINING HETERO ARYL MOIETIES AND TASTE MODIFIED COMESTIBLE COMPOSITIONS CONTAINING THE SAMESENOMYX, INC.

04/02/2005

60/650029US

PCT/US/2006/003956WO/2006/084186

C07D18497602/02/2006

תרכובות המכילים רוקחות תכשיריטריציקליות

PHARMACEUTICAL COMPOSITIONS CONTAINING TRICYCLIC COMPOUNDSHUNTER-FLEMING LIMITED

03/02/2005

0502267.8GB

PCT/GB/2006/000358WO/2006/082409

A01N18497720/01/2006

מחלות ולבקרת למניעת ושיטות תכשירים פיראזול בתרכובת המשתמשים בצמחים

קרבאוקסאמיד

COMPOSITIONS AND METHODS FOR PREVENTING AND CONTROLING PLANT DISEASES UTILYZING A PYRAZOLE CARBOXAMIDE COMPOUNDMITSUI CHEMICALS, INC.

04/02/2005

2005-029312JP

04/02/2005

2005-029313JP

PCT/JP/2006/300890WO/2006/082723


H04L18497816/02/2006

אינטרנט פרוטוקול כתובת להקצאת שיטהפס רחבת אלחוטית גישה במערכת

A METHOD OF ALLOCATING AN INTERNET PROTOCOL ADDRESS IN A BROADBAND WIRELESS ACCESS SYSTEMLG ELECTRONICS INC.

16/02/2005

10-2005-0012609KR

PCT/KR/2006/000537WO/2006/088319

H04Q18497925/04/2005

BASE RECEIVER STATION (BTS)ראשית מקמ"ש תחנת של סינכרוניזציהSYNCHRONIZATIONTRUEPOSITION, INC

11/02/2005

60/652265US

PCT/US/2005/014188WO/2006/088472

C08B18498001/02/2006

קפסולרי פוליסכאריד של טיהורסטרפטוקוקי

PURIFICATION OF STREPTOCOCCAL CAPSULAR POLYSACCHARIDENOVARTIS VACCINES AND DIAGNOSTICS S.R.L,

01/02/2005

0502096.1GB

PCT/IB/2006/000626WO/2006/082527


A61K18498101/02/2006

קפסולרים סכארידים של תצמידסטרפטוקוקים

CONJUGATION OF STREPTOCOCCAL CAPSULAR SACCHARIDESNOVARTIS VACCINES AND DIAGNOSTICS S.R.L,

01/02/2005

0502095.3GB

PCT/IB/2006/000756WO/2006/082530

C07D18498320/03/2006

–2–)4–אמינו–2–]5 של גביש–מתילפירידינ–1–איל[–5פוריל(פירימידינ–

2(1 Hאון–) לייצורו ותהליכים

CRYSTAL OF 5-[2-AMINO-4-(2-FURYL)PYRIMIDIN-5-YL]-1 -METHYLPYRIDIN-2(1H)-ONE AND PROCESSES FOR PRODUCING THE SAMEEISAI R&D MANAGEMENT CO. LTD.

21/03/2005

60/663580US

PCT/JP/2006/305563WO/2006/101081

C07D18498420/03/2006

לא או גבישית בצורה פירימידין תרכובתלייצורה ותהליך גבישית

PYRIMIDINE COMPOUND CRYSTAL OR AMORPHOUS FORM AND PROCESS FOR PRODUCING THE SAMEEISAI R&D MANAGEMENT CO. LTD.


21/03/2005

60/663580US

PCT/JP/2006/305565WO/2006/101082

G06F18498603/02/2006

INSTRUCTION PREFETCHמראש הוראות מנגנוןMECHANISMQUALCOMM INCORPORATED

03/02/2005

11/050932US

PCT/US/2006/006993WO/2006/084288

G06K18498701/02/2006

בנתוני שימוש תוך אמת בזמן תמונה גילויפולריזציה

REAL-TIME IMAGE DETECTION USING POLARIZATION DATAINTERGRAPH SOFTWARE TECHNOLOGIES COMPANY

02/02/2005

60/649260US

PCT/US/2006/003512WO/2006/083944

A61K18498830/01/2006

ושיטות גשר בחיבור מסומנות תרכובותבהן לשימוש

BRIDGEHEAD LABELLED COMPOUNDS AND METHODS OF USING THE SAMEMALLINCKRODT INC.

02/02/2005

05075259.1EP

PCT/US/2006/003600WO/2006/083983

G06F18498903/02/2006


של מדומות אוכלוסיות להגדרת שיטהפציינטים

METHOD FOR DEFINING VIRTUAL PATIENT POPULATIONSENTELOS, INC.

04/02/2005

60/649964US

PCT/US/2006/003970WO/2006/084196

B41J18499107/02/2006

PRINTING ARRANGEMENT ANDלייצורו ושיטה להדפסה מערךMETHOD OF MANUFACTUREXAAR TECHNOLOGY LIMITED

07/02/2005

0502440.1GB

PCT/GB/2006/000422WO/2006/082445

B44D18499402/02/2006

MEDICAL/DENTAL SUCTIONרפואית/דנטלית יניקה פיית עבור נרתיקNOZZLE HOLSTERPATIENT SHIELD CONCEPTS, LLC

04/02/2005

11/051649US

PCT/US/2006/003806WO/2006/084108

A61K18499508/02/2006

גידול לגורם המתחברים נוגדניםלהכנתם ? ושיטות טרנספורמציה

ANTIBODIES THAT BIND TRANSFORMING GROWTH FACTOR ? AND METHODS FOR THE PRODUCTION THEREOFGENZYME CORPORATION

08/02/2005

60/651343US

PCT/US/2006/004424WO/2006/086469


C07D18499608/02/2006

ותכשירי דיהידרואימידאזותיאזול תולדותאותן המכילים רוקחות

DIHYDROIMIDAZOTHIAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAMEPROSIDION LIMITED

08/02/2005

60/650906US

25/05/2005

60/684369US

24/01/2006

60/761666US

PCT/GB/2006/050031WO/2006/085118

A61P18499716/01/2006

לטיפול קינאז טירוזין במעכבי שימושבאף כרונית בסינוסיטיס

USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CHRONIC RHINOSINUSITISBOEHRINGER INGELHEIM INTERNATIONAL GMBH

04/02/2005

102005005505.2DE

02/08/2005

102005036216.8DE

PCT/EP/2006/050215WO/2006/082129

C07D18499816/02/2006

–קרביקסילאט1הטרוציקלים– של תולדותארומטי לא חנקן עם פירידיל המכילים

PYRIDYL NON-AROMATIC NITROGEN-CONTAINING HETEROCYCLIC-1-CARBOXYLATE DERIVATIVEASTELLAS PHARMA INC.

17/02/2005

2005-040197JP

18/10/2005

2005-303065JP


PCT/JP/2006/302698WO/2006/088075

H03D18499903/02/2006

מפריעים סינגלים להורדת ושיטה מערכתרחב פס רוחב עם מקבל מסיגנל צרי–פס

SYSTEM AND METHOD FOR REMOVING INTERFERING NARROWBAND SIGNALS FROM WIDE BANDWIDTH RECEIVE SIGNALHARRIS CORPORATION

07/02/2005

11/052312US

PCT/US/2006/003744WO/2006/086214

H03D18500006/02/2006

השוואת המבצע אלחוטי תקשורת מכשיר מטריצה של אומדנים על המבוסס מחסום

ועתיד בעבר, הווה אוטוקורלציה של

WIRELESS COMMUNICATIONS DEVICE PERFORMING BLOCK EQUALIZATION BASED UPON PRIOR, CURRENT AND/OR FUTURE AUTOCORRELATION MATRIX ESTIMATES AND RELATED METHODSHARRIS CORPORATION

09/02/2005

11/054157US

PCT/US/2006/003990WO/2006/086261

H03D18500106/02/2006

השוואת המספק אלחוטי תקשורת מכשירקשורות ושיטות מוגברת מחסום

WIRELESS COMMUNICATIONS DEVICE PROVIDING ENHANCED BLOCK EQUALIZATION AND RELATED METHODS


HARRIS CORPORATION09/02/2005

11/054158US

PCT/US/2006/003980WO/2006/086254

C07D18500312/06/2006

ושיטות אנדרוגני קולטן מאפננות תרכובותANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODSLIGAND PHARMACEUTICALS INC.

17/06/2005

60/691891US

PCT/US/2006/023111WO/2006/138347

G11B18500707/02/2006

אופטי, מנגנון דסקט ע"י להקלטה אמצעי להרצת ושיטההנ"ל להקלטת ושיטה ומנגנון הנ"ל

OPTICAL-DISK RECORDING MEDIUM, PLAYING APPARATUS AND METHOD FOR SAME, AND RECORDING APPARATUS AND METHOD FOR SAMESONY CORPORATION

07/02/2005

2005-030272JP

14/07/2005

2005-205439JP

PCT/JP/2006/302069WO/2006/082980

A23L18500808/02/2006


נוזליים מזון מוצרי לעיבוד ושיטה מנגנוןקרינה באמצעות

APPARATUS AND METHOD FOR RADIATION PROCESSING OF FLUENT FOOD PRODUCTSWYETH

10/02/2005

60/651796US

PCT/US/2006/004360WO/2006/086427

C07D18501014/02/2006

NKNK1 ANTAGONISTS 1 של אנטגוניסטיםF. HOFFMANN-LA ROCHE AG

22/02/2005

05101324.1EP

PCT/EP/2006/001310WO/2006/089658

A61K18501116/02/2006

שניתן משופר תרופתי חומר עם גלולותלפזרו

TABLETS WITH IMPROVED DRUG SUBSTANCE DISPERSIBILITYF. HOFFMANN-LA ROCHE AG

25/02/2005

05101458.7EP

PCT/EP/2006/001395WO/2006/089674

A61B18501229/03/2006

מוגבר לילה ראית אמצעי בעבור כנהדיגיטלי

MOUNT FOR DIGITALLY ENHANCED NIGHT VISION DEVICELITTON SYSTEMS, INC.


30/03/2005

60/594339US

28/03/2006

11/308462US

PCT/US/2006/011403WO/2006/105157

C07D18501321/02/2006

PREPARATION OF HIGH PURITYגבוה בטהר מותמר קינוקסלין של הכנתוSUBSTITUTED QUINOXALINEPFIZER PRODUCTS INC.

24/02/2005

60/656296US

PCT/IB/2006/000351WO/2006/090236

C07D18501420/03/2006

IMIDAZOPYRIDAZINE COMPOUNDSאימידזופירידזין תרכובותELI LILLY AND COMPANY

21/03/2005

60/663816US

PCT/US/2006/009942WO/2006/102194

C07D18501514/02/2006

NEW SYNTHESIS OF Aקמפטוטצין יחידת של חדשה סינטזהCAMPTOTHECIN SUBUNITF. HOFFMANN-LA ROCHE AG

22/02/2005

05101338.1EP

PCT/EP/2006/001306WO/2006/089657


C07D18501616/02/2006

COMPOUNDS FOR THE TREATMENTיתר שגשוג של סדרים באי לטיפול תרכובותOF PROLIFERATIVE DISORDERSSYNTA PHARMACEUTICALS, CORP.

17/02/2005

60/653890US

08/03/2005

60/660112US

04/11/2005

60/733912US

PCT/US/2006/005761WO/2006/089177

A61K18501706/02/2006

לשבר עמידה מתן צורת ליצור שיטהMETHOD FOR THE PRODUCTION OF A TAMPER-PROOF FORM OF ADMINISTRATIONGRUNENTHAL GMBH

04/02/2005

102005005449.8DE

PCT/EP/2006/001025WO/2006/082097

A61K18501806/02/2006

עמידות מושהה לשחרור מתן צורותלשבירה

BREAK-RESISTANT DELAYED-RELEASE FORMS OF ADMINISTRATIONGRUNENTHAL GMBH

04/02/2005

102005005446.3DE

PCT/EP/2006/001027WO/2006/082099

C08F18501908/11/2005

MACROPOROUS PLASTIC BEADנקבובי חרוזי פלסטי חומרMATERIALROHM GMBH & CO. KG


08/02/2005

102005005828.0DE

PCT/EP/2005/011907WO/2006/084490

A61K18502018/01/2006

USE IRON(III) COMPLEXערכי תלת ברזל תצמידי בתרכבות שימושCOMPOUNDSVIFOR (INTERNATIONAL) AG.

09/02/2005

05100907.4EP

PCT/EP/2006/050276WO/2006/084782

G01N18502103/02/2006

בשימוש בכבד שומן של אבחון שיטתביוכימיים בסמנים

DIAGNOSIS METHOD OF HEPATIC STEATOSIS USING BIOCHEMICAL MARKERSASSISTANCE PUBLIQUE-HOPITAUX DE PARIS

03/02/2005

11/050396US

PCT/IB/2006/000333WO/2006/082522

C07D18502302/02/2006

קינאז כמעכבי לשימוש תיאזולידינונים (PLK) פולו דמוי

THIAZOLIDINONES FOR USE AS INHIBITORS OF POLO-LIKE KINASE (PLK)BAYER SCHERING PHARMA AG

03/02/2005

102005005395.5DE

10/02/200560/651232US

PCT/EP/2006/001037WO/2006/082107


C07D18502402/02/2006

RAF INHIBITOR COMPOUNDS ANDלכך ושיטותRAF מעכבות תרכובותMETHODSGENENTECH, INC.

04/02/2005

60/650050US

PCT/US/2006/003654WO/2006/084015

A61F18502502/02/2006

מחומר העשוי סופג פנים–שופכתי סטנטבסיבים מחוזק מרוכב

FIBER-REINFORCED COMPOSITE ABSORBABLE ENDOURETERAL STENTPOLY-MED, INC.

04/02/2005

60/650240US

16/08/2005

11/204822US

PCT/US/2006/003619WO/2006/083991

C07C18502602/08/2007


ו/או פנימית לו הצמודים פעמי חד חיתול או אשפה שקית ו/או לחים מגבונים חיצונית

העור להגנת משחה ו/או ניילון שקית

DISPOSABLE DIAPER OR DISPOSABLE DIAPER PANTS ATTACHED WITH PRE MOISTENED TOWELLETTE (WIPES) AND/OR PLASTIC TRASH OR PLASTIC BAG AND/OR SKIN PROTECTION CREAM FROM THE INSIDE AND/OR THE OUTSIDE OF THE DIAPER OR PANTS

TAL GABAYגבאי טל

C12N18502708/02/2005

ספציפיים לאתרים רקומבינאזות סריןושימושיהם

SITE-SPECIFIC SERINE RECOMBINASES AND METHODS OF THEIR USEINTREXON CORPORATION

02/02/2005

11/049552US

PCT/US/2005/003851WO/2006/083253

C07C18502810/05/2006

איזובוטילגלוטרית מחומצה נקי פרגאבליןלהכנתו ותהליך

PREGABALIN FREE OF ISOBUTYLGLUTARIC ACID AND A PROCESS FOR PREPARATION THEREOF


10/05/2005

60/679784US

09/06/2005

60/689699US

26/10/2005

60/730584US

27/10/2005

60/731434US

01/11/2005

60/732745US

PCT/US/2006/018266


WO/2006/122255

C07C18502912/04/2006

PREPARATION OF TADALAFILטדלפיל של ביניים חומרי הכנתINTERMEDIATES


12/04/2005

60/671239US

PCT/US/2006/014052WO/2006/110893

C07D18503009/05/2006

PROCESS FOR MAKINGאזטראונם להכנת תהליךAZTREONAMSICOR INC.

09/05/2005

60/679313US

17/05/2005

60/681808US

PCT/US/2006/018261WO/2006/122253

C07C18503110/05/2006

METHOD FOR THE PREPARATION OFשלו ומלחים פרגאבלין להכנת שיטהPREGABALIN AND SALTS THEREOF


10/05/2005

60/679784US

09/06/2005

60/689699US

PCT/US/2006/018272WO/2006/122258


C07C18503210/05/2006

–קארבמוילמתיל–3 של אופטית רזולוציההקסנואית חומצה –מתיל5

OPTICAL RESOLUTION OF 3-CARBAMOYLMETHYL-5-METHYL HEXANOIC ACID


10/05/2005

60/679784US

09/06/2005

60/689699US

02/11/2005

60/733009US

09/11/2005

60/735634US

29/11/2005

60/740950US

PCT/US/2006/018273WO/2006/122259

C07C18503311/04/2006

להכנתו ותהליך מלקטם נקי פרגאבליןPREGABALIN FREE OF LACTAM AND A PROCESS FOR PREPARATION THEREOF


10/05/2005

60/679784US

09/06/2005

60/689699US

02/11/2005

60/733006US


08/11/2005

60/735069US

PCT/US/2006/013360WO/2006/121557

C07D18503501/02/2006

–אלקיל–3–דיפניל–N([– 4, 5 של תולדות )אמיד, תיאוריה –תיאניל(מתיל[ אמין2

ואוריאה( כאנטגוניסטים קנאבינואידים1CB לרצפטורים

DERIVATIVES OF N-[(4,5-DIPHENYL-3-ALKYL-2-THIENYL) METHYL] AMINE

(AMIDE, THIOUREA AND UREA )AS CANNABINOID CB1 RECEPTOR ANTAGONISTSSANOFI-AVENTIS

09/02/20050501366FR

PCT/FR/2006/000219WO/2006/084975

H04N18503707/02/2006

מקסום ידי על אדפטיבית רעש הפחתתפיקסלים יחסי

ADAPTIVE IMAGE DE-NOISING BY PIXELS RELATION MAXIMIZATION

.ULTRASPECT LTDבע"מ אולטרהספקט07/02/2005

60/649917US

PCT/IL/2006/000151WO/2006/082590

A61L18503902/02/2006

ARTICLE PROCESSING APPARATUSנילוות ושיטות פריטים לעיבוד התקןAND RELATED METHODSBIODEFENSE CORPORATION

04/02/2005

11/050651US

PCT/US/2006/003568WO/2006/083967


C12C18504008/02/2005

O16 2 H 1ALCOHLIC BEVERAGE ENRICHED ב מועשר אלכוהול משקהWITH 1H2 16OWOODFORD ASSOCIATES LIMITED

PCT/RU/2005/000044WO/2006/085784

A23L18504208/02/2005

O 16 2 H 1NON-ALCOHOLIC BEVERAGE ב מועשר אלכוהול לא משקהENRICHED WITH 1H2 16OWOODFORD ASSOCIATES LIMITED

PCT/RU/2005/000045WO/2006/085785

H04L18504403/02/2006

תקשורת אמצעי עבור מאובטחת היחלצותאלחוטיים

SECURE BOOTSTRAPPING FOR WIRELESS COMMUNICATIONSQUALCOMM INCORPORATED

04/02/2005

60/650358US

18/02/2005

60/654133US

PCT/US/2006/003947WO/2006/084183

H04Q18504503/02/2006

מיקום של הגדרה לביצוע והתקן שיטהמראש מתוכננת פעולה בעזרת

METHOD AND APPARATUS FOR PERFORMING POSITION DETERMINATION WITH PRE-SESSION ACTION


QUALCOMM INCORPORATED04/02/2005

11/050575US

PCT/US/2006/006992WO/2006/084287

G06F18504603/02/2006

לגיבוב מילה שברי לכתיבת רשם מבנהכושל באופן הערוכים נתונים של ישיר

FRACTIONAL-WORD WRITABLE ARCHITECTED REGISTER FOR DIRECT ACCUMULATION OF MISALIGNED DATAQUALCOMM INCORPORATED

03/02/2005

11/051037US

PCT/US/2006/006994WO/2006/084289

C07F18504907/02/2006

להכנתם אורגניים, שיטות כסף קומפלקסיבעזרתם דקות שכבות ליצירת ושיטות

ORGANIC SILVER COMPLEXES, THEIR PREPARATION METHODS AND THEIR METHODS FOR FORMING THIN LAYERSINKTEC CO, LTD.

07/02/2005

10-2005-0011478KR

11/02/2005

10-2005-0011631KR

06/02/2006

10-2006-0011083KR

PCT/KR/2006/000451WO/2006/083153


C07D18505014/02/2006

מותמרים אימידאזוליםבהטרוציקלילאמיד

HETEROCYCLYLAMIDE-SUBSTITUTED IMIDAZOLESAICURIS GMBH & CO.KG

23/02/2005

102005008183.5DE

PCT/EP/2006/001325WO/2006/089664

C25D18505122/11/2005

COLOR-CODED STAINLESS STEELצבועה אל–חלד מפלדת וטבעות אביזריםFITTINGS AND FERRULESSWAGELOK COMPANY

15/02/2005

60/653147US

PCT/US/2005/042422WO/2006/088526

C07K18505228/02/2006

TREATMENT OF BONE DISORDERSעצמות של סדרים באי טיפולGENENTECH, INC.

28/02/2005

60/656943US

PCT/US/2006/006998WO/2006/093923

A61K18505609/02/2006

זיהומים מניעת או לטיפול ושיטות תכשיריםפלאוויוירידים

COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING FLAVIVIRIDAE INFECTIONSMIGENIX, INC.

09/02/2005

60/651910US

21/03/2005

60/664297US

12/11/2005

60/735464US


PCT/US/2006/004927WO/2006/096285

F16L18505707/02/2006

ANOMALY DETECTOR FORצנרת לקווי אנומליה גלאיPIPELINESPURE TECHNOLOGIES LTD.

07/02/20052496150CA

PCT/CA/2006/000146WO/2006/081671

C07D18506315/02/2006

המכילים רוקחות פיראזול, תכשירי נגזרות לטיפול תרופות ליצור בהם ושימוש אותם

סרטן של ולמניעה

PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE THEREOF IN THE MANUFACTURE OF MEDICAMENTS FOR TREATMENT AND PREVENTION OF CANCERSASTRAZENECA AB

16/02/2005

60/653575US

01/12/2005

60/742138US

PCT/GB/2006/000513WO/2006/087530

H04L18506407/02/2006

הקשורות גרעין וחומצות רנ"א מיקרואליהם

MICRORNAS AND RELATED NUCLEIC ACIDS

.ROSETTA GENOMICS LTDבע"מ ג'נומיקס רוזטהDecember 3, 2007 –התשס"ח בכסלו כ"ג 347

6

07/02/2005

60/593696US

19/10/2005

60/728161US

23/11/2005

60/739522US

05/01/2006

60/743098US

19/01/2006

11/275628US

PCT/IB/2006/001400WO/2006/092738

H04Q18506514/02/2006

ITERATIVE DIVERSITY RECEPTIONעצמה על חוזרת מגוונת קליטהVIASAT, INC.

14/02/2005

60/653071US

PCT/US/2006/005275WO/2006/088926

G06F18506610/02/2006

שליחת באמצעות מותנית ביצוע הוראתמותנית הערכה עבור הוראה

CONDITIONAL INSTRUCTION EXECUTION VIA EMISSARY INSTRUCTION FOR CONDITION EVALUATIONQUALCOMM INCORPORATED

10/02/2005

11/055919US

PCT/US/2006/004892WO/2006/086713


G06F18506709/02/2006

נתונים העברת לשיפור זרימה בקרת שיטתמתג מטרית באמצעות

FLOW CONTROL METHOD TO IMPROVE DATA TRANSFER VIA A SWITCH MATRIXQUALCOMM INCORPORATED

10/02/2005

11/055922US

PCT/US/2006/004936WO/2006/086732

H04M18506806/02/2006

VIRTUAL MULTI-LINE TELEPHONEוירטואלי רב–קווי טלפוני שרותSERVICE

OUTSMART LTDבע"מ אאוטסמארט10/02/2005

11/055339US

PCT/IL/2006/000146WO/2006/085303

A01N18506907/02/2006

דם כלי בשיסועי לטיפול ושיטות התקניםDEVICES AND METHODS FOR TREATMENT OF VASCULAR BIFURCATIONS

B-BALLOON LTDבע"מ בי-בלון08/02/2005

60/651430US

PCT/IL/2006/000147WO/2006/085304

H04L18507014/02/2006

משולב מתקדמות טעויות תיקון פענוחעצמה על חוזרת מגוונת וקליטה

INTEGRATED FEC DECODING AND ITERATIVE DIVERSITY RECEPTIONVIASAT, INC.

14/02/2005

60/653068US


PCT/US/2006/005301WO/2006/088942

C07D18507114/02/2006

פיפראזין–פירזיניל מסוג פיפרדינים פעילות בעלי בהטרואריל המותמרים

CXCR 3ל– אנטגוניסטית

HETEROARYL SUBSTITUTED PYRAZINYL-PIPERAZINE-PIPERIDINES WITH CXCR3 ANTAGONIST ACTIVITYSCHERING CORPORATION

16/02/2005

60/653477US

PCT/US/2006/005122WO/2006/091428

C07D18507214/02/2006

הטרוציקלית בטבעת מותמרים פיפרזיניםCXCR3 ל– אנטגוניסטית פעילות בעלי

HETEROCYCLIC SUBSTITUTED PIPERAZINES WITH CXCR3 ANTAGONIST ACTIVITYSCHERING CORPORATION

16/02/2005

60/653309US

PCT/US/2006/005123WO/2006/088837

C07D18507314/02/2006

המותמרים פיפראזין מסוג פיפרדינים 3 ל– אנטגוניסטית פעילות בעלי בפירזיניל

CXCR

PYRAZINYL SUBSTITUTED PIPERAZINE-PIPERIDINES WITH CXCR3 ANTAGONIST ACTIVITYSCHERING CORPORATION

16/02/2005

60/653338US

PCT/US/2006/005267WO/2006/088921


C07D18507414/02/2006

ופניל בפירידיל מותמרים פיפרדינים פיפרזיןCXCR 3 ל– אנטגוניסטית פעילות בעלי

PYRIDYL AND PHENYL SUBSTITUTED PIPERAZINE PIPERIDINES WITH CXCR3 ANTAGONIST ACTIVITYSCHERING CORPORATION

16/02/2005

60/653337US

PCT/US/2006/005265WO/2006/088919

A23L18507508/03/2006

HMF) אנושי חלב לנוזל מרוכז חיזוק תוסף)

CONCENTRATED LIQUID HUMAN MILK FORTIFIER (HMF)ABBOTT LABORATORIES

09/03/2005

60/660087US

PCT/US/2006/008354WO/2006/099013

C07C18507614/02/2006

–אמינואלכוהולים3 להכנת תהליך1 בעמדה מותמרים

אננטיומרית טהורים

PROCESS FOR THE PREPARTION OF ENANTIOMERICALLY PURE 1-SUBSTITUTED-3-AMINOALCOHOLSLONZA AG

21/02/2005

05003657.3EP

PCT/EP/2006/001334WO/2006/087166


C07D18507722/02/2006

PURIFICATION OF RAPAMYCINרפמיצין של טיהורWYETH

02/03/2005

60/657910US

PCT/US/2006/006212WO/2006/093745

C07D18507822/02/2006

RECOVERY OF CCI-779 FROMאם מתמיסותCCI – 779 של שחזורMOTHER LIQUORSWYETH

02/03/2005

60/657534US

PCT/US/2006/006207WO/2006/093743

C12Q18508225/01/2006

SELECTION PROBE AMPLIFICATIONבחירה בחון הגברתPERLEGEN SCIENCES, INC.

14/02/2005

11/058432US

PCT/US/2006/002882WO/2006/088623

H01L18508310/12/2002

COMPLEMENTARY MIS DEVICE משליםMIS התקןTOKYO ELECTRON LTD

13/12/2001

2001-380534JP

PCT/JP/2002/012925WO/2003/054962


H04J18508426/10/2001

שנקלטו נתונים רצף לסנכרון שיטהבמקלט

A METHOD OF SYNCHRONIZING A DATA SEQUENCE RECEIVED IN A RECEIVERVIASAT, INC.

26/10/2000

09/695980US

PCT/US/2001/027784WO/2002/037744

C12N18508518/05/2005

GAFA מתחם המכיל פוליפפטיד אנושי פספודיאסטרז שלGAFB ומתחם

11( 11 PDEושיטות ) מאופני לזיהוי 11 PDEבו המשתמשות

A POLYPEPTIDE CONTAINING THE GAFA DOMAIN AND THE GAFB DOMAIN OF A HUMAN PHOSPHODIESTERASE

11(PDE11 )AND METHODS FOR IDENTIFYING PDE11 MODULATORS UTILIZING THE SAMENYCOMED GMBH

28/02/2005

102005009672.7DE

01/03/2005

102005009848.7DE

PCT/EP/2005/052273WO/2006/092175

C12N18508618/05/2005

GAFA מתחם המכיל פוליפפטיד אנושי פספודיאסטרז שלGAFB ומתחם

10(10 PDEושיטות ) 10 מאופני לזיהויPDEבו המשתמשות

A POLYPEPTIDE CONTAINING THE GAFA DOMAIN AND THE GAFB DOMAIN OF A HUMAN PHOSPHODIESTERASE

10(PDE10 )AND METHODS FOR IDENTIFYING PDE10 MODULATORS UTILIZING THE SAMENYCOMED GMBH


28/02/2005

102005009773.1DE

01/03/2005

102005009849.5DE

PCT/EP/2005/052271WO/2006/092174

A61P18508710/06/1999

עם בשילוב אסטרוגן של בררתי קולט מגווןמין סטרואיד של פרקורסור

SELECTIVE ESTROGEN RECEPTOR MODULATOR IN COMBINATION WITH A SEX STEROID PRECURSORENDORECHERCHE, INC.

11/06/1998

09/096284US

PCT/CA/1999/000538WO/1999/063974

H01L18508909/02/2006

חימצון–חיזור פעילות בעלי חומריםעליהם המושתתים ומתקנים

REDOX-ACTIVE STRUCTURES AND DEVICES UTILIZING THE SAME


10/02/2005

60/651228US

PCT/IL/2006/000169WO/2006/085319

G06F18509008/02/2006

של להקצבה–לפי–נושא ושיטה מערכתמחשב דרך הנגישה בסביבה פעילויות

SYSTEM AND METHOD FOR CATEGORIZING ACTIVITIES IN COMPUTER-ACCESSIBLE ENVIRONMENTS

NOTEA, AMIRנוטע שמעון אמיר08/02/2005

60/651805US

PCT/IL/2006/000164WO/2006/085315


G06F18509108/02/2006

תנועת של בקרה עבור מקרו פקודותפרוסות

WAFER MOVEMENT CONTROL MACROSLAM RESEARCH CORPORATION

08/02/2005

11/054143US

PCT/US/2006/004625WO/2006/086577

C07D18509207/02/2006

PYRAZOLOPYRIMIDINESפיראזולופירימידיניםBAYER CROPSCIENCE AG

17/02/2005

102005007534.7DE

PCT/EP/2006/001064WO/2006/087120

G01T18509308/02/2006

מוצק במצב וניוטרון אלפא חלקיקי גלאיבו והשימוש ליצורו ושיטות

SOILD-STATE NEUTRON AND ALPHA PARTICLES DETECTOR AND METHODS FOR MANUFACTURING AND USE THEREOF

של המחקר לפיתוח חברה יישוםבירושלים העברית האוניברסיטה

YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM

08/02/2005

60/650520US

PCT/IL/2006/000155WO/2006/085307

B22F18509427/01/2006


חלקיקי של ספיריים וגיבוב לגרעון שיטה בשיטה הנוצרים מתכת מתכת, חלקיקי

מתכת מחלקיקי המיוצרות ואנודות זואלו

METHODS FOR SPHERICALLY GRANULATING AND AGGLOMERATING METAL PARTICLES AND THE METAL PARTICLE PREPARED THEREBY, ANODES MADE FROM THE METAL PARTICLESNINGXIA ORIENT TANTALUM INDUSTRY CO. LTD

29/09/2005

200510108062.5CN

PCT/CN/2006/000184WO/2007/036087

G01C18509513/02/2006

באמצעות דיגיטלית דמות להשגת התקןפאסיבית ייצוב סריקת

DEVICE FOR ACQUIRING A DIGITAL IMAGE BY PASSIVE STABILIZATION SCANNINGTHALES

15/02/200505/01520FR

PCT/EP/2006/050878WO/2006/087307

C08G18509608/02/2006

ליצור בהם ושימוש פולימריים תכשירים או פעילים מרכיבים המכילים תכשירים

יעילים

POLYMER COMPOSITIONS AND THEIR USE IN THE PRODUCTION OF ACTIVE OR EFFECTIVE INGREDIENT COMPOSITIONSBASF AKTIENGESELLSCHAFT

09/02/2005

102005005931.7DE

PCT/EP/2006/001106WO/2006/084680


C12N18509721/02/2006

TISSUE SPECIFIC EXPRESSION OFבתרנגולים נוגדנים של ברקמה בררני ביטויANTIBODIES IN CHICKENSORIGEN THERAPEUTICS, INC.

18/02/2005

11/062325US

PCT/US/2006/006227WO/2006/089294

C08J18509827/02/2006

PROCESS FOR PREPARINGמצולבים פולימרים להכנת תהליךCROSSLINKED POLYMERSBOREALIS TECHNOLOGY OY

28/02/2005

05004358.7EP

PCT/EP/2006/001793WO/2006/089793

B24D18509921/02/2006

CMP עבור אישית מותאמות רפידותבהן ולשימוש לבנייתן ושיטות

CUSTOMIZED POLISHING PADS FOR CMP AND METHODS OF FABRICATION AND USE THEREOFNEOPAD TECHNOLOGIES CORPORATION

18/02/200511/060898US

18/02/200560/654104US


18/02/200560/654173US

02/05/200560/677062US

15/07/2005PCT/US2005/25330US

14/10/200511/251547US

PCT/US/2006/006176WO/2006/089293

A61M18510007/02/2006

גורם המכיל חד–פעמי לשימוש מכלולעור מנקב

DISPOSABLE ASSEMBLY CONTAINING A SKIN PIEERCING ELEMENTGLIDE PHARMACEUTICAL TECHNOLOGIES LIMITED

07/02/2005

0502840.2GB

PCT/GB/2006/000411WO/2006/082439

A61K18510115/02/2006

תימידילאז תולדת רב–אפיטופי פפטיד ונוגד אימונולוגית פעילות בעל סינטאזגידולים

POLY-EPITOPE PEPTIDE DERIVED FROM THYMIDYLATE SYNTHASE HAVING IMMUNOLOGICAL AND ANTI-TUMOUR ACTIVITYUNIVERSITA DEGLI STUDI DI SIENA

16/02/2005RM2005A000064IT

PCT/IT/2006/000078WO/2006/087756


C02F18510208/02/2006

ומיחזור אוזון עם נוזל לטיהור ושיטה התקןA DEVICE AND A METHOD FOR PURIFYING A LIQUID WITH OZONE AND RECIRCULATIONHOMEFLOW TECHNOLOGIES SA,

25/02/2005

05101456.1EP

PCT/EP/2006/050768WO/2006/089840

A61K18510317/03/2006

CAT ALLERGEN CONJUGATES ANDבהם ושימושים חתולי אלרגן של תצמידיםUSES THEREOFCYTOS BIOTECHNOLOGY AG

18/03/2005

60/662918US

PCT/EP/2006/060845WO/2006/097530

A01N18510416/03/2006

–3 על המבוססים עשבים קוטלי תכשירים– סולפונילאיזוקסזולינים3ו– פנילאורצילים

HERBICIDAL COMPOSITIONS BASED ON 3-PHENYLURACILS AND 3-SULFONYLISOXAZOLINESBASF AKTIENGESELLSCHAFT

17/03/2005

60/662362US

PCT/EP/2006/060792WO/2006/097509

B01J18510501/03/2006

המשתחררים מיקרוקפסולרים מוצריםמהיר באופן

FAST-RELEASE MICROCAPSULE PRODUCTSBASF AKTIENGESELLSCHAFT

01/03/2005

60/656895US

PCT/EP/2006/060359WO/2006/092409


C07D18510610/05/2006

ושיטות יציב מיקרוני צילקסטיל קנדסרטןלהכנתו

STABLE MICRONIZED CANDESARTAN CILEXETIL AND METHODS FOR PREPARING THEREOF


10/05/2005

60/679952US

11/05/2005

60/680115US

24/05/2005

60/684455US

10/08/2005

60/707417US

19/08/2005

60/709954US

13/09/2005

60/716995US

29/09/2005

60/722388US

PCT/US/2006/018265WO/2006/122254

C07C18510716/05/2006

PROCESS FOR PREPARINGהידרוכלוריד סינאקלסט להכנת תהליךCINACALCET HYDROCHLORIDE


16/05/2005

60/681671US

23/05/2005

60/684152US

05/07/2005

60/696981US

06/07/2005

60/697111US

11/07/2005

60/698613US


20/07/2005

60/701232US

26/07/2005

60/702918US

09/08/2005

60/706910US

24/10/2005

60/730050US

31/10/2005

60/732083US

02/11/2005

60/733008US

07/11/2005

60/734669US

08/11/2005

60/735126US

21/11/2005

60/738827US

22/11/2005

60/739215US

01/12/2005

60/741787US

05/12/2005

60/742626US

15/12/2005

60/750910US

24/04/2006

60/794804US

PCT/US/2006/019131WO/2006/125026

C07C18510823/05/2006

הידרוכלוריד סינאקלסט להכנת תהליכיםI פורם

PROCESSES FOR PREPARING CINACALCET HYDROCHLORIDE CRYSTAL FORM I


23/05/2005

60/684152US

05/07/2005

60/696981US

06/07/2005

60/697111US


11/07/2005

60/698613US

20/07/2005

60/701232US

26/07/2005

60/702918US

09/08/2005

60/706910US

24/10/2005

60/730050US

31/10/2005

60/732083US

02/11/2005

60/733008US

07/11/2005

60/734669US

08/11/2005

60/735126US

21/11/2005

60/738827US

01/12/2005

60/741787US

15/12/2005

60/750910US

24/04/2006

60/794804US

PCT/US/2006/020304WO/2006/127933

G01N18510906/01/2006

לאצטאמינופן, – אנושייםT2R P קולטני ולבדיקות ודנוטוניום רניטידין, סטריכנין

של אנושיים מאפננים לזיהוי הקשורותמר טעם

PHUMAN T2R RECEPTORS FOR ACETAMINOPHEN, RANITIDINE, STRYCHNINE, AND DENATONIUM, AND RELATED ASSAYS FOR IDENTIFYING HUMAN BITTER TASTE MODULATORSSENOMYX, INC.

08/02/2005

60/650555US

PCT/US/2006/002509WO/2006/086150


B29C18511008/02/2006

אורגנומיטליות תרכובות להכנת תהליכיםPROCESSES FOR THE PRODUCTION OF ORGANOMETALLIC COMPOUNDSPRAXAIR TECHNOLOGY, INC.

10/02/2005

11/053836US

PCT/US/2006/004166WO/2006/086329

G06F18511112/02/2006

זכרון דרישות לשיפור ושיטה מערכתבמהלך

FEC – MPE עיבוד

SYSTEM AND METHOD FOR MITIGATING MEMORY REQUIREMENTS DURING MPE-FEC PROCESSINGSIANO MOBILE SILICON LTD.

10/02/2005

60/650861US

PCT/IL/2006/000179WO/2006/085326

C07D18511302/03/2006

SUBSTITUTED PYRIDINEמותמרות פירידין נגזרותDERIVATIVESH. LUNDBECK A/S

03/03/2005PA200500321DK

PCT/DK/2006/000123WO/2006/092143

H04M18511608/08/2006

ע"י הנשלטת טלפון שיחת של הודעהטלפון שיחות ליצירת מערכת

CALL NOTIFICATION CONTROLLED BY CALL ORIGINATING SYSTEMPSYGNIFICANT SERVICES LIMITED


08/02/2005

0502581.2GB

08/03/2005

60/594059US

12/12/2005

0525249.9GB

PCT/GB/2006/000440WO/2006/085069

A61B18511710/02/2006

להפעלה ומכשיר, ושיטה חיישן, מערכתSENSING DEVICE, APPARATUS AND SYSTEM, AND METHOD FOR OPERATING THE SAMETHE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW

11/02/2005

0502886.5GB

17/03/2005

0505513.2GB

17/03/2005

0505512.4GB

PCT/GB/2006/000465WO/2006/085087

C07D18511810/10/2000

והשימוש מחומש, ייצורו הטרוציקלי נגזרותבתרופות בו

5-MEMBERED HETEROCYCLE DERIVATIVES,PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTSSOCIETE DE CONSEILS DE RECHERCHES ET D'APLICATIONS SCIENTIFIQUES (S.C.R.A.S.)

11/10/199999/12643FR

01/08/200000/10151FR

01/09/200000/11169FR

PCT/FR/2000/002805WO/2001/026656


C07K18511908/08/2007

ע"יHCV פוליפפטיד להכנת שיטההפרשתו

METHOD OF PRODUCING A SECRETED HCV POLYPEPTIDECHIRON CORPORATION

29/07/1994

08/282959US

25/07/1995

08/506608US

A01N18512522/02/2006

–D המכילים רפואיים תכשיריםENANTIOMERהלופוגינון של מבודד

PHARMACEUTICAL COMPOSITIONS OF THE ISOLATED D-ENANTIOMER OF THE QUINAZOLINONE DERIVATIVE HALOFUGINONE

COLLGARD BIOPHARMACEUTICALבע"מ ביופארמאסוטיקל קולגרדLTD.

23/05/2005

60/655413US

PCT/IL/2006/000236WO/2006/090376

F41A18512614/02/2006

כלי של קנה לתוך קליע להעברת התקןנשק

DEVICE FOR TRANSFERRING PROJECTILE INTO BARREL OF WEAPONPATRIA VAMMAS OY

15/02/2005

20055067FI

PCT/FI/2006/050064WO/2006/087425


G11C18512716/02/2006

לעיבוד במכשיר תהליך מידע של ניהולפלאזמה

PROCESSING INFORMATION MANAGEMENT IN A PLASMA PROCESSING TOOLLAM RESEARCH CORPORATION

18/02/2005

11/061414US

PCT/US/2006/005802WO/2006/089208

C07D18512920/11/2006

ותוצרי מונטלוקסט של ליצירה תהליךשלו ביניים

PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFORSYNTHON B.V.

18/11/2005

60/737752US

24/04/2006

60/794429US

01/09/2006

60/824382US

PCT/EP/2006/011127WO/2007/057225

C07C18513225/08/2006

מלחי של מתמיסות מתכת יוני סילוקי"אוניום" ו"אוניום" הידרוקסידים

REMOVAL OF METAL IONS FROM ONIUM HYROXIDES AND ONIUM SALT SOLUTIONSSACHEM INC.


02/09/2005

11/223247US

PCT/US/2006/033621WO/2007/027652

C07D18513510/02/2006

-PROCESS FOR PREPARING 2,3–דימותמרים3, 2 אינדולים להכנת תהליךDISUBSTITUTED INDOLESBOEHRINGER INGELHEIM INTERNATIONAL GMBH

11/02/2005

60/652072US

PCT/US/2006/004776WO/2006/086657

G08B18513709/02/2006

שווא, לביטול אזעקות להקטנת שיטותפנימית וגניבה מוצדקת שאינה אזעקה

TECHNIQUES TO REDUCE FALSE ALARMS, INVALID SECURITY DEACTIVATION, AND INTERNAL THEFTSENSORMATIC ELECTRONICS CORPORATION

10/02/2005

11/055293US

PCT/US/2006/004924WO/2006/086728


C12N18514213/03/2002

LENTIVIRAL PACKAGINGלאריזה לנטיוויראליים קונסטרוקטיםCONSTRUCTSNOVARTIS AG

13/03/2001

60/275275US

PCT/EP/2002/002807WO/2002/072851

C12Q18514310/02/2006

אנטיבקטריאליות מטרות של מקביל זיהויומעכבים

PARALLEL IDENTIFICATION OF ANTIBACTERIAL TARGETS AND INHIBITORSPINNACLE PHARMACEUTICALS, INC.

11/02/2005

60/652055US

PCT/US/2006/004853WO/2006/086696

C07D18514501/03/2006

CRYSTAL FORMS OF AN IMIDAZOLEאימידאזול של נגזרות של גבישיות צורותDERIVATIVEPFIZER INC.

11/03/2005

60/660592US

PCT/IB/2006/000754WO/2006/095268

C07D18514606/03/2006

בנזוקסזול של תרכובות לטיהור תהליךמותמר

PROCESS FOR THE PURIFICATION OF SUBSTITUTED BENZOXAZOLE COMPOUNDSWYETH

07/03/2005

60/659212US

PCT/US/2006/007887WO/2006/096624


C07K18514710/02/2006

REPLICATION-DEFICIENT RNAכחיסונים שכפול יכולת נטוליRNA וירוסיVIRUSES AS VACCINESMAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.

11/02/2005

10 2005 006 388.8

DE

PCT/EP/2006/001251WO/2006/084746

G06F18514804/04/2006

הקשור מידע לניהול ושיטות מערכותעבורם ומיכלים רפואיים בנוזלים

SYSTEMS AND METHODS FOR MANAGING INFORMATION RELATING TO MEDICAL FLUIDS AND CONTAINERS THEREFORMALLINCKRODT INC.

06/04/2005

60/668647US

06/04/2005

60/668681US

16/05/2005

60/681252US

12/09/2005

60/716166US

19/09/2005

60/718545US

PCT/US/2006/012620WO/2006/108026

G06F18514904/04/2006




06/04/2005

60/668647US

06/04/2005

60/668681US

16/05/2005

60/681252US

12/09/2005

60/716166US

19/09/2005

60/718545US

PCT/US/2006/012620WO/2006/108026

G06F18515004/04/2006

הקשור מידע לניהול ושיטות מערכתעבורם ומיכלים רפואיים בנוזלים


06/04/2005

60/668647US

06/04/2005

60/668681US

16/05/2005

60/681252US

12/09/2005

60/716166US

19/09/2005

60/718545US

PCT/US/2006/012620WO/2006/108026


G06F18515104/04/2006



06/04/2005

60/668647US

06/04/2005

60/668681US

16/05/2005

60/681252US

12/09/2005

60/716166US

19/09/2005

60/718545US

PCT/US/2006/012620WO/2006/108026

G06F18515204/04/2006



06/04/2005

60/668647US

06/04/2005

60/668681US

16/05/2005

60/681252US

12/09/2005

60/716166US


19/09/2005

60/718545US

PCT/US/2006/012620WO/2006/108026

G06F18515304/04/2006



06/04/2005

60/668647US

06/04/2005

60/668681US

16/05/2005

60/681252US

12/09/2005

60/716166US

19/09/2005

60/718545US

PCT/US/2006/012620WO/2006/108026

G06F18515404/04/2006




06/04/2005

60/668647US

06/04/2005

60/668681US

16/05/2005

60/681252US

12/09/2005

60/716166US

19/09/2005

60/718545US

PCT/US/2006/012620WO/2006/108026

G06F18515504/04/2006



06/04/2005

60/668647US

06/04/2005

60/668681US


16/05/2005

60/681252US

12/09/2005

60/716166US

19/09/2005

60/718545US

PCT/US/2006/012620WO/2006/108026

G06F18515604/04/2006



06/04/2005

60/668647US

06/04/2005

60/668681US

16/05/2005

60/681252US

12/09/2005

60/716166US

19/09/2005

60/718545US

PCT/US/2006/012620WO/2006/108026


G06F18515704/04/2006



06/04/2005

60/668647US

06/04/2005

60/668681US

16/05/2005

60/681252US

12/09/2005

60/716166US

19/09/2005

60/718545US

PCT/US/2006/012620WO/2006/108026

H01L18516223/03/2006

TWO F-NUMBER, TWO COLORמוקדים צבעים, שני שני חיישנים מערכתSENSOR SYSTEMRAYTHEON COMPANY

27/07/2005

11/190688US

PCT/US/2006/010470WO/2007/018616

C07D18516317/02/2006

– – פיראזולH 1 – – דיפניל5, 1) תולדות להכנתן, – איל( אוקסאדיאזול, שיטה3

בטיפולים ויישומן

(1,5 - DIPHENYL - 1H - PYRAZOL - 3 - YL )OXADIAZOLE DERIVATIVES,

PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICSSANOFI-AVENTIS

21/02/20050501860FR

PCT/FR/2006/000368


WO/2006/087480

C07D18516415/02/2006

ותרכובות חדשים איזותיאזולוקווינולוניםזיהום נגד כגורמים דומות

NEW ISOTHIAZOLOQUINOLONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTSACHILLION PHARMACEUTICALS, INC.

16/02/2005

60/653434US

PCT/US/2006/005522WO/2006/089054

C07D18516620/02/2006

2, 1–אריל–3 של חדשות תולדות אותן, המכילים בנזיסוקסאזול, הרכבים

בהן ושימוש

NOVEL 3-ARYL-1,2-BENZISOXAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOFAVENTIS PHARMA S.A.

22/02/20050501801FR

PCT/FR/2006/000375WO/2006/090052

A61M18516709/02/2006

WINDOW SHADE DEVICEחלון לתריס מתקןUZI KUPFERקופפר עוזי

14/02/2005

60/651979US

PCT/IL/2006/000177WO/2006/085325


G21B18516807/03/2006

PLASMA-ELECTRIC GENERATIONפלזמה–חשמלית ייצור מערכתSYSTEMTHE REGENTS OF THE UNIVERSITY OF CALIFORNIA

07/03/2005

60/659738US

07/03/2005

60/659525US

07/03/2005

60/659549US

07/03/2005

60/659767US

PCT/US/2006/008251WO/2006/096772

H03M18516909/02/2006

APPLIANCE WITH COMMUNICATIONתקשורת פרוטוקול חיקוי עם מתקןPROTOCOL EMULATION

M-SYSTEMS FLASH DISK PIONEERSבע"מ פיונירס דיסק פלש אם-סיסטמסLTD.

11/02/2005

60/651762US

PCT/IL/2006/000175WO/2006/085323


G11C18517009/02/2006

מסוג פלאש זיכרון מערכת ארכיטקטורתNAND

NAND FLASH MEMORY SYSTEM ARCHITECTURE

M-SYSTEMS FLASH DISK PIONEERSבע"מ פיונירס דיסק פלש אם-סיסטמסLTD.

11/02/2005

60/651762US

13/01/2006

60/758599US

PCT/IL/2006/000176WO/2006/085324

A61K18517129/01/2006

ATOMCHIP DEVICEשבב–אטום מתקן

למחקר הרשות בנגב גוריון בן אוניברסיטתופיתוח

BEN-GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY

14/02/2005

60/651982US

PCT/IL/2006/000118WO/2006/085299

C07F18517210/02/2006

SUBSTITUTED PROPANEפוספינית פרופאנית חומצה של אסטריםPHOSPHINIC ACID ESTERSAVENTIS PHARMACEUTICALS INC.

11/02/2005

60/652152US

PCT/US/2006/004938WO/2006/086734


C07D18517310/02/2006

מותמרות והטרואריל ביס–אריל תרכובות בררני5A2 HT של כאנטגוניסטים

SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUNDS AS SELECTIVE 5HT2A ANTAGONISTSAVENTIS PHARMACEUTICALS INC.

10/02/2005

60/651911US

PCT/US/2006/004879WO/2006/086705

G06F18517408/02/2006

בזכרונות נתונים קבצי של ישיר אחסוןפלאש

DIRECT DATA FILE STORAGE IN FLASH MEMORIESSANDISK CORPORATION

16/02/2005

11/060249US

PCT/US/2006/004658WO/2006/088727

G06F18517508/02/2006

ומחיקה נתונים קבצי של ישיר תכנותפלאש בזכרונות

DIRECT FILE DATA PROGRAMMING AND DELETION IN FLASH MEMORIESSANDISK CORPORATION

16/02/2005

11/060174US

PCT/US/2006/004585WO/2006/088723

C07F18517622/12/2003

נגזרות בהכנת המשמשים ביניים חומרי נגזרות של פעילים ומטבוליטים קווינאזולין

קווינאזולין פוספונואוקסי

INTERMEDIATES USED FOR THE PREPARATION OF QUINAZOLINE DERIVATIVES AND ACTIVE METABOLITES OF PHOSPHNOOXY QUINAZOLINE DERIVATIVES


ASTRAZENECA AB24/12/2002

02293238.8EP

02/06/2003

03291315.4EP

PCT/GB/2003/005613WO/2004/058781

G02B18517809/02/2006

ACTUATING DEVICE COMPRISINGמתכת דיסקיות שתי המכיל תפעול התקןBIMETAL DISKSSAGEM DEFENSE SECURITE

14/02/20050501474FR

PCT/FR/2006/000300WO/2006/085002

A61B18517906/03/2006

MEASURING ALERTNESSעירנות מדידתSLEEP DIAGNOSTICS PTY LTD.

04/03/2005

2005901026AU

PCT/AU/2006/000277WO/2006/092022

A61F18518320/06/2006

פרוייקציות המכילה בין–חולייתית תותבתעצמית להתחברות קבועות

INTERVERTEBRAL PROSTHESIS COMPRISING SELF-TAPPING FIXING PROJECTIONSCERVITECH, INC.

22/06/2005

05013517.7EP

PCT/EP/2006/005910WO/2006/136373

C07D18518506/02/2006


?– כמעכבי גואנידינים אזולילאצילסקרטאז

AZOLYLACYLGUANIDINES AS ?-SECRETASE INHIBITORSWYETH

14/02/2005

60/652696US

PCT/US/2006/004471WO/2006/088711

G06F18518708/02/2006

על לפיקוח מכשיר, שיטה, ומערכתהרכיב ברמת רשתות

)מודול(

DEVICE, METHOD, AND SYSTEM FOR MODULE LEVEL NETWORK SUPERVISION

ENURE NETWORKS LTDבע"מ רשתות אניור09/02/2005

60/651071US

PCT/IL/2006/000161WO/2006/085313

C07D18518814/02/2006

חדשות פירידין או פניל תרכובות עם הטרוציקלית בטבעת המותמרות

CXCR3 ל– אנטגוניסטית פעילות

NOVEL HETEROCYCLIC SUBSTITUTED PYRIDINE OR PHENYL COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITYSCHERING CORPORATION

16/02/2005

60/653332US

PCT/US/2006/005128WO/2006/088840

G01N18518916/02/2006

לדיאגנוזה, פרוגנוזה ומערכות שיטותללוקמיה טיפול ובחירת

METHODS AND SYSTEMS FOR DIAGNOSIS, PROGNOSIS AND SELECTION OF TREATMENT OF LEUKEMIAWYETH

16/02/2005

60/653117US

PCT/US/2006/005855


WO/2006/089233

A61B18519017/02/2006

PERCUTANEOUS SPINAL IMPLANTSושיטות השדרה לעמוד העור דרך שתליםAND METHODSKYPHON INC.

17/02/2005

11/059526US

01/07/2005

60/695836US

19/10/2005

11/252880US

19/10/2005

11/252879US

PCT/US/2006/005580WO/2006/089085

H04B18519128/02/2006

יבשתיים רדיו, ורכיבים שיטות, טרמינלי בטווח שימוש תוך התקשרות עבור מסייעיםאחר לוויין למפעיל המוקצה

METHODS, RADIOTERMINALS, AND ANCILLARY TERRESTRIAL COMPONENTS FOR COMMUNICATING USING SPECTRUM ALLOCATED TO ANOTHER SATELLITE OPERATORATC TECHNOLOGIES, LLC

08/03/2005

60/659463US

PCT/US/2006/006901WO/2006/096371


- תשכ"ז הפטנטים לחוק26 סעיף לפי הודעה1976

NOTICE UNDER SECTION 26 OF THE PATENTS LAW, 5727-1967

קובלו להלן מתפרסמים שפרטיהן הבקשות המעונין הפטנטים. כל לחוק17 סעיף לפי

מהבקשות בקשה פי על פטנט למתן להתנגד חדשים שלושה רשאי, תוך המתפרסמות

הפטנטים לרשם זה, להגיש יומן מתאריך לחוק30 סעיף לפי התנגדות הודעת

ואילך57 בתקנה הקבועה בדרך הפטנטים.1968 – הפטנטים, תשכ"ח לתקנות

The applications, particulars of which are set out below, have been accepted pursuant to Section 17 of the Patents Law. Any person wishing to oppose the grant of a patent on any of the applications published here, may, within three months from the date of this journal, give to the Commissioner of Patents notice under Section 30 of the Patents Law, in the manner prescribed in regulations 57 et seq of the Patents Regulations, 5728-1968

לפי מובאים ויישימים במידה הבקשות פרטיזה: סדר

Particulars of the applications, where applicable, are given in the following order:

Number of application [21] [11]הבקשה מספרTitle of invention [54]האמצאה שם

Application date [22]הבקשה תאריך מדינת – החוץ בקשות של ותאריך מספרהאגוד

[31] [32] [33] Number and date of foreign application – convention country.

.Int.Cl [51]*שביעית מהדורה – בינלאומי *סיווגApplication for patent of addition [61] מוסף לפטנט בקשהDivisional application [62]חלוקה בקשת

Applicant [71]המבקשInventor [72]הממציא

International Publication Number [87]הבינלאומית בקשה של מס' פרסום Address for service [74]מסמכים למסירת מען

Abridgement of invention (in the [57]הפירוט( ערוך בה )בשפה האמצאה תקצירlanguage in which the specification is drawn up)

מס' והמדגמים הפטנטים מיומן *הערה: החל לפי הסיווג פטנטים לבקשות ציון ניתן1/06

של הבינלאומי הסיווג של השמינית המהדורה(2006 )משנה פטנטים

*Note: As from Patents and Designs Journal No.1/06, patent applications are classified according to the Eighth Edition of the International Patent Classification (2006)

118579]21][11[


אנטיגן המכיל אימונוגני תכשירוליפופרוטאין

IMMUNOGENIC COMPOSITION COMPRISING AN ANTIGEN AND A LIPOPROTEIN

]54[

05.06.1996]22[US]33[07.06.1995]32[08/476656]31[US19.01.199608/588621

Int. Cl.8 A61K 039/02, 039/102, 039/116, 039/385, C07K 014/195, 014/20, 014/285]51[CONNAUGHT LABORATORIES, INC., U.S.A.

]71[

ROBERT S. BECKER, ROBERT C. HUEBNER, MARYANN GRAY, KAREN S. BISCARDI, LORNE F. ERDILE, BRUNO GUY

]72[

לביא, שמעון, ירושלים21 הרצוג

SIMON LAVIE, 21 HERZOG ST,.

JERUSALEM

]74[

]57 [Use of a first composition comprising at least one antigen and a second composition comprising an antigenic lipoprotein in the preparation of a medicament for use in inducing an immunological response in a host, wherein the antigenic lipoprotein is an expression product of a hybrid nucleic acid molecule

comprising a first nucleic acid sequence encoding a signal sequence of a lipoprotein and a second nucleic acid sequence encoding a mature protein, or fragment thereof, which is heterologous to the lipoprotein encoded by the first nucleic acid sequence.

__________


125177]21][11[

המותמרים פירולידין נגזרי – דיאוקסאוליל–3,1 – בבנזו

ותרכובות ובבנזופוראניל, הכנתםאותם הכוללות פרמצבטיות

BENZO-1,3-DIOXOLYL- AND BENZOFURANYL SUBSTITUTED PYRROLIDINE DERIVATIVES, THEIR

PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM

]54[

12.02.1997]22[US]33[13.02.1996]32[08/600625]31[US04.02.199708/794506

Int. Cl.8 A61K 031/40, A61P 043/00, C07D 207/16, 401/14, 403/02, 405/04, 413/04, 417/04, C07F 009/09, 009/141

]51[

ABBOTT LABORATORIES, U.S.A.]71[WO/1997/030045]87[

ושות', כהן שלמה ד"ראביב , תל11490 , ת.ד. 124 גבירול אבן

DR. SHLOMO COHEN & CO,. 124 IBN GABIROL ST,.

P.O.B. 11490 ,TEL AVIV 62038

]74[

]57 [A compound of the formula:

whereinZ is –C(R18)(R19) – or –C(O)- wherein R18 and R19 are independently selected from hydrogen and loweralkyl; n is 0 or 1;

R is –(CH2)m-W wherein m is an integer from 0 to 6 and W is

)a– (C(O)2-G wherein G is hydrogen or a carboxy protecting group,

)b– (PO3H2,)c– (P(O)(OH)E wherein E is hydrogen,

loweralkyl or aryalkyl,)d– (CN,

)e– (C(O)NHR17 wherein R17 is loweralkyl,)f (alkylaminocarbonyl,

)g (dialkylaminocarbonyl,)h (tetrazolyl,

)i (hydroxy,)j (alkoxy,

)k (sulfonamide,)l– (C(O)NHS(O)2R16 wherein R16 is

loweralkyl, haloalkyl, aryl or dialkylamino, )m– (S(O)2NHC(O)R16 wherein R16 is

defined as above,


R1 and R2 are independently selected from hydrogen, loweralkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxycarbonylalkyl, hydroxyalkyl, haloalkyl, halolkoxyalkyl, alkoxyalkoxyalkyl, thioalkoxyalkoxyalkyl, cycloalkyl, cycloalkylalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, aminocarbonylalkyl, aminocarbonylalkenyl, alkylaminocarbonylalkenyl,

dialkylaminocarbonylalkenyl, hydroxyalkenyl, aryl, arylalkyl, aryloxyalkyl, arylalkoxyalkyl, heterocyclic, (heterocyclic) alkyl and (Raa)(Rbb)N-Rcc- wherein Raa is aryl or arylalkyl, Rbb is hydrogen or alkanoyl and Rcc is alkylene, with the proviso that one or both of R1 and R2 is other than hydrogen;

R3 is (a)R4-C(O)-R5-, R4-R5a-, R6-S(O)2-R7- or R26-S(O)-R27- wherein R5 is (i) a covalent bond, (ii) alkylene, (iii)


alkenylene, (iv) –N(R20)-R8- or –R8a- N(R20)-R8-

wherein R8 and R8a are independently selected from the group consisting of alkylene and alkenylene and R20 is hydrogen, loweralkyl, alkenyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl,cycloalkyl or cycloalkylalkyl or (v) –O-R9 or –O-R9a-O-R9-wherein R9 and R9a are independently selected from alkylene; R5a is (i) alkylene or (ii) alkenylene;

R7 is (i) a covalent bond, (ii) alkylene, (iii) alkenylene or (iv) –N(R21)-R10- or –R10a- N(R21)-R10- wherein R10 and R10a are independently selected from the group consisting of alkylene and alkenylene and R21 is hydrogen, loweralkyl, alkenyl,

haloalkyl, alkoxyalkyl, haloalkoxyalkyl, aryl, or arylalkyl; R4 and R6 are independently selected from the group consisting of

)i) (R11)(R12(N- wherein R11 and R12 are independently selected fromhydrogen, loweralkyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, heterocyclic, arylalkyl, and (heterocyclic) alkyl loweralkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclic, (heterocyclic) alkyl, alkoxyalkyl, hydroxyalkyl, haloalkyl, haloalkenyl, haloalkoxyalkyl, haloalkoxy, alkoxyhaloalyl, alkylaminoalkyl, dialkylaminoalkyl, and

wherein z is 0-5 and R7a is alkylene;R26 is (i) loweralkyl, (ii) haloalkyl, (iii) alkenyl, (iv) alkynyl, (v) cycloalkyl, (vi) cycloalkylalkyl, (vii) aryl, (viii) arylalkyl (ix) heterocyclic, (x) (heterocyclic) alkyl, (xi) alkoxyalkyl or (xii) alkoxy-substituted haloalkyl; and R27 is alkylene or alkenylene;

)b (R22-O-C(O)-R23- wherein R22 is a carboxy protecting group or heterocyclic and R23 is (i) a covalent bond, (ii) alkylene, (iii) alkenylene or (iv) – N(R24)-R25- wherein R25 is alkylene and R24 ishydrogen or loweralkyl loweralkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, aryloxyalkyl, heterocyclic heterocyclic, (heterocyclic) alkyl, alkoxyalkyl, alkoxyalkoxyalkyl, or R13-C(O)-CH(R14)-

wherein R13 is amino, alkylamino or dialkylamino and R14 is aryl or R15-C(O)-wherein R15 is amino, alkylamino or dialkylamino; or a pharmaceutically acceptable salt thereof, wherein cycloalkyl by itself or as part of another group may be optionally substituted with one, two or

three groups independently selected from loweralkyl, haloalkyl, alkoxy, thioalkoxy, amino, alkylamino, dialkylamino, hydroxy, halo, mercapto, nitro, carboxaldehyde, carboxy, alkoxycarbonyl, and carboxamide,wherein aryl by itself or as part of another group may be optionally substituted by one, two or three substituents independently selected from loweralkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, alkenyloxy, alkoxy, alkoxyalkoxy, alkoxycarbonyl, alkoxycarbonylalkenyl, (alkoxycarbonyl) thioalkoxy, thioaloxy, amino, alkylamino, dialkylamino, aminoalkyl, trialkylaminoalkyl, aminocarbonyl, aminocarbonylalkoxy, alkanoylamino, aryalkoxy, aryloxy, mercapto, cyano, nitro, carboxaldehyde, carboxy, carboxyalkenyl, carboxyalkoxy, alkylsulfonylamino, cyanoalkoxy, (heterocylic) alkoxy, hydroxy, hydroxyalkoxy, phenyl and tetrazolyalkoxy or aryl may be tetrafluorophenyl or pentafluorophenyl, and wherein heterocyclic by itself or as part of another


group may be optionally substituted with one or two groups independently selected from hydroxy, halo, oxo, alkylimino, alkylamino, diallylamino, alkoxy, alkoxyalkoxy, aminoalkyl, trialkylaminoalkyl, haloalkyl, cycloalkyl, aryl, aryalkyl, -COOH, -SO3H, alkoxycarbonyl, nitro, cyano and loweralkyl or heterocyclic may be N-protected,provided that at least one of the following conditions apply:

)a (R16 is aryl other than phenyl,)b (R1 is selected from haloalkyl,

haloalkoxyalkyl, cycloalkylalkyl, arylalkyl, aryloxyalkyl and (heterocyclic) alkyl,

)c (R2 is selected from haloalkyl, haloalkoxyalkyl, cycloalkylalkyl, arylalkyl, aryloxyalkyl and (heterocyclic) alkyl,

)d (R3 is R4-R5a – other than alkyl, alkenyl, alkynyl, cycloalkylalkyl, arylalkyl, alkoxyalkyl or (heterocyclic) alkyl,

)e (R5 is –N(R20)-R8-wherein R8 is alkeneylene or R20 is haloalkyl, alkoxyalkyl or haloalkoxyalkyl,

)f (R5 is –R8a- N(R20)-R8-where R8 or R8a is alkenylene or R20 is haloalkyl, alkoxyalkyl or haloalkoxyalkyl,

)g (R7 is –N(R21)-R10- where R10 is selected from alkenylene or R21 is alkenyl, haloalkyl, alkylalkyl, haloalkoxyalkyl, aryl and arylalkyl,

)h (R7 is –R10a –N(R21)-R10,-

)i (R11 or R12 is selected from haloalkyl and haloalkoxyalkyl,

)j (R4 or R6 is selected from hydroxyalkyl, haloalkyl, haloalkenyl, haloalkoxyalkyl, haloalkoxy, alkoxyhaloalkyl, alkylaminoalkyl, dialkylaminoalkyl and (xx) ,

)k (at least one of said optionally substituted aryl groups has at least one substituent selected from hydroxyalkyl and cyano, or

)l (at least one of said optionally substituted heterocyclic groups has at least one substituent selected from alkoxycarbonyl, nitro and cyano,except that the following compounds are excluded:

where R3 is selected from


and, (b) compounds 1-210 in Table 2A and 1-21 in Table 3A of the specification where

the substituent R3 on the pyrrolidine ring nitrogen is selected from

___________


125464]21][11[

רגישות לקביעת ושיטות תכשירים ויראליות אנטי לתרופות והתנגדות

ויראליות אנטי תרופות וסינון

COMPOSITIONS AND METHODS FOR DETERMINING ANTI-VIRAL DRUG SUSCEPTIBILITY AND RESISTANCE AND ANTI-VIRAL DRUG SCREENING

]54[

29.01.1997]22[US]33[29.01.1996]32[08/593009]31[

Int. Cl.8 C12N 015/49, 015/64, 015/86, C12Q 001/02]51[VIROLOGIC INC., U.S.A.]71[

WO/1997/027319]87[ושות', ש. הורוביץ

, תל41-45 רוטשילד ציון, שדרות בית אביב

S. HOROWITZ & CO,. ZION HOUSE,

41-45 ROTHSCHILD BLVD,.TEL AVIV 65784

]74[

]57 [A method for determining susceptibility for an anti-HIV drug comprising:

)a (introducing a resistance test vector comprising a patient-derived segment and an indicator gene into a host cell;

)b (culturing the host cell from (a);)c (measuring expression of the indicator

gene in a target host cell, wherein the expression of the indicator gene is

dependent upon the patient-derived segment; and

)d (comparing the expression of the indicator gene from (c) with the expression of the indicator gene measured when steps (a)-(c) are carried out in the absence of the anti-HIV drug, wherein a test concentration of the anti-HIV drug is present at steps (a)-(c); at steps (b)-(c); or at step (c).

__________


126138]21][11[

בנזופיראנון או טטראלון של תולדותליצורן ושיטה

TETRALONE OR BENZOPYRANONE DERIVATIVES AND A METHOD FOR PRODUCING THEM

]54[

28.01.1998]22[JP]33[29.01.1997]32[9-28258]31[JP08.08.19979-225564

Int. Cl.8 A61K 031/122, 031/352, A61P 035/00, C07C 049/643, 049/697, C07D 311/00, 311/22

]51[

DAIICHI PHARMACEUTICAL CO., LTD., JAPAN

]71[

WO/98/032724]87[ושותפיו, הס יצחק ד"ר

אביב , תל6451 , ת.ד. 279 הירקון רחוב DR. YITZHAK HESS & PARTNERS,

279 HAYARKON ST,.P.O.B. 6451 ,

TEL AVIV 61063

]74[

]57 [A tetralone or benzopyranone derivative of the formula

wherein R1 and R2 represent a substituent substituted at the 6-position of said tetralone or the 7-position of said benzopyranone;

A is methylene or oxygenwherein A is a methylene (in a tetralone skeleton), R1 is a hydroxy group or a methoxy group at the 6-position of said tetralone, R2 is hydrogen,R3-R7 represents hydrogen, a hydroxy group, or alkyl or alkyloxy group having 1-2 carbon atoms, a halogen, a carboxy group

joined at R5 (4-position) or an amino group joined at R5 (4-position) substituted by two methyl groups, an alkylene dioxy group joined at R3 and R4, R4 and R5, R5 and R6, or R6 and R7, with the proviso that (a) when R1 is methoxy, R2-R6 are hydrogen, then R7

can not be hydrogen.)b (when R1 is methoxy, R2, R3, R4, R6 and

R7 are hydrogen, then R5 is not methoxy or halogen when A is oxygen (in a benzopyranone skeleton),


R1 is a hydroxy group or a methoxy group at the 7-position of said benzopranone, R2 is hydrogen,R3-R7 represents hydrogen., a hydroxy group, an alkyl or alkyloxy group having 1-2 carbon atoms, a halogen, an amino group substituted by two methyl groups, or an alkylene dioxy group joined at R3 and R4, R4 and R5, R5 and R6, or R6 and R7, with the proviso that

)a (when R1 is a hydroxy group, R2-R4, R6 and R7 are hydrogen, then R5 can not be a methoxy group;

)b (when R1 is a hydroxy group, R2, R3, R6 and R7 are hydrogen, R4 is methoxy, then R5 can not be a hydroxy group;

)c (when R1 is a hydroxy group, R2, R3, R6 and R7 are hydrogen, then both R4 and R5 can not be a hydroxy group.

__________

126971]21][11[

תכשירים להכנת באינטרפרון שימושאורומוקוסאלי למתן רוקחיים

USE OF INTERFERON FOR THE PREPARATION OF COMPOSITION FOR OROMUCOSAL CONTACT

]54[

05.05.1997]22[AU]33[09.05.1996]32[PN9765]31[AU03.12.1996PO3959AU24.12.1996PO4387

Int. Cl.8 A61K 038/21, A61P 025/28, 031/00, 031/04, 035/00, 037/00, C07K 014/555]51[PHARMA PACIFIC PTY. LTD., AUSTRALIA

]71[

WO/1997/041884]87[ושותפיו, כהן ריינהולד

, תל4060 , ת.ד. 21 העם אחד רחוב אביב

REINHOLD COHN AND PARTNERS,

21 AHAD HA'AM ST ,.P.O.B. 4060 ,

TEL AVIV 61040

]74[

]57 [Use of interferon in the preparation of a medicament for oromucosal contact to stimulate host defense mechanisms or an immune response in a human having an autoimmune, mycobacterial,

neurodegenerative, parasitic, neoplastic or viral condition, which medicament comprises a stimulating amount of the interferon, said amount being greater than 20 x 106 IU of interferon.

__________


128862]21][11[

[R –(R *R*) – ]2( – 4– –5 – – דיהידרוקסיß ,dפלואורופניל( –

–4 – – פניל3אתיל( – – מתיל1) – – פירול1H])פניאמינו( קרבוניל([ –

סידן מלחת המי הפטנואית – חומצה1גבישי )אטורואסטטין( הידראט

CRYSTALLINE [R-(R*R*)] - 2 - (4 - FLUOROPHENYL) - ß, ઠ - DELTA-DIHYDROXY - 5 - (1 - METHYLETHYL) - 3 - PHENYL - 4 - (PHENYLAMINO) CARBONYL] - 1H - PYRROLE - 1 - HEPTANOIC ACID HEMI CALCIUM SALT (ATORVASTATIN)HYDRATE

]54[

08.07.1996]22[US]33[17.07.1995]32[60/001452]31[

Int. Cl.8 A61K 031/40, A61P 003/06, C07D 207/34]51[DIVISION FROM 122118]62[WARNER-LAMBERT COMPANY LLC, U.S.A.

]71[

WO/1997/003959]87[ושות', ט. קולב סנפורד

,2273, ת.ד. , מרמורק4 הגיא שער רחובות

SANFORD T.COLB & CO,. P.O.B. 2273 ,

REHOVOT 76122

]74[

]57 [A crystalline Form I atorvastatin hydrate having an X-ray power diffraction

containing the following 2Ө value measured using CuKα radiation: 22.0.

מבקשה חלוקה בקשותפורסמו. שטרם זו

177377,The applications for division from this application have not yet been published

__________


129139]21][11[

גרעין סמות'נד, נוגדנים, חומצת חלבוני כימריים, אותם, חלבונים המקודדת

לייצורם מאכסן, תהליך וקטורים, תאישלהם ושימושים

SMOOTHENED PROTEINS, ANTIBODIES, NUCLEIC ACID ENCODING THE SAME, CHIMERIC PROTEINS, VECTORS, HOST CELLS, PROCESS FOR MANUFACTURE AND USES THEREOF

]54[

29.09.1997]22[US]33[30.09.1996]32[08/720484]31[

Int. Cl.8 A01K 067/027, C07K 014/46, 014/47, 014/705, 016/18, 019/00, C12N 001/19, 001/21, 005/10, 015/12, 015/63

]51[

GENENTECH, INC., U.S.A.]71[ושות', ש. הורוביץ




]74[

]57 [Isolated Smoothened polypeptide comprising an amino acid sequence having at least about 80% sequence identity with

residues 1 to 787 of SEQ ID NO: 4 or with residues 1 to 793 of SEQ ID NO:2.

__________

132226]21][11[

PROBE FOR INSERTION INTO Aהגוף לתוך להחדרה בדיקה מכשירBODY

]54[

10.02.1998]22[Int. Cl.8 A61M 025/16]51[BIOSENSE INC., U.S.A.]71[




REHOVOT 76122

]74[

]57 [A probe assembly for connection to a console comprising: a probe (20) for insertion into the body of a subject, said probe having distal and proximal ends and comprising a microcircuit (90) which

stores information relating to the probe, wherein the information relating to the probe comprises usage-related information of the probe and the usage related information comprises a usage code, which


controls availability of the probe to a user thereof; and a cable (21) for connecting the probe to the console, said cable comprising

access circuitry for accessing the microcircuit in the probe.

__________

133039]21][11[

תקשורת בקו חוזר לשידור משדרדו–כיווני

FULL DUPLEX RE-TRANSMITTER

]54[

18.11.1999]22[Int. Cl.8 G06F 013/00, 015/173, H04L 012/56]51[

בע"מ, רעננה אייבלסטרירון, רענננה ניר

EYEBLASTER LTD.NIR YARON

]71[

ושותפיו, כהן ריינהולד , תל4060 , ת.ד. 21 העם אחד רחוב

אביב



TEL AVIV 61040

]74[

]57 [A method for efficiently exploiting an upstream channel bandwidth of full-duplex connection between user terminal and data network, said method comprising: providing a coordination center to monitor data files downloaded by user terminals over said data network and maintain a register of the locations and file identifier of each of the downloaded data files amongst said user terminals; receiving by the coordination center from a first user terminal a request for a data file; determining by the coordination center

whether a location of the requested data file is registered in the register, and if registered, determining a second user terminal corresponding to the registered location of the requested data file; sending an instruction from the coordination center to the second user terminal to send the requested data file to the first user terminal through the upstream channel bandwidth of the second user terminal; receiving said requested data file on said first user terminal; causing said received data file to be re-transmitted through said upstream


channel bandwidth from said first user terminal to a first group of one or more other user terminals; and causing said received data file to be re-transmitted through said upstream channel bandwidth

from said first group of user terminals to a further group of one or more other user terminals, and repeating this step for all said user terminals requesting the same said data file.

__________

133282]21][11[

של תוך–תאיים נתיבים של מודולטוריםתאים והשרדות תאים מוות דלקות

MODULATORS OF INTRACELLULAR INFLAMMATION CELL DEATH AND CELL SURVIVAL PATHWAYS

]54[

01.06.1998]22[IL]33[05.06.1997]32[121011]31[IL30.06.1997121199IL11.09.1997121746

Int. Cl.8 A61K 038/17, C07K 014/47, 016/18, C12N 015/12]51[ YEDA RESEARCH ANDבע"מ, רחובות ופיתוח למחקר חברה ידע

DEVELOPMENT CO. LTD.]71[

WO/1998/055507]87[בע"מ, לאב אינטר

ציונה ויצמן, נס קרית INTERLAB LTD,.

KIRYAT WEIZMANN,NES ZIONA 76110

]74[

]57 [A DNA sequence comprising a nucleotide sequence selected from the group consisting of:

)a (nucleotide sequences encoding the amino acid sequence depicted in Fig. 3 of the specification;

)b (the nucleotide sequence depicted in Fig 3;

)c (nucleotide sequences being a fragment of a nucleotide sequence of (a) or (b);

)d (nucleotide sequences capable of hybridizing under moderately stringent conditions to a nucleotide sequence of any one of (a) to (c);

)e (nucleotide sequences encoding an amino acid sequence which differs by not


more than ten amino acid changes from an amino acid sequence encoded by a nucleotide sequence of any one of (a) to (c); and

)f (nucleotide sequences which deviate from a nucleotide sequence defined in any

one of (a) to (e) as a result of the degeneracy of the genetic code;

wherein the polypeptide encoded by the nucleotide sequence of any one of (c) to (f) is capable of

)i (activating NF-κB; and/or

__________

134366]21][11[

על מציפורים מקור תאי שורת של ייצור , שימושPGCs של ממושך תירבות ידי

כימרים וייצור לשיבוט בהם

PRODUCTION OF AVIAN EMBRYONIC GERM (EG) CELL LINES BY PROLONGED CULTURING OF PGCS AND USE THEREOF FOR CLONING AND CHIMERIZATION

]54[

04.08.1998]22[US]33[04.08.1997]32[60/054677]31[

Int. Cl.8 C12N 005/02, 005/10, 015/00]51[UNIVERSITY OF MASSACHUSETTS, U.S.A.

]71[





TEL AVIV 61040

]74[

]57 [A culturing method which provides for the isolation and maintenance of avian primordial germ cells (PGCs) and the production of embryonic germ (EG) cells comprising the following steps:

)i (isolating primordial germ cells from a desired avian; and

)ii (culturing said primordial germ cells is a culture medium containing at least the following growth factors contained in

amounts sufficient to maintain said PGCs for at least 25 days in tissue culture;

)1 (leukemia inhibitory factor (LIF),)2 (basic fibroblast growth factor (bFGF),

)3 (stem cell factor (SCF) and)4 (insulin-like growth factor (IGF),

for at least 25 days and at least until the culture has a compact multilayer like appearance that contains EG cells;

)iii (identifying EG cells contained therein.

__________


135020]21][11[

למניעת אמצעיים במכיל לשיניים שתלהעליון המבנה של סיבובו

DENTAL IMPLANT COMPARTMENT CONTAINING MEANS FOR ANTIROTATION OF ITS SUPERSTRUCTURE

]54[

12.03.2000]22[FR]33[12.03.1999]32[99/03054]31[

Int. Cl.8 A61C 008/00]51[GUY GABRIEL PELTIER, FRANCEJEANINE GOURLAOUEN-PREISSLER, FRANCE

]71[


אביב



TEL AVIV 61040

]74[

]57 [A dental implant comprising an implant body (1) intended to be implanted in the bony tissue (10) of the mandible or of the maxilla, a so-called post or abutment piece (2) which is to take a dental prosthesis, the assembly of the two pieces – implant and post – being intended to be secured by a transfixing screw (3), said two

pieces being pressed on to the other via two faces (11) having a large number of complementary radial teeth (4, 4a), in particular from 24 to 36 teeth, characterized in that the sections of the teeth have angles from 45 degrees to 90 degrees.


__________135036]21][11[

פעילות בעלי קוינולונים המכילים אנטימיקרוביאלית, תכשירים

בהם והשימוש אותם

ANTIMICROBIAL QUINOLONES, THEIR COMPOSITIONS AND USES

]54[

15.09.1998]22[US]33[15.09.1997]32[60/058891]31[US25.08.199809/139859

Int. Cl.8 A61K 031/47, A61P 031/00, C07D 401/10]51[THE PROCTER & GAMBLE COMPANY, U.S.A.

]71[





TEL AVIV 61040

]74[



wherein:)a (X is selected from

)b (R1 is selected from C3 to C5 cycloalkyl, C1 to C2 alkanyl, C2 to C3 linear alkenyl, C3 to C4 branched alkanyl or alkenyl, all such alkyl or cycloalkyl moieties being unsubstituted or substituted with from 1 to 3 fluoro; and phenyl, unsubstituted or substituted with from 1 to 3 fluoro, or with one hydroxy in the 4-position;

)c (R3 is hydrogen or hydroxy;)d (R5 is selected from hydrogen, hydroxy,

amino, halo, C1 to C2 alkanyl, C2 alkenyl, and methoxy, all such alkyl and methoxy moieties being unsubstituted or substituted with from 1 to 3 fluoro;

)e (R6 is selected from hydrogen, hydroxy, aminocarbonyl, cyano, C1 to C2 alkanyl, C2 to C4 alkenyl or alknyl, all such alkyl

moieties being unsubstituted or substituted with from 1 to 3 fluoro, or such methyl or ethyl moieties being optionally substituted with one hydroxy or amino;

)f (R8 is selected from chloro, bromo, methoxy, methylthio, C1 to C2 alkanyl, C2 to C4 alkenyl, all such alkyl, methoxy and methylthio moieties being unsubstituted or substituted with from 1 to 3 fluoro;

)g (R7 is amino which is attached to a ring carbon of X which is not adjacent to the ring nitrogen, the amino being unsubstituted or substituted with one or two C1 to C3 alkanyl; or aminoalkanyl which is attached to any ring carbon of X and is C1 to C3 alkanyl substituted with one amino, the amino being unsubstituted or substituted with one or two C1 to C3 alkanyl; and wherein R7 is an aminoalkanyl when X comprises a pyrrolidinyl ring;

)h (each R9 is independently selected from hydrogen, C1 to C4 alkanyl, C2 to C6 alkenyl or alkynyl, and a C3 to C6 fused or spirocycle alkyl ring, all such alkyl moieties being unsubstituted or substituted with from 1 to 3 fluoro; and

)j (a R7 moiety described in (g) and a R9 moiety described in (h) may optionally be connected thus forming a fused or spirocycle ring with the N-containing ring shown in (a), the fused or spirocycle ring comprising from 2 to 5 ring carbons and 0 or 1 ring nitrogen, but if such rings are fused, R8 is other than chloro or bromo; an optical isomer, diastereomer or enantiomer thereof; a pharmaceutically-acceptable salt, hydrate, or biohydrolyzable ester, amide or imide thereof.


__________

135343]21][11[

, ארילאוקסי–אלקיל–דיאלקילאמיניםאותם המכילים רוקחות ותכשרי הכנתם

ARYLOXY-ALKYL-DIALKYLAMINES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

]54[

14.10.1998]22[US]33[15.10.1997]32[08/950818]31[US28.09.199809/161653

Int. Cl.8 C07C 217/00]51[WYETH, U.S.A.]71[





TEL AVIV 61040

]74[


wherein:R1 and R2 are, independently, selected from H; C1-C12 alkyl or C1-C6 perfluronated

alkyl; X is selected from halogen, -O-SO2-CH3, -O-SO2-CF3, or a moiety of the structure;

Z is –NO2, halogen, -CH3 or –CF3;A is selected from –O- or –S-, -SO- or –

SO2;-m is an integer from 0 to 3;

R3, R4, R5, and R6 are independently selected from H, halogen, -NO2, alkyl, alkoxy, C1-C6 perfluorinated alkyl, OH or the C1-C6 perfluorinated alkyl, OH or the C1-C4 esters or alkyl ethers thereof, - CN, -


O-R1, -O-Ar, -S-R1, -S-Ar, -SO-R1, -SO-R1, -SO-Ar, -SO2-R1, -SO2-Ar, -CO-R1, -CO- Ar, -CO2-R1, or –CO2-Ar; and

Y is selected from:)a (the moiety;

wherein R7 and R8 are combined by –(CH2)p-wherein p is an integer from 2 to 6 so as to form a ring, the ring being optionally substituted by up to three substituents selected from the group of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 alkylsulfinyl, C1-C4

alkylsulfonyl, hydroxy (C1-C4) alkyl, -CO2H, -CN, -CONH(C1-C4) alkyl, - NH2, C1-C4 alkylamino, C1-C4 dialkylamino, -NHSO2(C1-C4)alkyl, -NHCO (C1-C4) alkyl, and –NO2;

)b (a five-membered saturated, unsaturated or partially unsaturated heterocycle containing up to two heteroatoms selected from the group consisting of –O-, -NH-, -N(C1-C4 alkyl)-, -N=, and –S(O)n-, wherein n is an integer of from 0-2, optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C1-C4

alkylthio, C1-C4 alkylsulfinyl, C1-C4

alkylsulfonyl, hydroxy (C1-C4) alkyl,)c (a six-membered saturated, unsaturated

or partially unsaturated heterocycle containing up to two heteroatoms selected from the group consisting of –O-, -NH-, -N(C1-C4 alkyl)-, -N=, and –S(O)n-, wherein n is an integer of from 0-2, optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C1-C4


alkylsulfonyl, hydroxy (C1-C4) alkyl, phenyl optionally substituted with 1-3 (C1-C4) alkyl, -CO2H, -CN, -CONHR1, -NH2, C1-C4 alkylamino, C1-C4 dialkylamino, - NHSO2R1, -NHCOR1, -NO2;

)d (a seven-membered saturated, unsaturated or partially unsaturated heterocycle containing up to two heteroatoms selected from the group consisting of –O-, -NH-, -N(C1-C4 alkyl)-, -N=, and –S(O)n-, wherein n is an integer of from 0-2, optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4

acyloxy, C1-C4 alkylthio, C1-C4

alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4) alkyl, phenyl optionally substituted with 1-3 (C1-C4) alkyl, -CO2H, -CN, -CONHR1, -NH2, C1-C4 alkylamino, C1-C4

dialkylamino, - NHSO2R1, -NHCOR1, -NO2- or

)e (a bicyclic heterocycle containing from 6-12 carbon atoms either bridged or fused and containing up to two heteroatoms selected from the group consisting of –O-, -NH-, -N (C1-C4 alkyl)-, and –S(O)n-, wherein n is an integer of from 0-2, optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C1-C4


alkylsulfonyl, hydroxy (C1-C4) alkyl, phenyl optionally substituted with 1-3 (C1-C4) alkyl, -CO2H, -CN, -CONHR1, -NH2,


C1-C4 alkylamino, C1-C4 dialkylamino, - NHSO2R1, -NHCOR1 or –NO2;

and the pharmaceutically acceptable salts thereof; providing that when X is halogen,

A is O and Y has formula (a) then the compounds are in the form of an acid addition salt.

__________

136076]21][11[

לציטוקין המקודד פולינוקליוטיד מםוג סלילים ארבעה בעל מיונקים

המקודד ופוליפפטידZcyto10 אלפאידו על

POLYNUCLEOTIDE ENCODING THE MAMMALIAN FOUR ALPHA HELIX CYTOKINE ZCYTO 10 AND POLYPEPTIDE ENCODED THEREBY

]54[

25.11.1998]22[US]33[26.11.1997]32[08/979156]31[

Int. Cl.8 A61K 038/19, A61P 001/02, 011/00, 017/00, 035/00, 037/02, 043/00, C07K 014/52, 016/24, 016/42, C12N 001/19, 001/21, 005/10, 015/19, 015/63, G01N 033/53

]51[

ZYMOGENETICS INC., U.S.A.]71[WO/1999/027103]87[


אביב



TEL AVIV 61040

]74[

]57 [An isolated polynucleotide which encodes a polypeptide, said polypeptide being at least 80% identical to one or more polypeptides selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:4, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:34, and SEQ ID NO:35, or an isolated

polynucleotide which encodes a polypeptide selected from the group consisting of SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO: 27, SEQ ID NO:28, SEQ ID NO: 29, SEQ ID NO:30, SEQ ID NO:31, and SEQ ID NO:32.

__________

137691]21][11[

FERMENTATIVE PREPARATIONאפותילונים להכנת תסיסה תהליךOF EPOTHILONES

]54[

17.02.1999]22[CH]33[19.02.1998]32[396/98]31[CH05.05.19981007/98

Int. Cl.8 A61K 031/427, A61P 035/00, B01D 015/08, C07D 493/04, C12P 017/18]51[NOVARTIS AG, SWITZERLAND]71[


WO/1999/042602]87[לוצאטו, את לוצאטו

שבע , באר5352, ת.ד. תעשייה, עומר גן LUZZATTO & LUZZATTO,

INDUSTRIAL PARK, OMER,P.O.B. 5352,

BEER-SHEVA 84152

]74[

]57 [A process for concentrating epothilones in a culture medium for the biotechnological preparation of these compounds, the process comprising use of microorganisms which produce these compounds, wherein one or more cyclodextrins are added to the medium as a complex-forming component, the cyclodextrins being selected from

)a (α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, δ-cyclodextrin, ε-cyclodextrin, ζ-cyclodextrin, ή-cyclodextrin and θ-cyclodextrin; or

)b (a cyclodextrin derivative selected from derivatives of

)1 (a cyclodextrin in which one or more up to all of the hydroxy groups are etherified to an alkyl ether; an aryl-hydroxyalkyl ether; a hydroxyalkyl ether, a carboxyalkyl ether; a derivatised carboxy lower alkyl ether in which the derivatised carboxy is aminocarbonyl, mono- or di-lower-alkylaminocarbonyl, morpholino-, piperidino-, pyrrolidino- or piperazino- carbonyl, or alkyloxycarbonyl; a sulfoalkyl ether;

)2 (a cyclodextrin in which one or more OH groups are etherified with a radical of the formula

-O-[alk-O-]n-H

wherein alk is alkyl and n is a whole number from and including 2 up to and including 12;

)3 (a cyclodextrin in which one or more OH groups are etherified with a radical of the formula

wherein R' is hydrogen, hydroxy, or –O-(alk-O)z-H; alk in all cases is alkyl;

m and z are a whole number from 1 to 12; and Y is OR1 NR2R3, wherein R1, R2 and R3, independently of one another, are hydrogen or lower alkyl, or R2 and R3, combined with the binding nitrogen signify morpholino, piperidino, pyrrolidino or piperazino; or

)4 (a branched cyclodextrin in which ether or acetal groupings are present with other sugar molecules, and which are selected

from glucosyl-, diglucosyl- (G2-β-cyclodextrin), maltosyl-and dimaltosyl-cyclodextrin, or N-acetylglucosaminyl-, glucosaminyl-, N-acetylgalactosaminyl- and galactosaminyl-cyclodextrin; and a lower alkanoyl-, such as acetylester of a cyclodextrin; or

)c (mixtures of two or more of the said cyclodextrin and/or cyclodextrin derivatives, and wherein the prefix "lower" indicates that the radical contains up to a maximum of 7 carbon atoms.


137766]21][11[

מנגיף מודיפיקציה שעברו ליבה חלבונישלהם ונגזרותB הפאטיטיס

MODIFIED HEPATITIS B CORE PROTEINS AND THEIR DERIVATIVES

]54[

11.02.1999]22[US]33[12.02.1998]32[60/074537]31[

Int. Cl.8 A61K 039/29, 039/385, 039/39, 047/48, A61P 031/20, C07K 014/02, 019/00, C12N 015/36

]51[

IMMUNE COMPLEX, CORPORATION, U.S.A.

]71[




REHOVOT 76122

]74[

]57 [A modified hepatitis B core protein conjugate comprising a modified hepatitis B core protein pendently linked to a hapten, wherein the modified hepatitis B core protein comprises an amino acid sequence corresponding to the hepatitis B core protein amino acid sequence of SEQ ID NO:2 including the amino acid residues numbered 10 to 140 and additionally

having an amino acid sequence insert in the region corresponding to amino acid residues number 50 to 100, said insert (i) being 1 to 40 amino acid residues in length, and (ii) containing a chemically-reactive amino acid residue, said hapten being pendently linked to the chemically-reactive amino acid residue in said modified hepatitis B core protein.

__________137809]21][11[

פנאומוקוקליים חיסונים עם המורכבים ומנינגוקוקליים12אינטרלאוקין–

PNEUMOCOCCAL AND MENINGOCOCCAL VACCINES FORMULATED WITH INTERLEUKIN-12

]54[

10.02.1999]22[US]33[12.02.1998]32[60/074528]31[

Int. Cl.8 A61K 039/09, 039/095, 039/385]51[WYETH HOLDINGS CORPORATION, U.S.A.

]71[




BEER-SHEVA 84152

]74[

]57 [A vaccine composition comprising a mixture of a pneumococcal capsular

polysaccharide conjugated to a carrier molecule, an adjuvant amount of


interleukin-12 and a mineral in suspension, and optionally comprising a physiologically acceptable vehicle.

__________

138034]21][11[

– ליגנד נוגדנים של סינרגיסטי שילובAPO–2HER–2ונוגד–

APO-2 LIGAND-ANTI-HER-2 ANTIBODY SYNERGISM

]54[

26.03.1999]22[US]33[27.03.1998]32[60/079683]31[

Int. Cl.8 A61K 039/395]51[GENENTECH, INC., U.S.A.]71[





TEL AVIV 61040

]74[

]57 [Use of a synergistically effective amount of Apo-2 ligand and anti-Her-2 antibody for preparing a pharmaceutical

composition for inducing apoptosis in mammalian cancer cells expressing Her-2 receptor.

__________

138221]21][11[

קונג'וגטים של לשמירה פורמולאציותאלפא –אינטרפרוןPEG של

FORMULATIONS FOR PROTECTION OF PEG-INTERFERON ALPHA CONJUGATES

]54[

24.03.1999]22[US]33[26.03.1998]32[09/048907]31[

Int. Cl.8 A61K 047/48]51[SCHERING CORPORATION, U.S.A.]71[

WO/1999/048535]87[ושות', כהן שלמה ד"ר

אביב , תל11490 , ת.ד. 124 גבירול אבן DR. SHLOMO COHEN & CO,.

124 IBN GABIROL ST,.P.O.B. 11490 ,

TEL AVIV 62038

]74[

]57 [An aqueous formulation that permits stabilization of PEG-interferon alpha

conjugates during and after lyophilization comprising polyethylene glycol (PEG)-


interferon alpha conjugates, a buffer, a stabilizer, a cryoprotectant and a solvent, wherein said cryoprotectant is sucrose.

__________

139687]21][11[

ß11α אינטגרין רצפטור במעכבי שימוש תכשירים להכנתß1 – TGF ובמעכבי

כליות במחלת לטיפול תרופתיים

USE OF α1ß1 INTEGRIN RECEPTOR INHIBITORS AND TGF-ß1 INHIBITORS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF KIDNEY DISEASE

]54[

19.05.1999]22[US]33[22.05.1998]32[60/086587]31[US02.06.199809/088766US09.09.199809/150485US15.04.199909/292534

Int. Cl.8 A01K 067/00, A61K 038/00, 038/39, 039/395]51[BOYS TOWN NATIONAL RESEARCH HOSPITAL, U.S.A.

]71[





TEL AVIV 61040

]74[

]57 [Use of an α 1β1 integrin receptor inhibitor for the preparation of a

pharmaceutical composition for limiting a kidney disorder.

__________

141145]21][11[

תירס ליבולי עשבים קוטלי תכשיריםעמידים או סובלניים

HERBICIDAL COMPOSITIONS FOR TOLERANT OR RESISTANT MAIZE CROPS

]54[

10.08.1999]22[DE]33[13.08.1998]32[19836737.

6]31[

DE30.04.199919919993.0Int. Cl.8 A01N 057/20]51[BAYER CROPSCIENCE GMBH, GERMANY

]71[


WO/2000/008936]87[צדק, וכהן איתן, פרל, לצר

, הרצליה12688 , ת.ד. 7 שנקר רחוב EITAN, PEARL, LATZER AND COHEN ZEDEK,

P.O.B. 12688 ,HERZLIYA 46733

]74[

]57 [A herbicidal composition comprising a herbicidal combination comprising:

)A (one or more broad spectrum herbicides selected from the group consisting of: (A1) compounds of the formula

in which Z is a radical of the formula –OH or a peptide radical of the formula –NHCH(CH3)CONHCH(CH3)COOH or – NHCH(CH3)CONHCH[CH2CH(CH3)2]CO

OH, and their esters and salts and other phosphinothricin derivatives,

)A2 (compounds of the formula

and their salts;)B (one or more herbicides selected from

the group consisting of:)B1 (herbicides selected from the group

consisting of cyanazine, benoxacor, rimsulfuron, fluthiamide, sulcotrione, mesotrione and penthoxamid;

)B2 (herbicides selected from the group consisting of metosulam, isoxaflutole, metribuzin, cloransulam, flumetsulam, linuron, florasulam and isoxachlortole; and

)B3 (herbicides selected from the group consisting of bromoxynil, thifensulfuron, carfentrazone, halosulfuron, diflufenzopyr and sulfosulfuron with the exception of herbicidal combinations which comprise

)a (the combination (A1) glufosinate and (B) isoxaflutole, flumetsulam, bromoxynil, linuron, thifensulfuron or rimsulfuron.

__________

141486]21][11[

גורם המכילים רוקחות תכשיריCD2ל– המתחבר

PHARMACEUTICAL COMPOSITIONS CONTAINING A

]54[


CD2 BINDING AGENT

31.08.1999]22[US]33[31.08.1998]32[60/098456]31[

Int. Cl.8 A61K 038/00, 038/17, 039/395, 048/00, A61P 001/00, 017/06, 029/00, C07K 014/705

]51[

ASTELLAS US LLC, U.S.A.]71[WO/2000/012113]87[

וגולר, וולף, ברגמן ,1352ב' , ת.ד. 19 היסוד קרן רחוב

ירושלים

WOLFF, BREGMAN AND GOLLER, 19B KEREN HAYESOD ST ,.

P.O.B. 1352,JERUSALEM 91013

]74[

]57 [Use of an effective amount of a CD2 binding agent selected from the group of anti-LFA-3 antibody homologs, soluble LFA-3 polypeptides, soluble CD2 polypeptides, CD2 mimetic agents, and LFA-3 mimetic agents for the preparation of a pharmaceutical composition for selectively reducing memory effector

CD45RO-positive T lymphocytes in a subject, thereby treating a medical condition, the condition being selected from the group consisting of psoriatic arthritis, multiple sclerosis, atopic dermatitis, uveitis, inflammatory bowel disease, Crohn's disease, ulcerative colitis and cutaneous T cell lymphoma.

__________

141899]21][11[

אנטגונעסט המכילים רוקחות תכשירי עם כמוקיין, יחד של לקולטן

ציקלוספורין

PHARMACEUTICAL COMPOSITIONS COMPRISING A CHEMOKINE RECEPTOR ANTAGONIST AND A CYCLOSPORIN

]54[

16.09.1999]22[EP]33[18.09.1998]32[98117697.

7]31[

Int. Cl.8 A61K 038/13, 038/19, A61P 037/06]51[APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.

]71[

WO/2000/016796]87[


בע"מ, מעבדות אינטרפארם ידע, עתירות לתעשיות ויצמן, פארק קרית

נס-ציונה

INTERPHARM LABORATORIES LTD,.


]74[

]57 [Use of a chemokine receptor antagonist in combination with a cyclosporin to produce a pharmaceutical

composition for treating or preventing the rejection of transplanted organs, tissues or cells.

__________

142629]21][11[

משאבת של בסיסי מלח להכנת תהליך ותהליך לחומצה הרגיש פרוטונים

את המכיל רוקחות תכשיר להכנתהתרכובות

PROCESS FOR MANUFACTURING AN ALKALINE SALT OF AN ACID SUSCEPTIBLE PROTON PUMP INHIBITOR AND A PROCESS FOR MANUFACTURING A PHARMACEUTICAL FORMULATION COMPRISING THE COMPOUND

]54[


15.11.1999]22[

SE]33[18.11.1998]32[9803952-2]31[SE18.11.19989803953-0

Int. Cl.8 A61K 031/395, A61P 001/04, C07D 235/28, 401/12, 401/14, 471/04, 495/04]51[ASTRAZENECA AB, SWEDEN]71[MAGNUS ERICKSON, ANDERS GUSTAVSSON, LARS JOSEFSSON

]72[




BEER-SHEVA 84152

]74[

]57 [A process for the manufacture of slightly soluble or less soluble alkaline salts of substituted sulphinyl heterocycles

containing an imidazole moiety of the formula

in racemic form, one of the single enantiomers or an enantiomeric enriched form

wherein Ar is


and X is

whereinN inside the benzene ring of the benzimidazole moiety means that one of the carbon atoms substituted by R7-R10 optionally may be exchanged for a nitrogen atom without any substituents;

R1, R2 and R3 are the same or different and selected from hydrogen, alkyl, alkylthio, alkoxy optionally substituted by fluorine, alkoxyalkoxy, dialkylamino, piperidino, morpholino, halogen, phenylalkyl and phenylalkoxy;

R4 and R5 are the same or different and selected from hydrogen, alkyl and aralkyl,R6 is hydrogen, halogen, trifluoromethyl, alkyl and alkoxy;

R7-R10 are the same or different and selected from hydrogen, alkyl, alkoxy, halogen, haloalkoxy, alkylcarbonyl,

alkoxycarbonyl, oxazolyl, trifluoroalkyl, or adjacent groups R7-R10 form ring structures which may be further substituted;

R11 is hydrogen or forms an alkylene chain together with R3 andR12 and R13 are the same or different and selected from hydrogen, halogen or alkyl,and wherein alkyl groups, alkoxy groups and moieties thereof may be branched and straight C1-C9-chains or comprise cyclic alkyl groups, for example cycloalkylalkyl,which process comprises the step of reacting the substituted sulphinyl heterocycle of Formula I with a source of the cation in the presence of a base, characterised by a washing step in which the prepared alkaline salt of the substituted sukphinyl compound is washed with a basic aqueous solvent mixture.

__________


143149]21][11[

רביס מחלת וירוס של יציבים מוטנטיםמהם שהוכנו חיים חיסון ותרכיבי

STABLE, ATTENUATED RABIES VIRUS MUTANTS AND LIVE VACCINES THEREOF

]54[

19.11.1999]22[EP]33[27.11.1998]32[98204001.

6]31[

Int. Cl.8 A61K 039/205, C12N 007/04]51[INTERVET INTERNATIONAL B.V., THE NETHERLANDS

]71[





TEL AVIV 61040

]74[

]57 [Recombinant rabies virus mutant comprising a mutation in the G protein gene of the viral genome, whereby said mutation comprises at least a substitution

of the codon in the G-protein gene of the viral genome that encodes Arg333 in the G protein with a GAC triplet or a CAC triplet.

__________

143153]21][11[

על נעות תמונות להקרנת סריקה מכשיראמת בזמן מסך

SCANNING DEVICE FOR PROJECTING MOVING PICTURES ON SCREEN IN REAL TIME

]54[

15.05.2001]22[Int. Cl.8 G02B 026/10]51[

]JOSEF ALEXANDER]71אלכסנדר, ירושלים יוסףאלכסנדר, יוסף

, ירושלים10 ניקרגואה JOSEF ALEXANDER,

10 NICARAGUA ST., JERUSALEM

]74[

הסריקה סטיית להגברת התקן] 57[ לייזר, המורכב קרן של סריקה ומהירות (3,4) מראות של אחד זוג מלפחות

במתח מתכופפות פיאזואלקטריות וחופפות, מקבילות חשמלי, שהם

מחזיר בחומר הפנימי בצידן מצופות גוף של אחד לצד ומקובעות מלא אור

הם החופשי בצידן כאשר המכשיר של ריטוט בתנועת מתכופפות זו והתרחקות זו לקראת זו התקרבות


המראות. בין הלייזר קרן מקפצת מזו, ובתווך

__________

143574]21][11[

התנגשות למניעת ושיטה מערכתבמערך בטיסה או קרובה טיסה ולמיקום

CLOSE/INTRA-FORMATION POSITIONING COLLISION AVOIDANCE SYSTEM AND METHOD

]54[

09.12.1999]22[US]33[30.12.1998]32[09/223533]31[

Int. Cl.8 G01S 013/93, G08G 005/04]51[AVIATION COMMUNICATION & SURVEILLANCE SYSTEMS, LLC, U.S.A.

]71[




TEL AVIV 61063

]74[

]57 [A system for collision avoidance in formation flight, the system comprising: data link transponder means, in a first aircraft, for receiving broadcast data comprising position information of a second aircraft; and traffic alert and collision avoidance system (TCAS) computer means, in the first aircraft, for communicating with said data link

transponder means; for processing the received broadcast data to determine relative aircraft position of the first and second aircraft; and for suppressing at least one of traffic advisories and resolution advisories when the identification information is associated with a formation member.


__________

144777]21][11[

]FUCOSYL TRANSFERASE GENE]54טרנספראז פוקוזיל גן

17.02.2000]22[AT]33[18.02.1999]32[A270/99]31[

Int. Cl.8 A01H 001/00, C12N 005/10, 009/10, 015/11, 015/29, 015/54, C12P 021/00, C12Q 001/68

]51[

FRIEDRICH ALTMANN, AUSTRIA]71[WO/2000/049153]87[


אביב



TEL AVIV 61040

]74[

]57 [A DNA molecule, characterized in that it comprises a sequence according to SEQ ID NO:1 with an open reading frame from base pair 211 to base pair 1740, or has at least 50% identity with the above sequence, or hybridizes with the above sequence under stringent conditions, or

comprises a sequence which has degenerated to the above DNA sequence due to the genetic code, with the sequence coding for a plant protein having fucosyl transferase activity or being complementary thereto.

__________


144799]21][11[

של פולימורפיים גבישיות צורותסלאקוקסיב

POLYMORPHIC CRYSTALLINE FORMS OF CELECOXIB

]54[

01.12.2000]22[US]33[09.12.1999]32[60/169856]31[

Int. Cl.8 A61K 009/14, 031/415, A61P 029/00, C07D 231/00, 231/12]51[PHARMACIA CORPORATION, U.S.A.

]71[




REHOVOT 76122

]74[

]57 [A form I crystalline form of celecoxib.

__________

144994]21][11[

פעולה של מרחוק לבקרת ומערכת שיטהפעילותו ולרישום נשק כלי

METHOD AND SYSTEM FOR REMOTELY CONTROLLING THE OPERATION OF A FIREARM AND RECORDING ITS ACTIVITY

]54[

20.08.2001]22[Int. Cl.8 F41A 017/00]51[

]YUVAL COHEN]71השרון כהן, רמת יובלכהן, יובל

השרון א', רמת רום , נווה3 רח' יסעור YUVAL COHEN,

3 YAS'OOR ST., NEVE ROM A' , RAMAT HASHARON

]74[

]57 [A system for real-time monitoring, supervising and controlling, by at least one Remote Control Center (RCC)-unit of the operation of a firearm, comprising:

)a (at the firearm:)a.1 (a microchip, comprising:

)a.1.1 (sensing means for acquiring:)i (a first data related to the identity of said

firearm and user of said firearm;)ii (a second data related to the current

status of said firearm;)iii (a third data related to the geographic

location of said firearm;

)a.1.2 (recording means for recording the time at which said firearm is utilized;

)a.1.3 (first communications means for receiving a query from said at least one RCC unit and for transmitting to said RCC unit a data signal, said data signal coveys at least one data from the group comprising said first data, said second data, said third data and time of each utilization of said firearm; and

)a.1.4 (a programmable controlling means, for accepting programming and signals relating to the identity of the firearm and its


user, to the firearm status and location, for interpreting said data, and for generating corresponding code data signal for transmission to said at least one RCC unit by the communications means.

)a.2 (a power source, for powering said means

)b (at the at least one RCC-unit;)b.1 (second communicatons means for

receiving from said firearm said first, second and third data signals, and said firearm status and location data signals, and for transmitting queries to said firearm;

)b.2 (comparator unit for comparing said first data to a fourth data stored in said at least one RCC unit;

)b.3 (display means for displaying a corresponding map, on which a real-time location and other data relevant to said firearm is displayed; and

)b.4 (input means for allowing response in accordance with the received second data, the comparison result of step (b.2), the firearm location and a predefined set of rules being dependent on various classifications of firearms.

לתקנות35 לתקנה בהתאם נבחן זה פירוט1968 – הפטנטים, תשכ"ח

This specification was examined in accordance with regulation 35 of the Patent Regulations, 5728 - 1968

__________


145307]21][11[

הביוסינטטי בנתיב אנזימים של קבוצה ומולקולות טריאצלגליצרול לייצור

DNAלאנזימים המקודדות רקומביננטי אלו

CLASS OF ENZYMES IN THE BIOSYNTHETIC PATHWAY FOR THE PRODUCTION OF TRIACYLGLYCEROL AND RECOMBINANT DNA MOLECULES ENCODING THESE ENZYMES

]54[

28.03.2000]22[EP]33[01.04.1999]32[99106656.

4]31[

EP10.06.1999991111321.8US07.02.200060/180687

Int. Cl.8 C12N 005/10, 009/10, 015/09, 015/54]51[BASF PLANT SCIENCE GMBH, GERMANY

]71[



REINHOLD COHN AND PARTNERS, 21 AHAD HA'AM ST ,.

P.O.B. 4060 ,TEL AVIV 61040

]74[

]57 [Use of an enzyme consisting of:)a (a polypeptide with an amino acid

sequence as set forth in SEQ ID No. 2 or 6;)b (a polypeptide encoded by a nucleotide

sequence as set forth in SEQ ID No. 1 or 5; or

)c (a polypeptide encoded by a nucleotide sequence encoding an amino acid sequence as set forth in SEQ ID No. 2 or 6,as a catalyst in an acyl-CoA-independent reaction of the transfer of fatty acids from phospholipids to diacylglycerol in the biosynthetic production of triacylglycerol.

__________


145757]21][11[

רוקחות ותכשירי פיראזול תולדותאותן המכילים

PYRAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

]54[

05.02.2001]22[US]33[05.02.2000]32[60/180506]31[US24.03.200060/191956US24.10.200060/242935

Int. Cl.8 C07D 231/00]51[VERTEX PHARMACEUTICALS, INC., U.S.A.

]71[

WO/2001/057022]87[וגולר, וולף, ברגמן

,1352ב' , ת.ד. 19 היסוד קרן רחוב ירושלים



]74[

]57 [A compound of the formula

or a pharmaceutically acceptable derivative or prodrug thereof, wherein:

R1 is selected from R, halogen, N(R8)2, OR, NRCOR,NRCON(R8)2, CON(R8)2, SO2R, NRSO2R, or SO2N(R8)2;

T is selected from a valence bond or a linker group selected from:

-O-, -S-, -NH2-, or an optionally substituted C1-6 alkylidene chain wherein up to two saturated carbons of the chain are optionally replaced by –C(=O)-, -CONH-, -

CONHNH-, -CO2-, -NHCO2-, -O-, -NHCONH-, -OC(=O)-, OC(=O)NH-, -NHNH-, -NHCO-, -S-, -S(O)-, -S(O)2-, -NH-, -SO2NH-, or NHSO2-; each R is independently selected from hydrogen or an optionally substituted aliphatic group having one to six carbons; R2 is selected from hydrogen, CN, halogen, aryl, aralkyl, heteroaryl, heterocyclyl, an optionally substituted acyclic aliphatic chain group having one to six carbons, or an optionally subsituted cyclic aliphatic group having


subsituted cyclic aliphatic group having four to ten carbons;

R3 is selected from R, OH, OR, N(R8)2, halogen, or CN;Q is J;J is –C(=O);-

R4 is –NHR5;R5 is –(CH2)yCH(R6)(R7);y is 0-6;

R6 is an optionally substituted group selected from an aryl, aralkyl, aralkoxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, heterocyclyl, heterocyclylalkyl, or heterocyclylalkoxy group;

R7 is independently selected from an optionally substituted aliphatic, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, or alkoxycarbonyl;

each R8 is independently selected from R, or two R8 on the same nitrogen taken together with the nitrogen optionally form a four to eight membered, saturated or unsaturated heterocyclic ring having one to three heteroatoms; and each substitutable ring nitrogen is optionally substituted by R, NR2, COR, CO2(C1-C6 optionally substituted alkyl), SO2(C1-C6 optionally substituted alkyl), CONR2, and SO2NR2.

__________

145922]21][11[

כליגנדים די–ארילית חומצה של תולדות רוקחות , תכשיריPPAR רצפטור של

להכנת בהן והשימוש אותן המכיליםתרופות

DI-ARYL ACID DERIVATIVES AS PPAR

RECEPTOR LIGANDS, PHARMACEUTICAL

COMPOSITIONS COMPRISING SAME AND

USE OF SAME IN THE PREPARATION

OF MEDICAMENTS

]54[

28.04.2000]22[US]33[28.04.1999]32[60/131455]31[

Int. Cl.8 A61K 031/33, A61P 003/00, 043/00, C07D 215/40, 263/32]51[SANOFI-AVENTIS DEUTSCHLAND GMBH, GERMANY

]71[



P.O.B. 12688 ,HERZLIYA 46733

]74[

]57 [A compound of the formula


wherein:

is oxazolyl or quinolinyl, which are optionally substituted by one or more ring

system substituents; a is 1; b is 0 or 1; R1, R2, R3 and R4 are hydrogen;

A is

R5, R6, R7, R8, R15, R16 are hydrogen:c is 0;d is 0;g is 2, 3, 4, or 5;B and E are a chemical bond;Z is R21O2C-, R21OC-, or R21O;-

R21 is hydrogen, alkyl, aryl, cycloalkyl, or aralkyl;

R' is hydrogen, lower alkyl, halo, alkoxy, aryloxy or aralkyloxy; and R" is lower alkyl, hydrogen, aralkyloxy, alkoxy, cycloalkylalkyloxy or halo; and a pharmaceutically acceptable salt thereof.


__________

145950]21][11[

]ZIPRASIDONE SUSPENSION]54זיפרסידון של תרחיף

08.05.2000]22[US]33[27.05.1999]32[60/136268]31[


Int. Cl.8 C07D 417/00; A61K 9/10]51[PFIZER PRODUCTS, INC., U.S.A.]71[




BEER-SHEVA 84152

]74[

]57 [A suspension comprising ziprasidone free base or a pharmaceutically acceptable ziprasidone acid addition salt, water, a

polysorbate, a viscosity agent, and colloidal silicon dioxide.

__________

146126]21][11[

פוליאמינים של אנלוגים של צמדים לטפול כתרופות בהם והשימוש וקינונים

הערמונית בלוטת ומחלות בסרטן

POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES

]54[

27.04.2000]22[US]33[30.04.1999]32[60/131809]31[

Int. Cl.8 A61K 047/48]51[CELLGATE, INC., U.S.A.]71[





]74[

]57 [A compound selected from the group consisting of

and any salt or stereoisomer thereof.


__________

146233]21][11[

מזון מוצר לייצור ותהליך שיחול מכונתקפוא

EXTRUDER AND PROCESS FOR PRODUCTION OF A FROZEN FOOD PRODUCT

]54[

17.05.2000]22[GB]33[28.05.1999]32[9912629.4]31[

Int. Cl.8 A23G 009/16, B29C 045/60, 047/60]51[UNILEVER PLC, UNITED KINGDOM

]71[





TEL AVIV 61040

]74[

]57 [Single screw extruder comprising an extruding screw and cooling means, said extruding screw being characterised by

between 2 and 6 thread starts and a pitch angle of between 28 and 45 degrees, preferably between 32 and 42 degrees.

__________

146681]21][11[

ליצורIAPP מעכבות בתרכובות שימוש שקיעת הקטנה אן לעיכוב תרופות

אמילואיד

USE OF IAPP-INHIBITING COMPOUNDS FOR THE MANUFACTURE OF MEDICAMENTS FOR INHIBITING OR REDUCING AMYLOID DEPOSITS

]54[

24.05.2000]22[


US]33[24.05.1999]32[60/135545]31[US09.07.199960/143123US23.05.200009/576677

Int. Cl.8 A61K 031/395, 031/66, 031/70, A61P 003/10, C07D 217/02, 217/12, 217/22, 401/00, 413/04, 491/04, C07F 009/38, C07H 003/02

]51[

NEUROCHEM (INTERNATIONAL) LIMITED, SWITZERLAND

]71[





TEL AVIV 61040

]74[

]57 [Use of an IAPP-inhibiting compound, or a phrmaceutically acceptable ester, acid or salt thereof for the manufacture of a medicament for inhibiting IAPP-associated amyloid deposits in a

subject, such that said IAPP-associated amyloid deposits are inhibited, wherein said IAPP-inhibiting compound is of the formula

wherein A1, A2, A3, A4, A5 and A6 are independently alkyl, O, S, or –NH; n (for each individual A group) is 0 or 1; m is 1; 1 m is 1; 1, p and q are independently 0, 1, or 2; R7, R8, R9, R10, R11, R12, R13, and R14

are independently hydrogen, an anionic group at physiological pH, alkyl, alicyclyl, heterocyclyl or aryl, and adjacent R groups may form an unsubstituted or substituted cyclic or heterocylic ring.




__________

147293]21][11[

PEPTIDES THAT LOWER BLOODבדם גלוקוז רמות המורידים פפטידיםGLUCOSE LEVELS

]54[


12.07.2000]22[US]33[12.07.1999]32[60/143591]31[EP09.08.199999610043.4

Int. Cl.8 C07K 014/575, 019/00]51[ZEALAND PHARMA A/S, DENMARK

]71[





TEL AVIV 61040

]74[

]57 [A peptide conjugate of an exendin-4(1-39) variant comprising a deletion of between 1 and 5 amino acid residues at positions corresponding to positions 34-38 of exendin-4,

wherein the exendin-4 variant is coupled via its C-terminus to an amino acid sequence Z, where Z comprises from 1 to 7 Lys amino acid residues.



__________

147522]21][11[

בממשקיPPP קישורי של עצמאי תזמוןUm–ו Rm

INDEPENDENT SYNCHRONIZATION OF PPP LINKS ON UM AND RM INTERFACES

]54[

14.07.2000]22[US]33[14.07.1999]32[09/353107]31[

Int. Cl.8 H04B 007/26, H04L 029/08, H04M 011/00, H04Q 007/32, 007/38]51[QUALCOMM INCORPORATED, U.S.A.

]71[




REHOVOT 76122

]74[

]57 [A method of resynchronizing a first Point-to-Point Protocol link on a Um interface without resynchronizing a second Point-to-Point Protocol link on a Rm interface, comprising: checking all packets being received by a MT2 device over said

Um interface to determine whether a received packet is a PPP packet for requesting option negotiating; negotiating option values of said Um interface, after said checking determines that said received


packet is said PPP packet for requesting option negotiating.

__________

147641]21][11[

( –R6, aR12) המכילים רוקחות תכשירי2,3,4,5,6,7,12, a122 – – הקסאהידרו–

– מתילן4, 3 – )6 – מתיל ,6' : 1', 2] – דיאוקסיפניל( פיראזינו

–4, 1 – [ אינדולb –4, 3] [ פירידו1דיאון

PHARMACEUTICAL COMPOSITIONS COMPRISING (R6, AR12 ) - 2,3,4,5,6,7,12, A12 - HEXAHYDRO - 2 METHYL - 6 - 3, 4 - METHYLENEDIOXYPHENYL) PYRAZINO - [2', 1' : 6, 1] PYRIDO [3, 4 -B ] - INDOLE - 1, 4 - DIONE

]54[

26.04.2000]22[US]33[03.08.1999]32[60/146924]31[

Int. Cl.8 A61K 031/4985, A61P 015/10, C07D 471/00]51[LILLY ICOS LLC, U.S.A.]71[




P.O.B. 4060 ,TEL AVIV 61040

]74[

]57 [A pharmaceutical formulation comprising an active compound of the formula


wherein said compound is provided as free drug comprising particles wherein at least 90% of the particles of the said compound have a particle size of less than about 40 microns; about 50% to about 85%, by weight, of a water-soluble diluent; a lubricant; a hydrophilic binder selected

from the group consisting of a cellulose derivative, povidone, and a mixture thereof; and a disintegrant selected from the group consisting of croscamelose sodium, crospovidone, and a mixture thereof.

__________

147871]21][11[

]FIREARM TRAINING DEVICE]54ירי לאימון התקן

28.01.2002]22[Int. Cl.8 F42B 008/00]51[

]AVI LEGMANN]71גת לגמן, קריית אביושותפיו, כהן ריינהולד




TEL AVIV 61040

]74[

]57 [A training round comprising: a casing (35) corresponding with a chamber of a firearm having a firing pin (44) adapted to strike a bullet (32) within the chamber, the casing having a fore end and

a rear end; a resisting member (34) projecting from a rear end of the casing, adapted to face said firing pin and being axially displaceable upon exerting thereto a forwardly directed force.


__________

147983]21][11[

לשימוש טרוקר מחט להחדרת מכשירטעינה וכלי חוזר

REPEATED USE TROCAR-NEEDLE INSERTION INSTRUMENT AND LOADING TOOL

]54[

04.02.2002]22[Int. Cl.8 A61B 017/34]51[

]WAISMED LTD.]71בע"מ, קיסריה וייס-מד]MICHAEL FLINT]72פלינט מיכאל

- לוי, גלוקסמן, חיפה6202א' , ת.ד. 10 אלחנן רחוב

GLUCKSMAN - LOWY, 10A ELHANAN ST,.

P.O.B. 6202 ,HAIFA 31061

]74[

]57 [A repeated use trocar-needle insertion gun (RUTI) operating in association with a loading tool, comprising: a needle portion of the RUTI being configured for gripping a trocar-needle before insertion into a bone, and for release of the trocar-needle upon insertion into the bone, a front portion of the RUTI being configured for adjusting insertion-depth of the trocar-needle into the bone, and for protecting the trocar-needle prior to release, a rear portion of the RUTI having a shooting mechanism operative for shooting the trocar-needle, and a catch adapted for retaining the shooting mechanism, and for releasing the shooting mechanism when triggered for shooting, and the front portion being releasably coupled to the rear portion, the rear portion comprising: a

housing (202) having a housing inside, a housing outside and a housing bottom, at least one spring (4) disposed inside the housing and residing in a first compressed condition associated with a loaded state of the RUTI before shooting the trocar-needle, and in a second released condition associated with a spent state of the RUTI after shooting the trocar-needle, at least one open loading opening being accommodated in the bottom of the housing of the RUTI to provide access therethrough, from the outside to the inside, for coupling the loading tool with the at least one spring, and a loading tool configured for coupling with and operative for reloading the RUTI in situ from the spent state to the loaded state via the at least one loading opening.


__________

148200]21][11[

של ומקומי פומי למתן רוקחות תכשיריבקלות מסיסים שאינם פעילים חומרים

PHARMACEUTICAL COMPOSITIONS FOR ORAL AND TOPICAL ADMINISTRATION OF POORLY SOLUBLE ACTIVE INGREDIENTS

]54[

17.08.2000]22[GB]33[17.08.1999]32[9919288.2]31[

Int. Cl.8 A61K 009/48, 031/337, 047/14]51[IVAX PHARMACEUTICALS S.R.O., CZECH REPUBLIC

]71[

WO/2001/012229]87[בע"מ, פרמצבטיות תעשיות טבע

תקוה , פתח3190 , ת.ד. 5 בזל TEVA PHARMACEUTICAL

INDUSTRIES LTD,. 5 BASEL ST., P.O.B. 3190,

PETAH TIQVA 49131

]74[


]57 [A pharmaceutical formulation for oral or topical administration including

)a (0.1 to 30% of one or more hydrophobic active ingredients;

)b (0.1 to 60% of one or more gelators selected from polyglycerol esters of fatty acids of the formula

CH2OR-CHOR-CH2O-[CH2CHOR-CH2O]nCH2-CHOR-CH2OR

wherein n is an integer from 4 to 13 and R is H or COR' wherein R' is C8-22 saturated, unsaturated or hydroxylated alkyl and wherein at least one group R is not hydrogen, having an HLB value not less than 10;

)c (0.1 to 60% of one or more gel-creating substances selected from polyglycerol-3-esters of oleic acid, having an HLB value not greater than 9;

)d (0.1 to 60% of one or more co-gelator substances selected from triglyceride macrogol glycerol esters, partial glycerides

or fatty acids or macrogel esters of fatty acids in which the average quantity of reacted ethylene oxide in the synthesis of these substances ranges between 50 to 150 mols and concurrently the ratio between components (b) and (d) is from 0.1:1 to 10:1;

)e (5.0 to 30% ethanol;wherein the above percentages are selected to total 100%; and wherein upon dilution with water the formulation forms a dispersion of polymorphous gel particles having a dimension of 0.2 to 500 μm.



__________

148209]21][11[

מרכז דרך שיחות לניהול ומכשיר שיטההנאה

METHOD AND APPARATUS FOR MANAGING CALLS THROUGH AN ENTERTAINMENT CENTER

]54[

17.02.2002]22[US]33[16.05.2001]32[09/855839]31[

Int. Cl.8 H04M 001/64, 003/436, 003/533, H04N 007/10]51[COMVERSE, INC., U.S.A.]71[

( בע"מ,1995) ג'י.אי.ארליך בגין מנחם ,רחוב15 אילון, קומה מגדל

גן , רמת11

G.E. EHRLICH (1995) LTD,. AYALON TOWER, 15TH FLOOR,

11 MENACHEM BEGIN ST,.RAMAT GAN 52521

]74[

]57 [A call management system comprising: a call management server residing in a telephony provider network and in communication with a subscriber

entertainment system via Internet and/or cable data networks, and holding a call on the telephony provider network for the subscriber entertainment system prior to


routing the call to the subscriber entertainment system; and a television call manager connected to the subscriber entertainment system to receive a held call signal from the call management server via the data network indicating a held call during a program play by the subscriber entertainment system, wherein the held call at the telephony-network-resident call management server is handled according to a selectable call handling option chosen from a group of call handling options comprising one or more of take the call, send the call to voice mail, forward the call

to another number, play a message, ignore the call, and reject the call, and the television call manager of the subscriber entertainment system transmits via the data network the selected call handling option to the telephony-network-resident call management server, and wherein the television call manager comprises a telephone to enable taking the held call directly at the television call manager by answering the held call using the telephone, or sending the held call to a user voice at the user's premise, or both.

__________148212]21][11[

צמחים ליצירת ושיטות אמצעים אלליזם ידי על המאופיינים ופטריותאקסוגני

MEANS AND METHODS FOR PRODUCING PLANTS AND FUNGI CHARACTERIZED BY EXOGENIC ALLELISM

]54[

27.08.2000]22[US]33[31.08.1999]32[60/151627]31[US04.10.199909/411863

Int. Cl.8 A01H 005/00, A01K 067/00, C12N 005/04, 015/12, 015/62, 015/63, 015/80, 015/82

]51[

]FERTISEED LTD.]71בע"מ, אשדוד פרטיסידWO/2001/016287]87[

( בע"מ,1995) ג'י.אי.ארליך בגין מנחם ,רחוב15 אילון, קומה מגדל

גן , רמת11



]74[


]57 [An expression cassette comprising:)a (a first segment comprising a first

transcribable polynucleotide sequence, said first transcribable polynucleotide sequence being operatively linked to a first promoter sequence, wherein the first segment is flanked by a pair of first site-specific recombination sequences; and

)b (a second segment, being linked to the first segment, the second segment comprising a second transcribable polynucleotide sequence that is operatively linked to a second promoter sequence, wherein the second segment is flanked by a pair of second site-specific recombination sequences.

לתקנות35 לתקנה בהתאם נבחן זה פירוט1968 – הפטנטים, תשכ"ח

This specification was examined in accordance with regulation 35 of the Patent Regulations, 5728 - 1968

__________

148216]21][11[

]DISPENSING TUBE]54מנפקת צינורית

22.08.2000]22[US]33[01.09.1999]32[09/387947]31[

Int. Cl.8 A23L 002/52, A47G 021/18, B65D 025/08, 081/32]51[BIOGAIA AB, SWEDEN]71[WO/2001/015985]87[


אביב



TEL AVIV 61040

]74[

]57 [A device for dispensing living cells of a probiotic microorganism into a liquid, comprising:

)a (a liquid impermeable dispensing tube (20) having an open bore (22) being surrounded by an inner tube wall (24) and extending from an open upper end (26) of the tube to an open lower end (28) of the

tube ;)b (a coating material (30) on a portion of

the inner tube wall, said coating material selected from the group consisting of oils and waxes and holding a suspension of the

living cells of the probiotic microorganism for long-term storage within the open bore adherent to the inner tube wall; and

)c (a flexible, essentially water vapor tight envelope (40) enclosing the tube for longterm storage and to protect the living cells of the probiotic microorganism from moisture; wherein the living cells of the probiotic microorganism may be removed from the inner tube wall and mixed with the liquid by placing the open end of the tube in the liquid and drawing the liquid through the bore.


__________

148309]21][11[

רוקחות תכשיר להכנת ברטיגבין שימושניאופאטי בכאב לטיפול

USE OF RETIGABINE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR TREATMENT OF NEUROPATHIC PAIN

]54[

22.09.2000]22[US]33[27.09.1999]32[406135]31[

Int. Cl.8 A61K 031/325, A61P 029/02, C07C 271/28]51[XCEL PHARMACEUTICALS, INC,.]71[


CHRIS RUNDFELDT, RENI BARTSCH, ANGELIKA ROSTOCK, CHRISTINE TOBER, RITA DOST

]72[

WO/2001/022953]87[( בע"מ,1995) ג'י.אי.ארליך

בגין מנחם ,רחוב15 אילון, קומה מגדל גן , רמת11



]74[

]57 [Use of the compound

or of its pharmaceutically usable salts for the preparation of a pharmaceutical composition for the prophylaxis or

treatment of allodynia, wherein allodynia is not postherpetic neuralgia.

__________

148327]21][11[

INFORMATION CONVERTINGלמידע המרה מערכתSYSTEM

]54[

25.06.2001]22[JP]33[26.06.2000]32[2000-

190725]31[

Int. Cl.8 G06K 009/54, G06T 007/20]51[IWANE LABORATORIES, LTD., JAPAN

]71[

WO/2002/001505]87[


לוצאטו, את לוצאטושבע , באר5352, ת.ד. תעשייה, עומר גן

LUZZATTO & LUZZATTO, INDUSTRIAL PARK, OMER,

P.O.B. 5352,BEER-SHEVA 84152

]74[

]57 [An information converting system comprising: a database in which attribute data including data indicative of properties of an object and an identification code of each of parts modeled on various objects are registered; a comparison part generating unit for generating one piece or a plurality of pieces of part information for comparison from said attribute data for each of said parts; an input unit for obtaining input information including information regarding an object; a comparison information generating unit for generating information for comparison in which information of said objects is not individually separated from said input information; a part specifying unit for specifying a part corresponding to said object by using the part information for comparison and the information for

comparison each having the same kind of data; and an output unit for outputting the identification code and at least a part of the attribute data of the specified part as a result of recognition of said object, and said part specifying unit comprising: a retrieving unit for retrieving a corresponding portion, which corresponds to at least a part of said part information for comparison, from said information for comparison sequentially with respect to one or plural piece(s) of part information for comparison of one or plural part(s); a recognizing unit for recognizing said corresponding portion in said information for comparison as an object; and a specifying unit for specifying a part having said part information for comparison as a part corresponding to said object.

__________148360]21][11[

רוקחות ותכשירי הרפס נגיף של מוטנטאותו המכילים

HERPES VIRAL MUTANT AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

]54[

02.02.2000]22[US]33[31.08.1999]32[60/151621]31[

Int. Cl.8 A61K 035/76, 045/00, 048/00, C07K 014/035, C12N 007/00, 007/02, 015/38, 015/869

]51[


THE GENERAL HOSPITAL CORPORATION, U.S.A.

]71[





]74[

]57 [A herpes viral mutant comprising:)a (a deletion or inactivating mutation in

both copies of the gene encoding γ34.5; and

)b (an insertion of at least one copy of the γ34.5 gene under the transcriptional control of a cell-specific and/or tumor-specific promoter.

__________

148532]21][11[

HYDROGELS FOR ORTHOPEDICאורתופדי רפוי עבור הידרוג'ליםREPAIR

]54[

08.09.2000]22[US]33[10.09.1999]32[60/153190]31[

Int. Cl.8 A61L 027/52]51[GENZYME CORPORATION, U.S.A.]71[




REHOVOT 76122

]74[

]57 [A composition for forming a water-absorbing, high modulus polymeric, hydrogel-forming material comprising at least one macromer and at least one monomer, wherein the macromer comprises hydrophobic and hydrophilic regions, has a molecular weight of 1000 to 100,000 Da and has at least two covalently polymerizable groups, and the macromer comprises at least 5% (wt/wt) of the composition, wherein the monomer contains at least one ethylenically unsaturated group and has a molecular weight of less than 1,000 Da, and wherein the monomer comprises at least 30% (wt/wt) of the composition, and wherein

the composition forms a gel upon polymerization, and wherein the gel is characterized as having the following properties: (a) absorbing water to less than 300% of its initial weight, on equilibration with water or body liquids;(b) having a tensile modulus of at least 500 kPa or greater at equilibrium swelling with an aqueous solution having a solids content of at least 20% after equilibration in water or bodily liquids, (c) having an elongation to failure of at least 25% at hydration equilibrium; and (d) being sufficiently biocompatible to permit the treatment or repair of biological tissue, or use as an implant in a patient.


__________

148635]21][11[

ומידע יישומים למסירת ושיטה מערכתרחוק המאוחסנים

SYSTEM AND METHOD FOR DELIVERING REMOTELY STORED APPLICATIONS AND INFORMATION

]54[

14.09.2000]22[US]33[14.09.1999]32[60/153917]31[US22.06.2000599382

Int. Cl.8 G06F 009/40, 009/445, 009/46, 012/00, 013/00, 015/163, H04L 012/00, 029/06, H04N 001/413

]51[

DROPLET, INC., U.S.A.]71[WO/2001/020848]87[

ושות', גבריאלי זליגסוןאביב , תל1426 , ת.ד. 31 רח' יבנה

SELIGSOHN GABRIELI & CO,. 31 YAVNE ST,.

P.O.B. 1426 ,TEL AVIV 61013

]74[

]57 [In a network configured computer processing system having a plurality of client computers and a plurality of host computers, a method for delivering interactive links for presenting applications and information from remote sources on the network, the method comprising:

retrieving, in response to a request of a client computer, over a first communication connection first information having computer program code embedded therein and executing the embedded computer program code for establishing a second communication connection to a second host computer; sending second information relating to the operating environment of the client

computer, from the client computer to the second host computer; retrieving, over the second communication connection, third information including presentation information for presenting an application and fourth information, the presentation information being based on the second information; presenting, at the client computer, the application and the fourth information based upon the presentational information; and storing, on the client computer, an interactive link for selectively reestablishing the second communication connection to the second host computer for retrieving the third information and presenting the application and the fourth information.


__________

148680]21][11[

עבור ומעגלים ארכיטקטורה, שיטותאנרגיה דלי זכרונות

ARCHITECTURE, METHOD(S) AND CIRCUITRY FOR LOW POWER MEMORIES

]54[

15.09.2000]22[US]33[17.09.1999]32[09/398735]31[

Int. Cl.8 G11C 008/00]51[CYPRESS SEMICONDUCTOR CORPORATION, U.S.A.

]71[

KEITH A. FORD, IULIAN C. GRADINARIU, BOGDAN I. GEORGESCU, SEAN B. MULHOLLAND, JOHN J. SILVER, DANNY L. ROSE

]72[



P.O.B. 12688 ,HERZLIYA 46733

]74[

]57 [A circuit comprising: a first and a second bitline each configured to read and write data to one or more of a plurality of groups of memory cells, wherein each of said plurality of groups of memory cells is interdigitated; and a control circuit (13)

configured to select an active group of said plurality of groups in response to one or more control signals, wherein said control circuit is implemented within said groups of memory cells.


__________

148875]21][11[

הידראזיד, הכנתן סולפוניל תולדותאותן המכילים רוקחות ותכשירי

SULFONYL HYDRAZIDE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

]54[

28.09.2000]22[EP]33[28.09.1999]32[99810870.

8]31[

Int. Cl.8 C07D 409/00]51[APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.

]71[

STEPHEN ARKINSTALL, SERGE HALAZY, DENNIS CHURCH, MONTSERRAT CAMPS, THOMAS REUCKLE, JEAN PIERRE GOTTELAND, MARCO BIAMONTE

]72[

WO/2001/023382]87[בע"מ, מעבדות אינטרפארם

ידע, עתירות לתעשיות ויצמן, פארק קרית נס-ציונה

INTERPHARM LABORATORIES LTD,.


]74[


]57 [Sulfonyl hydrazide derivatives of the formula

with their geometrical isomers in an optically active form as enantiomers, diastereomers, as well as in the form of racemates, as well as pharmaceutically acceptable salts thereof, wherein Ar1 and Ar2 are independently from each other an unsubstituted or substituted aryl or heteroaryl group, X1 and X2 are independently from each other O or S; R1, R2, R3 are independently from each other hydrogen or a C1-C6-alkyl substituent or R1 forms a substituted or unsubstituted 5-6 – membered saturated or unsaturated ring with Ar1; or R2 and R3 form a substituted or unsubstituted 5-6 – membered saturated or unsaturated ring; n is an integer from 0 to 5; G is selected from a group comprising or consisting of an unsubsituted or substituted 4-8 membered heterocycle containing at least one heteroatom, or G is a substituted or unsubstituted C1-C6-alkyl group;

whereby the term "substituted" means that said groups can be substituted with from 1 to 5 substituents selected from the group consisting of C1-C6-alkyl, C1-C6-alkyl aryl, C1-C6-alkyl heteroaryl, C2-C6-alkenyl, C2-C6-alkynyl, primary, secondary or tertiary amino groups or quartenary ammonium moieties, acyl, acyloxy, acylamino, amino-carbonyl, alkoxycarbonyl, aryl, heteroaryl, carboxyl, cyano, halogen, hydroxy, mercapto, nitro, sulfoxy, sulfonyl, alkoxy, thioalkoxy, trihalomethyl, wherein said substitution could also comprise situations where neighboring substituents have undergone ring closure thus forming lactams, lactones, cyclic anhydrides, acetals, thioacetals; with the proviso that if Ar1 is 4-chlorophenyl, Ar2 is thienyl, X1 and X2 are O, R1, R2 and R3 are H, n is 1, G shall not be selected from the following group:


__________

148925]21][11[

PERSONAL INFORMATIONולהחלפתו אישי מידע לבטיחות כליSECURITY AND EXCHANGE TOOL

]54[

22.07.1997]22[US]33[22.07.1996]32[022035]31[

Int. Cl.7 G06F 017/30, H04L 009/00]51[DIVISION FROM 128099]62[CYVA RESEARCH CORPORATION, U.S.A.

]71[





TEL AVIV 61040

]74[

]57 [An electronic bazaar comprising:a plurality of electronic personal information agents, each securely encapsulating personal information objects for a specific entity and exchange rules governing processing of the personal information objects; and an electronic

bazaar electronic broker which receives said electronic personal information agents over a distributed, electronic network, said electronic bazaar electronic broker securely processing transactions between electronic personal information agents seeking to exchange personal information processing


privileges for value or benefit, said electronic bazaar electronic broker ensuring that exchange rules are satisfied before a transaction is processed, while

maintaining the privacy of the personal information objects encapsulated within said personal information agents.

__________

149021]21][11[

–2 ביטוי גילוי על מבןסס ללפטין תבחיןANG

LEPTIN ASSAY BASED ON DETECTING ANG-2 EXPRESSION

]54[

05.10.2000]22[IL]33[10.10.1999]32[132313]31[

Int. Cl.8 C12N 015/85, C12Q 001/00, 001/68, G01N 033/68, 033/74]51[ YEDA RESEARCH ANDבע"מ, רחובות ופיתוח למחקר חברה ידע


MENACHEM RUBINSTEIN, BATYA COHEN

]72[

WO/2001/027319]87[בע"מ, לאב אינטר

ציונה ויצמן, נס קרית INTERLAB LTD,.


]74[


]57 [A method for determining the presence of leptin or a leptin-mimetic agent comprising contacting a sample with a cell or cell line that expresses Ang-2

(Angiopoietin-2) in response to leptin and measuring either Ang-2 in the culture medium, cellular RNA encoding Ang-2 or the activation of the Ang-2 promoter.

__________

149081]21][11[

APPARATUS AND METHOD FORניגרים לעיבוד ושיטה התקןPROCESSING FLUIDS

]54[

12.10.2000]22[GB]33[12.10.1999]32[9924085.5]31[

Int. Cl.8 C02F 003/12, C12M 001/04]51[CHRISTOPHER MALTIN, UNITED KINGDOM

]71[

WO/2001/027040]87[ושות' בע"מ, מ. בן-דוד ירמיהו

,45087, ת.ד. חוצבים המרפא, הר רחוב ירושלים

JEREMY M. BEN-DAVID & CO. LTD,.

HAR HOTZVIM HI-TECH PARK ,P.O.B. 45087 ,

JERUSALEM 91450

]74[

]57 [A method of treating a process fluid in a plurality of chambers interconnected with one another in sequence such that a process fluid can pass through them sequentially, comprising the steps of introducing gas at a low level into at least some of the chambers whereby to drive circulation of the process fluid within that or those chambers, withdrawing surplus

gas, including gas generated within the chamber by the process taking place therein, and varying at least one of the process parameters influencing the process to which the fluid is subject in at least one of the said chambers, whereby to encourage different steps of a treatment process to take place in different chambers of the system.

__________


149082]21][11[

APPARATUS FOR TREATINGבניגרים לטיפול התקןFLUIDS

]54[

11.04.2002]22[GB]33[12.10.1999]32[9924087.1]31[

Int. Cl.8 C02F 001/44, 003/12, C12M 001/04]51[CHRISTOPHER MALTIN, UNITED KINGDOM

]71[

WO/2001/027041]87[ושות' בע"מ, מ. בן-דוד ירמיהו

,45087, ת.ד. חוצבים המרפא, הר רחוב ירושלים



JERUSALEM 91450

]74[

]57 [Treatment apparatus (10) comprising a chamber for treatment of a process fluid and having at least two regions (17, 18) in each of which the process fluid is caused to follow a circulating path, and the two regions communicate with one another such that process fluid introduced into one

region is constrained to flow into the other region before leaving the vessel, at least part of the chamber wall in which an exit opening (14) is located being formed as a semi-permeable membrane contacted intimately by the process fluid following the said circulating path.


__________

149138]21][11[

PHARMACEUTICALמטפורמין המכילים רוקחות תכשיריCOMPOSITIONS CONTAINING METFORMIN

]54[

13.10.2000]22[US]33[03.11.1999]32[09/432465]31[

Int. Cl.8 A61K 031/155, 031/427, 031/64, 045/06, A61P 003/10, C07C 279/26]51[BRISTOL-MYERS SQUIBB COMPANY, U.S.A.

]71[





]74[

]57 [A low dose pharmaceutical formulation for first line treatment of diabetes in drug naïve patients comprising a low dose combination of metformin and at least one or more other antidiabetic agent which is one or more of a glucosidase inhibitor, a glucagon-like

peptide-1 (GLP-1), insulin, a PPAR α/γ dual agonist other than a thiazolidinedione, a meglitinide other than repaglinide, and an aP2 inhibitor, which provides at least substantially equivalent efficacy in treating diabetes in drug naïve patients, but with substantially reduced side effects, as


compared to combinations of metformin and the other antidiabetic agent, employed in substantially higher daily dosages, wherein the dose of metformin is in an

amount to provide a daily dosage within the range from about 160 mg to about 750 mg.

__________

149159]21][11[

סינרגיסטיים עשבים קוטלי תכשירים מעכבי מקבוצת עשבים קוטלי המכילים

דיאוקסיגנז ההידרוקסיפנילפירובט

SYNERGISTIC HERBICIDAL COMPOSITIONS COMPRISING HERBICIDES FROM THE GROUP OF THE HYDROXYPHENYLPYRUVATE DIOXYGENASE INHIBITORS

]54[

20.10.2000]22[DE]33[22.10.1999]32[19950943.

3]31[

Int. Cl.8 A01N 041/10, 043/54, 043/80, 061/00, C07C 317/14, C07D 239/28, 251/26, 261/04, 409/12

]51[

BAYER CROPSCIENCE GMBH, GERMANY

]71[



P.O.B. 12688 ,HERZLIYA 46733

]74[


]57 [A herbicidal composition, comprising an effective amount of

)A (at least one compound and its agriculturally customary salts (Component A) of the formula

in whichX is the radical

Q is the radical

Z is a radical Z1, CH2-Z1 or Z2;wherein Z1 is a five – to ten-membered monocyclic or bicyclic saturated, partially saturated, fully unsaturated or aromatic ring which is attached via carbon or nitrogen and which, in addition to carbon atoms, contains 1, 2, 3 or 4 heteroatoms from the group consisting of oxygen, sulfur and nitrogen and which is unsubstituted or mono-or polysubstituted by halogen, cyano, nitro, cyano-(C1-C4)-alkyl, CO-R15, (C1-C4) – alkyl, halo-(C1-C4) – alkyl, (C3-C8)-cycloalkyl, (C1-C4)-alkoxy, halo-(C1-

C4)-alkoxy, (C1-C4)-alkylthio, halo-(C1-C4)-alkylthio, di-(C1-C4)-alkyl-amino, by phenyl which is unsubstituted or mono-or polysubstituted by halogen, cyano, nitro, (C1-C4)-alkyl or halo-(C1-C4)-alkyl or by an oxo group;

Z2 is (C3-C12)-cycloalkyloxy-(C1-C4)-alkyl, aryloxy-(C1-C4)-alkyl, heteroaryloxy-(C1-C4)-alkyl, heterocyclyl-(C1-C4)-alkyl, halo-(C1-C4)-alkoxy-(C1-C4)-alkyl, aryl-(C1-C4)-alkoxy-(C1-C4)-alkyl, heteroaryl-(C1-C4)-alkoxy-(C1-C4)-alkyl, heterocyclyl-(C1-C4)-alkoxy-(C1-C4)-alkyl, aryl-(C3-C8)-


cycloalkylthio-(C1-C4)-alkyl, heteroaryl-(C3-C8)-cycloalkylthio-(C1-C4)-alkyl, heterocyclyl-(C3-C8)-cycloalkylthio-(C1-C4)-alkyl, (C3-C8)-cycloalkylsulfinyl-(C1-C4)-alkyl, (C3-C8)-cycloalkylsulfonyl-(C1-C4)-alkyl, (C3-C8)-cycloalkylamino-(C1-C4)-alkyl, (C3-C8)-cycloalkylsulfonyloxy-(C1-C4)-alkyl, (C3-C8)-cycloalkylsulfonylamino-(C1-C4)-alkyl, (C3-C8)-cycloalkylcarbonyl-(C1-C4)-alkyl, (C3-C8)-cycloalkylcarbonyloxy-(C1-C4)-alkyl, (C3-C8)-cycloalkoxycarbonyl-(C1-C4)-alkyl, (C3-C8)-cycloalkylcarbonylamino-(C1-C4)-alkyl, (C3-C8)-cycloalkylaminocarbonyl-(C1-C4)-alkyl, (C4-C12)-cycloalkyl-(C1-C4)-alkyl, (C2-C4)-cycloalkylthio-(C1-C4)-alkyl, (C4-C12)-cycloalkylsulfinyl-(C1-C4)-alkyl, (C4-C12)-cycloalkylsulfonyl-(C1-C4)-alkyl, (C4-C12)-cycloalkylamino-(C1-C4)-alkyl, (C4-C12)-cycloalkylsulfonyloxy-(C1-C4)-alkyl, (C4-C12)-cycloalkylsulfonylamino-(C1-C4)-alkyl, (C4-C12)-cycloalkylcarbonyl-(C1-C4)-alkyl, (C4-C12)-cycloalkylcarbonyloxy-(C1-C4)-alkyl, (C4-C12)-cycloalkyloxycarbonyl-(C1-C4)-alkyl, (C4-C12)-cycloalkyalkylcarbonylamino-(C1-C4)-alkyl, (C4-C12)-cycloalkylaminocarbonyl-(C1-C4)-alkyl, arylthio-(C1-C4)-alkyl, arylsulfinyl-(C1-C4)-alkyl, arylsulfonyl-(C1-C4)-alkyl, arylamino-(C1-C4)-alkyl, arylsulfonyloxy-(C1-C4)-alkyl, arylsulfonylamino-(C1-C4)-alkyl, arylcarbonyl-(C1-C4)-alkyl, arylcarbonyloxy-(C1-C4)-alkyl, aryloxycarbonyl-(C1-C4)-alkyl, arylcarbonylamino-(C1-C4)-alkyl, arylaminocarbonyl-(C1-C4)-alkyl, arylcarbonylamino-(C1-C4)-alkyl, arylaminocarbonyl-(C1-C4)-alkyl, arylcarbonyloxy-(C1-C4)-alkyl, aryloxycarbonyl-(C1-C4)-alkyl, arylcarbonylamino-(C1-C4)-alkyl, heteroarylthio-(C1-C4)-alkyl, heteroarylsulfinyl-(C1-C4)-alkyl, heteroarylsulfonyl-(C1-C4)-alkyl, heteroarylamino-(C1-C4)-alkyl, heteroarylsulfonyloxy-(C1-C4)-alkyl,

heteroarylsulfonylamino--(C1-C4)-alkyl, heteroarylcarbonyl-(C1-C4)-alkyl, heteroarylcarbonyloxy-(C1-C4)-alkyl, heteroaryloxycarbonyl-(C1-C4)-alkyl, heteroarylcarbonylamino-(C1-C4)-alkyl, heteroarylaminocarbonyl-(C1-C4)-alkyl, heterocyclylthio-(C1-C4)-alkyl, heterocyclosulfinyl-(C1-C4)-alkyl, hetrocyclylsulfonyl-(C1-C4)-alkyl, heterocyclylamino-(C1-C4)-alkyl, heterocyclylsulfonyloxy-(C1-C4)-alkyl, heterocycylsulfonylamino-(C1-C4)-alkyl, heterocyclylcarbonyl-(C1-C4)-alkyl, heterocyclylcarbonyloxy-(C1-C4)-alkyl, heterocyclyloxycarbonyl-(C1-C4)-alkyl, heterocyclylcarbonylamino-(C1-C4)-alkyl, heterocyclylaminocarbonyl-(C1-C4)-alkyl, halo-(C1-C4)-alkylthio-(C1-C4)-alkyl, halo-(C1-C4)-alkylsulfinyl-(C1-C4)-alkyl, halo-(C1-C4)-alkylsulfonyl-(C1-C4)-alkyl, halo-(C1-C4)-alkylamino-(C1-C4)-alkyl, halo-(C1-C4)-alkylsulfonyloxy-(C1-C4)-alkyl, halo-(C1-C4)-alkylsulfonylamino-(C1-C4)-alkyl, halo-(C1-C4)-alkylcarbonyl-(C1-C4)-alkyl, halo-(C1-C4)-alkylcarbonyloxy-(C1-C4)-alkyl, halo-(C1-C4)-alkyloxycarbonyl-(C1-C4)-alkyl, halo-(C1-C4)-alkylcarbonylamino-(C1-C4)-alkyl, halo-(C1-C4)-alkylaminocarbonyl-(C1-C4)-alkyl, aryl-(C1-C4)-alkylamino-(C1-C4)-alkyl, aryl-(C1-C4)-alkylsulfinyl-(C1-C4)-alkyl, aryl-(C1-C4)-alkylsulfonyl-(C1-C4)-alkyl, aryl-(C1-C4)-alkylamino-(C1-C4)-alkyl, aryl-(C1-C4)-alkylsulfonyloxy-(C1-C4)-alkyl, aryl-(C1-C4)-alkylsulfonylamino-(C1-C4)-alkyl, aryl-(C1-C4)-alkylcarbonyl-(C1-C4)-alkyl, aryl-(C1-C4)-alkylcarbonyloxy-(C1-C4)-alkyl, aryl-(C1-C4)-alkoxycarbonyl-(C1-C4)-alkyl, aryl-(C1-C4)-alkylcarbonylamino-(C1-C4)-alkyl, aryl-(C1-C4)-alkylaminocarbonyl-(C1-C4)-alkyl, heteroaryl-(C1-C4)-alkylthio-(C1-C4)-alkyl, heteroaryl-(C1-C4)-alkylsulfinyl-(C1-C4)-alkyl, heteroaryl-(C1-C4)-alkylsulfonyl-(C1-C4)-alkyl, heteroaryl-(C1-C4)-alkylamino-(C1-C4)-alkyl, heteroaryl-(C1-C4)-alkylsulfonyloxy-(C1-C4)-alkyl, heteroaryl-(C1-C4)-alkylsulfonylamino-(C1-C4)-alkyl,


heteroaryl-(C1-C4)-alkylcarbonyl-(C1-C4)-alkyl, heteroaryl-(C1-C4)-alkylcarbonyloxy-(C1-C4)-alkyl, heteroaryl-(C1-C4)-alkoxycarbonyl-(C1-C4)-alkyl, heteroaryl-(C1-C4)-alkylcarbonylamino-(C1-C4)-alkyl, heteroaryl-(C1-C4)-alkylaminocarbonyl-(C1-C4)-alkyl, heterocyclyl-(C1-C4)-alkylthio-(C1-C4)-alkyl, heterocyclyl-(C1-C4)-alkylsulfinyl-(C1-C4)-alkyl, heterocyclyl-(C1-C4)-alkylsulfonyl-(C1-C4)-alkyl, heterocyclyl-(C1-C4)-alkylamino-(C1-C4)-alkyl, heterocyclyl-(C1-C4)-

alkylsulfonyloxy-(C1-C4)-alkyl, heterocyclyl-(C1-C4)-alkylsulfonylamino-(C1-C4)-alkyl, heterocyclyl-(C1-C4)-alkylcarbonyl-(C1-C4)-alkyl, heterocyclyl-(C1-C4)-alkylcarbonyloxy-(C1-C4)-alkyl, heterocyclyl-(C1-C4)-alkoxycarbonyl-(C1-C4)-alkyl, heterocyclyl-(C1-C4)-alkylcarbonylamino-(C1-C4)-alkyl, heterocyclyl-(C1-C4)-alkylcarbonylamino-(C1-C4)-alkyl, heterocyclyl-(C1-C4)-alkylaminocarbonyl-(C1-C4)-alkyl,

or O-(CH2)p-O-(CH2)wR20;Y is O or NR26;

R1 is halogen, cyano, nitro, (Y)n-S(O)q-R28, (Y)n-CO-R15 or is (C1-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl or (C1-C4)-alkoxy which are substituted by v halogen atoms or k (C1-C4)-alkoxy groups;

R2, R3, R5 and R7 independently of one another are hydrogen or (C1-C6)-alkyl;

R4 is hydrogen, or is (C1-C6)-alkyl, (C3-C6)-cycloalkyl, tetrahydropyran-3-yl, tetahydropyran-4-yl or tetrahydrothiopyran-3-yl which are substituted by k radicals from the group consisting of halogen, (C1-C6)-alkylthio and (C1-C6)-alkoxy;

R6 is hydrogen, (C1-C6)-alkyl or CO2R15, orR4 and R6 together form a bond or a three- to six-membered carbocyclic ring;

R11 is hydrogen, (C1-C6)-alkyl, halo(C1-C6)-alkyl, (C3-C6)-cycloalkyl or halo-(C3-C6)-cycloalkyl;

R12 is hydrogen, (C2-C6)-alkoxycarbonyl, halo-(C2-C6)-alkoxycarbonyl, CO2H or cyano;

R15 is (C1-C4)-alkyl, halo-(C1-C4)-alkyl or NR26R27;

R16 and R17 independently of one another are (C1-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-

alkynyl, halo-(C1-C6)-alkyl, aryl or aryl-(C1-C6)-alkyl which are substituted by k radicals from the group consisting of halogen, cyano, nitro, (C1-C6)-alkyl, halo-(C1-C6)-alkyl, (C1-C6)-alkoxy and halo-(C1-C6)-alkoxy;

R18 and R19 independently of one another are hydrogen or R16, orR18 and R19 together form a (C2-C5)-alkenyl chain;

R20 is (C1-C4)-alkyl, (C2-C8)-alkenyl, (C2-C6)-alkynyl, halo-(C1-C6)-alkyl, halo-(C2-C6)-alkenyl, halo-(C2-C6)-alkynyl, (C1-C6)-alkoxy, (C2-C6)-alkenyloxy, (C2-C6)-alkynyloxy, halo(C1-C6)-alkoxy, halo-(C2-C6)-alkynyloxy or halo-(C2-C6)-alkenyloxy;R26 is hydrogen or (C1-C6)-alkyl;

R27 is hydrogen, (C1-C6)-alkyl or (C1-C6)-alkoxy, orR26 and R27 together form (CH2)2, (CH2)3, (CH2)4, (CH2)5, or (CH2)2O(CH2)2;

R28 is (C1-C4)-alkyl, halo-(C1-C4)-alkyl or NR26R27;k is 0, 1, 2 or 3;n is 0 or 1;p is 1, 2 or 3;q is 0, 1 or 2;v is 0, 1, 2, 3, 4 or 5;w is 0, 1, 2 or 3,


and as component (B) at least one herbicide from the group consisting of acetochlor, alachlor, atrazine, bromoxynil, carfentrazone-ethyl, diflufenzopyr, dimethenamide, flufenacet, flumetsulam, fluthiacet-methyl, halosulfuron, imazamox, imazapyr, imazaquin, imazethapyr, iodosulfuron, metolachlor, metosulam, meribuzin, nicosulfuron, pethoxamide, pendimethalin, primisulfuron, prosulfuron,

pyridate, rimsulfuron, thenylchlor, thifensulfuron-methyl, tritosulfuron and N-[(4,6-dimethoxypyrimidin-2-yl)-aminocarbonyl]-2-dimethylaminocarbonyl-5-formylbenzenesulfonamide, where this composition comprises the compounds of the formula (I) or their salts (Component A) and the compounds of groups B (Component B) in a ratio by weight of from 1:2000 to 2000:1.

__________

149188]21][11[

ממשק עם לשימוש ובקרה מידע לוחלרשת קישור יחידת של

INFORMATION AND CONTROL CONSOLE FOR USE WITH A NETWORK GATEWAY INTERFACE

]54[

16.10.2000]22[US]33[22.10.1999]32[60/161139]31[US03.04.200009/541877

Int. Cl.8 H04L 012/14, 012/26, 012/28, 012/66, 029/06, 029/08]51[NOMADIX, INC., U.S.A.]71[




BEER-SHEVA 84152

]74[

]57 [A method for communicating to a host computer information during an existing networking session, the method comprising: establishing, via a gateway interface, a network session between a host computer and a computer network; creating, during the established network session, information and control console packets; sending the information and

control console packets to the host computer repeatedly throughout the network session; and generating, during the established network session, one or more information and control consoles on a monitor of thee host computer, wherein the method provides a user an ability to re-configure the network session during the


established network session by input to the information and control console.

__________149227]21][11[

של מחדש להכוונה ושיטות מערכותברשת לאתר לגשת המנסים משתמשים

SYSTEMS AND METHODS FOR REDIRECTING USERS ATTEMPTING TO ACCESS A NETWORK SITE

]54[

20.10.2000]22[US]33[ ]32[60/161093]31[US22.10.199960/161181US22.10.199960/161139US22.10.199960/161189US22.10.199960/160973US22.10.199960/161182US22.10.199960/160890US08.12.199909/458602US08.12.199909/458569

Int. Cl.8 G06F 015/00, H04L 012/14, 012/26, 012/28, 012/56, 012/66, 029/06, 029/08, 029/12

]51[

NOMADIX, INC., U.S.A.]71[WO/2001/031886]87[




]74[

]57 [A method for redirecting an original destination address access request to a

redirected destination address, the method comprising the steps of: receiving, at a


gateway device, all original destination address access requests originating from a computer; determining, at the gateway device, which of the original destination address requests require redirection; storing the original destination address if redirection is required; modifying, at the gateway device, the original destination address access request and communicating the modified request to a redirection server if redirection is required; responding, at the redirection server, to the modified request

with a browser redirect message that reassigns the modified request to an administrator-specified, redirected destination address; intercepting, at the gateway device, the browser redirect message and modifying it with the stored original destination address; and sending the modified browser redirect message to the computer, which automatically redirects the computer to the redirected destination address.

__________

149260]21][11[

של מילה אורך להקטנת והתקן שיטה לשחזור והתקן ושיטה דיגיטלי קלט אותהדיגיטלי הקלט אות

METHOD AND APPARATUS FOR REDUCING THE WORD LENGTH OF A DIGITAL INPUT SIGNAL AND METHOD AND APPARATUS FOR RECOVERING THE DIGITAL INPUT SIGNAL

]54[

15.08.2001]22[EP]33[25.08.2000]32[00202977.

5]31[

Int. Cl.8 G11B 020/10]51[KONINKLIJKE PHILIPS ELECTRONICS N.V., THE NETHERLANDS

]71[

WO/2002/017318]87[



אביב



TEL AVIV 61040

]74[

]57 [Method for reducing the number of bits of a digital input signal (M1) comprising the steps of adding a pseudo-random noise signal (Na) to the digital input signal (Mi) to obtain an intermediate signal (Di), the pseudo-random noise signal (Na) being defined by noise parameters (Np); and quantising the intermediate signal (Di) having a word length of n bits to a reduced word length signal (Me) having a word length of m bits, n being larger than or equal to m, wherein the step of quantising the intermediate signal (Di) comprises a first transfer function which is non-linear, the first transfer function being

defined by non-linear device parameters (NLDp), in which the quantisation step of the first transfer function for small amplitudes is smaller than the quantisation step for large amplitudes and in which the gain of the first transfer function is substantially equal to one for small amplitudes and in which the gain decreases for large amplitudes, characterised in that the first transfer function equals the function Me/Di=C1 tanh (C2Di+C3), in which Me is the reduced word length signal, Di is the intermediate signal and C1, C2, C3 are the non-linear device parameters (NLDp).

__________

149419]21][11[

NON-VOICE COMPLETION OFקוליות שיחות של א-קולית השלמהVOICE CALLS

]54[

30.04.2002]22[US]33[30.04.2001]32[09/843771]31[

Int. Cl.8 H04L 012/58, H04M 003/53, 003/56, H04Q 007/38]51[]COMVERSE LTD.]71החייל בע"מ, רמת קומברס

]GIDEON FOSTICK]72פוסטיק גדעון( בע"מ,1995) ג'י.אי.ארליך




]74[

]57 [A system for enabling a calling party to use voice narration to send a text message to a wireless communications device, comprising: (i) a voice-enabled communications device for composing a voice message; (ii) a call answering system (CAS); (iii) an Automatic Voice Recognition Server for converting said

voice message to converted text, and transferring said converted text to said CAS; and (iv) an Interactive Voice Response System for selecting a pre-prepared message from a plurality of available pre-prepared messages; wherein said CAS provides the text message; including the pre-prepared message and


said converted text, wherein the plurality of available pre-prepared messages are pre-programmed by a called party.

__________

149625]21][11[

PROCESS FOR THE–קרבוקסיאנהידרידיםN להכנת תהליךPREPARATION OF N-CARBOXYANHYDRIDES

]54[

14.05.2002]22[FR]33[31.05.2001]32[01/07140]31[

Int. Cl.8 C07D 263/44, 413/04]51[ISOCHEM, FRANCE]71[


אביב



TEL AVIV 61040

]74[

]57 [Process for the preparation of N-carboxyanhydrides by reaction of the corresponding α-, β- or γ-amino acid or one of its salts with phosgene, diphosgene

and/or triphosgene in a solvent medium, characterized in that at least a portion of the reaction is carried out under a total pressure of less than 1000 mbar.

__________

149824]21][11[

ELECTROLUMINESCENCE SYSTEMלייצורה והתקן אור פולטת מערכתAND DEVICE FOR THE PRODUCTION THEREOF

]54[

23.05.2002]22[IT]33[25.05.2001]32[MC2001A000058]31[IT25.05.2001MC2001A000059


Int. Cl.8 H05B 033/12]51[MICHEL TRAMONTANA, ITALYFILIPPO DEGLI AZZONI AVOGADRO CARRADORI, ITALY

]71[

צדק, וכהן איתן, פרל, לצר, הרצליה12688 , ת.ד. 7 שנקר רחוב

EITAN, PEARL, LATZER AND COHEN ZEDEK,

P.O.B. 12688 ,HERZLIYA 46733

]74[

]57 [An electroluminescence system, comprising two electrodes (7, 11) and a dielectric layer (8) with a pigment layer (9), characterized in that it further

comprises a further dielectric layer (10) and, possibly, further pigment layers, characterized in that each layer is provided with a colour filter (13).

__________

149957]21][11[

MOBILE PHONE WITHהידברותית מדפסת עם סלולרי טלפוןINTERACTIVE PRINTER

]54[

27.11.2000]22[AU]33[01.12.1999]32[PQ4392]31[

Int. Cl.8 B41J 003/42, 021/00, 029/38, H04M 001/00, 001/2745, H04Q 007/32, 007/38, 009/00

]51[

SILVERBROOK RESEARCH PTY. LTD., AUSTRALIA

]71[





]74[


TEL AVIV 61040

]57 [A mobile telephone device including: a mobile telephone unit including: a first transmitter adapted to transmit data to a mobile telephony network; a first receiver adapted to receive data from a mobile telephony network; a printer mechanism adapted to receive document data and to

print an interface onto a surface, the interface being at least partially based on the document data, the document data including identity data indicative of at least one identity, the identity being associated with a region of the interface, the interface including coded data.

__________

150011]21][11[

MAPPING DATA IN Aתקשורת ברשת נתונים מיפויCOMMUNICATION NETWORK

]54[

04.06.2002]22[Int. Cl.8 H04J 003/06, 003/07, H04L 025/05, H04Q 011/04]51[

]ECI TELECOM LTD.]71תקוה בע"מ, פתח אי.סי.איי. טלקום AMIHAI VICKS, JACOBליטינסקי רוטשטיין, לב ויקס, יעקב עמיחי

RUTHSTEIN, LEV LITINSKY]72[

בע"מ, אי. סי. איי. טלקוםתקוה , פתח30הסיבים רחוב

ECI TELECOM LTD,. 30 HASIVIM ST,.

PETACH TIKVA 49517

]74[

]57 [A cyclic generator of enabling/disabling signals (EG) adapted to convert a continuous incoming data stream having a bit rate R1 into data frames of a continuous outgoing data stream having a higher bit rate R2, wherein R1 is substantially equal to mR2/n, m<n, m and

n – integers being parameters of said EG selected to provide m enable signals per n clocks of the bit rate R2, wherein the EG being capable of generating periodic enabling/disabling output signals such that the disable signals are optimally distributed among the enable signals, and wherein the


EG being a universal EG capable of converting R1 into R2 by using a coefficient m/n formed by any integers m and n, wherein m and n are constants per at least one frame of the

continuous outgoing data stream, and thereby capable of performing any synchronous and any asynchronous conversion of bit rates.

__________

150154]21][11[

אות של נתיב לזיהוי והתקן שיטהחיבור בנקודת למנוי וידאו להעברת

METHOD AND APPARATUS FOR IDENTIFYING A SIGNAL ROUTE FOR DELIVERY OF VIDEO-ON-DEMAND TO A SUBSCRIBER TERMINAL

]54[

12.01.2001]22[US]33[13.01.2000]32[60/176393]31[US12.01.2001759935

Int. Cl.8 H04N 007/10, 007/16, 007/173]51[NCUBE CORPORATION, U.S.A.]71[





TEL AVIV 61040

]74[

]57 [A video on demand delivery method for distributing video on demand to one or more groups of subscribers wherein each group of subscribers is serviced by one or more modulators connected to a headend,

each group of subscribers being assigned a unique plant identification, the method comprising: receiving the unique plant identification by a particular subscriber; generating a video on demand data request


by the particular subscriber to the headend, the video on demand data request including the unique plant identification, the data request and a unique subscriber identification; and selecting, at the

headend, a modulator from the one or more modulators assigned to the group of subscribers that the particular subscriber is part of, based on the unique plant identification.

__________

150182]21][11[

קרבונאט( )אליל פוליאול תכשירילפלמור הניתנים

POLYMERIZABLE POLYOL (ALLYL CARBONATE) COMPOSITIONS

]54[

13.12.2000]22[US]33[13.12.1999]32[459796]31[

Int. Cl.8 C08F 018/16]51[PPG INDUSTRIES OHIO, INC., U.S.A.

]71[





TEL AVIV 61040

]74[

]57 [A polymerizable composition comprising:

)a (from 51 to 99.9 percent by weight based on the total weight of the


polymerizable composition of a radically polymerizable first monomer represented by the formula

R-[-O-C(O)-O-R1]i

wherein R is a polyvalent residue of a polyol having at least two hydroxyl groups, R1 is an allyl group, and i is a whole number from 2 to 4; and

)b (from 0.1 to 49 percent based on the total weight of the polymerizable composition of a radically polymerizable second monomer represented by the formula

wherein R2 is a polyvalent linking group that is free of urethane linkages; R3 is a residue of a material having a single

hydroxyl group and at least one allyl group, R3 being free of urethane linkages; and j is a number from 2 to 4.

__________

150359]21][11[

]CHEMOTHERAPEUTIC AGENTS]54כימותרפים גורמים

22.12.2000]22[DE]33[22.12.1999]32[19962470.

4]31[

Int. Cl.8 A61K 031/47, A61P 031/04, C07D 215/00, 215/16, 401/02, 455/02, 471/02]51[HANS-HERRMANN SCHULZ, GERMANYGUNTHER SCHLIMBACH, GERMANY

]71[




P.O.B. 4060 ,TEL AVIV 61040

]74[

]57 [Use of at least one of the following compounds: 7-(3-amino-1-pyrrolidinyl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid (clinafloxacin), 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic

acid (gatifloxacin), 7-[4Z)-3-)-aminomethyl)-4-(methoxyimino)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid (gemifloxacin), 1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-


3-quinolinecarboxylic acid (grepafloxacin), (3S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido [1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (levofloxacin), 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS, 7aS)-octahydro-6H-pyrrolo [3,4-b] pyridine-6-yl]-4-oxo-3-quinolinecarboxylic acid (moxifloxacin), 5-amino-1-cyclopropyl-7-[(3R, 5S)-3,5-dimethyl-1-piperazinyl]-6,8-difluoro-1,4-

dihydro-4-oxo-3-quinolinecarboxylic acid (sparfloxacin), 7-(3-amino-1-pyrrolidinyl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid (tosufloxacin) and 7-(1α, 5α, 6α-6-amino-3-azabicyclo [3.1.0] hex-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-caboxylic acid (trovafloxacin) and/or at least one compound of the formula

in which: R1 is hydrogen or C1-C3-alkyl, andR2 is an optionally monosubstituted or polysubstituted mono-, bi- or tricyclic alicycle which is saturated or has at least one double bond and which optionally has at least one heteroatom in the ring system, or an aromatic mono-, bi- or tricycle optionally having at least one heteroatom, and/or it corresponding hydrate and/or its corresponding physiologically compatible acid addition salt and/or optionally its corresponding physiologically compatible salt of the carboxylic acid on which the

compounds enumerated are based and/or of the parent carboxylic acid for compounds of formula (II), in which R1 is H, and/or of corresponding enantiomers and/or corresponding diastereomers and/or of the corresponding mixture of at least two of the abovementioned compounds, and optionally other physiologically compatible auxiliary substances, for the preparation of a medicament for the topical and/or local treatment and/or for the prophylaxis of diseases caused by bacteria in humans or animals in the region of the mouth and/or teeth and/or jaws.

__________

150446]21][11[

מזהמות מתכות של יונים סילוק שיטתשפכים ממי

METHOD FOR THE REMOVAL OF CONTAMINANT METAL IONS FROM WASTEWATER

]54[

27.06.2002]22[Int. Cl.8 C02F 001/48, 001/52, 001/62]51[

]VERACON METAL LTD.]71בע"מ, צמח מטל ורהקון]PAVEL KOREN, IGAL RAZ, ]72 נוח, אזימוב, רמי רז, רוברט קורן, יגעל פול


,ROBERT AZIMOV, RAMI NOACHטרונקובסקי אירנהIRENA TRONKOVSKY

אגרנוב, דוד ד"ר, אלוני-אבא15, ת.ד.

DR. DAVID AGRANOV, P.O.B. 15,

ALONEY-ABA36005

]74[

[57] A method for the removal of ions of heavy metals from an aqueous solution by causing the formation of solid ferrites of said heavy metals and reducing concentration of the ions of the heavy metals in the aqueous solution to levels below 0.1 ppm, wherein said method is carried out as a single step physiochemical process during which the pH value of said aqueous solution is adjusted to a value

which is sufficient to induce formation of the solid ferrites of said heavy metals and during which the aqueous solution is simultaneously exposed to a magnetic field, which is defined by a magnetic strength of at least 300 Gauss, wherein said physiochemical process takes place in the presence of a chemically active iron ferrite seed, which is added to the aqueous solution.

__________

150480]21][11[

–N[–4[–2(–2 חומצה של גבישית צורה–H3–אוקסו–4–דיהידרו–7,4אמינו––5[פירימידין–d–2,3פירולו]

ותהליך –גלוטמיתLיל(אתיל[בנזויל[–להכנתה

CRYSTALLINE FORM OF N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR

]54[

12.02.2001]22[US]33[25.02.2000]32[60/184964]31[

Int. Cl.8 A61K 031/519, C07D 487/04]51[ELI LILLY AND COMPANY, U.S.A.]71[




BEER-SHEVA 84152

]74[

[57] A hydrate crystal form of disodium N-[4-[2-(2-amino-4, 7-dihydro-4-oxo-3H-pyrrolo [2, 3-d]-pyrimidin-5-yl) ethyl] ben-zoyl]-L-glutamic acid salt ("heptahydrate crystalline form"), having an X-ray

diffraction pattern, which comprises the following peaks corresponding to d spacing: 7.78±0.04 Å whn obtained at 22±2oC and ambient % relative humidity from a copper radiation source.

__________


150568]21][11[

עם הפה דרך לנתינה רוקחות תכשירימבוקר שחרור

CONTROLLED RELEASE ORAL DRUG DOSAGE FORM

]54[

30.01.2001]22[US]33[04.02.2000]32[09/498945]31[

Int. Cl.8 A61K 009/00, 009/20, 009/28]51[DEPOMED, INC., U.S.A.]71[





]74[

[57] A controlled-release oral drug dosage form for releasing a drug into at least a portion of region defined by the stomach and the upper gastrointestinal tract, said dosage form comprising:(a) a core comprising a first solid polymeric matrix with said drug dispersed therein, and (b) a shell encasing said core, said shell comprising a second solid polymeric matrix that swells upon imbibition of water to a size large enough to promote retention in the stomach while the stomach is in a fed mode, and said shell having a drug: polymer weight ratio that is equal to or less than 0.5 times the drug: polymer weight ratio of said core, said shell having a

thickness that is at least 0.5% of the longest linear dimension of said dosage form, said second polymeric matrix being of a material and thickness relative to said core such that when said dosage form is immersed in gastric fluid, said drug is released from said dosage form into said gastric fluid at a controlled rate limited at least in part by diffusion of said drug through said shell to an extent that at least 40% of said drug remains unreleased one hour after such immersion has begun and substantially all of said drug is released within about twenty-four hours after such immersion has begun, said shell remaining intact during substantially the entire period of drug release.

__________


150570]21][11[

METHODS FOR PROTEINחלבונים להעברת שיטותTRANSFER

]54[

03.01.2001]22[US]33[03.01.2000]32[09/476828]31[

Int. Cl.8 C07K 016/46, 019/00, C12N 005/02, 005/06, 005/16]51[TR ASSOCIATES, L.L.C., U.S.A.]71[

MARK. L. TYKOCINSKI, AOSHUANG CHEN, GUOXING ZHENG

]72[

WO/2001/049825]87[לנגר, אדוארד

אביב , תל4רח' ברקוביץ EDWARD LANGER, C/O SHIBOLET, YISRAELI, ROBERTS, ZISMAN &

CO,. 4 BERKOWITZ ST,.

TEL AVIV 64238

]74[

[57] A method for transferring a protein to a cell comprising: coating the surface of said cell with a first protein, wherein said first protein is a lipidated protein; and contacting said cell with a second protein,

wherein said second protein is a fusion protein comprised of a first domain having affinity for said first protein and a second domain having trans signaling and/or adhesion function.

__________

150690]21][11[

חומצתית תמיסה המכילים תכשירים פיזיולוגית מבחינה מאוזנת מיוננת

אותם המכילים ומוצרים

COMPOSITIONS CONTAINING PHYSIOLOGICALLY BALANCED, IONIZED, ACIDIC SOLUTION AND ARTICLES CONTAINING THEM

]54[

12.01.2001]22[US]33[12.01.2000]32[482159]31[

Int. Cl.8 A61K 031/74, 033/14, 033/40]51[


NOVACAL PHARMACEUTICALS INC., U.S.A.

]71[





TEL AVIV 61040

]74[

[57] A stable antimicrobial composition useful for wound treatment, burn treatment, tissue repair, regeneration or irrigation, cleaning or treatment of oral tissue, gargling, treatment of ophthalmic tissue or cleaning or treatment of dermal tissue, said composition comprising a physiologically-balanced, ionized, acidic solution having an HClO concentration of 0.1 ppm to 1000

ppm and a pH of 2 to 6, wherein said solution is generated from a starting solution having a total concentration of halide-comprising salts ranging from 4 g/L to 12 g/L in a container whose surfaces in contact with the composition are made of material which tends not to react with oxidizing agents, said composition having a shelf life of at least 60 days.

__________

150737]21][11[

קצף מעלה שאינה מרוכזת תמיסה קוטרנרי אמוניום תרכובות והמכילה

בה להשתמש ושיטות

CONCENTRATED, NON-FOAMING SOLUTION OF QUATERNARY AMMONIUM COMPOUNDS AND METHODS OF USE

]54[

26.01.2001]22[US]33[31.01.2000]32[494374]31[

Int. Cl.8 C07C 211/00]51[UNIVERSITY OF ARKANSAS, U.S.A.

]71[





TEL AVIV 61040

]74[

[57] A concentrated quaternary ammonium compound solution comprising: a quaternary ammonium compound with a concentration from greater than about 15% by weight to about

40% by weight; and at least one solubility enhancing agent, wherein at least one of said solubility enhancing agents is propylene glycol.

__________


150823]21][11[

SYSTEM AND METHOD FORהדהוד ביטול ליישום ושיטה מערכתIMPLEMENTATION OF AN ECHO CANCELLER

]54[

26.01.2001]22[US]33[27.01.2000]32[09/491933]31[

Int. Cl.8 H04B 003/20, H04M 001/60, 009/08]51[QUALCOMM INCORPORATED, U.S.A.

]71[




REHOVOT 76122

]74[

[57] A system for canceling an echo signal, comprising:(A) an acoustic processor that receives an input waveform;(B) an adaptive filter that determines whether said input waveform includes information representative of said echo signal; and (C) said acoustic processor including a variable attenuator that forms an output

waveform by attenuating a residual waveform if said input waveform includes information representative of said echo signal; wherein said variable attenuator attenuates said residual waveform by an attenuation factor that gradually changes from an initial attenuation value to a final attenuation value if said input waveform includes information representative of said echo signal.


__________

151135]21][11[

MECHANICAL HEARTBURN ANDוברפלוקס בצרבת לטפול מכני מתקןREFLUX TREATMENT APPARATUS

]54[

07.02.2001]22[US]33[10.02.2000]32[09/502074]31[

Int. Cl.8 A61B 017/12]51[OBTECH MEDICAL AG, SWITZERLAND

]71[



P.O.B. 12688 ,HERZLIYA 46733

]74[

[57] A heartburn and reflux disease treatment apparatus comprising: an adjustable non-inflatable restriction device (2) adapted to be implanted in a patient having heartburn and reflux disease to engage the esophagus or the stomach close to the cardia without forming an upper pouch of the stomach that substantially accumulates food to form a restricted cross-sectional area of the food

passageway in the stomach or esophagus, said restriction device being designed to work like an artificial sphincter to allow food to readily pass through the passageway, and a post-operation adjustment device (12) for mechanically non-invasively adjusting said restriction device to change the size of the cross-sectional area sufficiently so as to substantially prevent regurgitation of


stomach acids or foods into the patient's esophagus.

__________

151330]21][11[

של בו–זמני לתיאום והתקן שיטה ראשון מחשב על המתבצעת תוכנית

שרת על המתבצעת תוכנית באמצעות

METHOD AND DEVICE FOR SYNCHRONISING A PROGRAMME RUNNING ON A FIRST COMPUTER WITH A PROGRAMME RUNNING ON A SERVER

]54[

11.01.2001]22[DE]33[24.02.2000]32[10008616.

0]31[

Int. Cl.8 G06F 009/00, 015/163]51[SIEMENS AKTIENGESELLSCHAFT, GERMANY

]71[




P.O.B. 4060 ,TEL AVIV 61040

]74[

[57] A method for synchronizing a program running on a first computer with a program running on a server, where the program running on the server continues to run and makes state changes even when the

server is not connected to the first computer,(a) in which, as soon as an existing connection between the first computer and the server has been interrupted, the server


stores the state of the first computer within the program running on the server;(b) in which the program running on the server is continued after the connection to the first computer has been interrupted, with state changes in the program running on the server being logged, at least some of

which state changes are caused by the server; and(c) in which the first computer is reconnected to the server, and the stored state and the logged state changes are taken as a basis for synchronizing the program running on the first computer with the program running on the server.

__________

151402]21][11[

תקשורת לפרוטוקול וציוד מערכת לעיבוד במערכת בטוח אינטרנטקריאות

METHOD AND APPARATUS FOR SECURE INTERNET PROTOCOL COMMUNICATION IN A CALL PROCESSING SYSTEM

]54[

21.08.2002]22[US]33[10.01.2002]32[10/043589]31[

Int. Cl.8 G09C 001/00, H04L 009/14, 012/66, 029/06]51[AVAYA TECHNOLOGY CORP., U.S.A.

]71[

ושות', ט. קולב סנפורד ,2273, ת.ד. , מרמורק4 הגיא שער

רחובות


REHOVOT 76122

]74[

]57 [In a call processing system, a method for providing secure communications between two or more end units of the

system via a communication switch of the system, each of the end units being coupled between the communication switch and


one or more terminals of the system, the method comprising the steps of: storing in a memory associated with the communication switch a plurality of sets of session key lists including a set of session key lists for each of the end units; selecting as an end unit to end unit session key a session key from a session key list in a given one of the sets of session key lists associated with an originating end unit, the selected end unit to end unit session key being utilizable in providing secure communications between the originating end unit and at least one other end unit via the communication switch; wherein the end units have respective pluralities of

terminals associated therewith, a given one of the end units being configured to provide an interface between its associated terminals and the communication switch; wherein the given set of session key lists associated with the originating end units comprises session key lists for respective terminals associated with that end unit; and wherein the given set of session key lists is generated in the originating end unit and transmitted from the originating end unit to the communication switch in conjunction with an authentication protocol carried out between the originating end unit and the communication switch.

__________

151522]21][11[

FIREWALL WITH RAPIDמידע חבילות של מהיר סינון עם פיירוולPACKET FILTERING

]54[

26.02.2001]22[US]33[02.03.2000]32[09/517276]31[

Int. Cl.8 G06F 001/24, 011/30, 015/16, H04L 012/66, 029/06]51[


CHECK POINT SOFTWAREגן בע"מ, רמת טכנולוגיות פוינט צ'קTECHNOLOGIES LTD.

]71[

]GONEN FINK, AMIR HARUSH]72הרוש פינק, אמי גונןWO/2001/065343]87[

בע"מ, פרידמן מרק ד"ר ז'בוטינסקי , רח54אביב, ק. משה מגדל

, רמת- גן7

DR. MARK FRIEDMAN LTD,. MOSHE AVIV TOWER, 54TH

FLOOR ,7 JABOTINSKY ST ,.

RAMAT GAN 52520

]74[

]57 [A system for accelerated packet filtering, the system comprising:

)a (a source node for transmitting a packet;)b (a destination node for receiving said

packet;)c (a firewall interposed between said

source node and said destination node for performing packet filtering according to at least one rule; and

)d (a pre-filtering module separate from said firewall and being in communication

with said firewall, for receiving at least one instruction from said firewall and for receiving said packet before said firewall, such that if said packet is permitted according to said at least one instruction, said pre-filtering module handles said packet, and alternatively said pre-filtering module forwards said packet to said firewall for handling.

__________

151545]21][11[

METHOD FOR IMAGEבינארי באופן תמונה להצגת שיטהBINARIZATION

]54[

21.02.2001]22[


US]33[02.03.2000]32[09/519446]31[Int. Cl.8 G06K 009/62, G06T 005/20]51[IBM CORPORATION, U.S.A.]71[

WO/2001/065465]87[יבמ, מעבדות רוחני קניין מחלקת

הכרמל, חיפה הר חיפה אוניברסיטת IBM LABORATORIES,

HAIFA UNIVERSITY,HAIFA 31905

]74[

]57 [A method for image binarization, comprising: receiving a gray-level input image comprising a plurality of pixels having respective gray-level values; analyzing variations among the gray-level values of the pixels in the input image so as to determine image statistics with respect to gaps between the gray-level values of

neighboring pixels; responsive to the image statistics, determining a lower threshold and an upper threshold, which is greater than the lower threshold by a selected difference; assigning a first binary value to the pixels in the gray-level values between the lower and upper thresholds so as to determine optimal assignments of the pixels in the intermediate group to the first and second binary values.

__________

151602]21][11[


DEVICE, SYSTEM AND METHODצמחים להשקיית ושיטה התקן, מערכתFOR PLANT IRRIGATION

]54[

04.09.2002]22[Int. Cl.8 A01G 027/00]51[

]AHARON WINTER]71מימון וינטר, כפר אהרןוגולר, וולף, ברגמן


WOLFF, BREGMAN AND GOLLER,

19B KEREN HAYESOD ST ,.P.O.B. 1352,

JERUSALEM 91013

]74[

]57 [A device for delivering material to the roots of at least one plant growing in a substrate, said device comprising:

)a (at least one funnel-shaped receptacle (12) for receiving said material;

)b (at least one tubular conveying member (22) for conveying said material to said roots, said conveying member having a first end (24) fluidly associable with said receptacle and a second end (24') for

insertion within said substrate in close proximity to said roots;

)c (at least one retainer (26) for retaining a source (28) of said material, such that said material received by said receptacle is conveyed to said roots, and

)d (said retainer in association with said receptacle is disposed in an orientation such that said material is delivered to said receptacle.


__________

151637]21][11[

של מצומד דו–כווני קיבוץ אנאליזתמידע

COUPLED TWO-WAY CLUSTERING ANALYSIS OF DATA

]54[

09.03.2001]22[IL]33[09.03.2000]32[134994]31[

Int. Cl.8 C12Q 001/68, G01N 033/00, G06F 019/00]51[ YEDA RESEARCH ANDבע"מ, רחובות ופיתוח למחקר חברה ידע


WO/2001/067061]87[( בע"מ,1995) ג'י.אי.ארליך




]74[

]57 [A method for partitioning a first plurality of objects and a second plurality of objects, each of the first plurality of objects being related to at least one of the second plurality of objects according to at least one characteristic of each object, the method being performed by a data processor, the method comprising: partitioning the first plurality of objects

into a first plurality of objects according to a subset of the first plurality of objects to form a second plurality of object subsets, such that said partitioning of the second plurality of objects is coupled to said partitioning of the first plurality of objects and wherein said first and second plurality of objects are partitioned in an unsupervised manner.

__________

151703]21][11[

ניידת תחנה יישום עבור ומתקן שיטהארוז גולמי מידע ולשדר לקבל

METHOD AND APPARATUS FOR A MOBILE STATION APPLICATION TO RECEIVE AND TRANSMIT RAW PACKETIZED

]54[


DATA

29.03.2001]22[US]33[30.03.2000]32[09/539499]31[

Int. Cl.8 H04L 012/56, 029/06, H04Q 007/38]51[QUALCOMM INCORPORATED, U.S.A.

]71[




REHOVOT 76122

]74[

]57 [A method for a mobile station application to receive raw packetized data, the method comprising: creating, by the mobile station application, at least one socket; receiving, by at least one of a plurality of mobile station protocol layers, encapsulated raw packetized data from a communication network, the raw

packetized data lacking destination port information; transmitting, by at least one of the mobile station protocol layers, unencapsulated raw packetized data to the at least one socket; and transmitting, by the at least one socket, the raw packetized data to the mobile station application.

__________

151715]21][11[

–דה–אצטילתיוקולציסיןN תולדותאותן המכילים רוקחות ותכשירי

N-DEACETYLTHIOCOLCHICINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

]54[

12.03.2001]22[


IT]33[17.03.2000]32[MI2000A000554]31[Int. Cl.8 A61K 031/16, 031/17, A61P 019/00, 029/00, 035/00, 043/00, C07C 323/39, 323/41, 323/43

]51[

INDENA S.P.A., ITALY]71[WO/2001/068597]87[


אביב


P.O.B. 4060 ,TEL AVIV 61040

]74[

]57 [Compounds of the formula

wherein: n is an integer from 0 to 8 Y is CH2 group or, when n is 1, can also be a group of formula NH.

__________

151725]21][11[

METHOD AND APPARATUS FORמפסק מצב לבקרת והתקן שיטהSWITCH AND TOGGLE CONTROL

]54[

12.09.2002]22[Int. Cl.8 A47G 033/00]51[

]REUVEN NETANOV]71אביב נתנוב, תל ראובןנתנוב, ראובן

אביב , תל15/6רח' השקד REUVEN NETANOV,

15 HA'SHAKED ST., TEL AVIV]74[

]57 [An improved switch (10) for controlling switch position, comprising: a movable part (12) movable between at least two positions; a switch frame (14) encircling the movable part, the frame including at least one opening (16) and at

least one passage connected to the opening; and at least one locking member (18) to be inserted through the opening and passage, the locking member when sufficiently inserted through the opening and passage prevents movement of the movable part.


___________

151752]21][11[

DIAMOND RADIATIONמיהלום קרינה גלאיDETECTOR

]54[

13.03.2001]22[GB]33[15.03.2000]32[0006318.0]31[

Int. Cl.8 G01T 001/26]51[DE BEERS INDUSTRIAL DIAMOND (PROPRIETARY) LIMITED, SOUTH AFRICA

]71[





TEL AVIV 61040

]74[

]57 [A radiation detector comprising an overlayer of diamond grown on a surface of a boron-doped diamond substrate,

wherein the overlayer of diamond is produced epitaxially on the surface of the boron-doped diamond substrate.

__________

151816]21][11[

SYNERGISTIC HERBICIDALעשבים הקוטלות סינרגיסטיות תערובותMIXTURES

]54[

04.04.2001]22[US]33[04.04.2000]32[60/194383]31[US11.09.200060/231631


Int. Cl.8 A01N 043/40, C07D 209/48, 213/60, 249/08, 285/02]51[BASF AKTIENGESELLSCHAFT, GERMANY

]71[





TEL AVIV 61040

]74[

]57 [A herbicidal composition which comprises an agriculturally acceptable carrier and a herbicidally effective amount

of a combination of at least one 8-phenoxyprid-2-ylcarboxamide of the formula

wherein R1 represents a hydrogen or halogen atom or an alkyl or alkoxy group;

R2 represents a hydrogen atom or an alkyl group;

X each independently represents a halogen atom or an optionally substituted alkyl or alkoxy group or, an alkenyloxy, cyano, carboxy, alkoxycarbonyl, (alkylthio) carbonyl, alkylcarbonyl, amido, alkylamino, dialkylamido, nitro, alkylthio, haloalkylthio, alkenylthio, alkynylthio, alkylsulphinyl, alkylsulphonyl, alkyl-

oximinoalkyl or alkenyloximinoalkyl group;m represents 0 or an integer from 1 to 5;

Y each independently represents a halogen atom or an alkyl, nitro, cyano, haloalkyl, alkoxy or haloalkoxy group;

n represents 0 or an integer from 1 to 5; and at least one additional herbicidal compound selected from the group consisting of flufenacet, cinidon-ethyl and carfentrazone-ethyl.

__________

152027]21][11[

DESALINATION OF OCEANים מי התפלתWATER

]54[

29.03.2001]22[JP]33[31.03.2000]32[2000-

96811]31[

Int. Cl.8 B01D 003/34, C02F 001/04, F28F 013/00]51[


BIOMASS CONVERSIONS, L.L.C., U.S.A.

]71[

SEIJI HATA]72[WO/2001/074721]87[

ושות' בע"מ, מ. בן-דוד ירמיהו ,45087, ת.ד. חוצבים המרפא, הר רחוב

ירושלים



JERUSALEM 91450

]74[

]57 [A method for enhancing the evaporation of water in a container, comprising the steps of: making a mixture of water and a quantity of fine particles, the particles having an average diameter of 100

μm or less, spraying water into the container containing the mixture, and agitating the mixture within the container by means of an impeller whereby water vapor is released from the mixture.

__________152073]21][11[

להכנתו, והשימוש פרסיקווינין, תהליךרוקחי כתכשיר בו

PERCYQUINNIN, A PROCESS FOR ITS PRODUCTION AND ITS USE AS A PHARMACEUTICAL

]54[

24.03.2001]22[EP]33[07.04.2000]32[00107536.

5]31[

Int. Cl.8 A61K 031/337, A61P 003/06, C07D 305/14, 405/00, C12N 001/14]51[SANOFI-AVENTIS DEUTSCHLAND GMBH, GERMANY

]71[



P.O.B. 12688 ,HERZLIYA 46733

]74[

]57 [Percyquinnin, a compound of the formula


and its pharmaceutically acceptable salts.__________

152247]21][11[

METHOD FOR PRODUCINGאתריים אוקסים לייצור שיטהOXIME ETHERS

]54[

04.04.2001]22[DE]33[11.04.2000]32[10017724.

7]31[

Int. Cl.8 C07C 249/12, 251/34, 255/17]51[BASF AKTIENGESELLSCHAFT, GERMANY

]71[





TEL AVIV 61040

]74[

]57 [A process for preparing oxime ethersof the formula

in which the substituents R1 and R2 can be identical or different and can each by cyano, C1-C4 alkyl, C1-C4-haloalkyl, C3-C6-

cycloalkyl, phenyl and naphthyl, and R3 can be C1-C4-alkyl, by alkylation of oximes of the formula

under basic conditions with an alkylating agent from the group of alkyl halides, dialkyl sulfates and dialkyl carbonates, wherein the reaction is carried out in a mixture consisting of 5 to 25% by weight of polar aprotic solvents selected from the

group of nitriles, N-alkyl-pyrrolidones, cyclic urea derivatives, dimethylformamide and dimethylacetamide, 55 to 95% by weight of nonpolar solvents selected from the group of aliphatic hydrocarbons, aromatic hydrocarbons, alkyl


alkylcarboxylates and ethers, 0 to 25% by weight of water, the contents thereof totaling 100%.

__________

152340]21][11[

]CLEANING ARTICLE]54ניקוי אביזר

21.02.2001]22[JP]33[23.02.2001]32[2001-

047979]31[

Int. Cl.8 A47L 013/20]51[UNI-CHARM CORPORATION, JAPAN

]71[

YOSHINORI TANAKA]72[WO/2002/065887]87[


אביב



TEL AVIV 61040

]74[

]57 [A cleaning article to be used while being attached to a holder, the cleaning article comprising: a base sheet; a brush portion provided on one side of the base sheet; and a holding sheet provided on the other side of the base sheet, the base sheet and the holding sheet being fusion-bonded together to have at least two fusion-bonded portions which are spaced apart from each

other and define a holding space between the base sheet and the holding sheet for accommodating the holder, wherein the base sheet and the holding sheet are provided with mutually different colors so that the fusion-bonded portions have a color different from that of the holding sheet.


__________

152349]21][11[

בתקשורת בו לשימוש משדר–מקלטרדיו

TRANSCEIVERS AND METHOD FOR USE IN RADIO COMMUNICATIONS

]54[

17.10.2002]22[GB]33[17.10.2001]32[0124888.9]31[

Int. Cl.8 H04B 017/00, H04Q 007/34]51[MOTOROLA, INC., U.S.A.]71[


אביב



TEL AVIV 61040

]74[

]57 [A base transceiver for use in radio communication with distant transceiver units, the base transceiver being operable to send to the distant transceiver units a test signal to test whether the test signal is received by the distant transceiver units, characterized in that the base transceiver is operable to put itself periodically into an interference detection mode to detect for interference by jamming of a downlink radio transmission from the base transceiver and actively to take part in the interference detection mode by being operable: (i) to generate and send on a

control channel by polling to all mobile stations camped on the control channel a test signal which the mobile stations are programmed to recognize and respond to; (ii) to sense whether or not a response signal is received from any of the mobile stations in response to receipt of the test signal; and (iii) if no response signal is detected, optionally after further investigation, to generate an interference detection signal to indicate that interference to the downlink transmission has been detected.


__________

152409]21][11[

הצמדות המראים ונגזרותיהם פפטידיםוניתוק פיזור ופעילות תאים

PEPTIDES AND DERIVATIVES THEREOF SHOWING CELL ATTACHMENT, SPREADING AND DETACHMENT ACTIVITY

]54[

06.12.2000]22[KR]33[13.05.2000]32[2000/2566

5]31[

Int. Cl.8 A61K 038/08, 038/17, C07K 007/06]51[REGEN BIOTECH, INC., REPUBLIC OF KOREA

]71[





TEL AVIV 61040

]74[

]57 [A peptide and its derivatives having cell attachment, spreading and detachment

activity, comprising an amino acid sequence represented by XXDIX.

__________152494]21][11[

בעלי אותות לזיהוי כפול זיהוי הליךגבוהה תאוצתית אי–ודאות

DUAL DETECTION PROCESSING FOR DETECTING SIGNALS WITH HIGH ACCELERATION UNCERTAINTY

]54[

24.04.2001]22[US]33[28.04.2000]32[559664]31[

Int. Cl.8 G01S 003/14, 003/46, 007/02, 007/285, 007/292, G06F 017/14]51[LOCKHEED MARTIN CORPORATION, U.S.A.

]71[





TEL AVIV 61040

]74[

]57 [A signal detection system for detecting electromagnetic signals from target objects, the signal detection system

comprising: a receiver for receiving electromagnetic signals at the signal detection system, the electromagnetic


signals including target object signals having unknown values of velocity and acceleration, wherein a magnitude of an acceleration component corresponding to a particular target object tends to be inversely correlated to a distance between the particular target object and the signal detection system; means for transforming time domain data of the received electromagnetic signals into frequency domain templates of data; and signal processor for arranging the frequency

domain templates into an array matrix having acceleration bins; wherein the signal processor analyzes the acceleration bins to detect the presence of a target object signal, the acceleration values of the acceleration bins being analyzed having values lower than the highest expected acceleration of the target objects, and the signal processor periodically analyzes individual templates for the presence of a target object signal within the individual templates.

__________

152570]21][11[

– – הידרוקסי1 – ]4 להכנת תהליך4[ – 4 –

–1)הידרוקסידיפנילמתיל( – פיפרידיניל[ –

– בוטיל[ –אלפה, אלפה חומצה – דימתילבנזן

אצטית

PROCESS FOR THE PREPARATION OF 4 -

[1 - HYDROXY- 4 - (4 - (HYDROXYDIPHENYLMETHYL - )1

-PIPERIDINYL]- BUTYL ] ALPHA,

ALPHA -DIMETHYLBENZENE ACETIC ACID

]54[


31.10.2002]22[Int. Cl.8 C07D 211/22]51[DINAMITE DIPHARMA S.P.A., ITALY]71[

ושותפיו, כהן ריינהולד ,4060 , ת.ד. 21 העם אחד רחוב

אביב תל


P.O.B. 4060 ,TEL AVIV 61040

]74[

]57 [A process for the preparation ofFexofenadine

which comprises: (a) reaction of a compound of the formula

wherein R1 is a halogen or an alkyl or arylsulfonate group, with the compound of the formula

)b (condensation of the resulting compound of the formula

with a compound of the formula


wherein R2 is hydrogen or C1-C4 alkyl, and R3 is a halogen or an alkyl or arylsulfonate, in the presence of metal catalysts based on

copper (I) or mixtures of palladium (0) and copper (I) in the presence of a base;

)c (transformation of the resulting compound of the formula

into the compound

by treatment with water in the presence of a catalyst based on palladium, platinum or ruthenium, optionally in the presence of ligands, and

)d (conversion of the latter compound into Fexofenadine by reduction with metal hydrides and hydrolysis of the ester groups.

__________

152687]21][11[

ותהליך חדשים מתרחבים פורפריניםלהכנתם

EXPANDED PORPHYRINS AND PROCESS FOR THE SYNTHESIS THEREOF

]54[

23.05.2001]22[JP]33[12.06.2000]32[2000/1753

09]31[

Int. Cl.8 C07D 487/22]51[JAPAN SCIENCE AND TECHNOLOGY AGENCY, JAPAN

]71[




P.O.B. 4060 ,TEL AVIV 61040

]74[

]57 [An expanded porphyrin forming a macrocycle by alternate bonding of 7 or more pyrrole units with methane whose hydrogen is substituted by Ar group at α

position of the pyrrole, wherein Ar is 2,6-substituted phenyl group which can possess a substituent on 3, 4 or 5 position, 9-anthranyl group which can


possess a substituent or cyclohexyl group which can possess a substituent; and said substituent at 2 and 6 positions of the phenyl group can be selected from fluoro, chloro, bromo, iodo, lower alkyl of carbon number 1 to 4 or lower alkoxy; substituent at 3-5 positions, 9-anthranyl group and cyclohexyl group can be selected independently from the group consisting of substituted or non-substituted alkyl of carbon number 5 or 6, alkenyl group,

alkinyl group, substituted or non-substituted aryl group, alkyl or aryl sulfonyl group, alkyl or aryl cyano group, cyano group, nitro group, amino group, carboxy group, carboalkoxy group or ester, amide and salt thereof besides above mentioned substituents at 2 and 6 positions; and substituent of each Ar can be selected independently from the substituents mentioned above.

__________

152820]21][11[

STREAMING SERVICES INרדיו תקשורת במערכות שירותים ניתובRADIO NETWORKS

]54[

13.11.2002]22[GB]33[16.11.2001]32[0127540.3]31[

Int. Cl.8 H04L 012/56, 029/06]51[HUTCHISON WHAMPOA THREE G IP (BAHAMAS) LIMITED, BAHAMAS

]71[


אביב



TEL AVIV 61040

]74[

]57 [A radio transceiver for use in a packet switched streaming service in a WCDMA radio network in which a transmission frequency band is divided into a number of channels identified by a frequency and a code and a number of radio access bearers are multiplexed onto one channel, the

transceiver having means for receiving continuous media information from a network server and exchanging control information with the server, with the media information and the control information transmitted over separate radio access bearers.

__________


153110]21][11[

בר של הצפנה תכולות להארכת שיטהPDF 417 קוד

METHOD FOR EXTENDING BAR CODE PDF 417 CODING CAPACITIES

]54[

07.06.2001]22[FR]33[08.06.2000]32[00/07321]31[

Int. Cl.8 G06K 019/06]51[GIAT INDUSTRIES, FRANCE]71[WO/2001/095251]87[


אביב



TEL AVIV 61040

]74[

]57 [A process for increasing a data encoding capacity of a PDF 417 bar code, comprising: compressing data into the bar code; reading the data by a data acquisition hardware linked to a scanning hardware and connected to an information system; and distributing the data, using algorithms, into a series of four symbols that are dynamically linked to carry out a second

compression, wherein the compressed information from the second compression is reordered into packets of information using polynomial functions and an element is introduced to control an integrity of the data, and formatting and reading of the data is controlled directly by the information system, and wherein the data can be read in any order.

__________

153161]21][11[

DRINK DISPENSER ASSEMBLYשתיה לאספקת וקו שתיה ברז, מיכלAND CONTAINER FOR DRINK AND DRINK DISPENSING LINE

]54[

31.05.2001]22[NL]33[31.05.2000]32[1015368]31[

Int. Cl.8 B67D 001/06, 001/14]51[


HEINEKEN TECHNICAL SERVICES B.V., THE NETHERLANDS

]71[

WO/2001/092142]87[בע"מ, רוחני ושות',קניין פנסטר

, ת.ד. אריה , קרית1 כניסה12 בזל תקוה , פתח10256

FENSTER & COMPANY, INTELLECTUAL PROPERTY LTD,.

12 BASEL ST,.ENTRANCE 1,P.O.B. 10256,

PETACH TIKVA

]74[

]57 [Drink dispenser assembly comprising: a dispenser device, provided with a dispensing head, for accommodating a dispensing line, and a container, containing carbonated drink, connected during use to the dispensing line which has a coupling element at an outlet end for connection to the dispensing head,

characterized in that the coupling element comprises a shut-off valve that can be closed while placing the outlet end of the dispensing line into the dispensing head and, respectively, removing the outlet end of the dispensing line from the dispensing head.

__________

153234]21][11[

רוקחות ותכשירי אינדול תולדות של הטיפול עבור אותן המכיליםCNS הפרעות

INDOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF CNS DISORDERS

]54[


13.06.2001]22[DK]33[14.06.2000]32[PA200000919]31[

Int. Cl.8 A61K 031/395, A61P 025/00, C07D 401/14, 403/14, 413/14, 417/14]51[H. LUNDBECK A/S, DENMARK]71[WO/2001/096328]87[

ושותפיו, הס יצחק ד"ראביב , תל6451 , ת.ד. 279 הירקון רחוב

DR. YITZHAK HESS & PARTNERS, 279 HAYARKON ST,.

P.O.B. 6451 ,TEL AVIV 61063

]74[

]57 [A substituted indole derivative of the formula

wherein one of Y1 and Y2 is N, which is bound to Y4, and the other of Y1 and Y2 is CO, CS, SO, or SO2 and Y4 is CH2;

Y3 is Z-CH2, CH2-Z or CH2CH2, and Z is O or S; provided that when Y1 is N, Y3 may not be Z-CH2;

W is a bond or an O, S, CO, CS, SO or SO2

group;n is 0-5, m is 0-5 and m+n is 3-6; provided that when W is O or S, then n ≥2 and m≥1;

when W is CO, CS, SO or SO2, then n≥1 and m≥1;

X is C, CH or N; provided that when X is C, the dotted line indicates a bond, and when X is N or CH, the dotted line is not a bond;

R1-R9 are independently selected from hydrogen, halogen, cyano, nitro, amino,

hydroxyl, C1-6-alkyl-amino, di- C1-6-alkyl-amino, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C1-6-alkoxy, C1-6-alkylthio, C1-6-alkyl substituted with hydroxy or thiol,C3-8-cycloalkyl, C3-8-cycloalkyl- C1-6-alkyl, acyl, thioacyl, aryl, trifluoromethyl, trifluoromethylsulfonyl, and C1-6-alkylsulfonyl;

R10 is hydrogen, C1-6-alkyl, C2-6-alkenyl, C2-

6-alkynyl, C1-6-alkyl substituted with hydroxy or thiol, C3-8-cycloalkyl, C3-8-cycloalkyl- C1-6-alkyl, aryl, aryl- C1-6-alkyl, acyl, thioacyl, C1-6-alkylsulfonyl, trifluoromethylsulfonyl or arylsulfonyl, or a pharmaceutically acceptable acid addition salt thereof.

__________

153299]21][11[

לאזהרה אור אחרי העוקבת מערכתמוצק במצב מווסתת

SOLID STATE MODULATED BEACON TRACKING SYSTEM

]54[


18.04.2002]22[US]33[19.04.2001]32[09/838064]31[

Int. Cl.8 F41G 007/30, G01S 001/00, 003/784]51[RAYTHEON COMPANY, U.S.A.]71[




REHOVOT 76122

]74[

]57 [A system for tracking a missile in flight, the missile having an optical beacon generator that outputs a modulated signal having a predetermined frequency, comprising:

)a (an optical system (50, 52, 54) for transmitting image data along an optical path (68) onto an array of detectors (55); and

)b (means for processing (46) the image data transmitted onto the array of detectors

in order to locate the optical beacon, wherein each detector in the array receives substantially simultaneously the image data from the optical system, characterized in that the means for processing samples the image data at a first frequency during a first portion of the flight of the missile and at a second frequency during a second portion of the flight of the missile, wherein the second frequency is different from the first frequency.

__________

153490]21][11[

של מחדש וליצירה לתיקון ושיטה הרכבאחרות רקמות ושל סחוס

COMPOSITION AND METHOD FOR THE REPAIR AND REGENERATION OF CARTILAGE AND OTHER TISSUES

]54[


29.06.2001]22[US]33[29.06.2000]32[60/214717]31[

Int. Cl.8 A61L 027/00]51[BIOSYNTECH CANADA INC., CANADA

]71[




REHOVOT 76122

]74[

]57 [A polymer composition for use in repairing a tissue of a patient, said polymer composition being mixed with at least whole blood, said polymer composition when mixed with whole blood resulting in a mixture, said mixture turning into a non-liquid state in time or upon heating, said

mixture being retained at the site of introduction and adhering thereto for repairing the tissue, wherein said polymer composition comprises a polymer and is dissolved or suspended in a buffer containing an inorganic or organic salt.

__________

153509]21][11[

נגזרות של מזילטים להכנת תהליךפיפראזין

PROCESS FOR THE PREPARATION OF MESYLATES OF PIPERAZINE DERIVATIVES

]54[

14.02.2002]22[EP]33[16.02.2001]32[01200534.

4]31[

Int. Cl.8 C07D 413/00]51[SOLVAY PHARMACEUTICALS B.V., THE NETHERLANDS

]71[





TEL AVIV 61040

]74[

]57 [Process for the preparation of piperazine derivatives, characterized in that the mesylate of compounds of the formula

is prepared by reacting an amine of the formula


X-NH2

with a compound of the formula

and methanesulfonic anhydride, in whichformulae X represents a group of theformula

wherein R1 is hydrogen or fluoro,R2 is hydrogen, alkyl (1-4C), alkoxy (1-4C) or an oxo group,A represents a heterocyclic group of 5-7 ring atoms wherein 1-3 heteroatoms from the group O, N and S are present ,

Y is methyl, ethyl, ethyl substituted with one or more fluorine atoms, cycloalkyl (3-7C) methyl optionally substituted with one or more fluorine atoms, or a group of the formula

wherein Z is hydrogen, phenyl, phenyl substituted with 1-3 substituents form the group hydroxy, halogen, alkyl (1-4C) alkoxy (1-4C) or cyano, and R3 is hydrogen

or 1-3 substituents from the group halogen, hydrogen, hydroxy, alkyl (1-4C) or alkoxy (1-4C).

__________

153535]21][11[

נתונים וניתוח לעיבוד ומערכת שיטההקרקע פני של דיגיטאליים

METHOD AND SYSTEM FOR PROCESSING AND ANALYZING DIGITAL TERRAIN DATA

]54[


19.12.2002]22[Int. Cl.8 F41G 007/00, 007/34, G01C 021/20]51[

בע"מ, לחימה אמצעי לפיתוח רשות רפא"לחיפה

RAFAEL-ARMAMENT DEVELOPMENT AUTHORITY LTD.

]71[

YIGAL MOSCOVITZ, SERGEYעטיה ויצ'יק, מיכל מוסקוביץ, סרגי יגאלVICHIC, MICHAL ATTIA, RAMI BEN-ARI

]72[




]74[

]57 [A method for processing and analyzing digital terrain data, comprising:

)a (providing Digital Terrain Elevation Data (DTED);

)b (defining an approach azimuth and a visibility limitations angle;

)c (defining directional fans by determining a fan opening angle, a fan azimuth, and a maximal range for terrain analysis;

)d (constructing at least one directional fan data set, from at least one source point within the DTED, that contains the line of sight information between said source point and DTED points located within said directional fan; and

)e (interrogating said data sets by one or more queries to obtain terrain information for give approach conditions.

__________

153587]21][11[


]STABILIZED INTERLEUKIN 2]54 מיוצב2 אינטרלוקין

27.06.2001]22[US]33[28.06.2000]32[09/605577]31[

Int. Cl.8 A61K 038/17, 038/20]51[AICURIS GMBH & CO. KG, GERMANY

]71[





TEL AVIV 61040

]74[

]57 [A stable lyophilized pharmaceutical composition comprising approximaterly 1 to 4 milligrams per milliliter of a human IL-2 mutein and a stabilizing mixture comprising histidine, glycine, and sucrose, wherein said human IL-2 mutein consists

of the amino acid sequence of wild-type human IL-2 with one substitution consisting of the replacement of the amino acid asparagines at position 88 in the wild-type human IL-2 with the amino acid arginine.

__________

153739]21][11[

של האיכות לסימון ושיטה מערכתמידע תכולת

SYSTEM AND METHOD FOR SIGNALING QUALITY OF DATA CONTENT

]54[

29.06.2001]22[US]33[30.06.2000]32[60/215552]31[US19.09.200060/233691US28.06.2001897181US28.06.2001894789US28.06.2001984180

Int. Cl.8 G06F 017/30]51[FRANK J. PONZIO, JR., U.S.A.]71[





TEL AVIV 61040

]74[

]57 [A method for signaling content quality of preexisting independently created digital data between at least two digital devices having a digital source and a digital receiver, independent of a user, the preexisting independently created

digital data having a plurality of data records, each of the plurality of data records having a plurality of data fields,the method comprising the followingsteps:


analyzing quality of the content of the preexisting independently created digital data using one or more predefined sets of criteria without accessing the preexisting independently created digital data, the grade indicative of the quality of the

content of the preexisting independently created digital data using at least one or more predefined sets of criteria without user interaction; and ,

marking the preexisting independently created digital data with the grading results in at least one form without changing and without accessing the preexisting

independently created digital data and without user interaction;

wherein a first digital receiver dynamically accesses the mark of the preexisting independently created digital data without accessing the preexisting independently created digital data to determine suitability for subsequent use of the preexisting independently created digital data;

whereby a different digital receiver without user interaction can independently determine suitability from the mark for another subsequent use of the preexisting independently created digital data without accessing the preexisting digital data.

__________

153842]21][11[

]ANTENNA]54אנטנה

23.04.2001]22[RU]33[20.07.2000]32[200011921

3]31[

Int. Cl.8 H01Q 001/36]51[SAMSUNG ELECTRONICS CO., LTD., REPUBLIC OF KOREA

]71[




REHOVOT 76122

]74[

]57 [An antenna comprising: a spiral antenna (1) made by conductors disposed in a single plane and formed into a bifilar helix, turns of the bifilar helix being directed opposite to each other, two antenna elements (3) disposed in the same plane and coupled, opposite to each other, to termination points of the conductors at outer turns of the bifilar helix, respectively,

wherein said bifilar helix is a rectangular spiral made by line segments with right angles of the turns, each of the antenna elements forms an isosceles trapezoid and is coupled to a termination point of a conductor at a vertex of the smaller base of the isosceles trapezoid, the bases of the isosceles trapezoids being parallel to the line segments of the bifilar helix.


__________

154252]21][11[

לוחות של פעילות לבחינת והתקן שיטהמודפסים מעגלים

METHOD AND DEVICE FOR TESTING THE OPERATIVENESS OF PRINTED CIRCUIT BOARDS

]54[

01.08.2001]22[DE]33[05.08.2000]32[10038313.

0]31[

Int. Cl.8 G01R 031/309]51[BOTEST SYSTEMS GMBH, GERMANY

]71[




P.O.B. 4060 ,TEL AVIV 61040

]74[

]57 [Process for testing circuit boards for serviceability, characterized by the following steps: placing a flexible layer that is initially impermeable to current directly on at least one side of the circuit board, and making contact, the flexible layer being dynamically connected to a

current conductor, energizing the layer, creating a current passage partially at the contact points that delimit the respective conductor path to be tested, and measuring the current flow in the conductor path via the current conductor.

__________

154298]21][11[

]SCHIZOPHRENIA RELATED ]54לסכיזופרניה הקשורים וחלבון גן


GENE AND PROTEIN26.07.2001]22[

US]33[07.08.2000]32[60/223482]31[Int. Cl.8 C07K 014/435, 016/18, C12N 015/12, G01N 033/53]51[SERONO GENETICS INSTITUTE S.A., FRANCE

]71[

BERNARD BIHAIN, BARBARA BOUR, LYDIE BOUGUELERET

]72[

WO/2002/012279]87[ושות', בן-עמי

, רחובות94, ת.ד. BEN-AMI & ASSOCIATES,

P.O.B. 94, REHOVOT 76100]74[

]57 [An isolated polynucleotide being selected from the group consisting of:

)a (a polynucleotide encoding the polypeptide comprising the amino acid sequence of SEQ ID NO:2;

)b (a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1,3 or the complement thereof; and

)c (a polynucleotide which is at least 95% identical to a polynucleotide specified in (b).

__________154453]21][11[

גלים תקשורת ושיטה מערכת אנטנות ( במערךMMW) מילימטריים

ושידור הקלטה

MILLIMETRE WAVE (MMW) COMMUNICATION SYSTEM AND METHOD USING MULTIPLE RECEIVE AND TRANSMIT ANTENNAS

]54[

09.08.2001]22[US]33[16.08.2000]32[60/225657]31[

Int. Cl.8 H01Q 001/24, 003/26, H04B 007/10]51[ בע"מ, פס רחבות רשתות מילימטריקס

השלשה גבעת קבוץMILLIMETRIX BROADBAND NETWORKS LTD.

]71[

YEHESKEL DALAL, YOSSIשטיינברג דלל, יוסי יחזקאלSTEINBERG

]72[

WO/2002/015456]87[בע"מ, פרידמן מרק ד"ר

ז'בוטינסקי , רח54אביב, ק. משה מגדל , רמת- גן7



RAMAT GAN 52520

]74[

]57 [A millimeter-wave (MMW) communication system comprising: a transmit subsystem for providing signals to a plurality of transmit antenna elements; and a receive subsystem for receiving the signals from a plurality of receive antenna

elements; wherein the transmit and receive antenna elements are physically arranged so that each of the receive antenna elements receives the signals transmitted from all of the transmit antenna elements with differing degrees of phase shift.


__________

154616]21][11[

בלתי הרחבה סיב, שיטות על הגנהוהתקן פולשניות

FIBER PROTECTION AND NON-INTRUSIVE EXPANSION METHODS AND APPARATUS

]54[

24.08.2001]22[US]33[08.09.2000]32[657996]31[

Int. Cl.8 H04B 010/08, 010/213]51[AURORA NETWORKS, INC., U.S.A.]71[





TEL AVIV 61040

]74[

]57 [An apparatus, comprising: a first splitter-combiner coupleable to a headend, said first splitter-combiner including; a first signal splitter communicatively coupled to a first headend input and communicatively coupled to a first downstream output; and a first signal combiner communicatively coupled to said first signal splitter via a first shunt, communicatively coupled to a first upstream input, and communicatively coupled to a first headend output; and a second splitter-combiner communicatively coupleable to a first splitter – combiner,

said second splitter combiner including: a second signal splitter communicatively coupled to a second headend input and communicatively coupled to a second downstream output; and a second signal combiner communicatively coupled to said second signal splitter via a second shunt, communicatively coupled to a second upstream input, and communicatively coupled to a second headend output, wherein the first splitter combiner switches from a shut state to a bypass state when the second headend output is communicatively


coupled to the first upstream input and the second headend input is communicatively coupled to the first downstream output, signals from the first headend input switched to the second headend input and signals from the second headend output switched to the first headend output and wherein the first splitter - combiner is then switchable back to the shut state from the bypass state when either the second

headend output is communicatively decoupled from the first upstream input or the second headend input is communicatively decoupled from the first downstream output, signals from the first headend input switched to the first headend output via the shunt.

__________

154655]21][11[

יחידת ונשא כליבה בעלי מלחציים התקן הניתן באופן אליו המתחבר עבודה

לשחרור

CLAMPING APPARATUS WITH A CLAMPING CHUCK AND A WORK PIECE CARRIER RELEASABLY CONNECTABLE THERETO

]54[

27.02.2003]22[CH]33[11.03.2002]32[20020415/

02]31[

Int. Cl.8 B23B 031/107, B23Q 001/00]51[EROWA AG, SWITZERLAND]71[


רחובות


REHOVOT 76122

]74[

]57 [Chucking device with a chuck (1) and a chucking spigot (11) which can be chucked therein, the chuck being provided with a central opening (2) for accommodating the chucking spigot and a chucking mechanism for chucking the chucking spigot, the central opening of the chuck having a conically narrowing insertion section (3), characterized in that

the chucking spigot is provided with a plurality of exposed centring surface sections (12, 12a) for orienting the chucking spigot at the conically narrowing insertion section of the chuck and the X and/or Y direction, and in that the chuck, in the insertion section, is provided with gas-outlet openings (6) corresponding to the exposed centring surface sections of the


chucking spigot and intended for cleaning the exposed centring surface sections of the chucking spigot.

__________

154668]21][11[

טסטוסטרון של ג'ל המכילה חפיסהייצורה ושיטת

DOSE PACKET CONTAINING A TESTOSTERONE GEL AND METHOD FOR ITS MANUFACTURE

]54[

29.08.2001]22[US]33[30.08.2000]32[09/651777]31[

Int. Cl.8 A61K 031/565, 047/00, 047/10, 047/12, 047/14, A61P 005/26]51[LABORATORIES BESINS ISCOVESCO, U.S.A.

UNIMED PHARMACEUTICALS, INC., U.S.A.

]71[


, תל4060 , ת.ד. 21 העם אחד רחוב REINHOLD COHN AND PARTNERS,

]74[


., AHAD HA'AM ST 21 אביבP.O.B. 4060 ,

TEL AVIV 61040

] 57 [Method for making a dose packet containing a testosterone gel, comprising the steps of:providing a transdermal testosterone gel comprising (w/w):

0.1 to 10% of testosterone,

0.1 to 10% of testosterone,0.1 to 5.0% of polyacrylic acid,

0.141 to 7.05% of isopropyl myristate,30 to 98% of ethanol, placing said gel in a

foil packet comprising a polyethylene liner.

__________

154720]21][11[

APPARATUS AND METHOD FORחפצים בדיקת עבור ושיטות מתקןINSPECTION OF OBJECTS

]54[

05.08.1999]22[Int. Cl.8 G01B 011/30, G01N 021/956, G06K 009/48, 009/64, G06T 001/00]51[DIVISION FROM 131282]62[

]ORBOTECH LTD.]71בע"מ, יבנה אורבוטקושות', ט. קולב סנפורד



REHOVOT 76122

]74[

]57 [A system for inspecting electrical circuits comprising: a boundary identifier operative to generate a representation of boundaries of elements in an image of an electrical circuit which is under inspection; an element matching defect identifier operative to receive said representation of boundaries of elements and a reference representation including reference boundaries for said electrical circuit and to compare boundaries in said representation of boundaries to said reference boundaries to identify element matching defects, said element matching defects including at least one of: elements in said reference representation but missing from said

representation of boundaries, excess elements in said representation of boundaries that are missing from said reference representation, and elements in said representation of boundaries defining a different type of element than a corresponding element in said reference representation; and a boundary defect identifier operative to receive said boundaries of elements in said electrical circuit under inspection and to compare a plurality of coordinates along at least a portion of some boundaries with reference to a corresponding region of acceptable coordinates for said portion of some boundaries to detect boundary defects.


שטרם זו לבקשה הורה בקשתפורסמה

131282The parent application from which this application has been divided has not yet been published

__________

154835]21][11[

ידיותיים קרקעיים גורמים לזיהוי מערכתקרב בשדה עויינים או

FRIEND/FOE GROUND OBJECTS IDENTIFICATION SYSTEM FOR A BATTLEFIELD

]54[

10.03.2003]22[Int. Cl.8 F41J 002/00, G01S 013/78]51[

בע"מ, לחימה אמצעי לפיתוח רשות רפא"לחיפה

RAFAEL ARMAMENT DEVELOPMENT AUTHORITY LTD.

]71[

AVNER ROSENBERG, ALONדויטש רוזנברג, אלון אבנרDEUTSCH

]72[




]74[


]57 [An IFF transponder for ground application, comprising: encoder for forming an interrogating or response sequence of pulses, and conveying the same to a UWB transmitter; said UWB transmitter for getting said interrogating or response sequence of pulses, forming a corresponding interrogating or response signal of a sequence of UWB pulses, and transmitting the same via a UWB transmitting antenna (12);

a plurality of UWB receiving antennas (13-15), disposed away one from the other, for receiving either an interrogating signal or a response signal sent by another transponder;

a decoder (R3) for getting from at least one of said UWB receiving antennas received signals, decoding the same, comparing the decoded signal with a bank of pre-stored

signals, and determining whether a received signal is an interrogating or response signal; and a processing unit (4) for, upon receipt of a signal of response to an interrogation signal sent by the present transponder, calculating the location of the responding transponder by:

)a (determining the range R by the time delays between the interrogating and response signals;

)b (determining the direction vector to the responding transponder by evaluating the time differences between arrival of each response pulse to a plurality of receiving antennas; and

)c (determining the identity of the responding transponder by checking the received sequence of UWB pulses, assuming that the sequence of each transponder is unique.

__________


154862]21][11[

של רב–חתכי לשיחזור והתקן שיטותתמונות

METHODS AND APPARATUS FOR MULTI-SLICE IMAGE RECONSTRUCTION

]54[

11.03.2003]22[US]33[01.04.2002]32[113069]31[

Int. Cl.8 A61B 006/03, G01T 001/00]51[GE MEDICAL SYSTEMS GLOBAL TECHNOLOGY COMPANY, LLC, U.S.A.

]71[



P.O.B. 1426 ,TEL AVIV 61013

]74[

]57 [A method for generating an adaptively interpolated projection of an object with an imaging system, said method comprising: generating a first projection using a first interpolation kernel; generating a second projection using a

second interpolation kernel, different from the first interpolation kernel; and taking a difference between the first projection and the second projection to generate a differential signal.

__________

155207]21][11[

WET/DRY AUTOMATICאוטומטי יבש/רטוב מזרק מכלולINJECTOR ASSEMBLY

]54[

10.10.2001]22[US]33[10.10.2000]32[60/238447]31[

Int. Cl.8 A61M 005/20]51[MERIDIAN MEDICAL TECHNOLOGIES, INC., U.S.A.

]71[




REHOVOT 76122

]74[

]57 [An automatic injection device (10) containing a pre-loaded charge of medicament for automatically self-administering the medicament upon actuation thereof, said automatic injection

device comprising: a housing assembly (110); a dry compartment (160) located within the housing for storing a predetermined dry charge of dry medicament therein; a wet compartment


(150) located within the housing for storing a predetermined amount of liquid injection solution therein; an activation assembly for pressurizing the liquid injection solution in the wet compartment, wherein the activation assembly permits passage of the liquid injection solution from the wet compartment to the dry compartment upon activation of the automatic injection device, wherein the activation assembly includes a first pressure element (170) that applies pressure to the liquid injection solution within the wet compartment upon activation of the automatic injection device; and a needle assembly (140) for dispensing the liquid injection solution

containing the medicament dissolved therein; characterized by: the activation assembly including: a second pressure element (190) that compresses the dry medicament within the dry compartment upon activation of the automatic injection device, and a linking member (180) for transmitting a force from the first pressure element to the second pressure element; wherein in use a single actuation causes the activation assembly to mix the dry medicament and liquid injection solution and dispense the liquid injection solution containing the medicament through the needle assembly.

__________

155229]21][11[

תיל של אוטומטית להספקה התקן מפותלים, במיוחד הצמדה לחיבורי

צמחים ענפי עבור

AUTOMATIC WIRE FITTING APPARATUS FOR TWISTED ATTACHING TIES, PARTICULARLY FOR PLANT BRANCHES

]54[

04.10.2001]22[FR]33[04.10.2000]32[00/12681]31[

Int. Cl.8 A01G 017/10]51[PAPETERIES MATUSSIERE ET FOREST, FRANCE

]71[




BEER-SHEVA 84152

]74[


]57 [An appliance for the automatic fitting of twisted ties, comprising a body (2) equipped with means for the feeding of continuous wire (6), and for delivering this wire to a curved jaw (3) capable of being reclosed on itself so as to surround the article (45) or the like around which the tie is to be twisted, the body being equipped with a twister (29) driven in rotation during the twisting operation and with a device (30) for cutting the wire in order to form a tie, characterized in that it comprises a first motor (4) intended for carrying out the drive of the wire and the closing and

opening of the guide jaw, and a second motor (35) intended for actuating the twister and the wire cutting device, control means being provided for successively controlling the drive of the wire and the closing of the jaw for guiding the latter, by means of the first motor, then, the first motor being stopped, the simultaneous drive of the wire cutting device and of the twister with the aid of the second motor, and, finally, after the stopping of the second motor, the opening of the guide jaw and the delivery of wire to the latter.

__________

155271]21][11[

COMPACT ARCHITECTUREמחט חסר מזרק של קומפקטי מבנהNEEDLELESS SYRINGE

]54[

19.10.2001]22[FR]33[23.10.2000]32[00/13544]31[

Int. Cl.7 A61M 005/30]51[CROSSJECT, FRANCE]71[WO/2002/034317]87[


אביב



TEL AVIV 61040

]74[

]57 [A needleless syringe comprising a body, a gas generator, a chamber for expansion of said gases, a reservoir containing the active principle, and an

injection channel, characterized in that the body has a compact architecture inducing the misalignment of the gas generator and of the reservoir containing the active


principle, and the gas generator is triggered by a cap which covers said body, said cap being able to slide along said body.

__________

155298]21][11[

לעיבוד במתקן מקור הנעלת רושמינתונים

LOCKING SOURCE REGISTERS IN A DATA PROCESSING APPARATUS

]54[

11.02.2002]22[US]33[21.05.2001]32[09/860777]31[

Int. Cl.8 G06F 009/38]51[ARM LIMITED, UNITED KINGDOM]71[WO/2002/095575]87[


רחובות


REHOVOT 76122

]74[

]57 [A data processing apparatus, comprising: a processing unit comprising a pipeline for executing a sequence of instructions, said processing unit having a first mode of operation and a second mode of operation; a set of source registers for

storing source data required by the processing unit when executing instructions in the sequence; a locking mechanism for locking source registers dependent on configurable criteria, the configurable criteria being chosen to


ensure that source registers still required for completing execution of an instruction in the pipeline are locked to prevent predetermined types of access by a subsequent instruction, the subsequent instruction only being able to enter the pipeline if the source registers relevant to that instruction can be accessed as required by the instruction; wherein, the first mode of operation, the processing unit, responsive to a determination of at least one exception condition during execution of an instruction, invoking a process

external to the pipelined execution unit to enable execution of the instruction to be completed; in the second mode of operation, the processing unit completing execution of an instruction within the pipeline even if the presence of said at least one exception condition is determined; and wherein the locking mechanism altering the configurable criteria dependent on the mode of operation of the processing unit, such that a reduction in the number of source registers being locked can be achieved in the second mode of operation.

__________

155359]21][11[

ריקמה של אולטרסוני לניפוי מכשירתאית

ULTRASONIC CELLULAR TISSUE SCREENING TOOL

]54[

15.10.2001]22[US]33[13.10.2000]32[09/687128]31[

Int. Cl.8 A61B 008/00]51[SONOCINE, INC., U.S.A.]71[





]74[

]57 [A system for screening cellular tissue, comprising: an ultrasound scanning device

including an ultrasound probe (8); a location and orientation sensor system (25)


coupled with the ultrasound probe; a receiver (12) to receive images from the ultrasound scanning device, and a receiver to receive location and orientation data from the sensor system for each image,

wherein the progressive movement of the probe is matched to the frame capture rate of the ultrasound scanner associated with the probe.

__________

155425]21][11[

פולימרים המכילים תכשיריםUV וסופגי סינטטים תרמופלסטים

COMPOSITIONS CONTAINING THERMOPLASTIC SYNTHETIC POLYMERS AND UV ABSORBERS

]54[

15.10.2001]22[DE]33[26.10.2000]32[10053152.

0]31[

Int. Cl.8 C08K 005/3475]51[BAYER AKTIENGESELLSCHAFT, GERMANY

]71[




P.O.B. 4060 ,TEL AVIV 61040

]74[


]57 [Use of mixtures containing one or more different compounds of the formula

wherein R1 and R2 are identical or different and represent H, halogen, C1- to C10-alkyl, C5- to C10-cycloalkyl, C7- to C13-aralkyl, C6- to C14-aryl, -OR5 or-(CO)-O-R5, whereR5 is H or C1- to C4-alkyl,

R3 and R4 are identical or different and represent H, C1 to C4-alkyl, C5- to C6-cycloalkyl, benzyl or C6- to C14-aryl,m is 1, 2 or 3 andn is 1, 2, 3 or 4, andone or more different compounds of the formula

wherein R6 to R9 are identical or different and are H or alkyl or CN or halogen and X equals alkyl, wherein the content of the compounds according to Formula (I) and

the content of the compounds according to Formula (II) in the mixture fulfils the following condition:


for preparation of compositions containing polycarbonate for improving the extrusion properties to the extent that when extruding

the compositions to form sheets a good quality in the surface of the extruded sheets is obtained.

__________

155782]21][11[

בעלות למחצה מוליכות שדה דיודותאנכי מדמת

VERTICAL JUNCTION FIELD EFFECT SEMICONDUCTOR DIODES

]54[

18.10.2001]22[US]33[13.11.2000]32[09/712449]31[

Int. Cl.8 H01L 029/861]51[INTEGRATED DISCRETE DEVICES, LLC, U.S.A.

]71[




REHOVOT 76122

]74[

]57 [A diode comprising: a cylindrical vertical junction field effect device (320) (JFED) in a diode configuration including, a substrate (300) of a first conductivity type having a bottom surface (319) and a top surface (316) including a cylindrical pedestal (318) having a cylindrical side and a cylindrical top surface, a ring shaped

diffusion region (312) of a second conductivity type at the base of the cylindrical pedestal around a center line of the cylindrical pedestal, and a first conductive layer (314) on the top surface of the cylindrical pedestal coupling together the ring shaped diffusion region and the cylindrical top surface.


__________

155862]21][11[

שיפועים מרובות מוצק קרביד תותבותלעשייתן ושיטה מתכת לעיבוד

MULTIPLE GRADE CEMENTED CARBIDE INSERTS FOR METAL WORKING AND METHOD OF MAKING THE SAME

]54[

08.11.2001]22[SE]33[22.11.2000]32[0004273-9]31[

Int. Cl.8 B22F 007/02]51[SANDVIK INTELLECTUAL PROPERTY AB, SWEDEN

]71[





]74[

]57 [A multi-axial method of making a cemented carbide insert, the method comprising the steps of: providing a press tool with a main cavity, the main cavity having a floor defined by a moveable lower punch; filling a main cavity of the press tool with a cemented carbide powder of a

first grade; filling a second cavity of the press tool with a cemented carbide of a second grade, the cemented carbide of the second grade differing from the cemented carbide of the first grade in at least one of composition and grain size; withdrawing the lower punch of the main cavity;


introducing the cemented carbide of the second grade directly on top of the cemented carbide powder of the first grade; compacting the powder of the cemented

carbide of the first grade and the powder of the cemented carbide of the second grade to form a compact; and sintering the compact.

__________

155935]21][11[

METHOD OF STERILISING Aרוקחות תכשיר של לסטריליזציה שיטהPHARMACEUTICAL COMPOSITION

]54[

26.11.2001]22[GB]33[24.11.2000]32[0028763.1]31[GB14.05.20010111745.6

Int. Cl.8 A61L 002/00, 002/04, C07J 005/00]51[BREATH LIMITED, UNITED KINGDOM

]71[





]74[

]57 [A method of sterilising a pharmaceutical composition, comprising rapidly heating the pharmaceutical composition from ambient temperature to an elevated temperature, maintaining it at or above the elevated temperature for a

period of time, and rapidly cooling the pharmaceutical composition to ambient temperature, wherein the pharmaceutical composition is or contains a suspension of glucorticosteroid.


__________

156240]21][11[

DRIVE MECHANISM FOR ANהזרקה להתקן הפעלה מנגנוןINJECTION DEVICE

]54[

21.12.2001]22[GB]33[22.12.2000]32[0031466.6]31[

Int. Cl.8 A61M 005/145]51[DCA DESIGN INTERNATIONAL LIMITED, UNITED KINGDOM

]71[




REHOVOT 76122

]74[

]57 [A drive mechanism for an injection device in which piston means (180) are selectively driven to expel medicament from within a medicament cartridge, the drive mechanism cartridge, the drive mechanism comprising a drive means (170) associated with a first ratchet means (178), a second ratchet means (174) associated with the piston means, a housing, the first ratchet means and the second ratchet means being disposed within the housing, the second ratchet

means being biased by biasing means (182) towards the first ratchet means, in which the drive means is actuable reciprocally to drive the first ratchet means in a first angular direction such that the first ratchet means drives the second ratchet means along it longitudinal axis against the biasing means along at least a part of its movement and subsequently to drive the first ratchet means and the second ratchet means together in a second angular direction thereby to drive the piston means.

__________


156242]21][11[

בקרה יחידת עם עט מסוג מזרקאלקטרונית

PEN-TYPE INJECTOR HAVING AN ELECTRONIC CONTROL UNIT

]54[

21.12.2001]22[GB]33[22.12.2000]32[0031466.6]31[


]71[




REHOVOT 76122

]74[

]57 [An injection device for injection of a dose of a medicament from a medicament cartridge, the injection device comprising a main housing having an electronic control unit, a cover detection switch (28), a display panel (10) operative selectively to indicate to the user information relevant to the user, the display panel having an active state in which information is provided to the user and an inactive state in which no information is provided, and a cap or cover adapted to cover one end of the main

housing of the injection device, the cover detection switch being adapted to detect the presence of the cap or cover, the electronic control unit being adapted to control whether the display panel is in the active state or the inactive state, in which when the cover detection switch is actuated and the presence of the cap is detected, the electronic control unit switches the display panel to an active state for a predetermined period of time.


__________

156245]21][11[

DRIVE MECHANISM FOR ANהזרקה להתקן הפעלה מנגנוןINJECTION DEVICE

]54[

21.12.2001]22[GB]33[22.12.2000]32[0031466.6]31[


]71[




REHOVOT 76122

]74[

]57 [A drive mechanism for an injection device in which piston means (306) are selectively driven to expel medicament from within a medicament cartridge (40) and a drive mechanism for controlling the movement of the piston means, the drive mechanism comprising a housing (302), a shuttle (300) located for movement within the housing along a longitudinal axis

between a first position and a second position, drive means to move the shuttle within the housing, a gear component (304) located within the housing for rotation about the longitudinal axis and associated with the piston means, movement of the shuttle between each of the first and the second positions causing movement of the piston means.


__________

156554]21][11[

שיכבה בעל פגז עבור מתרסס תרמילליצורו ושיטה מפלסטיק פנימית

SHELL FRAGMENTING CASING WITH INNER PLASTIC LAYER AND METHODS FOR MANUFACTURING SAME

]54[

19.06.2003]22[DE]33[22.06.2002]32[10227955.

1]31[

Int. Cl.8 F42B 005/297]51[RHEINMETALL W & M GMBH, GERMANY

]71[

צדק, וכהן איתן, פרל, לצר, הרצליה12688 , ת.ד. 7 שנקר רחוב

EITAN, PEARL, LATZER AND COHEN ZEDEK,

P.O.B. 12688 ,HERZLIYA 46733

]74[

]57 [A shell having a fragmenting outer casing (2) and a plastics film (3) adjoining the outer casing on its internal face, in which plastics film an explosive charge is arranged, with the features:

)a (the plastics film has a structured area (5) provided with roof-shaped indentations (4) and at least one lateral smooth area (7,

8) adjoining the structured area and form-fittingly resting against the internal wall (6) of the outer casing;

)b (the structured area of the plastics film consists of a deformation-resistant plastics material and the smooth area of an elastic plastics material.


__________

156623]21][11[

]FILM COATING]54דקה שכבה של ציפוי

22.01.2002]22[SE]33[24.01.2001]32[0100200-5]31[

Int. Cl.8 A61K 009/00, 009/58, A61P 009/00]51[ASTRAZENECA AB, SWEDEN]71[ARNE HOLZER, JAN-ERIK LOFROTH, STAFFAN SCHANTZ

]72[





]74[

]57 [A film coating composition suitable for use in coating pharmaceutical formulations comprising:

)a (an acrylic polymer dispersion,

)b (a surfactant,)c (sodium stearyl fumarate and

)d (a water-containing liquid.

__________


156928]21][11[

ממומש מתכת-מבודד-מתכת קבלבנחושת

METAL-INSULATOR-METAL CAPACITOR IN COPPER

]54[

16.01.2002]22[US]33[17.01.2001]32[09/764832]31[

Int. Cl.8 H01G 007/00, H01L 029/00]51[INFINEON TECHNOLOGIES NORTH AMERICA CORP., U.S.A.IBM CORPORATION, U.S.A.

]71[

WO/2002/058117]87[יבמ, מעבדות רוחני קניין מחלקת

הכרמל, חיפה הר חיפה אוניברסיטת IBM LABORATORIES,

HAIFA UNIVERSITY,HAIFA 31905

]74[

]57 [A method of making a parallel plate capacitor in an integrated circuit employing copper interconnects, comprising the steps of: forming devices and lower level interconnects, at least some of which are formed from copper, of said integrated circuit, including a set of top lower level interconnects; forming an initial capacitor stack comprising a first cap layer having a first cap thickness, a conductive bottom plate layer disposed over said first cap layer, a capacitor dielectric layer disposed over said conductive bottom plate layer, a conductive top plate layer disposed over said capacitor dielectric layer, and a second cap layer having a second cap thickness disposed over said conductive top plate layer; etching said second cap layer and said top plate layer, stopping on said capacitor dielectric layer, to form a capacitor top plate covered by said second cap layer, said capacitor top plate being contained within a capacitor area that is offset from a closest one of said set of top lower level interconnects by at least a minimum offset distance; forming a third cap layer having a third cap thickness, whereby exposed portions of said capacitor dielectric layer are covered by said third cap layer and said conductive top plate is

covered by a top plate cap layer having a top plate cap thickness substantially equal to the sum of said second and third cap thicknesses, etching said third cap layer, said capacitor dielectric layer and said bottom plate layer, thereby forming a capacitor bottom plate covering said capacitor area and extending past said capacitor top plate on all sides, whereby all edges of said capacitor bottom plate are offset laterally from corresponding edges of said capacitor top plate by at least a top plate offset distance; depositing a layer of interlayer dielectric; forming a set of via apertures in said interlayer dielectric, stopping on said first and third cap layers; removing all of said third cap layer in a bottom plate and outside said top plate and removing only a portion of said third cap layer above said top plate in a top plate contact area, leaving a remaining thickness of said third cap layer in said top plate contact area; removing said capacitor dielectric in said bottom plate contact area; removing all of said remaining thickness of said third cap layer in said top plate contact area; and forming capacitor interconnect members of a set of upper level interconnects in said top plate contact area and said bottom plate contact area.


__________156972]21][11[

]PHASE-LOCKED LOOP]54נעולה פאזה מעגל

18.12.2001]22[GB]33[25.01.2001]32[0101954.6]31[

Int. Cl.8 H03L 007/18]51[QUALCOMM INCORPORATED, U.S.A.

]71[




REHOVOT 76122

]74[

]57 [An apparatus comprising: a phase-locked loop (10); a first register set (21, 22) for holding data defining a mode of operation of the phase-locked loop; and coupling means (27, 28, 29, 30) for coupling the first register set of the phase-locked loop to cause the same to operate in a mode defined by the data held therein or to receive data defining a new mode of operation, characterized by: a second register set (21, 22) for holding data defining a mode of operation of the phase-locked loop; and the coupling means being arranged to couple one of the first and

second register sets to receive data defining a new mode of operation while the outer of the first and second register set is connected to the phase-locked loop to cause the same to operate in the mode defined by the data in the other register set, and being reconfigurable to change the coupling so that the other register set is coupled to receive data defining a further new mode of operation while the one register set is connected to the phase-locked loop to cause the same to operate in the new mode of operation.

__________


157146]21][11[

CONTROL SYSTEM WITHקיבולת גלאי בעלת בקרה מערכתCAPACITIVE DETECTOR

]54[

30.01.2002]22[US]33[07.02.2001]32[60/267113]31[

Int. Cl.8 G08B 013/26]51[GERENRAICH FAMILY TRUST, U.S.A.

]71[




REHOVOT 76122

]74[

]57 [A capacitive sensor system for controlling operation of a device, the system comprising: sense electrodes for enabling establishment of an electric field for intercepting motion of a proximate object; and an electronic circuit for

providing a control output signal in response to a rate of change in capacitance of the sense electrodes due to motion of the proximate object within the field without intermediate electronic differentiation of signals related to a change in capacitance.

__________


157157]21][11[

הפוכה תצורה בעל בשדה מבוקר היתוךישירה אנרגיה והמרת

CONTROLLED FUSION IN A FIELD REVERSED CONFIGURATION AND DIRECT ENERGY CONVERSION

]54[

18.03.2002]22[US]33[19.03.2001]32[60/277374]31[US08.06.200160/297086US14.02.200210/076793

Int. Cl.8 H05H 001/12]51[THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, U.S.A.

]71[

NORMAN ROSTOKER, HENDRIK J. MONKHORST

]72[

WO/2002/082873]87[בע"מ, פרידמן מרק ד"ר

ז'בוטינסקי , רח54אביב, ק. משה מגדל , רמת- גן7



RAMAT GAN 52520

]74[

]57 [A method of converting fusion product energies into electric energy, comprising the steps of:

)a (injecting ions along a helical path within a generally cylindrical cavity (420);

)b (forming an electric field within the cavity,

)c (converting at least a portion of the ion energy into electrical energy, and

characterized in that the cavity has a surface formed by a plurality of electrodes (494) in spaced relation with one another with a plurality of elongate gaps there - between, the gaps extending along a longitudinal axis of the cavity, and the electric field having a multi-pole structure with more than two poles.

The applications for division,183993 מבקשה חלוקה בקשות


from this application haveפורסמו. שטרם זוnot yet been published

__________

157212]21][11[

]POLYMERIC COMPOSITE FOAM]54מרוכב פולימרי קצף

14.02.2002]22[AU]33[14.02.2001]32[PR3091]31[

Int. Cl.8 C08J 009/228, 009/35]51[STYROPHEN INTERNATIONAL PTY LTD., AUSTRALIA

]71[


,2273, ת.ד. , מרמורק4 הגיא שער SANFORD T.COLB & CO,.]74[

]57 [A polymeric composite foam comprising a continuous phase of a furan polymer or phenolic and furan polymer and a disperse phase of foamed polystyrene polymer wherein the composite foam is prepard by reacting a liquid foamable composition comprising 5-50% w/w of foamable unexpanded polystyrene beads, 50-95% w/w of a resin or resin mixture selected from the group of a furan resin, a

phenolic resin and furan resin, and a phenolic resin and furfuryl alcohol and an effective amount of an acid catalyst wherein the reacted foamable composition achieves temperatures sufficient to polymerise said resin or resin mixture and expand the polystyrene polymer without requiring the application of external heat or energy sources.

__________

157219]21][11[

עם נמוך ברעש רב–מוצא כח מעגללעיצוב ושיטה יעילים ליניאריים ווסתים

LOW-NOISE MULTI-OUTPUT POWER SUPPLY CIRCUIT FEATURING EFFICIENT LINEAR REGULATORS AND METHOD OF DESIGN

]54[

04.08.2003]22[US]33[15.08.2002]32[219121]31[

Int. Cl.8 H02M 003/335]51[GENERAL ELECTRIC COMPANY, U.S.A.

]71[



P.O.B. 1426 ,TEL AVIV 61013

]74[

]57 [A low noise, multiple output power supply circuit featuring a plurality of

efficient linear regulators comprising: a transformer (12) having a primary circuit


(6) with a primary transformer input winding, and a plurality of secondary circuits (8), wherein each secondary circuit has a secondary transformer output winding having at least one turn of secondary windings; wherein a saturable reactor core is placed in series with at least

one selected output winding of at least one selected secondary circuit to subtract a small amount of average voltage, volt-seconds, from the output voltage of the selected output winding, to allow different rectified DC voltages to be obtained from different output windings.

__________

157277]21][11[

של המנוע את לארגן ושיטה מעליתמעלית

LIFT INSTALLATION AND METHOD OF ARRANGING A DRIVE ENGINE OF A LIFT INSTALLATION

]54[

06.08.2003]22[EP]33[05.09.2002]32[02405768.

9]31[

Int. Cl.8 B66B 011/00]51[INVENTIO AG, SWITZERLAND]71[


אביב



TEL AVIV 61040

]74[

]57 [Lift installation with cage (11) and counterweight (12) in a shaft, with a drive engine mounted on a crossbeam, which

crossbeam is fastened to two counterweight guides and to a cage guide, characterized in that the drive engine is gearless and that the


crossbeam is fastened by way of each of two end regions to a respective counterweight guide and by a centre region

to the cage guide and that the two counterweight guides and the cage guide are fastened to a first wall.

__________

157542]21][11[

מערכות לשיקום ושיטה מערכת מחשבים מתכנת שניזוקו מחשבים

מזיקה

SYSTEM AND METHOD FOR RESTORING COMPUTER SYSTEMS DAMAGED BY A MALICIOUS COMPUTER PROGRAM

]54[

26.03.2002]22[US]33[30.03.2001]32[09/823673]31[

Int. Cl.8 G06F 001/00, 011/14]51[COMPUTER ASSOCIATES THINK, INC., U.S.A.

]71[




BEER-SHEVA 84152

]74[

]57 [A method for restoring a computer system modified by malicious code, comprising; scanning (51) the computer system for the malicious code; identifying the malicious code; retrieving (54) from a data file, information relating to the malicious code including at least one command used for restoring the computer

system to a state that existed prior to modification by the malicious code; and executing the at least one command to restore the computer system to the state as the computer system existed prior to modification by the malicious code, wherein the at least one command is used for restoring at least a portion of the


computer system other than a host file having the malicious code to the state that existed prior to the portion of the computer

system having been modified by the malicious code.

__________

157700]21][11[

]PORTABLE GRILL]54נייד גריל

02.09.2003]22[Int. Cl.8 A47J 037/06]51[

]AHARON KADOSH]71לציון קדוש, ראשון אהרון( בע"מ,1992) כלכלי וייעוץ פטנטים גולד

, חיפה43רובינשטיין GOLD PATENTS LTD,.

43 RUBINSTEIN ST,.HAIFA 34987

]74[

]57 [A portable grill for outdoor barbecuing comprising: a hollow body cut into two portions (22, 24) wherein said two portions are connected so that in a closed

state, a hollow is maintained within said body and in an open state, said two portions are partially separated; at least one burning chamber adapted to seat within at


least one of said two portions; at least one grate (26) adapted to cover said at least one burning chamber; at least one skewer (34) provided to one of said two portions wherein said at least one skewer is adapted to rotate; whereby the portable grill can be carried when in a closed state and can be used for horizontal or vertical barbecuing when in open state wherein for horizontal

barbecuing, food is supported on the grate and heated charcoal or stones is confined beneath the grate within the burning chamber and for vertical barbecuing, said body is vertically positioned and food is skewered on said at least one skewer and grilled by opposite positioned charcoal or stones confined within the burning chamber in one of said two portions.

__________

157761]21][11[

]BIOPESTICIDE COMPOSITIONS]54מדבירי-מזיקים חיידקיים תכשירי

01.03.2002]22[EP]33[05.03.2001]32[01200812.

4]31[

Int. Cl.8 A01N 063/00]51[FACULTE UNIVERSITAIRE DES SCIENCES AGRONOMIQUES DE GEMBLOUX, BELGIUM

]71[


, תל41-45 רוטשילד ציון, שדרות בית S. HOROWITZ & CO,.

ZION HOUSE,]74[


.,ROTHSCHILD BLVD 41-45אביבTEL AVIV 65784

]57 [Composition suitable for use against one or more pathogens, comprising at least one antagonistic micro-organism and at least one stimulating agent chosen from the

group consisting of one or more uronic acids, mannans, derivatives thereof and mixtures of said agents.

__________

157814]21][11[

מחלב המורכבים קוסמטיים תכשיריםשלו מרכיבים או גמלים

COSMETIC COMPOSITION COMPRISING CAMEL MILK OR COMPONENTS THEREOF

]54[

08.09.2003]22[Int. Cl.7 A61K 000/898000 A61Q 000/900000 001/90000]51[

]LEV-BAR LTD.]71להב בע"מ, קיבוץ לב-בר]HECTOR KALERMAN]72קלרמן הקטורלוצאטו, את לוצאטו



BEER-SHEVA 84152

]74[

]57 [A cosmetic composition comprising as an active ingredient heat-treated and

stabilized camel milk or a heat-treated and stabilized component of camel milk.

__________

158284]21][11[

על חוסם ציפוי להנחת שיטהחוסם וציפוי סובסטראט

METHOD FOR DEPOSITING A BARRIER COATING ON A SUBSTRATE AND A BARRIER COATING

]54[

19.02.2002]22[US]33[05.04.2001]32[09/828065]31[

Int. Cl.8 B05D 007/02, 007/24, C08G 061/02, C08J 007/04, C08L 065/04, H01H 013/00

]51[

HONEYWELL INTERNATIONAL INC., U.S.A.

]71[

WO/2003/002270]87[



אביב



TEL AVIV 61040

]74[

]57 [A method for depositing a barrier coating on a surface to protect an underlying substrate, the method comprising the steps of; depositing a first layer of a first parylene polymer on a clean surface portion of the substrate; depositing a second layer of a second parylene

polymer different from said first parylene polymer over said first layer; and annealing by heating the layer in the presence of a vacuum or an inert atmosphere at an annealing temperature for a time sufficient to improve the barrier properties of the barrier coating.

__________

158365]21][11[

של ספרית אברציה לתיקון והתקן שיטהאלקטרונים אלומת

METHOD AND APPARATUS FOR CORRECTING SPHERICAL ABERRATION OF AN ELECTRON BEAM

]54[

12.10.2003]22[US]33[23.10.2002]32[065489]31[

Int. Cl.8 H01J 029/56, H05G 001/26]51[GE MEDICAL SYSTEMS GLOBAL TECHNOLOGY COMPANY, LLC, U.S.A.

]71[



P.O.B. 1426 ,TEL AVIV 61013

]74[

]57 [A method for correcting spherical aberration in an electron beam having an upstream region and a downstream region, said method comprising: producing an electron beam; removing ions from the electron beam using electrical fields in the upstream region of the electron beam;

allowing ions to accumulate in the downstream region of the electron beam using an ion trap and a grounded tube; and adjusting a range of spherical aberration correction of the ion trap with the grounded tube.

__________

158470]21][11[

של מתכתית תחמוצת לייצור שיטותניוביום

METHODS OF MAKING A NIOBIUM METAL OXIDE

]54[


18.04.2002]22[US]33[19.04.2001]32[60/284822]31[

Int. Cl.8 H01G 009/08]51[CABOT CORPORATION, U.S.A.]71[

WO/2002/086923]87[ושות', גבריאלי זליגסון

אביב , תל1426 , ת.ד. 31 רח' יבנה SELIGSOHN GABRIELI & CO,.

31 YAVNE ST,.P.O.B. 1426 ,

TEL AVIV 61013

]74[

]57 [A method of forming a capacitor anode comprising a niobium oxide having an atomic ratio of niobium to oxygen of 1: less than 2.5, comprising forming said niobium oxide into the shape of an anode and sintering at a temperature of from about 800˚C to about 1200˚C for a time of from about 1 hour to about 10 hours;

anodizing at from about 16 to about 75 volts at a formation temperature of about 85˚C; annealing said anode at a temperature of from about 300˚ to about 350˚C for a time of from about 10 minutes to about 60 minutes; and manganizing said anode at a temperature of from about 220˚ to 280˚C.

__________

158621]21][11[

גבי על תאים בעל מתמשך לסינון התקןציר

CONTINUOUS FILTRATION DEVICE WITH PIVOTING CELLS

]54[

02.05.2002]22[BE]33[03.05.2001]32[010307]31[

Int. Cl.8 B01D 033/19]51[PRAYON TECHNOLOGIES, BELGIUM

]71[



P.O.B. 12688 ,HERZLIYA 46733

]74[

]57 [Continuous fluid filtration device, comprising:

filtration cells (1) each having an opening towards the top, through which they are supplied with fluid to be filtered and which is fitted with a filter bed (41) which, in the filtration position of the cells, allows passage of a filtrate and retention of a filtration cake, and a bottom (45), these cells being disposed in a carousel around a

rotation axis (2) and each arranged so as to be able to pivot about a tilt axis (3), tangential to a horizontal circle (4) having the rotation axis as its centre, means (8, 9) of supporting the filtration cells, which support each cell so that it can perform a revolution about the rotation axis, means (16, 19, 20) of driving the filtration cells which drive them in revolution about the rotation axis, mean (21, 23) of moving the


filtration cells which cause a tilting movement thereof about their tilt axis, during their revolution about the rotation axis, and means of discharging the filtrate from the cells, comprising at least one outlet orifice (42) at the bottom of each cell, a central collector (39) and connection means allowing flow of the filtrate between the said at least one outlet orifice and the collector, characterized in that the said

connection means for each cell comprise a flexible conduit (38), in which, in the filtration position of the cell, no area of the flexible conduit is lower than another area of this conduit situated downstream with respect to the flow of the filtrate, the flexible conduit being arranged so as not to undergo any elongation during the tilting of the cell.

__________

158845]21][11[

למחצה מוליכות שדה אפקט דיודותאנכית מתכת מתחמוצת

VERTICAL METAL OXIDE SEMICONDUCTOR FIELD-EFFECT DIODES

]54[

08.05.2002]22[US]33[23.05.2001]32[09/864436]31[

Int. Cl.8 H01L 029/861]51[INTEGRATED DISCRETE DEVICES, LLC, U.S.A.

]71[




REHOVOT 76122

]74[

]57 [A method of forming a diode comprising:

)a (providing a semiconductor body of a first conductivity type having a layer of a second conductivity type on a first surface thereof;

)b (forming a plurality of cylindrical oxide pedestals on the layer of a second conductivity type;

)c (directionally etching to form trenches in the layer of second conductivity type between pedestals;


)d (forming regions of the first conductivity type in the layer of second conductivity type between pedestals and extending somewhat under the pedestals;

)e (directionally etching to form deeper trenches extending through the layer of second conductivity type between pedestals and to remove the regions of the first conductivity type in the layer of second conductivity type between pedestals and not the part of the layer of second conductivity type extending somewhat under the pedestals;

)f (depositing a gate oxide;)g (depositing a heavily doped

polysemiconductor layer;)h (directionally etching the

polysemiconductor layer to remove the

polysemiconductor from the gate oxide between pedestals;

)i (implanting to convert the regions between pedestals from the first conductivity type to the second conductivity type;

)j (directionally etching to further reduce the height of the polysemiconductor layer on the gate oxide on the side walls of the pedestals to a level of the remainder of the layer of (d) above;

)k (removing the exposed gate oxide;)l (depositing a conductive layer as a first

electrical contact to the diode; and,)m (providing an electrical contact to the

semiconductor body as a second electrical contact to the diode.

__________

158872]21][11[

METHODS OF WINDINGאופטי סיב ליפוף של שיטותOPTICAL FIBER

]54[

15.05.2002]22[US]33[15.05.2001]32[60/291164]31[US26.09.2001963893

Int. Cl.8 G01C 019/72]51[FIBERSENSE TECHNOLOGY CORPORATION, U.S.A.

]71[

ALFRED W. HEALY]72[WO/2002/093226]87[

ושות' בע"מ, מ. בן-דוד ירמיהו ,45087, ת.ד. חוצבים המרפא, הר רחוב

ירושלים



JERUSALEM 91450

]74[

]57 [A method for winding optical fiber to an eigenfrequency, the method comprising: providing, for the optical fiber, a normal end and a reverse end, a normal breakout point and a reverse breakout point, a normal lead and a reverse lead provided from the normal and reverse breakout points toward the normal and reverse fiber ends, and a normal and a reverse connection point for connecting a normal

and a reverse splice to at least one of normal and reverse leads and normal and reverse ends, wrapping the optical fiber between the normal breakout point and the reverse breakout point, around a spool, wrapping the optical fiber from the normal and reverse breakout points, to the normal and reverse ends, around the spool, to cause a reversal of wrapping direction of at least one of the reverse splice, the reverse


connection point, and the reverse lead, providing a first length between the reversal and the reverse breakout point, providing a second length between the reversal and the reverse connection point, providing a third length between the normal connection point and the normal breakout point, providing a fourth length between the normal breakout point and the

reverse breakout point, providing a fifth length between the reverse end and the reverse connection point, providing a sixth length between the normal end and the normal connection point, adjusting at least one of the first length, second length, third length, fourth length, fifth length, and sixth length based on the eigenfrequency.

__________159075]21][11[

ופריט לניקוי ממחטות להחזקת מתקןבמתקן המשתמש לניקוי

DEVICE FOR HOLDING CLEANING WIPER AND CLEANING ARTICLE EMPLOYING HOLDING DEVICE

]54[

10.06.2002]22[JP]33[14.06.2001]32[2001-

180605]31[

Int. Cl.8 A47L 013/20]51[UNI-CHARM CORPORATION, JAPAN

]71[





TEL AVIV 61040

]74[

]57 [A device for holding a cleaning wiper (1), the holding device including: a synthetic resin body portion (10) bifurcated to have a pair of support plates (2) to be inserted into a tube (45) of the wiper; and a handle portion (30) extending from the body portion to be held by hand, each support plate being in an elongated plate form having a width larger than a thickness, the paired support plates extending parallel with each other to have inner side edges facing each other and

outer side edges facing in opposite directions, protrusions (15) having convexly curved edges being integrally formed on the respective outer side edges of the support plates, the paired support plates being elastically deformable to permit tip ends thereof to approach each other, wherein the support plate has a length of 70-170mm and load required to bring the tip ends of the support plates into contact with each other is 2.4-7.4N.


__________

159166]21][11[

שלילי טעון אמפיפילי קופולימר בלוק עם שלו וקומפלקס תרופה כנושאחיובית טעונה תרופה

NEGATIVELY CHARGED AMPHIPHILIC BLOCK COPOLYMER AS DRUG CARRIER AND COMPLEX THEREOF WITH POSITIVELY CHARGED DRUG

]54[

05.06.2002]22[KR]33[25.06.2001]32[2001-

36203]31[

Int. Cl.8 C08G 081/00]51[SAMYANG CORPORATION, REPUBLIC OF KOREA

]71[




TEL AVIV 61063

]74[

]57 [A block copolymer having the formula:

A-B-L-X-M+

wherein X represents an anionic group, M+ represents H+ or a metal cation, A is a biocompatible hydrophilic polymer, B is a

biodegradable hydrophobic polymer, and L represents a linker selected from the group

consisting of –O-, -NH-, -S- and –COO.-

__________


160189]21][11[

של ומארזים מוליכים לייצור שיטהמודפסים מעגלים

METHOD FOR PRODUCING CONTACTS AND PRINTED CIRCUIT PACKAGES

]54[

26.08.2002]22[DE]33[24.08.2001]32[10141571.

0]31[

DE24.08.200110141558.3DE06.06.200210225373.0

Int. Cl.8 H01L 021/44]51[SCHOTT AG, GERMANY]71[WO/2003/019653]87[


אביב



TEL AVIV 61040

]74[

]57 [A process for producing electrical contact connections for at least one component integrated in a substrate material having a first surface region and at least one terminal contact arranged at least partially in the first surface region for each component, the process comprising the steps of:

applying an optically transparent covering to the first surface region; producing at least one contact passage in the substrate material, the at least one contact passage running transversely with respect to the

first surface region; forming at least one contact location in a second surface region; thinning the substrate material starting from the second surface region substantially directly adjoining the at least one terminal contact; and producing at least one electrical contact connection from the at least one contact location to the at least one of the terminal contacts via the at least one contact passage, wherein before the at least one contact passage or the at least one contact location is produced, the optically transparent covering is applied.

__________

160738]21][11[

LIQUID FLOW MONITORINGנוזלים זרימת לניטור התקןAPPARATUS

]54[

04.03.2004]22[Int. Cl.8 A61M 037/00]51[

אביב עמישר, תל שירדומסקי, חיפה רונן

SHAI AMISARRONEN RADOMSKI

]71[

]BARUCH SEGAL]72סגל ברוך


עו"פ, רוטמן פיירניק ,10012 , ת.ד. 91 עציון, רח' הרצל בית

שבע באר

PYERNIK RUTMAN, BEIT ETSION,

91 HERZL ST,.P.O.B. 10012,

BEER SHEVA

]74[

]57 [Apparatus (10) for monitoring liquid flow including:

)a (a generally elongate housing (12) having first (16) and second (18) ends having formed therein a liquid inlet (20) and outlet (22), respectively, for permitting a liquid flow through said elongate housing, wherein said elongate housing has a cross-sectional profile which varies along the length of said elongate housing so as to

impart predetermined flow characteristics to a liquid flowing therethrough; and

)b (a flow rate indicator float (40) disposed within said elongate housing operative to be displaced therealong in accordance with a liquid flow rate therethrough; and

)c (flow rate indicator means associated with said flow rate indicator float, for providing a position-related indication of the rate of liquid flow through said elongate housing.

__________

160910]21][11[

ושיטות יקרה ממתכת מזרז של הרכבלהכנתו

PRECIOUS METAL CATALYST COMPOSITE AND METHODS FOR MAKING THE SAME

]54[

23.08.2002]22[US]33[17.09.2001]32[09/954235]31[

Int. Cl.8 B01J 021/18, 023/38]51[


ENGELHARD CORPORATION, U.S.A.

]71[





]74[

]57 [A catalyst composite comprising: a carbon support comprising a carbonaceous material, wherein the carbon support has a total pore surface area of between about

800 m2/g or more and about 2,000 m2/g or less, and about 20% or less of the total pore surface area is micro pore surface area; and a precious metal catalyst.

__________

161254]21][11[

פולסים לייצור ושיטה מתקןגבוה בלחץ אולטרסונים

DEVICE AND METHOD FOR PRODUCING HIGH-PRESSURE ULTRASONIC PULSES

]54[

04.10.2002]22[FR]33[04.10.2001]32[01/12774]31[

Int. Cl.8 A61B 008/00, B06B 001/02, H01L 041/00]51[INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE -I.N.S.E.R.M., FRANCE

]71[




BEER-SHEVA 84152

]74[

]57 [A device for producing high pressure ultrasound pulses, the device comprising: an ultrasound source comprising a piezoelectric type transducer (2) provided with electrodes (3) and presenting polarization in a given direction (F1); and means (4) for applying an electrical voltage to the electrodes of the ultrasound transducer, serving, in order to emit an ultrasound wave: to apply an electric field in the direction (F2) opposite to the

polarization direction in order to compress the ultrasound transducer; and then to apply a transient electric field having the same direction as the polarization direction, so as to cause a compression ultrasound wave to be emitted in the coupling medium; the device being characterized in that the means apply an electrical voltage with a rise time (t2m) for creating an electric field of direction opposite to the polarization direction for an application


duration (T) that is shorter than the duration leading to depolarization of the piezoelectric ultrasound transducer.

__________

161280]21][11[

מקלט בעל לערבוב כלי–קיבול או שקיתמנענע–נוזלים גוף עבור

MIXING BAG OR VESSEL HAVING A RECEIVER FOR A FLUID-AGITATING ELEMENT

]54[

02.10.2002]22[US]33[03.10.2001]32[60/326833]31[

Int. Cl.8 B01F 007/16, B01J 008/00, C12M 001/02]51[LEVTECH, INC., U.S.A.]71[

ALEXANDRE N. TERENTIEV]72[WO/2003/028869]87[

בע"מ, פרידמן מרק ד"ר ז'בוטינסקי , רח54אביב, ק. משה מגדל

, רמת- גן7



RAMAT GAN 52520

]74[

]57 [A vessel intended for receiving a fluid comprising a bag (10) for receiving and holding the fluid, the bag having a flexible portion (12) and a rigid portion (14)

characterized in that the rigid portion includes a receiver (16) for receiving and holding a fluid agitating element (18) at a home location or expected position within


the bag and that the receiver includes a peripheral flange forming a hermetic seal with the flexible portion of the bag.

__________

164113]21][11[

ושיטות ותאים אלקטרודות מבניאליהם הקשורות

ELECTRODE CONSTRUCTS AND RELATED CELLS AND METHODS

]54[

26.03.2003]22[US]33[26.03.2002]32[10/107747]31[

Int. Cl.8 C25B 011/00]51[LATTICE ENERGY, L.L.C., U.S.A.]71[

WO/2003/083965]87[ושות', גבריאלי זליגסון

אביב , תל1426 , ת.ד. 31 רח' יבנה SELIGSOHN GABRIELI & CO,.

31 YAVNE ST,.P.O.B. 1426 ,

TEL AVIV 61013

]74[

]57 [An electrode for an electrical cell, comprising:

)a (a non-conductive substrate;)b (an adhesion coating bonded to the non-

conductive substrate; and)c (a multilayer working electrode bonded

to said adhesion coating, said multilayer

working electrode including at least one layer of a first conductive metal, and at least one layer of a second conductive metal, wherein said substrate has a concave surface and said adhesion coating and multilayer working electrode are bonded upon said concave surface.

__________December 3, 2007 –התשס"ח בכסלו כ"ג 367

0

164578]21][11[

COMPOSITE STRUCTURALזהה להכנה ושיטה מרוכב מבני חומרMATERIAL AND METHOD OF MAKING SAME

]54[

14.10.2004]22[US]33[19.04.2002]32[10/125573]31[

Int. Cl.8 B32B 021/02, 027/12]51[HUNTER PAINE ENTERPRISES, LLC, U.S.A.

]71[




TEL AVIV 61063

]74[

]57 [A composite structural material comprised of a dimensionally stable core material ensheathed in a laminar covering that is bonded to the core material, wherein the laminar covering is comprised of at least one band of substantially parallel

reinforcing cords (19) bonded to at least one layer of dimensionally stable web material that is exterior to the cords, the web material being selected from the group consisting of rigidified paper (10) and rigidified cloth.

__________


164761]21][11[

אדים באמצעות טיפול ומערכת שיטההוגברה שפעילותם מחמצנים

ACTIVATED OXIDIZING VAPOR TREATMENT SYSTEM AND METHOD

]54[

24.04.2003]22[US]33[24.04.2002]32[60/375,85

1]31[

Int. Cl.8 A62D 003/00]51[STERIS INC., U.S.A.]71[

WO/2003/090875]87[ושות', כהן שלמה ד"ר

אביב , תל11490 , ת.ד. 124 גבירול אבן DR. SHLOMO COHEN & CO,.

124 IBN GABIROL ST,.P.O.B. 11490 ,

TEL AVIV 62038

]74[

]57 [A method of deactivating biological or chemical warfare agent residues characterized by: oxidizing the warfare agents with a strong oxidant which is in a

vapor phase, the strong oxidant including a peroxy compound; and adding an alkaline gas to the vapor phase oxidant to adjust a pH of the vapor phase oxidant.

__________

164977]21][11[

]POLYMERIC MICROEMULSIONS]54פולימריות מיקרואמולסיות

24.04.2003]22[US]33[03.05.2002]32[60/377901]31[

Int. Cl.8 A61K 047/10, C08G 002/00, 063/06, C08L 069/00]51[JANSSEN PHARMACEUTICA N.V., BELGIUM

]71[





TEL AVIV 61040

]74[

]57 [A diblock copolymer of formula A-B wherein polymer block A represents a linear pharmaceutically acceptable hydrophilic polymer with a molecular

weight <1,000, and polymer block B represents a polymer comprising at least two different monomers selected from glycolic acid, propiolactone, γ-


butyrolactone, δ-valerolactone, γ-valerolactone, ε-caprolactone, trimethylene carbonate, p-dioxanone, tetramethylene

carbonate, ε-lactone, 1,5-dioxepan-2-one characterized in that the diblock copolymer is liquid at a temperature below 50˚C.

__________

166160]21][11[

הכולל מתוברגים מהדקים עבור מניעסלילי הנע

SPIRAL DRIVE SYSTEM FOR THREADED FASTENERS

]54[

28.10.1998]22[US]33[31.10.1997]32[961626]31[

Int. Cl.8 F16B 023/00]51[DIVISION FROM 135871]62[PHILLIPS SCREW COMPANY, U.S.A.

]71[





TEL AVIV 61040

]74[

]57 [A driver for driving a recess headed fastener (10), the device having a longitudinal axis, and comprising: a shank; and a nib formed at the end of the shank, the nib having a central portion (20) and a plurality of wings (22) radiating outwardly from the central portion, each of the wings having an installation wall (24) and a removal wall (26), the wings being

configured so that at least one of the installation or removal walls defines a segment of a spiral that has an initial point spaced from the longitudinal axis by an initial radius and extends to an outer terminal point at a radius that is not more than about 3.5 times that of the initial radius.


__________166727]21][11[

נוזל לפליטת מיקרו–אלקטרומכני מתקןנייד נחיר מבנה המשלב

NOZZLE GUARD FOR AN INK JET PRINTHEAD

]54[

24.05.2000]22[Int. Cl.8 B41J 002/165]51[DIVISION FROM 153024]62[SILVERBROOK RESEARCH PTY. LTD., AUSTRALIA

]71[




BEER-SHEVA 84152

]74[

]57 [A micro-electromechanical fluid ejection device which includes a substrate (16) that incorporates drive circuitry and defines a plurality of ink inlet channels (48); and a plurality of nozzle arrangements (80) positioned on the substrate, each nozzle arrangement including an elongate actuator (28) that is fast at one end to the substrate, an opposite end being displaceable relative to the substrate when an electrical signal is

received by the actuator; a nozzle that is connected to the elongate actuator, the nozzle defining a nozzle opening (24); and a fixed nozzle chamber structure that bounds a respective ink inlet channel and, together with the nozzle defines a nozzle chamber (34) in fluid communication with the ink inlet channel, such that when the actuator and thus the nozzle is displaced relative to the substrate, fluid is ejected from the fluid ejection port.


__________

166920]21][11[

]ROTATING PLATEN MEMBER]54מסתובב דיו גליל של חלק

24.05.2000]22[Int. Cl.8 B41J 002/01, 002/165]51[DIVISION FROM 153033]62[SILVERBROOK RESEARCH PTY. LTD., AUSTRALIA

]71[




BEER-SHEVA 84152

]74[

]57 [A printhead assembly (11) that includes an elongate ink distribution structure (36) that defines a plurality of chip slots (19) and a plurality of converging ink conduits that terminate at the chip slots, the ink distribution structure being dimensioned to span a print medium; an inkjet printhead chip that is positioned in each slot, the slots being oriented so that the printhead chips define an array that spans the print medium, each printhead chip having a plurality of ink inlet passages

in fluid communication with respective ink conduits (42); an elongate ink distribution member (35) that is mounted on the ink distribution structure, the ink distribution member defining at least one ink duct that generally extends the length of the ink distribution structure and a plurality of ports in fluid communication with the ink conduits; and an ink inlet arrangement (34) for feeding ink into the, or each, duct of the ink distribution member.


__________

168911]21][11[

המסוגל גז לשריפת ותהליך מבערמוצקים תוצרים ליצירת להגיב

BURNER AND PROCESS FOR COMBUSTION OF A GAS CAPABLE OF REACTING TO FORM SOLID PRODUCTS

]54[

01.06.2005]22[US]33[07.06.2004]32[862851]31[

Int. Cl.8 F23C 007/00, F23D 014/00]51[AIR PRODUCTS AND CHEMICALS, INC., U.S.A.

]71[


אביב



TEL AVIV 61040

]74[

]57 [In a combustion apparatus comprising; a combustion chamber (1) having an entrance to an interior portion and an exit therefrom; a precombustion chamber (2) having an entrance and an exit with the exit in communication with the entrance of said combustion chamber; a multi-wall burner (3) having at least one nozzle (21) for injecting a feed gas

containing a gas capable of forming solid phase oxidation products, at least one lift gas nozzle (22) for injecting a lift gas, and at least one oxidant nozzle (23) for injecting an oxidant; the respective nozzles directed for injecting into the entrance of said precombustion chamber; the improvement which comprises: a pathway (14), formed between the exterior of the


precombustion chamber and the interior portion of said combustion chamber, whereby said pathway permits the introduction of a secondary oxidant

exterior to the precombustion chamber and into the interior portion of the combustion chamber.

__________

172040]21][11[

מערכת ביצועי על לפיקוח והתקן שיטהגז טורבינת

METHOD AND APPARATUS FOR MONITORING THE PERFORMANCE OF A GAS TURBINE SYSTEM

]54[

19.01.2004]22[US]33[30.01.2003]32[10/354824]31[

Int. Cl.8 F02C 007/00, 009/00]51[DIVISION FROM 159933]62[GENERAL ELECTRIC COMPANY, U.S.A.

]71[



P.O.B. 1426 ,TEL AVIV 61013

]74[

]57 [A method for monitoring performance of a gas turbine system, said method comprising: providing a plurality of combustor cans (100); placing (110) a plurality of temperature sensors (40) circumferentially around an exhaust plane of said plurality of combustor cans; operating (115) said plurality of combustor

cans while varying a plurality of gas turbine operating parameters, wherein exhaust gas issues from the combustor can of said plurality of combustor cans during operation; measuring temperature (120) of said exhaust gas in said exhaust plane using said plurality of temperature sensors to obtain a plurality of individual


temperature measurements; determining a correlation (125) of said individual temperature measurements of exhaust gas temperature with corresponding individual combustor cans of said plurality of combustor cans issuing said exhaust gas; developing (130) a swirl model (70), wherein said model uses said correlation to predict swirl values in said exhaust plane as a function of said gas turbine operating parameters; setting (135) said plurality of combustor cans to operate at a selected set of predetermined operating conditions; measuring real-time (140) exhaust gas temperature data during operation of said plurality of combustor cans at said selected set of operating conditions using said

plurality of temperature sensors; calculating (145) at least one actual swirl value based upon said real-time exhaust gas temperature data; calculating (150) at least one predicted swirl value for said selected set of operating conditions using said model; comparing said actual swirl value and said predicated swirl value and calculating (155) at least one failure test statistic; comparing (160) said failure statistic to a standard; and generating at least one failure flag signal when said failure test statistic exceeds said standard, wherein said at least one failure flag signal indicates a presence of a failed combustor can in said plurality of combustor cans.


__________


PATENTSפטנטים

שניתנו פטנטיםPATENTS GRANTED

140467140272139577139576139133138497120605101116157500157232157083156846156795156733156724140641158522158401158354158313158206157733157630157579160285160034159631159408159062159045159038158665145765145694130160128229163521162556162281160806146472146382146370146221146045145934145897145812147855147794147721147681147589147208147043146614148649148607148555148539148440148305148157147890149455149369149306149275149252149038148979148961150427149847149804149775149753149642149530149517135109134388133832133427132633150561150509150464150907150807150720136718136456136249136163135687152375152354152314152229151932151631151609150986153999153581153268153255153239152932152928152610155177155052154978154863154776154726154230154032156221156036155863155761155618155537155406155205127366126460125864125752125497124996103052156448142694142350142137142103142092142011141694127652144461144436144242144216144133143554143047142757168553166704145226145197144908144866144695144561

176718175604


שחודשו פטנטיםPATENTS RENEWED

918699185591820917529171691663916129135310687692097920229200791949919419193391882107174107166107117107116107099107049107030107007107301107263107230107217107208107187107185107183107394107382107380107378107370107366107357107319121719121616121590120933120858107626107401107398121894121877121849121815121814121785121730121720121967121961121925121921121919121910121901121900121997121991121988121984121978121976121971121969125205124939124728123815123540123509122942122005127931127762127355127285127155126918126115125855128817128812128756128745128703128695128586128578129022129020129018129016129012129006128993128973129242129240129198129195129194129166129152129066129391129390129367129329129298129292129267129251130062129770129512129471129464129452129447129395136310135345132507132119131842131509131346130143138705137954137893137617137257136827136802136647141410140899140745140744140703140670140667140032145090144411143287143093143076142787141761141710145619145574145517145500145483145424145362145125146145146103146076146030146008145905145723145668147510147441147328147327147265146619146385146232148287148137148042148037148003147767147672147513149645149580149356149063148953148779148406148356150175150173149984149898149894149777149748149730152186151789151314151000150888150628150490150177155028155006154951154914154682154504154303153043156877155429155426155227155223155214155211155187160696160163160034159096158429157789157647157258

165886165885165884164842164542161917

חידוש אגרת תשלום אי בגלל פקעו שתוקפם פטנטיםPATENTS NOT IN FORCE DUE TO NON-PAYMENT OF RENEWAL

FEES

8926689253892478923189227892128919889196894558942489368893498934189331893018926710463989559895518950789494894828948189479104740104733104716104708104685104673104657104647104879104875104874104869104834104828104808104748104986104973104949104942104941104925104924104897120206120186120175113710112993110829110182104990120276120271120267120264120243120240120231120217124226121995121824121660120400120364120353120321125722125643125636125550125410125117125107124482125871125870125842125836125811125800125778125729130876126709126159126071126030126004125962125873141690141638132781132057132056132055132054132053144487143085141854141853141837141817141776141711151066150682148390147691146258145737145461144825

155929153349153197152036151664151607151122


שחודשו הארכה צוויEXTENSION ORDERS RENEWED

76608

תוקפם שפג פטנטיםPATENTS EXPIRED

8356783539835258352383522835218351083484836778366883656836378362783608836058358183793837918378783736837358372883687836849743797436889238384483814837988379583794

10841910303910113297438


בקשות הוגשו שלגביהם פטנטים פרק פי על ההגנה תקופת להארכת

הפטנטים לחוק1ב' ד' סימן

Patents for which applications have been filed for extension of the patent term under chapter 4, part B1 of the Patents Law

11745988534

NOTICE UNDER SECTION 64P.(4) OF THE PATENTS LAW-

הפטנטים ( לחוק4טז.)64 סעיף לפי הודעה –

Patents for which period for filing application for extension order has been extended

להגשת המועד הוארך שלגביהם פטנטים הארכה צו למתן בקשה

154668

NOTICE UNDER SECTION 64P.(2) OF THE PATENTS LAW-

הפטנטים ( לחוק2טז.)64 סעיף לפי הודעה –

Patent extension order פטנט הארכת צוGranted to Patent No. 83148 מס לפטנט ניתן 'Until: 25.6.2010 ליום עד :


בפנקס רשומים בפרטים שינוייםCHANGES IN PARTICULARS ENTERED IN REGISTER

הבעלים שם שינויCHANGE OF NAME OF PROPRIETORS

:185288No. of Patent, 142674מס' פטנט::Previous nameהקודם: השם

AMERICAN BIOSCIENCE, INC.:New nameהחדש: השם

AMERICAN PHARMACEUTICAL PARTNERS, INC.

ביומן המופיעים למדינת קודיםCOUNTRY CODES APPEARING IN THIS JOURNAL

Code Country or OrganizationAR ArgentinaAT AustriaAU AustraliaBA HerzegovinaBE BelgiumBR BrazilCA CanadaCH SwitzerlandCN ChinaCU CubaCZ Czech RepublicDE GermanyDK DenmarkEC EcuadorEP European Patent OfficeES SpainFI FinlandFR FranceGB United KingdomGE GeorgiaGR GreeceGT GuatemalaHR CroatiaHU HungaryIE IrelandIL Israel


IN IndiaIT ItalyJP JapanKR Republic of KoreaLK Sri LankaLU LuxembourgLV LatviaMX Mexico

MY MalaysiaNL The NetherlandsNO NorwayNZ New ZealandPL PolandPT PortugalRU Russian FederationSE SwedenSG SingaporeSI SloveniaSK SlovakiaTH ThailandTR TurkeyTW TaiwanUA UkraineUS United States of AmericaUY UruguayUZ UzbekistanWO World Intellectual Property Organization (W.I.P.O.)ZA South Africa

DESIGNS מדגמיםשנרשמו מדגמים

DESIGNS REGISTERED

40015Class 19(06) סוג

2.12.2004MERZ & KRELL GMBH & CO. KGAA

Writing utensil כתיבה מכשירConvention date (Germany)

הברית( )ארצות אמנה תאריך

9.6.2004 )גרמניה( האמנה תאריך

40469Class 11(01) סוג

13.3.2005ASHER ASSAF YIFRACH יפרח אסף אשרPendant תליון

40951Class 8(08) סוג

4.7.2005MEDITEX LTD. בע"מ מדיטקסHanger for tube לשפורפרת מתלה

41183Class 22(01) סוג

8.8.2005OR MECHANICS (G.M.) LTD. )ג.מ.( בע"מ מכניקה אורTelescopic night sight adapter כוונת לילה לטלסקופ מתאם



7.9.2005ELITE CONFECTIONERY LTD. בע"מ ממתתקים עליתCup ספל


22.1.2006ASAAF SHILOH שילה אסףSystem of coffee cups קפה ספלי מערכת

42017Class 10(04) סוג

13.2.2006S.A.E. AFIKIM COMPUTERIZED - DAIRY

חליבה מערכות – צ.ח.מ. אפיקים ממוחשבות

Milk sampling apparatus חלב לדגימת אביזר


15.2.2006AMISHAY MARKETING COMPANY (1980) LTD.

(1980) לשיווק חברה עמישי בע"מ

Spring door stop קפיצי דלת בלם

42092, 42093Class 9(03) סוג

28.2.2006DUDU HADIL LTD. בע"מ הדיל דודוDrink bag שתייה שקית

42166Class 12(16) סוג

15.3.2006AVIAD SHAWVITZ, ELAD HAR-ZAHAV AND URI COHEN

הר-זהב שייביץ, אלעד אביעד כהן ואורי

Pen holder for car air conditioners הרכב למזגן עט אוחז

42215Class 26(04) סוג

22.3.2006MASS TECHNOLOGY (H.K.) LTD.

Fluorescent tube פלואורסצנטית נורהConvention date (Hong Kong)

הברית( )ארצות אמנה תאריך

29.9.2005 קונג( )הונג האמנה תאריך

42277, 42278, 42279, 42280Class 25(01) סוג

4.4.2006KLIL INDUSTRIES LTD. בע"מ תעשיות קלילProfile פרופיל

42317Class 11(02) סוג

11.4.2006DORON MERDINGER LTD. בע"מ מרדינגר דורוןDecorative magnifying glass דקורטיבית מגדלת זכוכית

42318Class 11(02) סוג

11.4.2006DORON MERDINGER LTD. בע"מ מרדינגר דורוןDecorative letter opener דקורטיבי מכתבים פותחן


20. 6.2006DART INDUSTRIES INC.

Plate צלחתConvention date (U.S.A.)

הברית( )ארצות אמנה תאריך 20.1.2006 הברית( )ארצות האמנה תאריך


27.7.2006TWITOPLAST LTD. בע"מ טויטופלסט


Supporting stand תמיכה רגלית

42827Class 19(04) סוג

30.7.2006MENACHEM YAKOV FILIPOVSKY

פיליפובסקי יעקב מנחם

Text base לטקסט בסיס

42842, 42843, 42844Class 25(01) סוג

3. 8.2006A.R. APEX ISRAEL (EXPORT) LTD.

)שיווק( ישראל א.ר. אפקס חברת בע"מ

Profile פרופיל


28.9.2006MENASHE ROGOTNER רוגוטנר מנשהPackaging אריזה


15.10.1996I.M.A. 1990 – ITZUR MUTZAREI ARIZA

אריזה מוצרי ייצור– 1990י.מ.א.

Packaging אריזה


18.10.2006DAR PLAST LTD. בע"מ פלסט דרBulb holder פקעות מחזיק

43355Class 11(01) סוג

21.11.2006

AIAZ JEWELRY LTD. בע"מ תכשיטים איאזJewel תכשיט


29.11.2006LOOL INDUSTRIAL DESIGN LTD. בע"מ תעשייתי עיצוב לולTag holder לדסקית מחזיק


4.12.2006MENASHE ROGOTNER רוגוטנר מנשהBox קופסא

43430Class 11(01) סוג

7.12.2006ODYSSEY INVESTMENTS AND HOLDINGS LTD. AND DINA CASPI

והחזקות השקעות אודיסאה כספי ודינה בע"מ

Pendant תליון


14.12.2006SHALAM PRODUCTS PACKAGING (1998) LTD.

( בע"מ1998) אריזות שלם מוצרי

Cover מכסה

43518Class 20(03) סוג

19.12.2006YAIR GALOR גלאור יאירDisplay packet תצוגה מארז


21.12.2006UNILEVER PLC

Container מיכלConvention date (United Kingdom) 21.7.2006 )הממלכה האמנה תאריך


תאריךהברית( )ארצות אמנה

המאוחדת(

43592, 43593Class 25(01) סוג

4.1.2007DOMA MARKETING FOR BUILDING AND TRADE (1996) LTD.

(1996) וסחר לבניין שיווק דומא בע"מ

Constructional anchor לבנייה עוגן

43620Class 14(03) סוג

14.1.2007PANORAMA ANTENNAS LIMITED

Antenna אנטנה

43633Class 25(02) סוג

17.1.2007EMIL ELKOBY אלקובי אמילDoorframe protector דלת למסגרת מגן

43641Class 23(02) סוג

18.1.2007SIMCHA AFEK-SHPAK )שפק( אפק שמחהToilet stool שימוש לבית שרפרף

43665Class 11(01) סוג

24.1.2007אפריים ואלוף בע"מ יהלומים פלד

PELED DIAMONDS LTD. AND ALOOF EFRAIMPrecious stone יקרה אבןConvention date (Switzerland)

הברית( )ארצות אמנה תאריך 31.8.2006 )שוויץ( האמנה תאריך

43669, 43670, 43671, 43672, 43673, 43674Class 13(03) סוג

25.1.2007GEWISS S.P.A.

Switch מפסקConvention date (OHIM)

הברית( )ארצות אמנה תאריך 27.7.2006 )אוהיים( האמנה תאריך


29.1.2007MENASHE ROGOTNER רוגוטנר מנשהBox קופסא


30.1.2007OUTFORM LTD. בע"מ אאוטפורםBottle opener בקבוקים פותחן

43727Class 25(01) סוג

4.2.2007KLIL INDUSTRIES LTD. בע"מ תעשיות קלילProfile פרופיל

43771Class 23(01) סוג

12.2.2007BERMAD ברמדFilter valve פילטר שסתום


19.2.2007EDEN SPRINGS LTD. בע"מ עדן מעיינותBottle בקבוק

43796Class 19(07) סוג

20.2.2007EXTREMPARK LTD. בע"מ אקסטרמפארקBuilding model for sport לספורט מבנה של מודל



21.2.2007HAZORFIM LTD. בע"מ הצורפיםLock מנעול


25.2.2007ANTELOPE SHIVUK (1994) LTD. ( בע"מ1994) שיווק אנטילופSole סוליה


1.3.2007MORDEHAY CABASSO קבסו מרדכיApparatus for spices לתבלינים מתקן

43895Class 23(02) סוג

1.3.2007R.A.M. CASTING LTD. בע"מ ר.א.מ. יציקותSink כיור

43901, 43902, 43904, 43905, 43906Class 11(01) סוג

1.3.2007H. STERN COMERCIO E INDUSTRIA S.A.

Jewel תכשיט

43925, 43926, 43927Class 11(01) סוג


Jewel תכשיט

43933Class 26(03) סוג

8.3.2007SCHREDER

Exterior lighting apparatus ציבורית לתאורה התקןConvention date (Colombia)

הברית( )ארצות אמנה תאריך 11.9.2006 )קולומביה( האמנה תאריך

43969

Class 13(03) סוג22.3.2007

BTICINO S.P.A.Protective box for electrical apparatus חשמל למכשירי הגנה תיבתConvention date (OHIM)


43980, 43981, 43982, 43983Class 6(07) סוג

26.3.2007BLECHER SUPPLY AND AGRICULTURE LTD.

וחקלאות בנין חומרי – בלכר בע"מ

Frame profile למסגרת פרופיל


26.3.2007DIGRIS IMPORT LTD. בע"מ יבוא דיגריסPants מכנסיים


26.4.2007SANTOS

Juice squeezer למיצים מסחטהConvention date (Europe)

הברית( )ארצות אמנה תאריך 27.10.2006 )אירופה( האמנה תאריך


26.4.2007UNILEVER PLC

Bottle בקבוקConvention date (OHIM)


44092Class 23(04) סוג

30.4.2007SARA LEE HOUSEHOLD AND BODY CARE NEDERLAND B.V.

Refill bottle for air deodorizing apparatus אויר טיהור למתקן מילוי


43987, 43988Class 23(01) סוג

26.3.2007HANSGROHE AG

Sanitary faucet סניטרי ברזConvention date (OHIM)



28.3.2007DAN MOSHE משה דןGlass כוס


11. 2.2007DOMICILE IMPORT EXPORT LTD. בע"מ ויצוא יבוא דומיסילHandle ידית


10.4.2007ANTELOPE SHIVUK (1994) LTD. ( בע"מ1994) שיווק אנטילופSole סוליה

44029, 44030, 44031, 44032, 44034, 44036, 44038, 44040, 44041, 44042, 44043, 44044

Class 8(06) סוג12.4.2007

BOAZ COHEN כהן בועזHandle ידית

44033, 44037Class 8(08) סוג

12.4.2007BOAZ COHEN כהן בועזShelf holder מדף תומך

44065Class 26(05) סוג

18.4.2007SCHREDER

Lighting apparatus תאורה מגנוןConvention date (OHIM)


3698

Convention date (OHIM)הברית( )ארצות אמנה תאריך

19.2.2007 )אוהיים( האמנה תאריך

44093Class 23(04) סוג

30.4.2007SARA LEE HOUSEHOLD AND BODY CARE NEDERLAND B.V.

Air deodorizing apparatus אוויר לטיהור מתקןConvention date (OHIM)


44094Class 12(16) סוג

30.4.2007SKODA AUTO A.S.

Rear bumper for automobile מכונית של אחורי פגושConvention date (Czech Republic)

תאריךהברית( )ארצות אמנה

19.11.2006 )צ'כיה( האמנה תאריך

44096Class 11(01) סוג


Jewel תכשיט

שחודשו מדגמיםDESIGNS RENEWED

28616282372788927888278872788627885278842894628945289442882228821286632863528634370143692436830368293636936304307122895237197371963714337108370323701737016370153727637275372743727337231372263719937198

372793727837277


שבוטלו מדגמיםDESIGNS VOID

19988199761997519974199731996419963199622772227706276832767827676276752001219989362313623036229362283622736226277262772536253362523625136249362483624636245362443629136289362873628636285362573625536254

3631936318363173631636309

Dr. Meir NoamCommissioner of Patents,Designs and Trade Marks

נועם מאיר ד"רהפטנטים, המדגמים רשם

מסחר וסימני

שקובלו לבקשות מפתחותINDICES OF APPLICATIONS ACCEPTED

NAME INDEXשמי מפתח

147871 לגמן אבי157700 קדוש אהרון151602 וינטר אהרן

154720 בע"מ אורבוטק150011 בע"מ אי.סי.איי. טלקום

133039 בע"מ אייבלסטר148200 אהוד אלמון

148200 אהוד גרנדייר

147983 בע"מ וייס-מד150446 בע"מ מטל ורהקון

148200 ישראל חרמוני

בע"מ ופיתוח למחקר חברה ידע133282 ,149021 ,151637

144994 כהן יובל143153 אלכסנדר יוסף

157814 בע"מ לב-בר

בע"מ פס רחבות רשתות מילימטריקס154453

133039 ירון ניר

148212 בע"מ פרטיסיד

151522 בע"מ טכנולוגיות פוינט צ'ק

149419 בע"מ קומברס

151725 נתנוב ראובן160738 רדומסקי רונן

לחימה אמצעי לפיתוח רשות רפא"ל153535 בע"מ

לחימה אמצעי לפיתוח רשות רפא"ל154835 בע"מ

160738 עמישר שי

ABBOTT LABORATORIES 125177AHARON KADOSH 157700AHARON WINTER 151602AICURIS GMBH & CO. KG 153587AIR PRODUCTS AND CHEMICALS, INC. 168911AKZO NOBEL N.V. 143149ALMON EHUD 148200APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. 141899, 148875ARM LIMITED 155298ASTELLAS US LLC 141486ASTRAZENECA AB 142629, 156623AURORA NETWORKS, INC. 154616AVAYA TECHNOLOGY CORP. 151402AVI LEGMANN 147871AVIATION COMMUNICATION & SURVEILLANCE SYSTEMS, LLC

143574

BASF AKTIENGESELLSCHAFT 151816BASF AKTIENGESELLSCHAFT 152247BASF PLANT SCIENCE GMBH 145307BAYER AKTIENGESELLSCHAFT 155425BAYER CORPORATION 153587BAYER CROPSCIENCE GMBH 141145, 149159BIOGAIA AB 148216Biogen Idec MA Inc. 141486BIOMASS CONVERSIONS, L.L.C. 152027BIOSENSE INC. 132226BIOSYNTECH CANADA INC. 153490BOTEST SYSTEMS GMBH 154252

BOYS TOWN NATIONAL RESEARCH HOSPITAL 139687BREATH LIMITED 155935BRISTOL-MYERS SQUIBB COMPANY 149138

CABOT CORPORATION 158470CARL ZEISS STIFTUNG TRADING AS SCHOTT GLASSWERKE 160189CELLGATE, INC. 146126CHECK POINT SOFTWARE TECHNOLOGIES LTD. 151522CHERMONI ISRAEL 148200CHRISTOPHER MALTIN 149081, 149082COMPUTER ASSOCIATES THINK, INC. 157542COMVERSE LTD. 149419COMVERSE, INC. 148209CONNAUGHT LABORATORIES, INC. 118579CROSSJECT 155271CYPRESS SEMICONDUCTOR CORPORATION 148680CYVA RESEARCH CORPORATION 148925

DAIICHI PHARMACEUTICAL CO., LTD. 126138DCA DESIGN INTERNATIONAL LIMITED 156240, 156242, 156245DE BEERS INDUSTRIAL DIAMOND (PROPRIETARY) LIMITED 151752DEPOMED, INC. 150568DINAMITE DIPHARMA S.P.A. 152570DROPLET, INC. 148635

ECI TELECOM LTD. 150011ELI LILLY AND COMPANY 150480ENGELHARD CORPORATION 160910EROWA AG 154655EYEBLASTER LTD. 133039

FACULTE UNIVERSITAIRE DES SCIENCES AGRONOMIQUES DE GEMBLOUX 157761

FERTISEED LTD. 148212FIBERSENSE TECHNOLOGY CORPORATION 158872FILIPPO DEGLI AZZONI AVOGADRO CARRADORI 149824FRANK J. PONZIO, JR. 153739FRIEDRICH ALTMANN 144777

GE MEDICAL SYSTEMS GLOBAL TECHNOLOGY COMPANY, LLC 154862, 158365GENENTECH, INC. 129139, 138034GENERAL ELECTRIC COMPANY 157219, 172040GENZYME CORPORATION 148532GERENRAICH FAMILY TRUST 157146GIAT INDUSTRIES 153110GRENADIER EHUD 148200GUNTHER SCHLIMBACH 150359GUY GABRIEL PELTIER 135020

H. LUNDBECK A/S 153234HANS-HERRMANN SCHULZ 150359HEINEKEN TECHNICAL SERVICES B.V. 153161HONEYWELL INTERNATIONAL INC. 158284HUNTER PAINE ENTERPRISES, LLC 164578HUTCHISON WHAMPOA THREE G IP (BAHAMAS) LIMITED 152820

IBM CORPORATION 151545IBM CORPORATION 156928IMMUNE COMPLEX, CORPORATION 137766INDENA S.P.A. 151715INFINEON TECHNOLOGIES NORTH AMERICA CORP. 156928INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE -I.N.S.E.R.M. 161254INTEGRATED DISCRETE DEVICES, LLC 155782, 158845

December 3, 2007 –התשס"ח בכסלו כ"ג ii

INTERVET INTERNATIONAL B.V. 143149INVENTIO AG 157277ISOCHEM 149625IVAX PHARMACEUTICALS S.R.O. 148200IWANE LABORATORIES, LTD. 148327

JANSSEN PHARMACEUTICA N.V. 164977JAPAN SCIENCE AND TECHNOLOGY AGENCY 152687JEANINE GOURLAOUEN-PREISSLER 135020JOSEF ALEXANDER 143153

KONINKLIJKE PHILIPS ELECTRONICS N.V. 149260

L-3 COMMUNICATIONS CORPORATION 143574LABORATORIES BESINS ISCOVESCO 154668LATTICE ENERGY, L.L.C. 164113LEV-BAR LTD. 157814LEVTECH, INC. 161280LILLY ICOS LLC 147641LOCKHEED MARTIN CORPORATION 152494

MEDA PHARMA GMBH & CO. KG 148309MERIDIAN MEDICAL TECHNOLOGIES, INC. 155207MICHEL TRAMONTANA 149824MILLIMETRIX BROADBAND NETWORKS LTD. 154453MOTOROLA, INC. 152349

NCUBE CORPORATION 150154NEUROCHEM (INTERNATIONAL) LIMITED 146681NEUROCHEM (INTERNATIONAL) LIMITED 146681NIR YARON 133039NOMADIX, INC. 149188, 149227NOVACAL PHARMACEUTICALS

INC. 150690NOVARTIS AG 137691

OBTECH MEDICAL AG 151135ORBOTECH LTD. 154720

PAPETERIES MATUSSIERE ET FOREST 155229PFIZER PRODUCTS, INC. 145950PHARMA PACIFIC PTY. LTD. 126971PHARMACIA CORPORATION 144799PHILLIPS SCREW COMPANY 166160PPG INDUSTRIES OHIO, INC. 150182PRAYON TECHNOLOGIES 158621

QUALCOMM INCORPORATED 147522QUALCOMM INCORPORATED 150823, 151703, 156972QUEEN'S UNIVERSITY AT KINGSTON 146681

RAFAEL ARMAMENT DEVELOPMENT AUTHORITY LTD. 154835RAFAEL-ARMAMENT DEVELOPMENT AUTHORITY LTD. 153535RAYTHEON COMPANY 153299REGEN BIOTECH, INC. 152409REUVEN NETANOV 151725RHEINMETALL W & M GMBH 156554RONEN RADOMSKI 160738

SAMSUNG ELECTRONICS CO., LTD. 153842SAMYANG CORPORATION 159166SANDVIK AB (publ) 155862SANDVIK INTELLECTUAL PROPERTY AB 155862SANDVIK INTELLECTUAL PROPERTY HB 155862SANOFI-AVENTIS DEUTSCHLAND GMBH 152073SANOFI-AVENTIS DEUTSCHLAND GMBH 145922SCHERING CORPORATION 138221SCHOTT AG 160189

SERONO GENETICS INSTITUTE S.A. 154298SHAI AMISAR 160738SIEMENS AKTIENGESELLSCHAFT 151330SILVERBROOK RESEARCH PTY. LTD. 166727, 166920SILVERBROOK RESEARCH PTY. LTD. 149957SLIL BIOMEDICAL CORPORATION 146126SOLVAY PHARMACEUTICALS B.V. 153509SONOCINE, INC. 155359STERIS INC. 164761STYROPHEN INTERNATIONAL PTY LTD. 157212

THE GENERAL HOSPITAL CORPORATION 148360THE PROCTER & GAMBLE COMPANY 135036THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 157157TR ASSOCIATES, L.L.C. 150570

UNI-CHARM CORPORATION 152340, 159075UNILEVER PLC 146233

UNIMED PHARMACEUTICALS, INC. 154668UNIVERSITY OF ARKANSAS 150737UNIVERSITY OF MASSACHUSETTS 134366

VERACON METAL LTD. 150446VERTEX PHARMACEUTICALS, INC. 145757VIROLOGIC INC. 125464

WAISMED LTD. 147983WARNER-LAMBERT COMPANY LLC 128862WYETH 135343WYETH HOLDINGS CORPORATION 137809

XCEL PHARMACEUTICALS, INC., 148309

YEDA RESEARCH AND DEVELOPMENT CO. LTD. 133282, 149021, 151637YUVAL COHEN 144994

ZEALAND PHARMA A/S 147293ZYMOGENETICS INC. 136076

December 3, 2007 –התשס"ח בכסלו כ"ג iv

ענייני מפתחSUBJECT MATTER INDEX

A01G – 151602, 155229

A01N – 141445, 151816, 157761

A23G – 146233

A47G – 151725

A47J – 157700

A47L – 152340, 159075

A61B – 147983, 151135, 154862, 155359 ,161254

A61C – 135020

A61K – 118579, 126971, 137809, 138034 ,138221 ,139687, 141486 ,141899 ,143149, 146126 ,146681 ,147641, 148200 ,150359 ,150480, 150568 ,150690 ,152409, 153540 ,153587 ,154668,

156623 ,157814

A61L – 148532, 153490, 155935

A61M – 132226, 155207, 155271, 156240 ,156242 ,156245,

160738

A62D – 164761

B01D – 158621

B01J – 160910, 161280

B05B – 158284

B21K – 166160

B22F – 155862

B23Q – 154655

B32B – 164578

B41J – 166727, 166920

B65D – 148216

B66B – 157277

B67D – 153161

C02F – 150446, 152027

C07C – 135343, 148309, 149138, 150737 ,151715 ,152247

C07D – 125177, 126138, 128862, 135036 ,142629 ,144799, 145757 ,145922 ,145950, 148875 ,149159 ,149625, 152073 ,152570 ,153234,

153509

C07J – 157212

C07K – 133282, 147293, 150570

C08F – 150182

C08G – 159166, 164977

C08K – 155425

C12L – 149081, 149082

C12N – 129139, 134366, 136076, 137766 ,144777 ,145307, 148212 ,148360 ,149021

C12P – 137691

C12Q – 125464, 151637

C25B – 164113

F02C – 172040

F23C – 168911

F41A – 144994

F41G – 153535

F41J – 154835

F42B - 147871, 156554

G01C – 158872

G01N – 154298, 154720

G01R – 154252

G01S – 152494, 153299

G01T – 151752

G02B – 143153

G06F – 133039, 148635, 151330, 153739 ,155298 ,157542

G06K – 153110

G06T – 148327, 151545

G08B – 157146

G08G – 143574

G11B – 149260

G11C – 148680

H01G – 158470

H01J – 158365

H01L – 155782, 156928, 158845, 160189

H01Q – 153842

H02M – 157219

H03L – 156972H04B – 150823, 152349, 154453,

154616

H04J – 150011

H04L – 148925, 149188, 149227, 149419 ,151402 ,151522,

152820

H04N – 150154

H04Q – 147522, 149957, 151703

H05B – 149824

H05H – 157157

המשפטים, ירושלים הפטנטים, משרד רשות ע"י נערךהממשלתי, ירושלים במדפיס והודפס הופק

EDITED BY THE PATENT OFFICE, MINISTRY OF JUSTICE, JERUSALEMPRINTED AND PUBLISHED BY THE GOVERNMENT PRINTER

journal0907 - justice.gov.il€¦ · web viewg01s 181711 05/03/2007 מערכת רדאר...

Documents